<SEC-DOCUMENT>0000950123-11-073065.txt : 20110805
<SEC-HEADER>0000950123-11-073065.hdr.sgml : 20110805
<ACCEPTANCE-DATETIME>20110804184858
ACCESSION NUMBER:		0000950123-11-073065
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20110630
FILED AS OF DATE:		20110805
DATE AS OF CHANGE:		20110804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOGENEX PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000949858
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				954343413
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	033-80623
		FILM NUMBER:		111011793

	BUSINESS ADDRESS:	
		STREET 1:		1522 217TH PLACE S.E.
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021
		BUSINESS PHONE:		4254879500

	MAIL ADDRESS:	
		STREET 1:		1522 217TH PLACE S.E.
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SONUS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19950825
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>c20581e10vq.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 10pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 10pt"><B>FORM 10-Q</B>
</DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 12pt">
<TR style="font-size: 10pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT style="font-family: Wingdings">&#254;</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR>
</TABLE>
</DIV>

<!-- xbrl,dc -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 12%"><B>FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2011</B></DIV>
<!-- /xbrl,dc -->

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>or</B></DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 12pt">
<TR style="font-size: 10pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT style="font-family: Wingdings">&#111;</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR>
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 12%"><B>FOR THE TRANSITION PERIOD FROM <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> TO <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>
Commission file number 033-80623</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 10pt"><B>OncoGenex Pharmaceuticals, Inc.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">
(Exact Name of Registrant as Specified in Its Charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>95-4343413</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or Other Jurisdiction of
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer Identification Number)</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">Incorporation or Organization)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>1522 217 </B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>th</b></SUP> <b>Place SE, Suite&nbsp;100, Bothell, Washington 98021</B><BR>
(Address of Principal Executive Offices)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>(425)&nbsp;686-1500</B><BR>
(Registrant&#146;s telephone number, including area code)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Indicate by check whether the registrant (1)&nbsp;has filed all reports required to be filed by Section
13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for such
shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to
such filing requirements for the past 90&nbsp;days. Yes <FONT style="font-family: Wingdings">&#254;</FONT> No <FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T during the preceding 12&nbsp;months (or for such shorter
period that the registrant was required to submit and post such files). Yes <FONT style="font-family: Wingdings">&#254;</FONT> No <FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See definition of &#147;accelerated filer and
large accelerated filer&#148; in Rule&nbsp;12b-2 of the Exchange Act.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Large accelerated filer <FONT style="font-family: Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Accelerated filer<FONT style="font-family: Wingdings">&#254;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Non-accelerated filer <FONT style="font-family: Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" nowrap>Smaller reporting company <FONT style="font-family: Wingdings">&#111;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" nowrap>(Do not check if a smaller reporting company)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule
12b-2). Yes <FONT style="font-family: Wingdings">&#111;</FONT> No <FONT style="font-family: Wingdings">&#254;</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Indicate the number of shares outstanding of each of the issuer&#146;s classes of common stock, as of
the latest practicable date.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Class</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>Outstanding at August&nbsp;1, 2011</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">Common Stock, $0.001 par value
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">9,725,489</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>




<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">
<DIV align="left">
<!-- TOC -->
</DIV>
<DIV align="left">
<A name="C20581tocpage"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>OncoGenex Pharmaceuticals, Inc.<BR>
Index to Form&nbsp;10-Q</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="86%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Page</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Number</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C20581101"><B>Part I. Financial Information</B></A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C20581102">Item&nbsp;1. Financial Statements (unaudited)</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C20581103">Consolidated Balance Sheets as of June&nbsp;30, 2011 (unaudited)&nbsp;and December&nbsp;31, 2010</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C20581104">Consolidated Statements of Loss (unaudited)&nbsp;for the three and six months ended
June&nbsp;30, 2011 and June&nbsp;30, 2010</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C20581105">Consolidated Statements of Cash Flows (unaudited)&nbsp;for the three and six months
ended June&nbsp;30, 2011 and June&nbsp;30, 2010</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C20581106">Notes to Consolidated Financial Statements (unaudited)</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C20581107">Item&nbsp;2. Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C20581108">Item&nbsp;3. Quantitative and Qualitative Disclosures About Market Risk</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C20581109">Item&nbsp;4. Controls and Procedures</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C20581110"><B>Part II. Other Information</B></A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C20581111">Item&nbsp;1A. Risk Factors</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C20581112">Item&nbsp;6. Exhibits</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C20581113">Items 1, 2, 3, 4, and 5 are not applicable and therefore have been omitted.</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C20581114">Signatures</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c20581exv31w1.htm">Exhibit 31.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c20581exv31w2.htm">Exhibit 31.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c20581exv32w1.htm">Exhibit 32.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c20581exv32w2.htm">Exhibit 32.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="ogxi-20110630.xml">EX-101 INSTANCE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="ogxi-20110630.xsd">EX-101 SCHEMA DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="ogxi-20110630_cal.xml">EX-101 CALCULATION LINKBASE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="ogxi-20110630_lab.xml">EX-101 LABELS LINKBASE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="ogxi-20110630_pre.xml">EX-101 PRESENTATION LINKBASE DOCUMENT</A></FONT></TD></TR>
</TABLE>
</DIV>
<DIV align="left">
<!-- /TOC -->
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left">
<A name="C20581101"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>PART I. </B><U><B>FINANCIAL INFORMATION</B></U>
</DIV>

<DIV align="left">
<A name="C20581102"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;1.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Consolidated Financial Statements</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>OncoGenex Pharmaceuticals, Inc.</B>
</DIV>

<DIV align="left">
<A name="C20581103"></A>
</DIV>
<!-- xbrl,bs -->
<DIV align="center" style="font-size: 10pt"><B>Consolidated Balance Sheets</B></DIV>
<!-- xbrl,body -->

<DIV align="center" style="font-size: 10pt"><B>(Unaudited)</B></DIV>

<DIV align="center" style="font-size: 10pt">(In thousands of U.S. dollars)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>ASSETS</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Current</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents<I>&#091;note 4&#093;</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,876</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23,533</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Restricted cash</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">502</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">502</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Short-term investments <I>&#091;note 4&#093;</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54,536</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61,574</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Amounts receivable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,498</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,224</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Prepaid expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,397</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,485</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total current assets</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>78,809</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>89,318</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Property and equipment, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">207</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">87</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">509</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">513</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total assets</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>79,525</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>89,918</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Current</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accounts payable and accrued liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,643</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">893</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deferred Collaboration Revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current portion of long-term obligations <I>&#091;note 6&#093;</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,384</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,314</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Warrant liability <I>&#091;note 4, note 5&#093;</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,828</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,269</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total current liabilities</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>27,855</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>27,476</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deferred Collaboration Revenue, net of current</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,866</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,622</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Long-term obligation, less current portion <I>&#091;note 6&#093;</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,606</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,695</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total liabilities</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>44,327</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>45,793</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Commitments and contingencies <I>&#091;note 7&#093;</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Shareholders&#146; equity:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Common shares <I>&#091;note 5&#093;</I>:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">$0.001 par value 25,000,000 shares authorized and
9,718,251 issued and outstanding at June&nbsp;30, 2011
and 9,693,591 issued and
outstanding at December&nbsp;31, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Additional paid-in capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">108,224</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">107,579</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accumulated deficit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(75,644</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(66,069</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accumulated other comprehensive income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,608</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,605</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total shareholders&#146; equity</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>35,198</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>44,125</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total liabilities and shareholders&#146; equity</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>79,525</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>89,918</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><I>Subsequent events &#091;note 9&#093;</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt">See accompanying notes.
</DIV>
<!-- /xbrl,bs -->

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>OncoGenex Pharmaceuticals, Inc.</B>
</DIV>

<DIV align="left">
<A name="C20581104"></A>
</DIV>
<!-- xbrl,in -->

<DIV align="center" style="font-size: 10pt"><B>Consolidated Statements of Loss</B></DIV>
<!-- xbrl,body -->

<DIV align="center" style="font-size: 10pt"><B>(Unaudited)</B></DIV>

<DIV align="center" style="font-size: 10pt">(In thousands of U.S. dollars, except per share and share amounts)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three months</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six months</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Ended June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Ended June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>COLLABORATION REVENUE</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,887</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,701</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,086</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,401</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>EXPENSES</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,409</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,079</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,262</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,459</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,471</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,475</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,042</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,825</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,880</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,554</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,304</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,284</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>LOSS FROM OPERATIONS</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,993</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,853</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,218</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,883</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>OTHER INCOME (EXPENSE)</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">119</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">87</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(7</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">83</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(26</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Gain (loss)&nbsp;on warrants <I>&#091;note 5&#093;</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,687</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">441</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total other income (expense)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,537</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">643</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(7</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Loss for the period before
income taxes</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,530</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,846</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,575</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,890</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Income tax expense (recovery)
<I>&#091;note 3&#093;</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,000</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net loss (income)</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>6,530</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(154</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>9,575</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>2,890</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Basic and diluted loss (income)
per common share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0.67</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(0.02</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0.99</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0.45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted average number of
common shares:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Basic</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,718,251</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,400,081</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,715,846</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,366,861</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,718,251</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,529,482</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,715,846</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,366,861</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt">See accompanying notes.
</DIV>
<!-- /xbrl,in -->

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>OncoGenex Pharmaceuticals, Inc.</B>
</DIV>

<DIV align="left">
<A name="C20581105"></A>
</DIV>
<!-- xbrl,cf -->
<DIV align="center" style="font-size: 10pt"><B>Consolidated Statements of Cash Flows</B></DIV>
<!-- xbrl,body -->

<DIV align="center" style="font-size: 10pt"><B>(Unaudited)</B></DIV>

<DIV align="center" style="font-size: 10pt">(In thousands of U.S. dollars)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six months ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>OPERATING ACTIVITIES</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss for the period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,575</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,890</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Add items not involving cash</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Depreciation and amortization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Stock-based compensation <I>&#091;note 5(c)&#093;</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">554</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">311</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Change in value of warrants <I>&#091;note 5&#093;&#093;</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(440</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Changes in non-cash items</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Amounts receivable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(274</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,696</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Restricted cash</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(502</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Prepaid expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,091</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,619</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts payable and accrued liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">750</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(12,786</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Lease obligation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(19</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(599</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred collaboration revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,755</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,393</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash used in operating activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(9,631</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(17,756</B></TD>
    <TD nowrap><B>)</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>FINANCING ACTIVITIES</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Proceeds from issuance of common stock under stock option and
employee purchase plans</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">91</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">521</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash provided by financing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>91</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>521</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>INVESTING ACTIVITIES</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Proceeds from sale of investments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51,259</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">500</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Purchase of investments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(44,222</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(12,291</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Purchase of property and equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(68</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(27</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash provided by (used in) investing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>6,969</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(11,818</B></TD>
    <TD nowrap><B>)</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Effect of exchange rate changes on cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(86</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Decrease in cash and cash equivalents during the period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,657</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29,040</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents, beginning of the period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>23,533</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>62,051</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash and cash equivalents, end of the period</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>20,876</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>33,011</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Supplemental cash flow information</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Property and equipment acquired under lease obligation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">90</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt">See accompanying notes.
</DIV>
<!-- /xbrl,cf -->

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<!-- xbrl,ns -->
<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>OncoGenex Pharmaceuticals, Inc.</B>
</DIV>
<DIV align="left">
<A name="C20581106"></A>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>Notes to Consolidated Financial Statements</B></DIV>

<DIV align="center" style="font-size: 10pt"><B>(Unaudited)</B></DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>1. NATURE OF BUSINESS AND BASIS OF PRESENTATION</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">OncoGenex Pharmaceuticals, Inc. (the &#147;Company&#148; or &#147;OncoGenex&#148;) is committed to the development and
commercialization of new therapies that address treatment resistance in cancer patients. The
Company was incorporated in the state of Delaware and, together with its subsidiaries, has a
facility in Bothell, Washington and an office in Vancouver, British Columbia (Canada).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The unaudited financial statements have been prepared in accordance with generally accepted
accounting principles in the United States for interim financial information and with the
instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes
required to be presented for complete financial statements. The accompanying unaudited consolidated
financial statements reflect all adjustments (consisting only of normal recurring items) which are,
in the opinion of management, necessary for a fair presentation of the results for the interim
periods presented. The accompanying consolidated Balance Sheet at December&nbsp;31, 2010 has been
derived from the audited consolidated financial statements included in the Company&#146;s Annual Report
on Form 10-K for the year then ended. The consolidated financial statements and related disclosures
have been prepared with the assumption that users of the interim financial information have read or
have access to the audited consolidated financial statements for the preceding fiscal year.
Accordingly, these financial statements should be read in conjunction with the audited consolidated
financial statements and the related notes thereto included in the Annual Report on Form 10-K for
the year ended December&nbsp;31, 2010 and filed with the United States Securities and Exchange
Commission (&#147;SEC&#148;) on March&nbsp;10, 2011.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The consolidated financial statements include the accounts of OncoGenex and our wholly owned
subsidiary, OncoGenex Technologies Inc. (&#147;OncoGenex Technologies&#148;). All intercompany
balances and transactions have been eliminated.
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>2. ACCOUNTING POLICIES</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Recently Adopted Accounting Policies</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In April&nbsp;2010, the Financial Accounting Standards Board, or FASB, issued ASU No.&nbsp;2010 &#151; 17 &#151;
Revenue Recognition &#151; Milestone Method (Topic 605): Milestone Method of Revenue Recognition. This
standard provides guidance on defining a milestone and determining when it may be appropriate to
apply the milestone method of revenue recognition for certain research and development
transactions. Under this new standard, a company can recognize as revenue consideration that is
contingent upon achievement of a milestone in the period in which it is achieved, only if the
milestone meets all criteria to be considered substantive. This standard was effective for us on a
prospective basis beginning in the quarter ended March&nbsp;31, 2011. The adoption of this standard did
not have a significant impact on our financial position or results of operations.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In January&nbsp;2010, the FASB issued amended guidance on fair value measurements and disclosures. The
new guidance requires additional disclosures regarding fair value measurements, amends disclosures
about post-retirement benefit plan assets, and provides clarification regarding the level of
disaggregation of fair value disclosures by investment class. This guidance is effective for
interim and annual reporting periods beginning after December&nbsp;15, 2009, except for certain Level 3
activity disclosure requirements that will be effective for reporting periods beginning after
December&nbsp;15, 2010. Accordingly, we adopted this amendment in the quarter ended March&nbsp;31, 2010,
while the additional Level 3 requirements were adopted
in the quarter ended March&nbsp;31, 2011. The adoption of this standard did not have a significant
impact on our financial position or results of operations.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Recent Accounting Pronouncements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In May&nbsp;2011, the FASB issued ASU No.&nbsp;2011-04, &#147;Fair Value Measurement.&#148; This ASU clarifies the
concepts related to highest and best use and valuation premise, blockage factors and other premiums
and discounts, the fair value measurement of financial instruments held in a portfolio and of those
instruments classified as a component of shareowners&#146; equity. The guidance includes enhanced
disclosure requirements about recurring Level 3 fair value measurements, the use of nonfinancial
assets, and the level in the fair value hierarchy of assets and liabilities not recorded at fair
value. The provisions of this ASU are effective prospectively for interim and annual periods
beginning on or after December&nbsp;15, 2011. Early application is prohibited. We are currently
evaluating the impact of this new ASU.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In June&nbsp;2011, the FASB issued ASU No.&nbsp;2011-05, &#147;Comprehensive Income.&#148; This ASU intends to enhance
comparability and transparency of other comprehensive income components. The guidance provides an
option to present total comprehensive income, the components of net income and the components of
other comprehensive income in a single continuous statement or two separate but consecutive
statements. This ASU eliminates the option to present other comprehensive income components as part
of the statement of changes in shareowners&#146; equity. The provisions of this ASU will be applied
retrospectively for interim and annual periods beginning after December&nbsp;15, 2011. Early application
is permitted. We are currently evaluating the impact of this new ASU.
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>3. COLLABORATION AGREEMENT</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">On December&nbsp;20, 2009, the Company, through its wholly-owned subsidiary, OncoGenex Technologies,
entered into a Collaboration Agreement with Teva Pharmaceutical Industries Ltd., or Teva, for the
development and global commercialization of custirsen (and related compounds), a pharmaceutical
compound designed to inhibit the production of clusterin, a protein we believe is associated with
cancer treatment resistance, or the Licensed Product. Under the Collaboration Agreement, Teva paid
the Company upfront payments in the aggregate amount of $50&nbsp;million and has agreed to pay up to
$370&nbsp;million upon the achievement of developmental and commercial milestones and royalties at
percentage rates ranging from the mid-teens to mid-twenties on net sales, depending on aggregate
annual net sales of the Licensed Product.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">On the same date, the Company and Teva also entered into a stock purchase agreement, or Stock
Purchase Agreement, pursuant to which Teva made an additional $10&nbsp;million equity investment in the
Company at a 20% premium to a thirty-day average closing price, resulting in the issuance of
267,531 of our common shares purchased at a price of $37.38 per share. The 20% share premium was
included as consideration for the custirsen license and has been included in collaboration revenue.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In connection with the Collaboration Agreement and pursuant to the terms of agreements between the
Company and Isis relating to custirsen, the Company paid Isis Pharmaceuticals, Inc., or Isis, $10
million which was recorded as research and development expense in 2009. The Company also paid
approximately $333,333 to the University of British Columbia, or UBC, pursuant to the terms of
their license agreement relating to custirsen, which has been recorded as research and development
expense in 2009. Pursuant to the terms of the third-party agreements, the Company anticipates that
it would be required to pay third parties 31% of any milestone payments that are not based on a
percentage of net sales of the Licensed Product. Pursuant to the terms of third-party agreements,
the Company anticipates it will pay royalties to third-parties of 4.88% to 8.00% of net sales,
unless the Company&#146;s royalties are adjusted for competition from generic compounds, in which case
royalties to third parties will also be subject to adjustment on a country-by-country basis.
Certain third-party royalties are tiered based on the royalty rate received by the Company. Minimum
royalty rates payable by the Company assume certain third-party royalties are not paid
at the time that the Licensed Product is marketed due to the expiration of patents held by such
third parties. Maximum royalty rates assume all third-party royalty rates currently in effect
continue in effect at the time the Licensed Product is marketed.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Teva has the exclusive worldwide right and license to develop and commercialize products containing
custirsen and related compounds. The Company has an option to co-promote any Licensed Product in
the United States and Canada.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Teva is responsible for all costs relating to product commercialization including costs incurred in
relation to the Company&#146;s co-promotion option, except for start-up costs in advance of
commercialization.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Teva and the Company have developed a Clinical Development Plan under which three phase 3 clinical
trials will be initiated:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>
The ongoing phase 3 clinical trial, referred to as the Synergy trial, or SYNERGY, to evaluate a survival benefit for
custirsen in combination with first-line docetaxel treatment in patients with castrate resistant prostate cancer, or CRPC.
Expected timing of results from the survival primary endpoint for the custirsen SYNERGY Phase 3 clinical trial remains
unchanged at Q4 2013. During discussions regarding the Prostate Cancer SATURN trial, or SATURN, Special Protocol
Assessment, or SPA, amendment, U.S. Food and Drug Administration, or FDA, stated that an application supported primarily
by the results of SYNERGY alone would be acceptable for submission.
We expect to enroll at least 800 patients in SYNERGY.
</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>
An ongoing phase 3 clinical trial, referred to as SATURN, to evaluate a durable pain palliation benefit for
custirsen in combination with docetaxel as second-line chemotherapy in approximately 300 patients with CRPC. We have
revised the custirsen SATURN Phase 3 trial protocol to expand the eligible patient population, and to align with the
recently approved chemotherapy, cabazitaxel. We are awaiting final, written FDA agreement on the SPA amendment that will
allow patients to receive either docetaxel re-treatment or cabazitaxel as second-line chemotherapy. Recruitment efforts
are ongoing to enroll more patients in the SATURN study, which has had few patients accrued due to restrictive enrollment
criteria regarding docetaxel retreatment and stable pain criteria. Expected timing of results for the pain palliation
primary endpoint is now projected to be Q4 2013 rather than Q2 2013.
</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>
A phase 3 clinical trial to evaluate a survival benefit for custirsen in combination with first-line chemotherapy in
patients with non-small cell lung cancer, or NSCLC. The initiation of the Phase 3 clinical trial evaluating custirsen
in patients with NSCLC has been delayed as we determine the optimal
chemotherapeutic combination based on safety considerations and the
current and evolving standard of care. We believe NSCLC is
a promising indication and remain committed to the advancement of custirsen in NSCLC.
</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Teva will be responsible for conducting any other studies and development work necessary to obtain
required regulatory approvals. The Company may assume some of these activities if assigned by the
joint steering committee. Teva will be responsible for all such costs. The joint steering committee
will oversee the development and regulatory approval of any Licensed Product. The Company may
terminate its participation in the joint steering committee at any time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Funding responsibilities for the Clinical Development Plan will be allocated as follows:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company will be required to spend $30&nbsp;million in direct and indirect development
costs, and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Teva will fund all other expenses under the Clinical Development Plan.</TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Collaboration Agreement will remain in effect, on a country-by-country basis, until the
expiration of the obligation of Teva to pay royalties on sales of the Licensed Product in such
country (or earlier termination under its terms). After the completion of all three phase 3
clinical trials set forth in the Clinical Development Plan, or upon early termination due to a
material adverse change in the Company&#146;s patent rights related to custirsen or safety issues or
&#147;futility&#148; as defined in the Collaboration Agreement, Teva may
terminate the Collaboration Agreement at its sole discretion upon three months&#146; notice if notice is
given prior to regulatory approval of a Licensed Product and upon six months&#146; notice if notice is
given after such regulatory approval. If Teva terminates the Collaboration Agreement for any
reasons other than an adverse change in custirsen patent rights, safety issues or &#147;futility&#148;
determination as previously described, it will remain responsible for paying for any remaining
costs of all three phase 3 clinical trials, except for specified development expenses that are the
responsibility of the Company. Either party may terminate the Collaboration Agreement for an
uncured material breach by the other party or upon the bankruptcy of either party. If the
Collaboration Agreement is terminated by the Company for other than an uncured material breach by
Teva, the Company will pay Teva a royalty on sales of Licensed Products. The percentage rates of
such royalties (which are in the single digits) vary depending on whether termination occurs prior
to the first regulatory approval in the United States or a primary European Market or after one of
these approvals. These royalties would expire on a country-by-country basis on the earlier of ten
years after the first commercial sale of a Licensed Product or certain thresholds related to
generic competition.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In the event of a change of control of the Company, within 90&nbsp;days of the change of control, Teva
may terminate the joint steering committee at its sole discretion, terminate the co-promotion
option at its sole discretion if not then exercised by the Company or if exercised but not yet
executed by the Company, or terminate the co-promotion option if in its commercially reasonable
opinion co-promotion with the Company&#146;s successor would be materially detrimental to Teva&#146;s
interests.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Upon entering into the Collaboration Agreement, the Company assessed whether withholdings taxes
were owed to the Israeli Tax Authority, or ITA, resulting from the Collaboration Agreement. It was
the Company&#146;s position that withholdings taxes were not owed, and a claim was issued to the ITA
accordingly. For accounting purposes, management concluded that the withholdings tax claim was an
uncertain tax position, and $3&nbsp;million, which represented the potential withholdings tax
obligation, once received from Teva was initially recorded as restricted cash pending the ITA
review of our claim and a corresponding liability of $3&nbsp;million was included in accounts payable
and accrued liabilities. In June&nbsp;2010, the Company received approval from the ITA for our request
for a withholdings tax exemption on amounts received from Teva in relation to the Collaboration
Agreement. Following receipt of this approval from the ITA the $3&nbsp;million was released to the
Company from escrow. Subsequently, the Company released the $3&nbsp;million liability and recorded a $3
million income tax recovery in the second quarter of 2010.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Revenue for the three and six months ended June&nbsp;30, 2011 was $1.9&nbsp;million, and $3.1&nbsp;million which
consists of partial recognition of deferred collaboration revenue representing OncoGenex&#146;s
contribution to the custirsen phase 3 development plan under our Collaboration Agreement with Teva
and custirsen manufacturing costs incurred by OncoGenex in the year ended December&nbsp;31, 2010 that
are reimbursable from Teva. At June&nbsp;30, 2011, a remaining balance of $19.9&nbsp;million of the up-front
payment was recorded in deferred collaboration revenue. There was $1.7&nbsp;million and $6.4&nbsp;million in
revenue recorded in the three and six months ended June&nbsp;30, 2010 as a result of the Collaboration
Agreement with Teva.
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>4. FAIR VALUE MEASUREMENTS</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">With the adoption of Accounting Standards Codification, or ASC, 820 &#147;Fair Value Measurements and
Disclosures&#148;, beginning January&nbsp;1, 2008, assets and liabilities recorded at fair value in the
balance sheets are categorized based upon the level of judgment associated with the inputs used to
measure their fair value. For certain of the Company&#146;s financial instruments including cash and
cash equivalents, amounts receivable, and accounts payable the carrying values approximate fair
value due to their short-term nature.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those
valuation techniques are observable or unobservable. In accordance with ASC 820, these inputs are
summarized in the three broad levels listed below:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Level 1 &#151; Quoted prices in active markets for identical securities;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Level 2 &#151; Other significant observable inputs that are observable through
corroboration with market data (including quoted prices in active markets for similar
securities); and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Level 3 &#151; Significant unobservable inputs that reflect management&#146;s best estimate of
what market participants would use in pricing the asset or liability.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As quoted prices in active markets are not readily available for certain financial instruments, the
Company obtains estimates for the fair value of financial instruments through third party pricing
service providers.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In determining the appropriate levels, the Company performed a detailed analysis of the assets and
liabilities that are subject to ASC 820.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Company invests its excess cash in accordance with investment guidelines that limit the credit
exposure to any one financial institution other than securities issued by the U.S. Government. Our
securities are not collateralized and mature within one year.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">A description of the valuation techniques applied to the Company&#146;s financial instruments measured
at fair value on a recurring basis follows.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Financial Instruments</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Cash</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Significant amounts of cash are held on deposit with a large well established Canadian financial
institution.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Government and Agency Securities</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U>Government Securities</U> U.S. and Canadian Government securities are valued using quoted
market prices. Valuation adjustments are not applied. Accordingly, U.S. and Canadian government
securities are categorized in Level 1 of the fair value hierarchy.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U>U.S. Agency Securities</U> U.S. agency securities are comprised of two main categories
consisting of callable and non-callable agency-issued debt securities. Non-callable agency-issued
debt securities are generally valued using quoted market prices. Callable agency issued debt
securities are valued by benchmarking model-derived prices to quoted market prices and trade data
for identical or comparable securities. Actively traded non-callable agency issued debt securities
are categorized in Level 1 of the fair value hierarchy. Callable agency issued debt securities are
categorized in Level 2 of the fair value hierarchy.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Corporate and Other Debt</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U>Corporate Bonds and Commercial Paper</U> The fair value of corporate bonds and commercial
paper is estimated using recently executed transactions, market price quotations (where
observable), bond spreads or credit default swap spreads adjusted for any basis difference between
cash and derivative instruments. The spread data used are for the same maturity as the bond. If the
spread data does not reference the issuer, then data that reference a comparable issuer are used.
When observable price quotations are not available, fair value is determined based on cash flow
models with yield curves, bond or single name credit default swap spreads and recovery rates based
on collateral values as significant inputs. Corporate bonds and commercial paper are generally
categorized in Level 2 of the fair value hierarchy; in instances where prices, spreads or any of
the other aforementioned key inputs are unobservable, they are categorized in Level 3 of the
hierarchy.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The following table presents information about our assets and liabilities that are measured at fair
value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we
utilized to determine such fair value:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">(in thousands)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Level 1</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Level 2</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Level 3</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Assets</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,824</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,824</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Money market securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">7,830</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">7,830</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Government securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Corporate bonds and commercial paper</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">60,260</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">60,260</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>15,654</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>60,260</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>75,914</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Liabilities</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right">14,828</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right">14,828</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Marketable securities consist of the following:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Gross</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Gross</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amortized</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Unrealized</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Unrealized</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Estimated</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">(in thousands)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Cost</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Gain</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Loss</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Fair Value</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>2011</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,824</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,824</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Money market
securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">7,329</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">7,329</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Government securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,998</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Corporate bonds and
commercial paper</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,715</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(1</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,723</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash and cash
equivalents</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>20,866</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>11</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B>$</B></TD>
    <TD align="right"><B>(1</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>20,876</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Money market
securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">502</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">502</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Restricted cash</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>502</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>&#151;</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>&#151;</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>502</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Corporate bonds and
commercial paper</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">54,578</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(45</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">54,536</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Short-term
investments</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right"><B>54,578</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right"><B>3</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B>$</B></TD>
    <TD align="right"><B>(45</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right"><B>54,536</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">All securities included in cash, and cash equivalents have maturities of 90&nbsp;days or less at the
time of purchase. All securities included in short-term investments have maturities of within one
year of the balance sheet date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">There were no significant realized or unrealized gains or losses on the sales of marketable
securities in the six months ended June&nbsp;30, 2011 and no significant unrealized gains or losses are
included in accumulated other comprehensive income as at June&nbsp;30, 2011. Realized gains and losses
are transferred out of accumulated other comprehensive income into interest income using the
specific identification method.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">All of the marketable securities held as of June&nbsp;30, 2011 had maturities of one year or less. The
Company only invests in A (or equivalent) rated securities with maturities of one year or less.
Given the quality of the investment portfolio, its short-term nature, and subsequent proceeds
collected on sale of securities that
reached maturity, the Company does not believe that there are any other than temporary impairments
related to its investments in marketable securities at June&nbsp;30, 2011.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Company has recorded a $14,828,000 warrant liability as of June&nbsp;30, 2011. The Company
reassesses the fair value of the common stock warrants at each reporting date utilizing a
Black-Scholes pricing model. Inputs used in the pricing model include estimates of stock price
volatility, expected warrant life and risk-free interest rate. The computation of expected
volatility was based on the historical volatility of comparable companies from a representative
peer group selected based on industry and market capitalization. See note 5(d) in the Notes to
Financial Statements for further details on the inputs used in the Black-Scholes pricing model used
to recalculate the warrant liability.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The following table presents the changes in fair value of the Company&#146;s total Level 3 financial
liabilities for the six months ended June&nbsp;30, 2011:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="58%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Liability at</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Remaining</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Gain (loss) on</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Liability at June</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>(In thousands)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>warrants</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B> 30, 2011</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Warrant liability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">15,269</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">441</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">14,828</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>5. COMMON STOCK</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>&#091;a&#093; Authorized</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">25,000,000 authorized common shares, par value of $0.001, and 5,000,000 preferred shares, par value
of $0.001.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>&#091;b&#093; Issued and Outstanding Shares</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">During the six month period ended June&nbsp;30, 2011 the Company issued 24,660 common shares upon
exercise of stock options (period ended June&nbsp;30, 2010 &#151; 117,643) to satisfy stock option
exercises.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>&#091;c&#093; Stock options</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>2010 Performance Incentive Plan</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">At the 2011 Annual Meeting of Stockholders of the Company held on May&nbsp;26, 2011, stockholders of the
Company approved an amendment to the Company&#146;s 2010 Performance Incentive Plan. As a result of this
amendment, the 2010 Plan was amended to provide for an increase in the total shares of common stock
available for issuance under the 2010 Plan from 450,000 to 1,050,000. As at June&nbsp;30, 2011 the
Company has reserved, pursuant to various plans, 1,598,075 common shares for issuance upon exercise
of stock options by employees, directors, officers and consultants of the Company, of which 777,359
are reserved for options currently outstanding, and 820,716 are available for future option grants.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Stock Option Summary</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Options vest in accordance with terms as determined by the board of directors of the Company, or
the Board, typically over four years for employee grants and one to three years for Board option
grants. The expiry date for each option is set by the Board, which is typically seven to ten years.
The exercise price of the options is determined by the Board but generally will be at least equal
to the fair value of the share at the grant date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Stock option transactions and the number of stock options outstanding are summarized below:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Number <BR>
of</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Weighted</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Optioned</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Average</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Common</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Exercise</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Price</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>#</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Balance, December&nbsp;31, 2010</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>744,913</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>8.73</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Option grants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75,900</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17.03</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Option expirations/cancellations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,112</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13.86</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Option exercises</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(24,660</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.67</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Option forfeitures</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(12,682</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12.66</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Balance, June&nbsp;30, 2011</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>777,359</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>9.59</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The fair value of each stock award is estimated on the grant date using the Black-Scholes
option-pricing model based on the weighted-average assumptions noted in the following table:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Six months ended June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Risk-free interest rates</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">2.39</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">2.41</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected dividend yield</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">0</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">0</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected life</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" nowrap align="right">6 years</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" nowrap align="right">6 years</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected volatility</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">75</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">74</TD>
    <TD nowrap>%</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The expected life was calculated based on the simplified method as permitted by the SEC&#146;s Staff
Accounting Bulletin 110, Share-Based Payment. The computation of expected volatility was based on
the historical volatility of comparable companies from a representative peer group selected based
on industry and market capitalization. The Company considers the use of these methods of
calculating expected term and volatility appropriate because of the lack of sufficient historical
exercise data following the reverse takeover of Sonus. The risk-free interest rate was based on a
U.S. Treasury instrument whose term is consistent with the expected life of the stock options. In
addition to the assumptions above, as required under ASC 718, management made an estimate of
expected forfeitures and is recognizing compensation costs only for those equity awards expected to
vest.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The results for the periods set forth below included share-based compensation expense in the
following expense categories of the consolidated statements of loss:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six Months</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">(In thousands)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">122</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">243</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">142</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">161</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">70</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">311</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">169</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total share-based compensation</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>283</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>144</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>554</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>311</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Options vest in accordance with terms as determined by the Board, typically over three or four
years for employee grants and over one or three years for Board of Director option grants. The
expiry date for each option is set by the Board with, which is typically seven to ten years.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As at June&nbsp;30, 2011 and December&nbsp;31, 2010 the total unrecognized compensation expense related to
stock options granted is $3,176,000 and $2,962,000 respectively, which is expected to be recognized
into expense over a period of approximately four years.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As of June&nbsp;30, 2011 and December&nbsp;31, 2010 a total of 2,364,660 and 2,332,214 options and warrants,
respectively, have not been included in the calculation of potential common shares as their effect
on diluted per share amounts would have been anti-dilutive.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>&#091;d&#093; Stock Warrants</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">At June&nbsp;30, 2011, there were exercisable warrants outstanding to purchase 1,587,301
shares of common stock at an exercise price of $20 per share, expiring in October&nbsp;2015.
No warrants were exercised during the six months ended June&nbsp;30, 2011 or six months ended
June&nbsp;30, 2010.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The estimated fair value of warrants issued is reassessed at each balance sheet date
using the Black-Scholes option pricing model. The following assumptions were used to
value the warrants on the following balance sheet dates:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Six months ended June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Risk-free interest rates</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1.43</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected dividend yield</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">0</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected life</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="2" nowrap align="right">4.3 years</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected volatility</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">76</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>6. RESTRUCTURING ACTIVITIES</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">On August&nbsp;21, 2008, Sonus Pharmaceuticals, Inc., or Sonus, completed a transaction, or &#147;the
Arrangement&#148;, with OncoGenex Technologies whereby Sonus acquired all of the outstanding preferred
shares, common shares and convertible debentures of OncoGenex Technologies. Sonus then changed its
name to OncoGenex Pharmaceuticals, Inc. Prior to the Arrangement, Sonus entered into a
non-cancellable lease arrangement for office space located in Bothell, Washington, which is
considered to be in excess of the Company&#146;s current requirements. The Company is currently in the
process of evaluating opportunities to exit or sublet portions of the leased space and recorded an
initial restructuring charge of $2,084,000 on August&nbsp;21, 2008 as part of the purchase price
allocation. The liability is computed as the present value of the difference between the remaining
lease payments due less the estimate of net sublease income and expenses and has been accounted for
in accordance with the then effective EITF No.&nbsp;95-3, &#147;Recognition of Liabilities in Connection with
a Purchase Business Combination&#148;. This represents the Company&#146;s best estimate of the liability.
Subsequent changes in the liability due to changes in estimates of sublease assumptions are
recognized as adjustments to restructuring charges.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In June&nbsp;2009, the Company revised its sublease income assumptions used to estimate the excess lease
facility liability. These assumptions were subsequently revised again in December&nbsp;2009 and
September
2010. These changes in estimate resulted in increases in the value of the excess lease liability of
$494,000, $3,457,000, and $4,038,000 and a corresponding expense recorded in June&nbsp;2009, December
2009, and September&nbsp;2010, respectively, to reflect these changes in estimate. The estimated value
of the liability remaining with respect to excess facilities was $7,467,000 as of December&nbsp;31,
2010. In the six months ended June&nbsp;30, 2011, with respect to excess facilities, $140,000 was
amortized into income resulting in a remaining liability of $7,327,000 at June&nbsp;30, 2011.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Remaining</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amortization</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Additional</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Remaining</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Liability at</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>of excess</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Liability</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Liability</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>(In thousands)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>December 31, 2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>lease facility</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Recorded</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>at June 30, 2011</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current portion of
excess lease
facility</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,303</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(53</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,356</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Long-term portion
of excess lease
facility</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6,164</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">193</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,971</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>7,467</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>140</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>&#151;</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right"><B>7,327</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>7. COMMITMENTS AND CONTINGENCIES</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Teva Pharmaceutical Industries Ltd.</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Under the Collaboration Agreement, Teva made upfront payments in the aggregate amount of $50
million, may make up to $370&nbsp;million in additional payments upon the achievement of developmental
and commercial milestones and may be required in the future to pay royalties at percentage rates
ranging from the mid-teens to mid-twenties on net sales. The Company is required to contribute $30
million in direct and indirect costs towards the Clinical Development Plan. As of June&nbsp;30, 2011,
$10.1&nbsp;million of these costs have been incurred by OncoGenex, resulting in a remaining funding
responsibility of $19.9&nbsp;million which has been recorded under Current and Long-term Deferred
Collaboration Revenue as of June&nbsp;30, 2011. Teva will fund all other expenses under the Clinical
Development Plan. See note 3 in the Notes to Financial Statements for further details on our
Collaboration Agreement with Teva.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Isis Pharmaceuticals Inc. and University of British Columbia</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">To facilitate the execution and performance of the Collaboration Agreement with Teva, OncoGenex and
Isis agreed to amend the Isis License Agreement and the Company and UBC agreed to amend the UBC
License Agreement, in each case, effective December&nbsp;19 and December&nbsp;20, 2009, respectively.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The amendment to the Isis License Agreement provides, among other things, that if the Company is
the subject of a change of control with a third party, where the surviving company immediately
following such change of control has the right to develop and sell the product, then (i)&nbsp;a
milestone payment of $20&nbsp;million will be due and payable to Isis 21&nbsp;days following the first
commercial sale of the product in the United States; and (ii)&nbsp;unless such surviving entity had
previously sublicensed the product and a royalty rate payable to Isis by the Company has been
established, the applicable royalty rate payable to Isis will thereafter be the maximum amount
payable under the Isis License Agreement. Any non-royalty milestone amounts previously paid will be
credited toward the $20&nbsp;million milestone if not already paid. As a result of the $10&nbsp;million
milestone payment payable to Isis in relation to the Collaboration Agreement, the remaining amount
owing in the event of change of control discussed above is a maximum of $10&nbsp;million. As the Company
has now licensed the product to Teva and established a royalty rate payable to Isis, no royalty
rate adjustments would apply if Teva acquires the Company and is the surviving company. If the $30
million in advanced reimbursement of development activities has not been spent by OncoGenex prior
to the third anniversary of the Collaboration Agreement between OncoGenex and Teva, OncoGenex will
pay Isis an amount equal to 30% of any un-spent portion less $3.5&nbsp;million.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In addition, we are required to pay to Isis 30% of all Non-Royalty Revenue we receive on custirsen
sales. Isis has disclosed in its SEC filings that it is entitled to receive 30% of the up to $370
million in milestone payments we may receive from Teva as part of the Collaboration Agreement;
however, we believe that certain of the milestone payments related to sales targets may qualify as
Royalty Revenue, and therefore be subject to the lesser payment obligations. No assurance can be
provided that we will be entitled to receive these milestone payments or, if we are, that the
applicable amount payable to Isis will be less than 30%.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Pursuant to license agreements the Company has with the UBC and Isis, the Company is obligated to
pay milestone payments of up to CAD $1.6&nbsp;million and $7.75&nbsp;million, respectively, upon the
achievement of specified product development milestones related to OGX-427 and OGX-225 and
royalties on future product sales. We paid Isis and UBC $750,000 and CAD $100,000, respectively, in
2010 upon the initiation of a phase 2 clinical trial of OGX-427 in patients with CRPC. We do not
anticipate making any royalty payments to Isis in 2011.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Unless otherwise terminated, the Isis agreements for custirsen and OGX-427 will continue for each
product until the later of 10&nbsp;years after the date of the first commercial product sale, or the
expiration of the last to expire of any patents required to be licensed in order to use or sell the
product, unless OncoGenex Technologies abandons either custirsen or OGX-427 and Isis does not elect
to unilaterally continue development. The Isis agreement for OGX-225 will continue into perpetuity
unless OncoGenex Technologies abandons the product and Isis does not elect to unilaterally continue
development.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We are also obligated to pay to UBC certain patent costs and annual license maintenance fees for
the extent of the patent life of CAD $8,000 per year relating to custirsen, OGX-427 and OGX-225.
The UBC agreements have effective dates ranging from November&nbsp;1, 2001 to April&nbsp;5, 2005 and each
agreement expires upon the later of 20&nbsp;years from its effective date or the expiry of the last
patent licensed thereunder, unless otherwise terminated.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Bayer HealthCare LLC</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">On August&nbsp;7, 2008, Sonus completed an exclusive in-licensing agreement with Bayer HealthCare LLC,
or Bayer, for the right to develop, commercialize or sublicense a family of compounds known as
caspase activators presently in pre-clinical research. Under terms of the agreement, Sonus was
granted exclusive rights to develop two core compounds for all prophylactic and therapeutic uses in
humans. Additionally, Sonus was granted rights to all other non-core compounds covered under the
patents for use in oncology.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Under the terms of the agreement, Bayer received an upfront license fee of $450,000. OncoGenex will
make annual payments to Bayer on the anniversary date (Anniversary Payments), with an initial
payment of $100,000 paid in 2008. The payments increase by $25,000 each year until the initiation
of the first phase 3 clinical trial, at which point the Anniversary Payments reset to $100,000 each
year and increase by $25,000 until the Company achieves either the first New Drug Application, or
NDA, filing in the United States or the European Union. OncoGenex is obligated to pay royalties on
net future product sales in addition to aggregate milestone payments of up to $14,000,000 for
clinical development and regulatory milestones. No milestone payments are triggered prior to the
initiation of a phase 3 clinical trial. OncoGenex has the option to terminate this contract upon 60
days written notice to Bayer.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Lease Arrangements</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Company has an operating lease agreement for office space in Vancouver, Canada, which expires
in September&nbsp;2014.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Future minimum annual lease payments under the Vancouver lease are as follows (in thousands):
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="86%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">CAD</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right">53</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2012</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">107</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2013</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">107</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2014</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">80</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>347</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In November&nbsp;2006, prior to the Arrangement , Sonus entered into a non-cancellable operating
lease agreement for office space in Bothell, Washington, expiring in 2017 (note 6). In connection
with the lease, Sonus was required to provide a cash security deposit of approximately $497,000,
which is included in Other Long Term Assets. In addition, a standby letter of credit was issued in
2010, and $502,000 was deposited in a restricted money market account as collateral. The Company is
currently in the process of evaluating opportunities to exit or sublet portions of the leased space
and has recorded a liability in the excess facilities lease charge of $7,327,000 as at June&nbsp;30,
2011 (note 6).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If the Company is unable to exit or sublet portions of this leased space, the future minimum annual
lease payments are as follows (in thousands):
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="86%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,027</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2012</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,117</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2013</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,180</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2014</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,246</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2015</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,313</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Remainder</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,837</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>14,720</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Consolidated rent expense relating to both the Vancouver, Canada and Bothell, Washington
offices for the periods ended June&nbsp;30, 2011 and 2010 was $1,313,000 and $1,092,000 respectively.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Guarantees and Indemnifications</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">OncoGenex indemnifies its officers and directors for certain events or occurrences, subject to
certain limits, while the officer or director is or was serving at our request in such capacity.
The term of the indemnification period is equal to the officer&#146;s or director&#146;s lifetime.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The maximum amount of potential future indemnification is unlimited; however, we have obtained
director and officer insurance that limits our exposure and may enable it to recover a portion of
any future amounts paid. We believe that the fair value of these indemnification obligations is
minimal. Accordingly, we have not recognized any liabilities relating to these obligations as of
June&nbsp;30, 2011.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We have certain agreements with certain organizations with which we do business that contain
indemnification provisions pursuant to which we typically agree to indemnify the party against
certain types of third-party claims. We accrue for known indemnification issues when a loss is
probable and can be reasonably estimated. There were no accruals for or expenses related to
indemnification issues for any period presented.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>8. COMPREHENSIVE LOSS</B>
</DIV>

<!-- xbrl,body -->
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six Months</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">(In thousands)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss (income)&nbsp;for the period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,530</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(154</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,575</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,890</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Unrealized gain on cash
equivalents and marketable
securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(14</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(14</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Unrealized loss on cash
equivalents and short-term
investments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Comprehensive loss (income)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,562</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(154</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,607</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,890</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>9. SUBSEQUENT EVENTS</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Company has performed an evaluation of events occurring subsequent to June&nbsp;30, 2011. Based on
our evaluation, no material events have occurred requiring financial statement disclosure.
</DIV>

<!-- /xbrl,ns -->




<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="left">
<A name="C20581107"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;2.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>INFORMATION REGARDING FORWARD LOOKING STATEMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">This document contains &#147;forward-looking statements&#148; within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and
uncertainties. We caution readers that any forward-looking statement is not a guarantee of future
performance and that actual results could differ materially from those contained in the
forward-looking statement. These statements are based on current expectations of future events.
Such statements include, but are not limited to, statements about future financial and operating
results, plans, objectives, expectations and intentions, costs and expenses, interest rates,
outcome of contingencies, financial condition, results of operations, liquidity, business
strategies, cost savings, objectives of management and other statements that are not historical
facts. You can find many of these statements by looking for words like &#147;believes,&#148; &#147;expects,&#148;
&#147;anticipates,&#148; &#147;estimates,&#148; &#147;may,&#148; &#147;should,&#148; &#147;will,&#148; &#147;could,&#148; &#147;plan,&#148; &#147;intend,&#148; or similar
expressions in this document or in documents incorporated by reference into this document . We
intend that such forward-looking statements be subject to the safe harbors created thereby.
Examples of these forward-looking statements include, but are not limited to:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>progress and preliminary and future results of clinical trials conducted by us or our
collaborators;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>anticipated regulatory filings, requirements and future clinical trials conducted by us
or our collaborators;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our anticipated future capital requirements and the terms of any capital financing
agreements;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>timing and amount of future contractual payments, product revenue and operating
expenses;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>market acceptance of our products and the estimated potential size of these markets;
and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our anticipated future capital requirements and the terms of any capital financing
agreements.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">These forward-looking statements are based on the current beliefs and expectations of our
management and are subject to significant risks and uncertainties. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results may differ materially from
current expectations and projections. The following factors, among others, could cause actual
results to differ from those set forth in the forward-looking statements:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>uncertainty relating to the timing, feasibility and results of clinical trials;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>dependence on Teva&#146;s ongoing commitment and ability to develop and commercialize
custirsen;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>dependence on the development and commercialization of our product candidates,
particularly on custirsen;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the risk that research or previous clinical trial results may not be indicative of
results in humans or in future studies;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>uncertainties regarding the safety and effectiveness of our product candidates and
technologies;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the timing, expense and uncertainty associated with the development and regulatory
approval process for our product candidates;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>uncertainties regarding our future operating results, and the risk that our product
candidates will not obtain the requisite regulatory approvals to commercialize or that the
future sales of our product candidates may be less than expected or nil;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>future capital requirements and uncertainty of obtaining additional funding through
debt or equity financings on terms acceptable to us;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>acceptance of our products by the medical community;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the uncertainty associated with exiting or subleasing our excess office and laboratory
space;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to build out our product candidate pipeline through product in-licensing,
acquisition activities, or otherwise;</TD>
</TR>


</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changes in the treatment landscape, general competitive conditions within the drug
development and pharmaceutical industry and new developments or therapies that may not
work in combination with our product candidates;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the potential for product liability issues and related litigation;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our dependence on key employees;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>proper management of our operations;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the potential inability to successfully protect and enforce our intellectual property
rights;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the reliance on third parties who license intellectual property rights to us to comply
with the terms of such agreements and to enforce, prosecute and defend such intellectual
property rights;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the reliance on third parties to manufacture and supply our product candidates;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the effect of current, pending or future legislation, regulations and legal actions in
the United States, Canada and elsewhere affecting the pharmaceutical and healthcare
industries;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>volatility in the value of our common stock; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>general economic conditions.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">You are cautioned not to place undue reliance on these forward-looking statements, which speak only
as of the date of this document or, in the case of documents referred to or incorporated by
reference, the date of those documents.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">All subsequent written or oral forward-looking statements attributable to us or any person acting
on our behalf are expressly qualified in their entirety by the cautionary statements contained or
referred to in this section. We do not undertake any obligation to release publicly any revisions
to these forward-looking statements to reflect events or circumstances after the date of this
document or to reflect the occurrence of unanticipated events, except as may be required under
applicable U.S. securities law. If we do update one or more forward-looking statements, no
inference should be drawn that we will make additional updates with respect to those or other
forward-looking statements.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>MD&#038;A Overview</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations, we
explain the general financial condition and the results of operations for our Company, including:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an overview of our business;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>results of operations and why those results are different from the prior year; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>capital resources we currently have and possible sources of additional funding for
future capital requirements.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Overview of the Company</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">OncoGenex is a biopharmaceutical company committed to the development and commercialization of new
cancer therapies that address treatment resistance in cancer patients. We have four product
candidates in our pipeline, custirsen, OGX-427, OGX-225, and CSP-9222, each of which has a distinct
mechanism of action and represents a unique opportunity for cancer drug development. Of the product
candidates in our pipeline, custirsen, and OGX-427 are clinical-stage assets.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our product candidates custirsen, OGX-427 and OGX-225 focus on mechanisms for treating resistance
in cancer patients and are designed to address treatment resistance by blocking the production of
specific proteins that we believe promote survival of tumor cells and are over-produced in response
to a variety of cancer treatments. Our aim in targeting these particular proteins is to disable the
tumor cell&#146;s adaptive defenses, thereby rendering the tumor cells more susceptible to attack with a
variety of cancer therapies, including chemotherapy. We believe this approach will increase
survival time and improve the quality of life for cancer patients. Product candidate CSP-9222 is
the lead compound from a family of caspase
activators that have been in-licensed from Bayer and demonstrate activation of programmed cell
death in pre-clinical models.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">






<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Product Candidate Custirsen</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As discussed above, in December&nbsp;2009, we announced our entry into the Collaboration Agreement with
Teva for the development and global commercialization of custirsen (and related compounds targeting
clusterin, excluding OGX-427 and OGX-225).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Teva and the Company have developed a Clinical Development Plan under which two phase 3 clinical
trials have been initiated and one additional phase 3 clinical trial is planned to be initiated:
</DIV>



<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>
The ongoing phase 3 clinical trial, referred to as the Synergy trial, or SYNERGY, to evaluate a survival benefit for
custirsen in combination with first-line docetaxel treatment in patients with castrate resistant prostate cancer, or CRPC.
Expected timing of results from the survival primary endpoint for the custirsen SYNERGY Phase 3 clinical trial remains
unchanged at Q4 2013. During discussions regarding the Prostate Cancer SATURN trial, or SATURN, Special Protocol
Assessment, or SPA, amendment, U.S. Food and Drug Administration, or FDA, stated that an application supported primarily
by the results of SYNERGY alone would be acceptable for submission.
We expect to enroll at least 800 patients in SYNERGY.
</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>
An ongoing phase 3 clinical trial, referred to as SATURN, to evaluate a durable pain palliation benefit for
custirsen in combination with docetaxel as second-line chemotherapy in approximately 300 patients with CRPC. We have
revised the custirsen SATURN Phase 3 trial protocol to expand the eligible patient population, and to align with the
recently approved chemotherapy, cabazitaxel. We are awaiting final, written FDA agreement on the SPA amendment that will
allow patients to receive either docetaxel re-treatment or cabazitaxel as second-line chemotherapy. Recruitment efforts
are ongoing to enroll more patients in the SATURN study, which has had few patients accrued due to restrictive enrollment
criteria regarding docetaxel retreatment and stable pain criteria. Expected timing of results for the pain palliation
primary endpoint is now projected to be Q4 2013 rather than Q2 2013.
</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>
A phase 3 clinical trial to evaluate a survival benefit for custirsen in combination with first-line chemotherapy in
patients with non-small cell lung cancer, or NSCLC. The initiation of the Phase 3 clinical trial evaluating custirsen
in patients with NSCLC has been delayed as we determine the optimal
chemotherapeutic combination based on safety considerations and the
current and evolving standard of care. We believe NSCLC is
a promising indication and remain committed to the advancement of custirsen in NSCLC.
</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">For detailed information regarding our relationship with Teva and the Collaboration Agreement,
refer to the discussion under the heading &#147;Business&#151;License and Collaboration Agreements&#151;Teva
Pharmaceutical Industries Ltd.&#148; included in our 2010 Annual Report on Form 10-K filed on March&nbsp;10,
2011.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Custirsen received Fast Track designations from the FDA for the treatment of progressive metastatic
prostate cancer in combination with docetaxel for both first- and second-line docetaxel treatment.
The FDA has agreed on the design of two phase 3 registration trials, each in CRPC, via the special
protocol assessment, or SPA, process. OncoGenex has submitted to the FDA a revision to the approved
SPA for the SATURN trial. The proposed revision would permit participants to receive either
docetaxel re-treatment or cabazitaxel as chemotherapy in the clinical study. The study design would
otherwise remain unchanged and all patients would be randomized to receive custirsen or placebo in
conjunction with chemotherapy. In addition, the pain palliation endpoints remain unchanged. The
SYNERGY trial design investigates overall survival as the primary endpoint for custirsen in
combination with first-line chemotherapy, whereas the SATURN trial investigates pain palliation as
the primary endpoint for custirsen in combination with second-line chemotherapy.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We have also received written, scientific advice from the European Medicines Agency, or EMA,
on our development plan for custirsen for treating patients with CRPC in combination with
docetaxel, which advice corresponded with our development plan regarding the proposed pre-clinical
studies and both the
study designs and analyses for the phase 3 trials. In addition, the Committee for Medicinal
Products for Human Use, or CHMP, agreed that the intended safety database would enable a sufficient
qualified risk-benefit assessment for market approval.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our phase 3 registration trials are designed to build on our phase 2 clinical trials, including:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A randomized phase 2 trial evaluating the benefit of combining custirsen with
first-line docetaxel, the final results of which were published in the September&nbsp;20, 2010
issue of the Journal of Clinical Oncology. Analyses indicating a survival benefit in
patients treated with custirsen in combination with first-line docetaxel compared to
docetaxel alone, the latter being the current standard of care for patients with advanced,
progressive metastatic prostate cancer requiring initial chemotherapy, are described in
our 2010 Annual Report on Form 10-K filed on March&nbsp;10, 2011 under the heading
&#147;Business&#151;Our Product Candidates&#151;Custirsen&#151; Summary of Final Results of Custirsen Phase
2 Clinical Trial in Patients With CRPC Receiving Custirsen and Docetaxel as First-Line
Chemotherapy.&#148; Due to the results of the phase 2 trial, the SYNERGY trial will evaluate
the survival benefit of custirsen in patients treated with first-line chemotherapy.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Durable pain palliation, defined as pain palliation of 12&nbsp;weeks or greater, which has
been observed in another phase 2 trial evaluating patients with metastatic CRPC who
progressed while receiving, or within six months of completing, first-line docetaxel
treatment. Of the patients on this trial who had pain or were on opioids for pain control
and were retreated with docetaxel as second-line treatment in combination with custirsen,
approximately 50% had durable pain palliation. This is favorable even when compared to the
35% pain responses of three weeks or greater observed in the phase 3 trial, which
supported the registration of docetaxel as first-line chemotherapy in patients with CRPC,
and when compared to the pain responses for cabazitaxel of 9.2% and for mitoxantrone of
7.7% observed in the Phase 3 TROPIC trial. As of August&nbsp;13, 2010, the estimated median
over survival duration for the custirsen plus mitoxantrone arm was 11.5&nbsp;months for the
custirsen plus docetaxel re-treatment arm, the median overall survival was estimated at
15.8&nbsp;months for the 20 randomized patients and 12.8&nbsp;months for the 45 combined patients
which included 25 additional patients with high serum clusterin levels at enrolment beyond
the 20 randomized patients. Due to the results of our phase 2 trial, the SATURN trial is
evaluating the durable pain palliation benefit of custirsen in patients treated with
cabazitaxel or docetaxel as second-line chemotherapy, pending FDA approval of the former.
We expect the SATURN trial will enroll patients who have previously responded to
first-line docetaxel therapy, but who subsequently experienced disease progression
involving prostate cancer-related pain despite opioid usage.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A phase 2 trial evaluating 81 patients with advanced NSCLC who received custirsen in
combination with gemcitabine and a platinum chemotherapy (cisplatin or carboplatin) as
first-line chemotherapy. The median overall survival was 14.1&nbsp;months and 54% of patients
survived at least one year. Thirty percent of patients who received custirsen with
first-line chemotherapy survived at least two years. For comparison, published studies
using a platinum-based regimen plus gemcitabine as first-line chemotherapy for advanced
NSCLC reported median survivals of 8 to 11&nbsp;months and one-year survival rates of 33% to
43%. Market approval for Avastin plus paclitaxel and carboplatin chemotherapy for NSCLC
was based on results showing a median survival of 12.3&nbsp;months compared to 10.3&nbsp;months for
patients treated with chemotherapy alone. Survival rates for Avastin plus chemotherapy
versus chemotherapy alone were reported as 51% versus 44% at one year and 23% versus 15%
at two years, respectively. The protocol for the custirsen phase 3 registration trial in
advanced, unresectable NSCLC has yet to be finalized. Recent non-clinical studies and
drug-to-drug interaction studies have given conflicting results regarding the effect of
custirsen on the enzymes which break down paclitaxe1, one of the chemotherapeutic agents
intended for use in this trial. Based on the above, both OncoGenex and Teva believe it is
unlikely that a Phase 3 trial will be initiated in 2011.</TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Product Candidate OGX-427</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">OGX-427 is a product candidate that, in pre-clinical experiments, inhibits production of Hsp27, a
cell survival protein found at elevated levels in many human cancers, including prostate, lung,
breast, ovarian, bladder, renal, pancreatic, multiple myeloma and liver cancer. Many anti-cancer
therapies are known to further elevate Hsp27 levels. For example, Hsp27 levels increased four-fold
in prostate cancer patients after treatment with chemotherapy or hormone therapy. Increased levels
of Hsp27 in some human cancers are associated with metastases, poor prognosis and resistance to
radiation or chemotherapy.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">OGX-427 has been evaluated in a phase 1 trial in patients with breast, prostate, ovarian, or NSCLC
who have failed potentially curative treatments or for which a curative treatment does not exist.
Final results of this phase 1 trial were presented during an oral presentation at the American
Society of Clinical Oncology, or ASCO, 2010 annual meeting. The phase 1 trial evaluated 36 patients
treated with OGX-427 as a single agent and 12 patients with OGX-427 in combination with docetaxel
who had failed up to six prior chemotherapy treatments. OGX-427 as a single agent administered
weekly was evaluated at doses from 200 mg up to 1000 mg in five cohorts of approximately six
patients in each cohort. Two further cohorts tested OGX-427 at the 800 and 1000 mg doses combined
with docetaxel. Patients could receive up to 10 21-day cycles.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">OGX-427 was well tolerated both as a monotherapy and in combination with docetaxel. Most adverse
events were mild (grade 1 or 2) and mainly occurred during the three &#147;loading doses&#148; given over
nine days prior to weekly dosing. The majority of adverse events potentially related to OGX-427
consisted of grade 1 or 2 fever, chills, itching, or flushing (associated with the infusion of
OGX-427) and fatigue. Despite evaluating OGX-427 at very high doses, a maximum tolerated dose for
OGX-427 was not reached in this trial.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Of particular interest was the decrease at all doses and in all diseases evaluated in the trial for
both total CTCs, and CTCs which were positive for Hsp27, Hsp27(&#043;) CTCs. Recent studies have shown
that the presence of CTCs in peripheral blood may be of prognostic significance for patients with
solid tumors, and patients with values of five tumor cells or less are generally considered to have
a more favorable prognosis.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">When OGX-427 was used as monotherapy, 3 of 17 evaluable patients had a decrease in measurable
disease of 20% or greater. In this heavily pretreated patient population, two of four patients with
ovarian cancer had a decrease of 25% or greater in CA-125 (an ovarian tumor marker) and 3 of 15
patients with prostate cancer had a decrease of 30% or greater in PSA (a prostate tumor marker).
Hsp27&#043;CTCs decreases were noted in 89% of evaluable patients and were observed at all dose levels
and all diseases evaluated. In 9 of 26 (31%) patients with &#8805;5 Hsp27&#043;CTCs at baseline, Hsp27 &#043; CTCs
had decreased to five tumor cells or less. In addition, serum Hsp27 protein levels were decreased
by 30% or greater over a period of at least six weeks in approximately 25% of patients at the 800
and 1000 mg doses.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">When OGX-427 was combined with docetaxel, 5 of 10 patients had a decrease in measurable disease of
20% or greater. Five of nine patients with prostate cancer had a decrease of 30% or greater in PSA.
Again, decreases in both total CTCs and Hsp27(&#043;) CTCs were observed. Hsp27&#043;CTCs were decreased in
71% of evaluable patients. In four of seven patients with &#8805;5 Hsp&#043;CTCs at baseline, Hsp&#043; CTCs had
decreased to five cells or less. Serum Hsp27 protein levels were decreased by 30% or greater over a
time period of at least six weeks in approximately 35% of patients.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">An investigator-sponsored phase 1 clinical trial evaluating OGX-427 when administered directly into
the bladder in patients with bladder cancer was initiated in August&nbsp;2009. The investigators are in
the process of accruing patients for this trial, in which they will enroll up to 36 patients. The
trial is designed to determine the safety and potential benefit of OGX-427 administered directly
into the bladder using a catheter, which is known as intravesical instillation. In addition, the
trial will measure the direct effect of OGX-427 on expression of Hsp27 in bladder tumor cells, as
well as determine the pharmacokinetics and
pharmacodynamics of OGX-427 when delivered by intravesical instillation. This
investigator-sponsored trial is funded by the National Cancer Institute of Canada.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In September&nbsp;2010, we announced the initiation of a separate investigator-sponsored, randomized
phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with CRPC.
The randomized, controlled phase 2 trial will enroll up to 72 patients who have minimally
symptomatic or asymptomatic advanced prostate cancer and who have not yet received chemotherapy,
and is designed to determine the potential benefit of OGX-427 by evaluating the number of patients
who are without disease progression at 12&nbsp;weeks post-trial treatment with or without OGX-427. This
phase 2 trial will also measure the direct effect of OGX-427 on PSA levels, time to progression by
PSA or measurable disease, numbers of CTCs and other relevant secondary endpoints.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We expect to initiate a phase 2 clinical trial of OGX-427 in patients with metastatic bladder
cancer in the second half of 2011. The proposed trial design is a three-arm, randomized phase 2 in
combination with gemcitabine and cisplatin in the first-line metastatic setting. Each arm would
enroll approximately 60 patients and the trial would be initiated in sites throughout the United
States, Canada and Europe. This trial will complement the phase 2 clinical trial in prostate
cancer, and phase 1 clinical trial in superficial bladder cancer.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We are currently evaluating various alternatives, including partnering, which would allow us to
expand the OGX-427 development plan beyond the ongoing bladder cancer and CRPC trials and the
planned randomized phase 2 bladder cancer trial.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Product Candidates OGX-225 and CSP-9222</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">OGX-225, an inhibitor of insulin growth factor binding proteins 2 and 5, and CSP-9222 are in
pre-clinical development.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Collaboration Revenue</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We recorded $3.1&nbsp;million of collaboration revenue in connection with our Collaboration Agreement
with Teva in the six months ended June&nbsp;30, 2011, as compared to $6.4&nbsp;million in the six months
ended June&nbsp;30, 2010. At June&nbsp;30, 2011, an aggregate of $19.9&nbsp;million of the upfront payment was
included in the balance sheet line items Current and Long-term Deferred Collaboration Revenue,
which we are recognizing as we perform our deliverables under the Collaboration Agreement.
Management currently expects this performance period to end in the fourth quarter of 2013. Further,
we are eligible to receive payments of up to $370&nbsp;million upon the achievement of developmental and
commercial milestones. At present, we are unable to predict the timing or likelihood of such
milestone payments, although we do not expect to receive any milestone payments from Teva in the
year ending December&nbsp;31, 2011. Moreover, Isis has disclosed in its Securities and Exchange
Commission, or SEC, filings that it is entitled to receive 30% of the up to $370&nbsp;million in
milestone payments we may receive from Teva as part of the Collaboration Agreement. We disagree
with their assessment but believe there may be some lesser payment obligation. See note 3 in the
Notes to Financial Statements for further details on our collaboration with Teva.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Research and Development Expenses</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Research and development, or R&#038;D, expenses consist primarily of costs for milestone payments to
third parties, clinical trials, materials and supplies, facilities, personnel, including salaries
and benefits, regulatory activities, pre-clinical studies, and allocations of other R&#038;D-related
costs. External R&#038;D expenses include fees paid to universities, hospitals and other entities that
conduct certain R&#038;D activities and that manufacture our product candidates for use in our clinical
trials. Currently, we manage our clinical trials through independent medical investigators at their
sites and at hospitals and expect this practice to continue.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Until July&nbsp;2, 2008, custirsen was being co-developed with Isis and R&#038;D expenses for custirsen were
shared 65% by us and 35% by Isis. On July&nbsp;2, 2008, we and Isis amended the agreement to provide for
unilateral development of custirsen by us. In connection with the Collaboration Agreement and
pursuant to the terms of agreements between us and Isis relating to custirsen, we paid $10&nbsp;million
to Isis in the first quarter of 2010, which was included in R&#038;D expenses in 2009. We also paid
$333,333 to UBC in the first quarter of 2010 pursuant to the terms of the license agreement
relating to custirsen, which was also included in R&#038;D expenses in 2009.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Under the Collaboration Agreement with Teva, we are required to spend $30&nbsp;million towards
development of custirsen, which will include our personnel costs for certain development
activities. Teva will fund all other expenses incurred pursuant to the Clinical Development Plan.
Costs that we incurred totaling $3.5&nbsp;million in 2009, $4.9&nbsp;million in 2010, and $1.7&nbsp;million in the
six months ended June&nbsp;30, 2011 have been applied against our $30&nbsp;million funding commitment,
resulting in a remaining funding commitment of $19.9&nbsp;million at June, 2011. We expect aggregate
full-time equivalent reimbursement of between $1.5 and $2.5&nbsp;million annually from 2011 to 2012,
which will be applied against our funding commitment, or reimbursed to us from Teva on a cash
basis. We currently expect that we will incur all remaining costs associated with the Clinical
Development Plan by the fourth quarter of 2013.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Several of our clinical trials have been supported by grant funding that was received directly by
the hospitals and/or clinical investigators conducting the clinical trials, thereby allowing us to
complete these clinical trials at a lower cost to us.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Since our drug candidates are in the early stages of development, we cannot estimate completion
dates for development activities or when we might receive material net cash inflows from our R&#038;D
projects, if ever.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our projects or intended R&#038;D activities may be subject to change from time to time as we evaluate
our R&#038;D priorities and available resources.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We expect our R&#038;D expenses to increase in 2011 and into the future, likely significantly, as we
further expand development of custirsen, OGX-427 and our other programs. Our programs or
anticipated programs may be subject to change from time to time as we evaluate our R&#038;D priorities
and available resources.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>General and Administrative Expenses</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">General and administrative, or G&#038;A, expenses consist primarily of salaries and related costs for
our personnel in executive, business development, human resources, external communications, finance
and other administrative functions, as well as consulting costs, including market research and
business consulting, and intellectual property. Other costs include professional fees for legal and
auditing services, insurance and facility costs. We believe that G&#038;A resources are sufficient to
carry on existing development activities. We anticipate that G&#038;A expenses will increase in the
future as we continue to expand our operating activities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Restructuring Activities</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">On August&nbsp;21, 2008, Sonus entered into the Arrangement with OncoGenex Technologies whereby Sonus
acquired all of the outstanding preferred shares, common shares and convertible debentures of
OncoGenex Technologies. Sonus then changed its name to OncoGenex Pharmaceuticals, Inc. Prior to the
Arrangement, Sonus entered into a non-cancellable lease arrangement for office space located in
Bothell, Washington, which is considered to be in excess of the Company&#146;s current requirements. The
Company is currently in the process of evaluating opportunities to exit or sublet portions of the
leased space and recorded an initial restructuring charge of $2,084,000 on August&nbsp;21, 2008 as part
of the purchase price allocation. The liability is computed as the present value of the difference
between the remaining lease payments due less the estimate of net sublease income and expenses and
has been accounted for in accordance with the then
effective EITF No.&nbsp;95-3, &#147;Recognition of Liabilities in Connection with a Purchase Business
Combination&#148;. This represents the Company&#146;s best estimate of the liability. Subsequent changes in
the liability due to changes in estimates of sublease assumptions are recognized as adjustments to
restructuring charges.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In June&nbsp;2009, the Company revised its sublease income assumptions used to estimate the excess lease
facility liability. These assumptions were subsequently revised again in December&nbsp;2009 and
September&nbsp;2010. These changes in estimate resulted in increases in the value of the excess lease
liability of $494,000, $3,457,000, and $4,038,000 and a corresponding expense recorded in June
2009, December&nbsp;2009, and September&nbsp;2010, respectively, to reflect these changes in estimate. The
estimated value of the liability remaining with respect to excess facilities was $7,467,000 as of
December&nbsp;31, 2010. In the six months ended June&nbsp;30, 2011, with respect to excess facilities,
$140,000 was amortized into income resulting in a remaining liability of $7,327,000 at June&nbsp;30,
2011.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Results of Operations</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Three Months Ended June&nbsp;30, 2011 Compared to the Three Months Ended June&nbsp;30, 2010</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Revenue</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Revenue for the three months ended June&nbsp;30, 2011 increased to $1.9&nbsp;million, from $1.7&nbsp;million for
the three months ended June&nbsp;30, 2010. The increase in 2011 as compared to 2010 was due to increased
effort, and therefore higher revenue earned through our strategic collaboration with Teva.
Collaboration revenue for the three months ended June&nbsp;30, 2011 includes recognition of $1.2&nbsp;million
from the $30.0&nbsp;million upfront payment, as well as $0.7&nbsp;million earned through collaborative
research, which has been reimbursed to us on a cash basis. At June&nbsp;30, 2011, $19.9&nbsp;million of the
upfront payment received from Teva in December&nbsp;2009 was included on our consolidated balance sheet
as Current and Long-term Deferred Collaboration Revenue, which we are recognizing as we perform our
deliverables under the Collaboration Agreement. Management currently expects this performance
period to end in the fourth quarter of 2013. See Note 3 of Notes to Consolidated Financial
Statements included elsewhere in this document for further details on our collaboration with Teva.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Research and Development Expenses</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our research and development expenses for our clinical development programs are as follows (in
thousands):
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three months ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Clinical development programs:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">custirsen</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,718</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,573</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">OGX-427</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,357</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">209</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,334</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,297</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total research and development expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>5,409</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>3,079</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Costs for clinical development programs include external direct expenses such as patient treatment
costs, clinical trial site costs, clinical research organization costs and contract manufacturing
fees incurred for preclinical, clinical, manufacturing and regulatory activities associated with
preparing the compounds for submissions of NDAs or similar regulatory filings to the FDA, EMA or
other regulatory agencies outside the United States and Europe. Other research and development
includes indirect operating costs such as our
personnel and occupancy expenses associated with our clinical development programs and other
research and development costs associated with the development of our other product candidates. Our
internal resources, employees, and infrastructure are not directly tied to any individual research
project and are typically deployed across multiple projects. Through our clinical development
programs, we are developing each of our product candidates in parallel for multiple disease
indications. Due to the number of ongoing projects and our ability to utilize resources across
several projects, we do not record or maintain information regarding the indirect operating costs
incurred for our research and development programs on a program-specific basis. In addition, we
believe that allocating costs on the basis of time incurred by our employees does not accurately
reflect the actual costs of a project. The majority of our costs incurred prior to 2010 were
related to the development of custirsen.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">R&#038;D expenses for the three months ended June&nbsp;30, 2011 increased to $5.4&nbsp;million from $3.1&nbsp;million
in the three months ended June&nbsp;30, 2010. The increase in 2011 as compared to 2010 was due primarily
to higher clinical trial and manufacturing costs for OGX-427, higher employee expenses including
stock based compensation, and higher costs associated with the custirsen phase 3 clinical trials in
2011. Certain costs for the custirsen phase 3 clinical trials are applied against the
non-refundable upfront payments received from Teva in December&nbsp;2009, while costs unassociated with
the SATURN trial, such as manufacturing costs and compensation for work performed by our employees
on the SYNERGY trial are reimbursable from Teva on a cash basis. We expect R&#038;D expenses to increase
as we further develop our proprietary product candidates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>General and Administrative Expenses</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">G&#038;A expenses for the three months ended June&nbsp;30, 2011 were unchanged at $1.5&nbsp;million. Higher
employee expenses, including stock-based compensation expenses incurred in the three months ended
June&nbsp;30, 2011 were offset by lower legal fees, as compared to the same period in 2010.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Net Interest Income (Expense)</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Interest income for the three months ended June&nbsp;30, 2011 increased to $63,000 from $14,000 for the
three months ended June&nbsp;30, 2011 due to higher balances of interest-bearing securities in 2011 as
compared to 2010.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Other Income (Expense)</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Other income for the three months ended June&nbsp;30, 2011 increased to $87,000 from $7,000 in expense
for the three months ended June&nbsp;30, 2011. The income in the three months ended June&nbsp;30, 2011
relates to foreign exchange gains, while the expense in the three months ended June&nbsp;30, 2010
relates to foreign exchange losses offset by gains on the sales of equipment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Gain (loss)&nbsp;on Warrants</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We recorded a $1.7&nbsp;million loss on revaluation of the warrants at June&nbsp;30, 2011 which is included
on our consolidated statement of loss as gain (loss)&nbsp;on warrants. We revalue the warrants at each
balance sheet date to fair value. If unexercised, the warrants will expire in October&nbsp;2015. There
was no comparable charge in 2010.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Six Months Ended June&nbsp;30, 2011 Compared to the Six Months Ended June&nbsp;30, 2010</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Revenue</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Revenue for the six months ended June&nbsp;30, 2011 decreased to $3.1&nbsp;million, from $6.4&nbsp;million for the
six months ended June&nbsp;30, 2010. The decrease in 2011 as compared to 2010 was due to lower
reimbursement revenue earned through our strategic collaboration with Teva resulting from
manufacturing costs now
being paid directly by Teva. Collaboration revenue for the six months ended June&nbsp;30, 2011 includes
recognition of $1.8&nbsp;million from the $30.0&nbsp;million upfront payment, as well as $1.3&nbsp;million earned
through collaborative research, which has been reimbursed to us on a cash basis. At June&nbsp;30, 2011,
$19.9&nbsp;million of the upfront payment received from Teva in December&nbsp;2009 was included on our
consolidated balance sheet as Current and Long-term Deferred Collaboration Revenue, which we are
recognizing as we perform our deliverables under the Collaboration Agreement. Management currently
expects this performance period to end in the fourth quarter of 2013. See Note 3 of Notes to
Consolidated Financial Statements included elsewhere in this document for further details on our
collaboration with Teva.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Research and Development Expenses</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our research and development expenses for our clinical development programs are as follows (in
thousands):
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six months ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Clinical development programs:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">custirsen</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,727</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6,276</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">OGX-427</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,604</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">440</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,931</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,743</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total research and development expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>10,262</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>9,459</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">R&#038;D expenses for the six months ended June&nbsp;30, 2011 increased to $10.3&nbsp;million from $9.5&nbsp;million in
the six months ended June&nbsp;30, 2010. The increase in 2011 as compared to 2010 was due primarily to
higher OGX-427 clinical trial and manufacturing costs, higher employee expenses, including stock
based compensation, offset by lower custirsen manufacturing costs, as these costs are now being
paid directly by Teva. Certain costs for the custirsen phase 3 clinical trials are applied against
the non-refundable upfront payments received from Teva in December&nbsp;2009, while costs unassociated
with the SATURN trial, such as manufacturing costs and compensation for work performed by our
employees on the SYNERGY trial, are reimbursable from Teva on a cash basis. We expect R&#038;D expenses
to increase as we further develop our proprietary product candidates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>General and Administrative Expenses</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">G&#038;A expenses for the six months ended June&nbsp;30, 2011 increased to $3.1&nbsp;million from $2.8&nbsp;million for
the six months ended June&nbsp;30, 2010. The increase in 2011 was due primarily to higher employee
expenses, including stock-based compensation expenses, offset by lower severance related charges
and legal fees.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Net Interest Income (Expense)</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Interest income for the six months ended June&nbsp;30, 2011 increased to $119,000 from $19,000 for the
six months ended June&nbsp;30, 2011 due to higher balances of interest-bearing securities in 2011 as
compared to 2010.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Other Income (Expense)</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Other income for the six months ended June&nbsp;30, 2011 decreased to $83,000 from $26,000 in expense in
the six months ended June&nbsp;30, 2010. The income in the three months ended June&nbsp;30, 2011 relates to
foreign exchange gains, while the expense in the three months ended June&nbsp;30, 2010 relates to
foreign exchange losses offset by gains on the sales of equipment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Gain (loss)&nbsp;on Warrants</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We recorded a $0.4&nbsp;million gain on revaluation of the warrants at June&nbsp;30, 2011 which is included
on our consolidated statement of loss as gain (loss)&nbsp;on warrants. We revalue the warrants at each
balance sheet date to fair value. If unexercised, the warrants will expire in October&nbsp;2015. There
was no comparable charge in 2010.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Liquidity and Capital Resources</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We have incurred an accumulated deficit of $75.6&nbsp;million through June&nbsp;30, 2011, and we expect to
incur substantial and increasing additional losses in the future as we expand our R&#038;D activities
and other operations, as more fully described below. We have not generated any revenue from product
sales to date, and we do not expect to generate product sales revenue for several years, if ever.
In the six months ended June&nbsp;30, 2011, we generated $3.1&nbsp;million in collaboration revenue from the
Collaboration Agreement with Teva.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">All of our operations to date have been funded through the sale of our equity securities, and
payments received from Teva. As of June&nbsp;30, 2011, our cash, cash equivalents, and short-term
investments decreased to $75.4&nbsp;million in the aggregate from $85.1&nbsp;million as of December&nbsp;31, 2010.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As of June&nbsp;30, 2011, we do not have any borrowing or credit facilities. Based on our current
expectations, we believe our capital resources at June&nbsp;30, 2011 will be sufficient to fund our
currently planned operations into 2014. Our currently planned operations are set forth below under
the heading &#147;Operating Capital and Capital Expenditure Requirements.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Cash Flows</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Cash Used in Operations</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">For the six months ended June&nbsp;30, 2011, net cash used in operating activities decreased to $9.6
million, from $17.8&nbsp;million in cash used in operations in the six months ended June&nbsp;30, 2010. The
decrease in cash used in operations is primarily attributable to payments made to Isis and UBC in
the first quarter of 2010 resulting from the Collaboration Agreement with Teva and lower custirsen
manufacturing costs, as these costs are now being paid directly by Teva, offset by higher OGX-427
clinical and manufacturing costs in 2011.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Cash Provided by Financing Activities</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">For the six months ended June&nbsp;30, 2011, net cash provided by financing activities decreased to $91
thousand from $521 thousand in the six months ended June&nbsp;30, 2010. All net cash provided by
financing activities in the six months ended June&nbsp;30, 2011 and June&nbsp;30, 2010 was the result of
proceeds from the issuance of common shares on stock option exercises.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Cash Used/Provided by Investing Activities</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Net cash provided by investing activities for the six months ended June&nbsp;30, 2011 increased to $7.0
million from $11.8&nbsp;million in cash used in investment activities the six months ended June&nbsp;30,
2010. Net cash used in or provided by investing activities in the six months ended June&nbsp;30, 2011
and June&nbsp;30, 2010 were due to transactions involving marketable securities in the normal course of
business.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Operating Capital and Capital Expenditure Requirements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We believe that our cash, cash equivalents and short-term investments will be sufficient to fund
our currently planned operations into mid-2014, including:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>completing the SATURN trial, a phase 3 clinical trial that is evaluating a durable pain
palliation benefit for custirsen in combination with second-line chemotherapy in patients
with CRPC;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>completing the SYNERGY trial, a phase 3 clinical trial that is evaluating a survival
benefit for custirsen in combination with docetaxel as first-line chemotherapy patients
with CRPC;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>completing an investigator-sponsored phase 2 clinical trial evaluating OGX-427
treatment in patients with prostate cancer;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>completing a phase 2 clinical trial evaluating OGX-427 in combination with standard
first-line chemotherapy in approximately 180 patients with metastatic bladder cancer; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>completing an investigator-sponsored phase 1 clinical trial evaluating OGX-427
treatment in patients with superficial bladder cancer.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As of June&nbsp;30, 2011, we have a remaining commitment to fund $19.9&nbsp;million towards the three phase 3
trials of custirsen, while Teva is required to fund all additional expenses under the clinical
development plan. The final results from the phase 3 trials may be released at a date that is
beyond the period for which we currently project we have available cash resources. In addition, if
we desire to conduct development activities with respect to our other product candidates beyond
those development activities mentioned in the list above, we will require additional funding to
support such operations. If we need to extend our cash availability, or to conduct any such
currently unplanned development activities, we would seek such necessary funding through the
licensing or sale of certain of our product candidates, by executing a partnership or collaboration
agreement, or through private or public offerings of our equity or debt.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our future capital requirements will depend on many factors, including:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>timing, costs and results of clinical trials, preclinical development and regulatory
approvals;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>success of custirsen and achieving milestones and royalties;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>maintaining our relationship with Teva and Teva&#146;s ongoing level of focus and efforts to
develop custirsen;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>timing, costs and results of drug discovery and R&#038;D;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>entering into new collaborative or product license agreements for products in our
pipeline;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to obtain additional funding through a partnership or collaboration
agreement with a third party or licenses of certain of our product candidates, or through
private or public offerings of our equity or debt; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>costs related to obtaining, defending and enforcing patents.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Off-Balance Sheet Arrangements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We do not have any off-balance sheet financing arrangements at June&nbsp;30, 2011.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Inflation</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We do not believe that inflation has had a material impact on our business and operating results
during the periods presented.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Contingencies and Commitments</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We previously disclosed certain contractual obligations and contingencies and commitments relevant
to the Company within the financial statements and Management Discussion and Analysis of Financial
Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December
31, 2010, as filed with the SEC on March&nbsp;10, 2011. There have been no significant changes to our
&#147;Contractual Obligations&#148; table in Part&nbsp;II, Item&nbsp;7, &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations&#148; of our 2010 Form 10-K. For more
information regarding our current contingencies and commitments, see note 7 to the financial
statements included above, which is incorporated by reference herein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Material Changes in Financial Condition</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">(In thousands)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">79,525</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">89,918</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44,327</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45,793</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Shareholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35,198</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44,125</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The decrease in assets from December&nbsp;31, 2010 primarily relates to decreased cash, cash equivalents
and marketable securities as these assets have been used to fund operations. The decrease in
liabilities from December&nbsp;31, 2010 relates predominantly to the revaluation of the warrant
liability, amortization of restructuring-related liabilities, and the recognition of deferred
collaboration revenue.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Critical Accounting Policies and Estimates</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The preparation of financial statements in accordance with GAAP requires management to make
estimates and assumptions that affect reported amounts and related disclosures. We have discussed
those estimates that we believe are critical and require the use of complex judgment in their
application in our 2010 Form 10-K filed with the SEC on March&nbsp;10, 2011. Since the date of our 2010
Form 10-K, there have been no material changes to our critical accounting policies or the
methodologies or assumptions we apply under them.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>New Accounting Standards</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">See Note 2, &#147;Accounting Policies,&#148; of the consolidated financial statements for information related
to the adoption of new accounting standards in 2011, none of which had a material impact on our
financial statements, and the future adoption of recently issued accounting standards, which we do
not expect to have a material impact on our financial statements.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="left">
<A name="C20581108"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;3.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Quantitative and Qualitative Disclosures About Market Risk</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Interest Rate Risk</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Interest rate risk is the risk that the fair values and future cash flows of financial instruments
will fluctuate because of the changes in market interest rates. We invest our cash in a variety of
financial instruments, primarily in short-term bank deposits, money market funds, and domestic and
foreign commercial paper and government securities. These investments are denominated in U.S.
dollars, and our exposure to interest rate changes is monitored. We have very limited interest rate
risk due to the few assets or liabilities subject to fluctuations in interest rates. Our
investment portfolio includes only marketable securities with active secondary or resale markets to
help ensure portfolio liquidity. Due to the nature of our highly liquid marketable securities, a
change in interest rates would not materially change the fair market value.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Foreign Currency Exchange Risk</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We are exposed to risks associated with foreign currency transactions on certain contracts and
payroll expenses related to our Canadian subsidiary, OncoGenex Technologies, denominated in
Canadian dollars and we have not hedged these amounts. As our unhedged foreign currency
transactions fluctuate, our earnings might be negatively affected. Accordingly, changes in the
value of the U.S. dollar relative to the Canadian dollar might have an adverse effect on our
reported results of operations and financial condition, and fluctuations in exchange rates might
harm our reported results and accounts from period to period. We have estimated the effect on our
reported results of operations of a hypothetical increase of 10&nbsp;percent in the exchange rate of the
Canadian dollar against the U.S. dollar to be $100,000 for the quarterly period ended June&nbsp;30,
2011.
</DIV>

<DIV align="left">
<A name="C20581109"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;4.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Controls and Procedures</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Evaluation of Disclosure Controls and Procedures</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We maintain disclosure controls and procedures that are designed to ensure that material
information required to be disclosed in our periodic reports filed or submitted under the
Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed,
summarized and reported within the time periods specified in the SEC&#146;s rules and forms. Our
disclosure controls and procedures are also designed to ensure that information required to be
disclosed in the reports we file or submit under the Exchange Act are accumulated and communicated
to our management, including its principal executive officer and principal financial officer as
appropriate, to allow timely decisions regarding required disclosure.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">During the quarter ended June&nbsp;30, 2011, we carried out an evaluation, under the supervision and
with the participation of our management, including the principal executive officer and the
principal financial officer, of the effectiveness of the design and operation of our disclosure
controls and procedures, as defined in Rules&nbsp;13a-15(e) and 15d-15(e) under the Exchange Act. Based
upon that evaluation, our principal executive officer and principal financial officer concluded
that our disclosure controls and procedures were effective, as of the end of the period covered by
this report.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Changes in Internal Control Over Financial Reporting</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We have not made any changes to our internal control over financial reporting (as defined in Rule
13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June&nbsp;30, 2011 that have
materially affected, or are reasonably likely to materially affect, our internal control over
financial reporting.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="left">
<A name="C20581110"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>PART II. </B><U><B>OTHER INFORMATION</B></U>
</DIV>

<DIV align="left">
<A name="C20581111"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;1A.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Risk Factors</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Risks Related to Our Business</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the
risks and uncertainties described below, together with all of the other information contained in
this Quarterly Report on Form&nbsp;10-Q, before deciding to invest in our common stock. If any of the
following risks materialize, our business, financial condition, results of operation and future
prospects will likely be materially and adversely affected. In that event, the market price of our
common stock could decline and you could lose all or part of your investment.</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Risks Related to Our Business</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We have a limited operating history, have incurred losses since inception and anticipate that we
will continue to incur losses for the foreseeable future. We have never had any products available
for commercial sale and we may never achieve or sustain profitability.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We are a clinical-stage biopharmaceutical company with a limited operating history. We are not
profitable and have incurred losses in each year since our inception. We have never had any
products available for commercial sale and we have not generated any revenue from product sales nor
do we anticipate that we will generate revenue from product sales in the foreseeable future. Our
only revenue to date has been collaboration revenue under our Collaboration Agreement with Teva. We
have not yet submitted any products for approval by regulatory authorities and we continue to incur
research and development and general and administrative expenses related to our operations. We
expect to continue to incur losses for the foreseeable future, and we expect these losses to
increase as we continue our research activities and conduct development of, and seek regulatory
approvals for, our product candidates, and prepare for and begin to commercialize any approved
products. If our product candidates fail in clinical trials or do not gain regulatory approval, or
if our product candidates do not achieve market acceptance, we may never become profitable. Even if
we achieve profitability in the future, we may not be able to sustain profitability in subsequent
periods.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Our clinical trials may be suspended or terminated at any time, including by the FDA, other
regulatory authorities, the Institutional Review Board overseeing the clinical trial at issue, by a
clinical trial site or investigator, by Teva in the case of custirsen, or by us. Any failure or
significant delay in completing clinical trials for our product candidates could materially harm
our financial results and the commercial prospects for our product candidates.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We do not know whether any of our currently planned clinical trials for custirsen or OGX-427 will
proceed or be completed on schedule, if at all, or, with respect to our other product candidates,
whether we will be able to initiate any future pre-clinical studies or clinical trials, as
applicable, beyond those currently planned. The completion or commencement of future pre-clinical
studies or clinical trials could be substantially delayed or prevented by several factors,
including:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>limited number of, and competition for, suitable patients with the particular types of
cancer required for enrollment in our clinical trials;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>limited number of, and competition for, suitable sites to conduct clinical trials;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>decrease in Teva&#146;s level of focus and efforts to develop custirsen;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>introduction of new product candidates to the market in therapeutic areas similar to
those that we are developing our product candidates;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>concurrent evaluation of new investigational product candidates in therapeutic areas
similar to those that we are developing our product candidates;</TD>
</TR>


</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delay or failure to obtain the FDA&#146;s or non-U.S. regulatory agencies&#146; approval or
agreement to commence a clinical trial, including our phase 3 or registration clinical
trials or amendment of those trials under an SPA;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delay or failure to obtain required future additional funding, when needed, through
private or public offerings of our equity securities, debt financings, or the execution of
a licensing, partnership or collaboration agreement with a third party for any of our
product candidates;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delay or failure to obtain sufficient manufacturing supply of custirsen;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delay or failure to obtain sufficient supplies of the product candidate for our
clinical trials;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delay or failure to reach agreement on acceptable clinical trial agreement terms or
clinical trial protocols with prospective sites or investigators; and</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delay or failure to obtain the approval of the Institutional Review Board to conduct a
clinical trial at a prospective site.</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The completion of our clinical trials currently in progress could also be substantially delayed or
prevented by several factors, including:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>slower than expected rates of patient recruitment and enrollment;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>failure of patients to complete the clinical trial;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>unforeseen safety issues;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>lack of efficacy evidenced during clinical trials;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>termination of our clinical trials by one or more clinical trial sites or
investigators;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>inability or unwillingness of patients or medical investigators to follow clinical
trial protocols;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>inability to monitor patients adequately during or after treatment;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>introduction of competitive products that may impede our ability to retain patients in
clinical trials;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delay or failure to obtain sufficient manufacturing supply of custirsen; and</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delay or failure to obtain future additional funding through private or public
offerings of our equity securities, debt financings, or the execution of a licensing,
partnership or collaboration agreement with a third party for any of our product
candidates in the event of material unforeseen costs relating to our clinical trials
currently in progress.</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">For example, the SATURN trial has had few patients accrued due to the restrictions regarding
docetaxel re-treatment and stable pain criteria on entry. We have submitted a proposed revision to
the approved SPA for the SATURN trial to the FDA, which would expand the treatment population by
including patients who progressed during 1st- line docetaxel treatment, who currently cannot
participate in this trial under the existing SPA. However, we have no assurance that the proposed
revisions to the SPA protocol will address the recruitment challenges.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory
authorities, the Institutional Review Board overseeing the clinical trial at issue, any of our
clinical trial sites with respect to that site, or us. Any failure or significant delay in
completing clinical trials for our product candidates could materially harm our financial results
and the commercial prospects for our product candidates. We are highly dependent on the success of
our lead product candidate, custirsen, and we cannot give any assurance that custirsen, or any of
our other product candidates, will receive regulatory approval or will be successfully
commercialized.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Custirsen has been evaluated in five phase 2 clinical trials, the results of which were previously
disclosed. If competitive products developed by third parties show significant benefit in the
cancer indications in which we are developing our product candidates, any planned supportive or
primary registration trials may be delayed, altered or not initiated and custirsen may never
receive regulatory approval. In order to market custirsen, we and Teva must, among other things,
conduct additional clinical trials, including phase 3 or registration clinical trials, to
demonstrate safety and efficacy. We have initiated two registration trials with custirsen in CRPC.
A third registration trial in NSCLC is also planned. OGX-427 has been evaluated in
humans, although we have very limited safety data and have not yet established efficacy in humans.
Additional clinical trials will be required for OGX-427 to establish the safety and efficacy of
this product candidate. Neither OGX-225 nor CSP-9222 has been tested in humans. Our pre-clinical
testing of these product candidates may not be successful and we may not be able to clinically
evaluate them. Our clinical development programs for our product candidates may not receive
regulatory approval either if such product candidates fail to demonstrate that they are safe and
effective in clinical trials and consequently fail to obtain necessary approvals from the FDA, or
similar non-U.S. regulatory agencies, or if we have inadequate financial or other resources to
advance these product candidates through the clinical trial process. Any failure to obtain
regulatory approval of custirsen or our other product candidates could have a material and adverse
effect on our business.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We depend on our collaborative relationship with Teva to further develop and commercialize
custirsen, and if our relationship is not successful or is terminated, we may not be able to
effectively develop and/or commercialize custirsen, which would have a material adverse effect on
our business.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We depend on Teva to collaborate with us to develop and globally commercialize custirsen.
Furthermore, under the Collaboration Agreement, we and Teva must agree on any changes to the
Clinical Development Plan for custirsen. As a result of our dependence on Teva, the eventual
success or commercial viability of custirsen is largely beyond our control. The financial returns
to us, if any, under the Collaboration Agreement depend in large part on the achievement of
development and commercialization milestones, plus a share of any revenue from sales. Therefore,
our success, and any associated financial returns to us and our investors, will depend in large
part on Teva&#146;s performance under the Collaboration Agreement. We are subject to a number of
additional specific risks associated with our dependence on our collaborative relationship with
Teva, including:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>adverse decisions by Teva or the Joint Steering Committee regarding the development and
commercialization of custirsen;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>possible disagreements as to the timing, nature and extent of our development plans,
including clinical trials or regulatory approval strategy;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>loss of significant rights if we fail to meet our obligations under the Collaboration
Agreement;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our limited control over clinical trials of custirsen;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changes in key management personnel at Teva that are members of the Joint Steering
Committee; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>possible disagreements with Teva regarding the Collaboration Agreement, sharing of
costs for clinical trials or ownership of proprietary rights.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If we and Teva are unable to reach an agreement under the Clinical Development Plan, or if either
we or Teva fail to perform our respective obligations or effectively manage our relationship, any
clinical trial, regulatory approval or development progress could be significantly delayed or
halted, could result in costly or time-consuming litigation or arbitration and could have a
material adverse effect on our business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Decisions by Teva to either reduce or eliminate its participation in the oncology field, to
emphasize other competitive agents currently in its portfolio, or to add additional competitive
agents to its portfolio could result in a decision to terminate the Collaboration Agreement, in
which event, among other things, we may be responsible for paying any remaining costs of all three
phase 3 clinical trials. Any such termination could adversely affect the timing and extent of our
development and commercialization activities, which could cause significant delays and funding
shortfalls for those activities and seriously harm our business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Clinical trials may not demonstrate a clinical benefit of our product candidates.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Positive results from pre-clinical studies and early clinical trials, including those results from
the custirsen clinical trials conducted to date, should not be relied on as evidence that
later-stage or large-scale clinical trials will succeed. We will be required to demonstrate with
substantial evidence through well-controlled clinical trials that our product candidates are safe
and effective for use in a diverse population before we
can seek regulatory approvals for their commercial sale. Success in early clinical trials does not
mean that future clinical trials will be successful because product candidates in later-stage
clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the
FDA and other non-U.S. regulatory authorities despite having progressed through initial clinical
trials.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Even after the completion of our planned phase 3 clinical trials, the FDA or other non-U.S.
regulatory authorities may disagree with our clinical trial design and our interpretation of data,
and may require us to conduct additional clinical trials to demonstrate the efficacy of our product
candidates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If our competitors develop and market products that are more effective, safer or less expensive
than our future product candidates, our clinical trials and commercial opportunities will be
negatively affected.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The life sciences industry is highly competitive, and we face significant competition from many
pharmaceutical, biopharmaceutical and biotechnology companies that are researching and marketing
products designed to address cancer indications for which we are currently developing products or
for which we may develop products in the future. We are aware of several other companies which are
developing therapeutics that seek to promote tumor cell death by inhibiting proteins believed to
promote cell survival. For example, cabazitaxel and abiraterone were recently approved by the FDA
for the treatment of patients with CRPC. Any products we may develop in the future are also likely
to face competition from other drugs and therapies. Many of our competitors have significantly
greater financial, manufacturing, marketing and drug development resources than we do. Large
pharmaceutical companies, in particular, have extensive experience in clinical testing and in
obtaining regulatory approvals for drugs. These companies also have significantly greater research
and marketing capabilities than we do. In addition, many universities and private and public
research institutes are, or may become, active in cancer research, which products may directly
compete with ours. If our competitors market products that are more effective, safer or less
expensive than our future product candidates, if any, or that reach the market sooner than our
future product candidates, if any, we may not achieve commercial success.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We rely, in part, on third parties to conduct clinical trials for our product candidates and plan
to rely on third parties to conduct future clinical trials. If these third parties do not
successfully carry out their contractual duties or meet expected deadlines, we may be unable to
obtain regulatory approval for or commercialize our current and future product candidates.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">To implement our product development strategies, we rely on third parties, such as collaborators,
contract research organizations, medical institutions, clinical investigators and contract
laboratories, to conduct clinical trials of our product candidates. In particular, we will have
limited control over the two custirsen phase 3 trials over which Teva will have primary oversight.
Although we rely on third parties to conduct our clinical trials, we are responsible for ensuring
that each of our clinical trials is conducted in accordance with our investigational plan and
protocol. Moreover, the FDA and non-U.S. regulatory authorities require us to comply with
regulations and standards, commonly referred to as Good Clinical Practices, or GCPs, for
conducting, monitoring, recording and reporting the results of clinical trials to ensure that the
data and results are scientifically credible and accurate and that the clinical trial subjects are
adequately informed of the potential risks of participating in clinical trials. Our reliance on
third parties does not relieve us of these responsibilities and requirements. If the third parties
conducting our clinical trials do not perform their contractual duties or obligations, do not meet
expected deadlines or need to be replaced, or if the quality or accuracy of the clinical data they
obtain is compromised due to the failure to adhere to GCPs or for any other reason, we may need to
enter into new arrangements with alternative third parties and our clinical trials may be extended,
delayed or terminated. In addition, a failure by such third parties to perform their obligations in
compliance with GCPs may cause our clinical trials to fail to meet regulatory requirements, which
may require us to repeat our clinical trials.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We rely on third parties to manufacture and supply our product candidates.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We do not own or operate manufacturing facilities, and we depend on third-party contract
manufacturers for production of our product candidates. We lack the resources and the capability to
manufacture any of our product candidates ourselves. To date, our product candidates have been
manufactured in limited quantities for pre-clinical studies and clinical trials. All API for
custirsen has been manufactured for us by Isis or Avecia Biotechnology Inc., and all drug product
has been manufactured for us by Formatech, Inc., Pyramid Laboratories, Inc. and Laureate
Biopharmaceutical Services, Inc., in each case pursuant to a purchase order or short-term contract
that has been fulfilled. Avecia Biotechnology Inc. is our contract manufacturer for additional
quantities of custirsen to complete our phase 3 clinical trials.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">All API for OGX-427 for IND-enabling toxicology studies and initial clinical trials has been
manufactured for us by Avecia Biotechnology Inc. and all drug product has been manufactured for us
by Laureate Biopharmaceutical Services, Inc., in each case pursuant to a purchase order or
short-term contract which has been fulfilled.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If, in the future, one of our product candidates is approved for commercial sale, we, or a
pharmaceutical partner that has licensed such product candidate, will need to manufacture that
product candidate in commercial quantities. We cannot provide assurance that the third-party
manufacturers with which we have contracted in the past will have sufficient capacity to satisfy
our future manufacturing needs, that we will be able to negotiate additional purchases of API or
drug product from these or alternative manufacturers on terms favorable to us, if at all, or that a
pharmaceutical partner that has licensed such product candidate will have sufficient capacity or
expertise to satisfy future needs.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Third-party manufacturers may fail to perform under their contractual obligations, or may fail to
deliver the required commercial quantities of bulk API or finished drug product on a timely basis
and at commercially reasonable prices. We have experienced manufacturing quality issues resulting
in an unusable lot of product candidate. Any performance failure on the part of our contract
manufacturers could delay clinical development or regulatory approval of our product candidates or
commercialization of our future product candidates, depriving us of potential product revenue and
resulting in additional losses. If we are required to identify and qualify an alternate
manufacturer, we may be forced to delay or suspend our clinical trials, regulatory submissions,
required approvals or commercialization of our product candidates, which may cause us to incur
higher costs and could prevent us from commercializing our product candidates successfully. If we
are unable to find one or more replacement manufacturers capable of production at a reasonably
favorable cost, in adequate volumes, of adequate quality, and on a timely basis, we would likely be
unable to meet demand for our product candidates and our clinical trials could be delayed or we
could lose potential revenue. Our ability to replace an existing API manufacturer may be difficult
because the number of potential manufacturers is limited to approximately five manufacturers, and
the FDA must inspect any replacement manufacturer and review information related to product
produced at the manufacturer before they can begin manufacturing our product candidates. It may be
difficult or impossible for us to identify and engage a replacement manufacturer on acceptable
terms in a timely manner, if at all. We expect to continue to depend on third-party contract
manufacturers for the foreseeable future.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our product candidates require precise, high-quality manufacturing. Any of our contract
manufacturers will be subject to ongoing periodic unannounced inspection by the FDA and non-U.S.
regulatory authorities to ensure strict compliance with cGMP, and other applicable government
regulations and corresponding standards. If our contract manufacturers fail to achieve and maintain
high manufacturing standards in compliance with cGMP regulations, we may experience manufacturing
errors resulting in patient injury or death, product recalls or withdrawals, delays or
interruptions of production or failures in product testing or delivery, delay or prevention of
filing or approval of marketing applications for our product candidates, cost overruns or other
problems that could seriously affect our business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Significant manufacturing scale-up may require additional validation studies, which the FDA must
review and approve. Additionally, any third-party manufacturers we retain to manufacture our
product candidates
on a commercial scale must pass an FDA pre-approval inspection for conformance to cGMP regulations
before we can obtain approval of our product candidates. If we are unable to successfully increase
the manufacturing capacity for a product candidate in conformance with cGMP regulations, the
regulatory approval or commercial launch of any related products may be delayed or there may be a
shortage in supply.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If new therapies become broadly used, we may need to conduct clinical trials of our product
candidates in combination with these new therapies to demonstrate safety and efficacy of the
combination. Additional trials will delay the development of our product candidates and increase
our costs. The failure of certain of our product candidates to work in combination with these new
therapies would have an adverse effect on our business.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our intention is to combine certain of our product candidates with therapies that are broadly used
by clinicians and considered highly effective. As new therapies are developed, we will need to
assess these therapies to determine whether to conduct clinical trials of our product candidates in
combination with them to demonstrate safety and efficacy of the combination. If we determine that
it is appropriate to conduct additional clinical trials of our product candidates in combination
with these new therapies, the development of our product candidates will be delayed and our costs
will be increased. If these clinical trials generate safety concerns or lack of efficacy, our
business would be adversely affected.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If our product candidates are approved in combination with a specific therapy that is broadly used
and that therapy is displaced by another product, the market for our product candidate may
decrease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Our product candidates may cause undesirable and potentially serious side effects during clinical
trials that could delay or prevent their regulatory approval or commercialization.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Custirsen was administered to 294 patients with various types of cancer in phase 1 and phase 2
clinical trials. Some patients experienced various adverse events, the majority of which are
associated with other treatments in the protocol and the disease. The majority of adverse events
were mild and the most common adverse events associated with custirsen consisted of flu-like
symptoms. The most common serious adverse events associated with custirsen were neutropenia,
vomiting, dehydration, pyrexia, pleural effusion and difficulty breathing (also known as
&#147;dyspnea&#148;), which occurred in greater than 2% of patients.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">OGX-427 was administered to 59 patients with various types of cancer in a phase 1 clinical trial.
Enrollment is complete in five cohorts with dose-escalation of OGX-427 as monotherapy and in two
cohorts in which docetaxel was administered in combination with OGX-427. There was only one
dose-limiting toxicity; thus, the maximum tolerated dose was not reached. Of the 46 patients
presented at the ASCO 2010 annual meeting, the majority of the adverse events were infusion
reactions, which were documented in 72% of patients and increased in incidence with increasing
dose. The majority (93%) were grade 1 or 2. Grade 3/4 laboratory events, which occurred in
decreasing frequency, were lymphopenia, prolonged PTT, neutropenia, hyponatremia, anemia, elevated
creatinine and thrombocytopenia. During monotherapy and when OGX-427 was administered as
combination therapy, there was evidence of decreases in tumor markers (CA-125 and PSA), decreases
in Hsp27&#043; circulating tumor cells, and reduction of serum Hsp27 protein levels.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Since patients in our clinical trials have advanced stages of cancer, we expect that additional
adverse events, including serious adverse events, will occur.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Undesirable side effects caused by any of our product candidates could cause us or regulatory
authorities to interrupt, delay or halt clinical trials and could result in the denial of
regulatory approval by the FDA or non-U.S. regulatory authorities for any or all targeted
indications. This, in turn, could prevent us from commercializing our product candidates and
generating revenue from their sale. In addition, if our product candidates receive marketing
approval and we or others later identify undesirable side effects caused by the product:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Teva may elect to terminate the ongoing clinical trials and cease development of
custirsen;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>regulatory authorities may withdraw their approval of the product;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we may be required to recall the product, change the way the product is administered,
conduct additional clinical trials or change the labeling of the product;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a product may become less competitive and product sales may decrease; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our reputation may suffer.</TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Any one or a combination of these events could prevent us from achieving or maintaining market
acceptance of the affected product or could substantially increase the costs and expenses of
commercializing the product, which in turn could delay or prevent us from generating significant
revenue from the sale of the product. Recent events have raised questions about the safety of
marketed drugs and may result in increased cautiousness by the FDA in reviewing new drugs based on
safety, efficacy or other regulatory considerations and may result in significant delays in
obtaining regulatory approvals, additional clinical trials being required, or more stringent
product labeling requirements. Any delay in obtaining, or the inability to obtain, applicable
regulatory approvals would prevent us from commercializing our product candidates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Because we depend on financing from third parties for our operations, our business may fail if such
financing becomes unavailable or is not available on commercially reasonable terms.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">To date, we have financed our operations primarily through the sale of our equity securities and
from the upfront payment we received pursuant to the Collaboration Agreement with Teva. We believe
that our existing capital resources and interest on such resources, including the financing we
completed in October&nbsp;2010, will be sufficient to meet our current operating requirements into 2014.
If, however, the Collaboration Agreement with Teva were to terminate or if Teva fails to fulfill
its obligations under the Collaboration Agreement, or if the trials proceed slower than expected or
are initiated later than expected, or if we change our development plans, acquire rights to new
product candidates or cannot find third-party collaborators for our other product candidates, we
may need additional capital sooner than we expect. Our future capital requirements will depend on
many factors, including, without limitation:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>maintaining our partnership with Teva and Teva&#146;s ongoing commitment to develop
custirsen in a timely manner;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>whether we experience delays in our pre-clinical and clinical development programs, or
slower-than-anticipated product development;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the scope and results of our pre-clinical studies and clinical trials;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>whether opportunities to acquire additional product candidates arise and the costs of
acquiring and developing those product candidates;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>whether we are able to enter into additional third-party collaborative partnerships to
develop and/or commercialize any of our other product candidates on terms that are
acceptable to us;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the timing and requirements of, and the costs involved in, conducting studies required
to obtain regulatory approvals for our product candidates from the FDA and comparable
foreign regulatory agencies;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the availability of third parties to perform the key development tasks for our product
candidates, including conducting pre-clinical studies and clinical trials and
manufacturing our product candidates to be tested in those studies and trials and the
associated costs of those services; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the costs involved in preparing, filing, prosecuting, maintaining, defending the
validity of and enforcing patent claims and other costs related to patent rights and other
intellectual property rights, including litigation costs and the results of such
litigation.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If we are unable to raise funds on acceptable terms when it becomes necessary to do so, we may not
be able to continue developing our product candidates, acquire or develop additional product
candidates or respond to competitive pressures or unanticipated requirements. For these reasons,
any inability to raise additional funds when we require it could have a material adverse effect on
our business.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Even if we or Teva receive regulatory approval to market our product candidates, the market may not
be receptive to our products.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Even if our product candidates obtain regulatory approval, they may not gain market acceptance
among physicians, patients, healthcare payors and/or the medical community. We believe that the
degree of market acceptance will depend on a number of factors, including:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>timing of market introduction of competitive products;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>safety and efficacy of our products;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>prevalence and severity of any side effects;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>potential advantages or disadvantages over alternative treatments;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>strength of marketing and distribution support;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>price of our products, both in absolute terms and relative to alternative treatments;
and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>availability of coverage and reimbursement from government and other third-party
payors.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If our future product candidates fail to achieve market acceptance, we may not be able to generate
significant revenue or achieve or sustain profitability.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Although we have entered into a Collaboration Agreement with Teva for custirsen, we have not yet
partnered with third-party collaborators with respect to any of our other product candidates, and
we cannot control whether we will be able to do so on favorable terms, if at all.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our business strategy relies in part on potentially partnering successful product candidates with
larger companies to complement our internal development and commercialization efforts. While we
have successfully entered into a Collaboration Agreement with Teva with respect to custirsen, it
may be difficult for us to find third parties that are willing to enter into a collaboration on
acceptable economic terms, if at all, with respect to our other product candidates. We also will be
competing with many other companies as we seek partners for our other product candidates and may
not be able to compete successfully against those companies. If we are not able to enter into
collaboration arrangements for our other product candidates, we would be required to undertake and
fund further development, clinical trials, manufacturing and commercialization activities solely at
our own expense and risk. If we are unable to finance and/or successfully execute those expensive
activities, our business could be materially and adversely affected, and we may be forced to
discontinue clinical development of these product candidates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If we were to be successfully sued related to our products or operations, we could face substantial
liabilities that may exceed our resources.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We may be held liable if any of our products or operations cause injury or death or are found
otherwise unsuitable during product testing, manufacturing, marketing or sale. These risks are
inherent in the development of pharmaceutical products. We currently maintain Commercial General
and Umbrella Liability policies with combined limits of $10&nbsp;million per occurrence and in the
aggregate, in addition to a $10&nbsp;million per claim and annual aggregate product liability insurance
policy related to our clinical trials consistent with industry standards. When necessary for our
products, we intend to obtain additional product liability insurance. Insurance coverage may be
prohibitively expensive, may not fully cover potential liabilities or may not be available in the
future. Inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to
protect against potential product liability claims could prevent or inhibit the commercialization
of our products. If we were to be sued for any injury caused by or associated with our products or
operations, the litigation could consume substantial time and attention of our management, and the
resulting liability could exceed our total assets.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If we fail to acquire and develop products or product candidates at all or on commercially
reasonable terms, we may be unable to grow our business.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We currently do not have internal discovery capabilities and depend on pharmaceutical and
biotechnology companies and other researchers to sell or license products or product candidates to
us. To date, three of our product candidates have been derived from technologies discovered by the
Vancouver Prostate Centre and licensed to us by UBC, and one candidate has been in-licensed from
Bayer. We intend to continue to rely on the Vancouver Prostate Centre, UBC and other research
institutions and other biotechnology or pharmaceutical companies as sources of product candidates.
We cannot guarantee that the Vancouver Prostate Centre or UBC will continue to develop new product
candidate opportunities, that we will continue to have access to such opportunities or that we will
be able to purchase or license these product candidates on commercially reasonable terms, if at
all. If we are unable to purchase or license new product candidates from the Vancouver Prostate
Centre or UBC, we will be required to identify alternative sources of product candidates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The success of our product pipeline strategy depends on our ability to identify, select and acquire
pharmaceutical product candidates. Proposing, negotiating and implementing an economically viable
product acquisition or license is a lengthy and complex process. We compete for partnering
arrangements and license agreements with pharmaceutical and biotechnology companies and academic
research institutions. Our competitors may have stronger relationships with third parties with whom
we are interested in collaborating and/or may have more established histories of developing and
commercializing products. As a result, our competitors may have a competitive advantage in entering
into partnering arrangements with such third parties. In addition, even if we find promising
product candidates, and generate interest in a partnering or strategic arrangement to acquire such
product candidates, we may not be able to acquire rights to additional product candidates or
approved products on terms that we find acceptable, if at all. If we fail to acquire and develop
product candidates from others, we may be unable to grow our business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We expect that any product candidate that we acquire rights to will require additional development
efforts prior to commercial sale, including extensive clinical evaluation and approval by the FDA
and non-U.S. regulatory authorities. All product candidates are subject to the risks of failure
inherent in pharmaceutical product development, including the possibility that the product
candidate will not be shown to be sufficiently safe and effective for approval by regulatory
authorities. Even if the product candidates are approved, we can make no assurance that we would be
capable of economically producing the product or that the product would be commercially successful.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We will need to retain additional personnel and expand our other resources in order to promote
custirsen in the event we exercise our co-promotion option and develop our other product
candidates. If we fail to effectively expand our operations, including attracting and retaining key
management and scientific personnel, we may be unable to successfully develop or commercialize our
product candidates and our business may be materially adversely affected.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We will need to expand and effectively manage our managerial, operational, financial, development
and other resources in order to successfully pursue our research, development and commercialization
efforts for our existing and future product candidates. Our success depends on our continued
ability to attract, retain and motivate highly qualified personnel, such as management,
pre-clinical and clinical personnel, including our executive officers Michelle Burris, Scott
Cormack, and Cindy Jacobs. In addition, although we have entered into employment agreements with
each of Ms.&nbsp;Burris, Mr.&nbsp;Cormack, and Dr.&nbsp;Jacobs, such agreements permit the executive to terminate
his or her employment with us at any time, subject to providing us with advance written notice.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Should custirsen receive marketing approval in the United States and Canada, or should we exercise
our co-promotion option, which is unlikely without sufficient funds, we would need to hire a
substantial number of specialized personnel, including field-based medical affairs representatives.
In turn, we would need to
increase our administrative headcount to support such expanded development and commercialization
operations with respect to our product candidates. Our ability to attract and retain qualified
personnel in the future is subject to intense competition for qualified personnel among
biotechnology, pharmaceutical and other businesses and our current financial position. The loss of
the services of any of our senior management could delay or prevent the development and
commercialization of our product candidates, or have other adverse effects on our business for an
indefinite term. In particular, if we lose any members of our current senior management team, we
may not be able to find suitable replacements in a timely fashion, if at all and our business may
be harmed as a result. If any of such events were to occur, among other things, we may not be able
to comply with our contractual obligations to Teva under our Collaboration Agreement or advance our
product candidates, which could have a material adverse effect on our business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We have scientific and clinical advisors who assist us in formulating our development and clinical
strategies. These advisors are not our employees and may have commitments to, or consulting or
advisory contracts with, other entities that may limit their availability to us. In addition, our
advisors may have arrangements with other companies to assist those companies in developing
products or technologies that may compete with ours.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We may encounter difficulties in managing our expected growth and in expanding our operations
successfully.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As we advance our product candidates custirsen, OGX-427, OGX-225, and CSP-9222 through development
and clinical trials, we will need to develop or expand our development, regulatory, manufacturing,
marketing and sales capabilities or contract with third parties to provide these capabilities for
us. Maintaining additional relationships and managing our future growth will impose significant
added responsibilities on members of our management. We must be able to manage our development
efforts effectively, manage our clinical trials effectively, hire, train and integrate additional
management, development, administrative and sales and marketing personnel, improve our managerial,
development, operational and finance systems, and expand our facilities, all of which may impose a
strain on our administrative and operational infrastructure.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Under the Collaboration Agreement, Teva is responsible for the commercialization costs associated
with custirsen; however, if we were to exercise our co-promotion option, which we do not anticipate
having sufficient funds to do, we would need to expand our marketing and sales capabilities. In
addition, as we have primary responsibility for the oversight of the second-line trial in CRPC, we
must be able to manage our development responsibilities effectively, which may impose a strain on
our administrative and operational infrastructure.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Furthermore, we may acquire additional businesses, products or product candidates that complement
or augment our existing business. Integrating any newly acquired business, product or product
candidate could be expensive and time-consuming. We may not be able to integrate any acquired
business, product or product candidate successfully or operate any acquired business profitably.
Our future financial performance will depend, in part, on our ability to manage any future growth
effectively and our ability to integrate any acquired businesses. We may not be able to accomplish
these tasks, which failure could prevent us from successfully growing our business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We may be adversely affected if our controls over external financial reporting fail or are
circumvented.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We regularly review and update our internal controls, disclosure controls and procedures, and
corporate governance policies. In addition, we are required under the Sarbanes Oxley Act of 2002 to
report annually on our internal control over financial reporting. If it were to be determined that
our internal control over financial reporting is not effective, such shortcoming could have an
adverse effect on our business and financial results and the price of our common stock could be
negatively affected. This reporting requirement could also make it more difficult or more costly
for us to obtain certain types of insurance, including director and officer liability
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">insurance,
and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. Any system of
internal controls, however well designed and operated, is based in part on certain assumptions and
can provide only reasonable, not absolute, assurances that the objectives of the system are met.
Any failure or circumvention of the controls and procedures or failure to comply with regulation
concerning control and procedures could have a material effect on our business, results of
operation and financial condition. Any of these events could result in an adverse reaction in the
financial marketplace due to a loss of investor confidence in the reliability of our financial
statements, which ultimately could negatively affect the market price of our shares, increase the
volatility of our stock price and adversely affect our ability to raise additional funding. The
effect of these events could also make it more difficult for us to attract and retain qualified
persons to serve on our Board and our board committees and as executive officers.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Risks Related to Our Intellectual Property</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Our proprietary rights may not adequately protect our technologies and product candidates.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our commercial success will depend on our ability to obtain patents and/or regulatory exclusivity
and maintain adequate protection for our technologies and product candidates in the United States
and other countries. We will be able to protect our proprietary rights from unauthorized use by
third parties only to the extent that our proprietary technologies and future product candidates
are covered by valid and enforceable patents or are effectively maintained as trade secrets.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We and our collaborators, including Teva, intend to apply for additional patents covering both our
technologies and product candidates, as we deem appropriate. We or our collaborators may, however,
fail to apply for patents on important technologies or product candidates in a timely fashion, if
at all. Our existing patents and any future patents we or our collaborators obtain may not be
sufficiently broad to prevent others from practicing our technologies or from developing competing
products and technologies. In addition, we do not always control the patent prosecution of subject
matter that we license from others. Accordingly, we are sometimes unable to exercise a significant
degree of control over such intellectual property as we would over our own. Moreover, the patent
positions of biopharmaceutical companies are highly uncertain and involve complex legal and factual
questions for which important legal principles remain unresolved. As a result, the validity and
enforceability of our patents cannot be predicted with certainty. In addition, we cannot guarantee
that:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we or our licensors were the first to make the inventions covered by each of our issued
patents and pending patent applications;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we or our licensors were the first to file patent applications for these inventions;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>others will not independently develop similar or alternative technologies or duplicate
any of our technologies;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any of our or our licensors&#146; pending patent applications will result in issued patents;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any of our or our licensors&#146; patents will be valid or enforceable;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any patents issued to us or our licensors and collaboration partners will provide us
with any competitive advantages, or will not be challenged by third parties; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we will develop additional proprietary technologies that are patentable, or the patents
of others will not have an adverse effect on our business.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The actual protection afforded by a patent varies on a product-by-product basis, from country to
country and depends on many factors, including the type of patent, the scope of its coverage, the
availability of regulatory related extensions, the availability of legal remedies in a particular
country and the validity and enforceability of the patents. Our ability or the ability of our
collaborators to maintain and solidify our proprietary position for our product candidates will
depend on our success in obtaining effective claims and enforcing those claims once granted. Our
issued patents and those that may issue in the future, or those licensed to us or our
collaborators, may be challenged, invalidated, unenforceable or circumvented, and the rights
granted under any issued patents may not provide us with proprietary protection or competitive
advantages against competitors with similar products. Due to the extensive amount of time required
for the
development, testing and regulatory review of a potential product, it is possible that, before any
of our product candidates can be commercialized, any related patent may expire or remain in force
for only a short period following commercialization, thereby reducing any advantage of the patent.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We and our collaborators, including Teva, also rely on trade secrets to protect some of our
technology, especially where it is believed that patent protection is appropriate or obtainable.
However, trade secrets are difficult to maintain. While we use reasonable efforts to protect our
trade secrets, our or our collaboration partners&#146; employees, consultants, contractors or scientific
and other advisors may unintentionally or willfully disclose our proprietary information to
competitors. Enforcement of claims that a third party has illegally obtained and is using trade
secrets is expensive, time consuming and uncertain. In addition, non-U.S. courts are sometimes less
willing than U.S. courts to protect trade secrets. If our competitors independently develop
equivalent knowledge, methods and know-how, we would not be able to assert our trade secrets
against them and our business could be harmed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We and our collaborators, including Teva, may not be able to protect our intellectual property
rights throughout the world.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Filing, prosecuting and defending patents on all of our product candidates and products, when and
if we have any, in every jurisdiction would be prohibitively expensive. Competitors may use our
technologies in jurisdictions where we or our licensors have not obtained patent protection to
develop their own products. These products may compete with our products, when and if we have any,
and may not be covered by any of our or our licensors&#146; patent claims or other intellectual property
rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The laws of some non-U.S. countries do not protect intellectual property rights to the same extent
as the laws of the United States, and many companies have encountered significant problems in
protecting and defending such rights in foreign jurisdictions. The legal systems of certain
countries, particularly certain developing countries, do not favor the enforcement of patents and
other intellectual property protection, particularly those relating to biotechnology and/or
pharmaceuticals, which could make it difficult for us to stop the infringement of our patents.
Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost
and divert our efforts and attention from other aspects of our business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>The intellectual property protection for our product candidates depends on third parties.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">With respect to custirsen, OGX-427 and OGX-225, we have exclusively licensed from UBC certain
issued patents and pending patent applications covering the respective antisense sequences
underlying these product candidates and their commercialization and use and we have licensed from
Isis certain issued patents and pending patent applications directed to product compositions and
chemical modifications used in product candidates for commercialization, use and the manufacturing
thereof, as well as some alternative antisense sequences. We have also received a sublicense from
Isis under certain third-party patent portfolios directed to such modifications. We have entered
into an exclusive in-licensing agreement with Bayer for development of caspase activators that are
presently being evaluated in pre-clinical studies.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The patents and pending patent applications underlying our licenses do not cover all potential
product candidates, modifications and uses. In the case of patents and patent applications licensed
from Isis, we do not have and have not had any control over the filing, prosecution or enforcement
of these patents or patent applications. In the case of patents and patent applications licensed
from Bayer, we did not have any control over the filing of the patents and patent applications
before the effective date of the Bayer license, and have had control over the filing and
prosecution of these patents and patent applications after the effective date of the Bayer license.
Under certain circumstances, we also have the right to enforce patents and patent applications
licensed from Bayer. We cannot be certain that such prosecution efforts have been or will be
conducted in compliance with applicable laws and regulations or will result in valid and
enforceable patents. We also cannot be assured that our licensors or their respective licensing
partners will agree to enforce any such patent rights at our request or devote sufficient efforts
to attain a desirable result. Any failure by our licensors or any of their respective licensing
partners to properly protect the intellectual
property rights relating to our product candidates could have a material adverse effect on our
financial condition and results of operation.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We may become involved in disputes with Teva or potential future collaborators over intellectual
property ownership, and publications by our research collaborators and scientific advisors could
impair our ability to obtain patent protection or protect our proprietary information, which, in
either case, could have a significant effect on our business.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Inventions discovered under research, material transfer or other such collaborative agreements,
including our Collaboration Agreement with Teva, may become jointly owned by us and the other party
to such agreements in some cases and the exclusive property of either party in other cases. Under
some circumstances, it may be difficult to determine who owns a particular invention, or whether it
is jointly owned, and disputes could arise regarding ownership of those inventions. These disputes
could be costly and time consuming and an unfavorable outcome could have a significant adverse
effect on our business if we were not able to protect or license rights to these inventions. In
addition, our research collaborators and scientific advisors generally have contractual rights to
publish our data and other proprietary information, subject to our prior review. Publications by
our research collaborators and scientific advisors containing such information, either with our
permission or in contravention of the terms of their agreements with us, may impair our ability to
obtain patent protection or protect our proprietary information, which could significantly harm our
business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>The patent protection for our product candidates or products may expire before we are able to
maximize their commercial value, which may subject us to increased competition and reduce or
eliminate our opportunity to generate product revenue.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The patents for our product candidates have varying expiration dates and, when these patents
expire, we may be subject to increased competition and we may not be able to recover our
development costs. For example, certain of the U.S. patents directed to custirsen and its use that
have been licensed from UBC are scheduled to expire in 2020 and 2021. In some of the larger
economic territories, such as the United States and Europe, patent term extension/restoration may
be available to compensate for time taken during aspects of the product candidate&#146;s regulatory
review. We cannot, however, be certain that an extension will be granted or, if granted, what the
applicable time period or the scope of patent protection afforded during any extended period will
be. In addition, even though some regulatory agencies may provide some other exclusivity for a
product candidate under its own laws and regulations, we may not be able to qualify the product
candidate or obtain the exclusive time period.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If we are unable to obtain patent term extension/restoration or some other exclusivity, we could be
subject to increased competition and our opportunity to establish or maintain product revenue could
be substantially reduced or eliminated. Furthermore, we may not have sufficient time to recover our
development costs prior to the expiration of our U.S. and non-U.S. patents.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We may incur substantial costs as a result of litigation or other proceedings relating to patent
and other intellectual property rights and we may be unable to protect our rights to, or use of,
our technology.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If we choose to go to court to stop someone else from using the inventions claimed in our patents
or our licensed patents, that individual or company has the right to ask the court to rule that
these patents are invalid and/or should not be enforced against that third party. These lawsuits
are expensive and would consume time and other resources even if we were successful in stopping the
infringement of these patents. In addition, there is a risk that the court will decide that these
patents are invalid or unenforceable and that we do not have the right to stop the other party from
using the inventions. There is also the risk that, even if the validity or unenforceability of
these patents is upheld, the court will refuse to stop the other party on the grounds that such
other party&#146;s activities do not infringe our rights.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If we wish to use the technology or compound claimed in issued and unexpired patents owned by
others, we will need to obtain a license from the owner, enter into litigation to challenge the
validity or enforceability of the patents or incur the risk of litigation in the event that the
owner asserts that we infringed its patents. The failure to obtain a license to technology or the
failure to challenge an issued patent that we may require to discover, develop or commercialize our
product candidates may have a material adverse effect on us.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If a third party asserts that we infringed its patents or other proprietary rights, we could face a
number of risks that could seriously harm our results of operations, financial condition and
competitive position, including:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>patent infringement and other intellectual property claims, which would be costly and
time consuming to defend, whether or not the claims have merit, and which could delay the
regulatory approval process and divert management&#146;s attention from our business;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>substantial damages for past infringement, which we may have to pay if a court
determines that our product candidates or technologies infringe a competitor&#146;s patent or
other proprietary rights;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a court prohibiting us from selling or licensing our technologies or future drugs
unless the third party licenses its patents or other proprietary rights to us on
commercially reasonable terms, which it is not required to do; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if a license is available from a third party, we may have to pay substantial royalties
or lump-sum payments or grant cross licenses to our patents or other proprietary rights to
obtain that license.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The biotechnology industry has produced a proliferation of patents, and it is not always clear to
industry participants, including us, which patents cover various types of products or methods of
use. The coverage of patents is subject to interpretation by the courts, and the interpretation is
not always uniform. If we are sued for patent infringement, we would need to demonstrate that our
product candidates or methods of use either do not infringe the patent claims of the relevant
patent, and/or that the patent claims are invalid, and/or that the patent is unenforceable and we
may not be able to do this. Proving invalidity, in particular, is difficult since it requires a
showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued
patents.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">U.S. patent laws as well as the laws of some foreign jurisdictions provide for provisional rights
in published patent applications beginning on the date of publication, including the right to
obtain reasonable royalties, if a patent subsequently issues and certain other conditions are met.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Because some patent applications in the United States may be maintained in secrecy until the
patents are issued, because patent applications in the United States and many foreign jurisdictions
are typically not published until 18&nbsp;months after filing, and because publications in the
scientific literature often lag behind actual discoveries, we cannot be certain that others have
not filed patent applications for technology covered by our licensors&#146; issued patents or our
pending applications or our licensors&#146; pending applications, or that we or our licensors were the
first to invent the technology.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Patent applications filed by third parties that cover technology similar to ours may have priority
over our or our licensors&#146; patent applications and could further require us to obtain rights to
issued patents covering such technologies. If another party files a U.S. patent application on an
invention similar to ours, we may elect to participate in or be drawn into an interference
proceeding declared by the U.S. Patent and Trademark Office to determine priority of invention in
the United States. The costs of these proceedings could be substantial, and it is possible that
such efforts would be unsuccessful, resulting in a loss of our U.S. patent position with respect to
such inventions. Some of our competitors may be able to sustain the costs of complex patent
litigation more effectively than we can because they have substantially greater resources. In
addition, any uncertainties resulting from the initiation and continuation of any litigation could
have a material adverse effect on our ability to raise the funds necessary to continue our
operations. We cannot predict whether third parties will assert these claims against us or against
the licensors of technology licensed to us, or whether those claims will harm our business. If we
are forced to defend
against these claims, whether they are with or without any merit and whether they are resolved in
favor of or against us or our licensors, we may face costly litigation and diversion of
management&#146;s attention and resources. As a result of these disputes, we may have to develop costly
non-infringing technology, or enter into licensing agreements. These agreements, if necessary, may
be unavailable on terms acceptable to us, if at all, which could seriously harm our business or
financial condition.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If we breach any of the agreements under which we license rights to our product candidates or
technology from third parties, we could lose license rights that are important to our business.
Certain of our license agreements may not provide an adequate remedy for a breach by the licensor.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We license the development and commercialization rights for most of our product candidates,
including custirsen, OGX-427, OGX-225 and CSP-9222, and we expect to enter into similar licenses in
the future. Under such licenses, we are subject to various obligations such as sublicensing,
royalty and milestone payments, annual maintenance fees, limits on sublicensing, insurance
obligations and the obligation to use commercially reasonable best efforts to develop and exploit
the licensed technology. If we fail to comply with any of these obligations or otherwise breach
these agreements, our licensors may have the right to terminate the license in whole or in part or
to terminate the exclusive nature of the license. Loss of any of these licenses or the exclusivity
rights provided by the licenses could harm our financial condition and results of operations. In
addition, certain of our license agreements with UBC eliminate our ability to obtain money damages
in respect of certain claims against UBC.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Under the terms of our Collaboration Agreement with Teva, we are required to use commercially
reasonable efforts to maintain and not to breach in any material manner certain of our third-party
license agreements relating to custirsen. If we breach any of these agreements in a material
manner, we would be in breach of the Collaboration Agreement, which would allow Teva to terminate
the Collaboration Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We may be subject to damages resulting from claims that we, or our employees or consultants, have
wrongfully used or disclosed alleged trade secrets of third parties.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Many of our employees were previously employed, and certain of our consultants are currently
employed, at universities or biotechnology or pharmaceutical companies, including our competitors
or potential competitors. Although we have not received any claim to date, we may be subject to
claims that these employees or consultants or we have inadvertently or otherwise used or disclosed
trade secrets or other proprietary information of these current or former employers. Litigation may
be necessary to defend against these claims. If we fail in defending such claims, in addition to
paying monetary damages, we may lose valuable intellectual property rights or personnel. We may be
subject to claims that employees of our partners or licensors of technology licensed by us have
inadvertently or otherwise used or disclosed trade secrets or other proprietary information of
their former employers. We may become involved in litigation to defend against these claims. If we
fail in defending such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights or personnel.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Risks Related to our Common Stock and Other Securities</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>The price for our common stock is volatile.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The market prices for our common stock and that of emerging growth companies generally have
historically been highly volatile. Future announcements concerning us or our competitors may have a
significant effect on the market price of our common stock. The stock markets also experience
significant price and volume fluctuation unrelated to the operating performance of particular
companies. These market fluctuations may also adversely affect the market price of our common
stock.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">An increase in the market price of our common stock, which is uncertain and unpredictable, may be
the sole source of gain from an investment in our common stock. An investment in our common stock
may not
be appropriate for investors who require dividend income. We have never declared or paid cash
dividends on our capital stock and do not anticipate paying any cash dividends on our capital stock
in the foreseeable future. We currently intend to retain all available funds and any future
earnings to fund the development and growth of our business. As a result, capital appreciation, if
any, of our common stock will be the sole source of gain for stockholders for the foreseeable
future. Accordingly, an investment in our common stock may not be appropriate for investors who
require dividend income.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If we raise additional financing, the terms of such transactions may cause dilution to existing
stockholders or contain terms that are not favorable to us.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">To date, our sources of cash have been limited primarily to proceeds from the private or public
placement of our securities and proceeds from the Collaboration Agreement with Teva. In the future,
we may seek to raise additional financing through private placements or public offerings of our
equity or debt securities. We cannot be certain that additional funding will be available on
acceptable terms, if at all. To the extent that we raise additional financing by issuing equity
securities, our stockholders may experience significant dilution. Any debt financing, if available,
may involve restrictive covenants, such as limitations on our ability to incur additional
indebtedness, limitations on our ability to acquire or license intellectual property rights and
other operating restrictions that could adversely affect our ability to conduct our business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We are at risk of securities class action litigation.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In the past, securities class action litigation has often been brought against a company following
a decline in the market price of its securities. This risk is especially relevant for us because
our stock price and those of other biotechnology and biopharmaceutical companies have experienced
significant stock price volatility in recent years. If we face such litigation, it could result in
substantial costs and a diversion of management&#146;s attention and resources, which could harm our
business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Anti-takeover provisions in our stockholder rights plan, our charter documents and under Delaware
law could make a third-party acquisition of us difficult.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We have a stockholder rights plan that may have the effect of discouraging unsolicited takeover
proposals. Specifically, the rights issued under the stockholder rights plan could cause
significant dilution to a person or group that attempts to acquire us on terms not approved in
advance by our Board. In addition, our certificate of incorporation and bylaws contain provisions
that may discourage unsolicited takeover proposals that stockholders may consider to be in their
best interests. These provisions include the ability of our Board to designate the terms of and
issue new series of preferred stock and the ability of our Board to amend our bylaws without
stockholder approval. In addition, as a Delaware corporation, we are subject to Section&nbsp;203 of the
Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in
any business combination with any interested stockholder for a period of three years following the
date that the stockholder became an interested stockholder, unless certain specific requirements
are met as set forth in Section&nbsp;203. Collectively, these provisions could make a third-party
acquisition of us difficult or could discourage transactions that otherwise could involve payment
of a premium over prevailing market prices for our common stock.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Risks Related to Our Industry</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>The regulatory approval process is expensive, time consuming and uncertain and may prevent us from
obtaining approvals for the commercialization of some or all of our product candidates.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of
drug products are subject to extensive regulation by the FDA and non-U.S. regulatory authorities,
which regulations differ from country to country. We are not permitted to market our product
candidates in the United States until we receive approval of a NDA from the FDA. We have not
submitted an application for or received marketing approval for any of our product candidates.
Obtaining approval of an NDA can be a
lengthy, expensive and uncertain process. In addition, failure to comply with FDA, non-U.S.
regulatory authorities&#146; or other applicable United States and non-U.S. regulatory requirements may,
either before or after product approval, if any, subject us to administrative or judicially imposed
sanctions, including:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>restrictions on the products, manufacturers or manufacturing process;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>warning letters;</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">





<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>civil and criminal penalties;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>injunctions;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>suspension or withdrawal of regulatory approvals;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>product seizures, detentions or import bans;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>voluntary or mandatory product recalls and publicity requirements;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>total or partial suspension of production;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>imposition of restrictions on operations, including costly new manufacturing
requirements; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>refusal to approve pending NDAs or supplements to approved NDAs.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Regulatory approval of an NDA or NDA supplement is not guaranteed, and the approval process is
expensive and may take several years. The FDA also has substantial discretion in the drug approval
process. Despite the time and expense exerted, failure can occur at any stage, and we could
encounter problems that could cause us to abandon clinical trials or to repeat or perform
additional pre-clinical studies and clinical trials. The number of pre-clinical studies and
clinical trials that will be required for FDA approval varies depending on the drug candidate, the
disease or condition that the drug candidate is designed to address, and the regulations applicable
to any particular drug candidate. The FDA can delay, limit or deny approval of a drug candidate for
many reasons, including:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a drug candidate may not be deemed safe or effective;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the FDA may not find the data from pre-clinical studies and clinical trials sufficient;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the FDA might not approve our third-party manufacturer&#146;s processes or facilities;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the FDA may change its approval policies or adopt new regulations; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>third-party products may enter the market and change approval requirements.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Even if we obtain regulatory approvals for our product candidates, the terms of approvals and
ongoing regulation of our product candidates may limit how we manufacture and market our product
candidates, which could materially affect our ability to generate revenue.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If any of our product candidates are approved, the approved product and its manufacturer will be
subject to continual review. Any regulatory approval that we receive for a product candidate is
likely to be subject to limitations on the indicated uses for which the end product may be
marketed, or include requirements for potentially costly post-approval follow-up clinical trials.
In addition, if the FDA and/or non-U.S. regulatory authorities approve any of our product
candidates, the labeling, packaging, adverse event reporting, storage, advertising and promotion
for the end product will be subject to extensive regulatory requirements. We and the manufacturers
of our products, when and if we have any, will also be required to comply with cGMP regulations,
which include requirements relating to quality control and quality assurance, as well as the
corresponding maintenance of records and documentation. Further, regulatory agencies must approve
these manufacturing facilities before they can be used to manufacture our products, when and if we
have any, and these facilities are subject to ongoing regulatory inspection. If we fail to comply
with the regulatory requirements of the FDA and other non-U.S. regulatory authorities, or if
previously unknown problems with our products, when and if we have any, manufacturers or
manufacturing processes are discovered, we could be subject to administrative or judicially imposed
sanctions, including:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>restrictions on the products, manufacturers or manufacturing process;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>warning letters;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>civil or criminal penalties or fines;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>injunctions;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>product seizures, detentions or import bans;
</TD>
</TR>
</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->49<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>voluntary or mandatory product recalls and publicity requirements;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>suspension or withdrawal of regulatory approvals;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>total or partial suspension of production;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>imposition of restrictions on operations, including costly new manufacturing
requirements; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>refusal to approve pending NDAs or supplements to approved NDAs.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In addition, the FDA and non-U.S. regulatory authorities may change their policies and additional
regulations may be enacted that could prevent or delay regulatory approval of our product
candidates. We cannot predict the likelihood, nature or extent of government regulation that may
arise from future legislation or administrative action, either in the United States, Canada or
abroad. If we are not able to maintain regulatory compliance, we would likely not be permitted to
market our future product candidates and we may not achieve or sustain profitability.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>There is a high risk that our drug development activities will not result in commercial products.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our product candidates are in various stages of development and are prone to the risks of failure
inherent in drug development. We will need to complete significant additional clinical trials
before we can demonstrate that our product candidates are safe and effective to the satisfaction of
the FDA and non-U.S. regulatory authorities. Clinical trials are expensive and uncertain processes
that take years to complete. Failure can occur at any stage of the process, and successful early
clinical trials do not ensure that later clinical trials will be successful. Product candidates in
later-stage clinical trials may fail to show desired efficacy and safety traits despite having
progressed through initial clinical trials. A number of companies in the pharmaceutical industry
have suffered significant setbacks in advanced clinical trials, even after obtaining promising
results in earlier clinical trials. In addition, a clinical trial may prove successful with respect
to a secondary objective, but fail to demonstrate clinically significant benefits with respect to a
primary objective. Failure to satisfy a primary objective in a phase 3 clinical trial (registration
trial) would generally mean that a product candidate would not receive regulatory approval.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If government and third-party payors fail to provide coverage and adequate reimbursement rates for
our product candidates, our revenue and potential for profitability will be reduced.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In the United States and elsewhere, our product revenue will depend principally on the
reimbursement rates established by third-party payors, including government health administration
authorities, managed-care providers, public health insurers, private health insurers and other
organizations. These third-party payors are increasingly challenging the price, and examining the
cost-effectiveness, of medical products and services. In addition, significant uncertainty exists
as to the reimbursement status, if any, of newly approved drugs, pharmaceutical products or product
indications. We may need to conduct post-marketing clinical trials in order to demonstrate the
cost-effectiveness of our products, if any. Such clinical trials may require us to commit a
significant amount of management time and financial and other resources. If reimbursement of such
product is unavailable or limited in scope or amount or if pricing is set at unsatisfactory levels,
our revenue could be reduced.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In some countries other than the United States, particularly the countries of the European Union
and Canada, the pricing of prescription pharmaceuticals is subject to governmental control. In
these countries, obtaining pricing approval from governmental authorities can take six to 12&nbsp;months
or longer after the receipt of regulatory marketing approval of a product for an indication. To
obtain reimbursement or pricing approval in some countries, we may be required to conduct a
clinical trial that compares the cost-effectiveness of one of our product candidates to other
available therapies. If reimbursement of such product candidate is unavailable or limited in scope
or amount or if pricing is set at unsatisfactory levels, our revenue could be reduced.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->50<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Domestic and foreign governments continue to propose and pass legislation designed to reduce the
cost of healthcare, including drugs. In the United States, there have been, and we expect that
there will continue to be, federal and state proposals to implement similar governmental control.
In addition, increasing emphasis
on managed care in the United States will continue to put pressure on the pricing of pharmaceutical
products. For example, the Medicare Prescription Drug Improvement and Modernization Act of 2003
reforms the way Medicare will cover and reimburse pharmaceutical products. The legislation expands
Medicare coverage for drug purchases by the elderly and eventually will introduce a new
reimbursement methodology based on average sales prices for certain drugs. In addition, the new
legislation provides authority for limiting the number of outpatient drugs that will be covered in
any therapeutic class. As a result of the new legislation and the expansion of federal coverage of
drug products, we expect that there will be additional pressure to contain and reduce costs. The
Medicaid program and state healthcare laws and regulations may also be modified to change the scope
of covered products and/or reimbursement methodology. Cost control initiatives could decrease the
established reimbursement rates that we receive for any products in the future, which would limit
our revenue and profitability. Legislation and regulations affecting the pricing of pharmaceutical
products, including custirsen, may change at any time, which could further limit or eliminate
reimbursement rates for custirsen or other product candidates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Failure to obtain regulatory approval outside of the United States and Canada would prevent us or
Teva from marketing our product candidates abroad.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We intend to market certain of our existing and future product candidates outside of the United
States and Canada. In order to market our existing and future product candidates in the European
Union and many other non-North American markets, we must obtain separate regulatory approvals. We
have had limited interactions with non-North American regulatory authorities. Approval procedures
vary among countries and can involve additional testing, and the time required to obtain approval
may differ from that required to obtain FDA approval. Approval by the FDA or other regulatory
authorities does not ensure approval by regulatory authorities in other countries, and approval by
one or more non-North American regulatory authorities does not ensure approval by regulatory
authorities in other countries or by the FDA. The non-North American regulatory approval process
may include all of the risks associated with obtaining FDA approval. We may not obtain non-North
American regulatory approvals on a timely basis, if at all. We may not be able to file for
non-North American regulatory approvals and may not receive necessary approvals to commercialize
our existing and future product candidates in any market.
</DIV>

<DIV align="left">
<A name="C20581112"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;6.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Exhibits</B></TD>
</TR>
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="86%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" colspan="3"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">31.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of President and Chief Executive Officer
pursuant to Rule&nbsp;13a-14(a) or 15d-14(a) of the Securities
Exchange Act of 1934, as adopted pursuant to Section&nbsp;302 of
the Sarbanes-Oxley Act of 2002</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">31.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of Chief Financial Officer pursuant to Rule
13a-14(a) or 15d-14(a) of the Securities Exchange Act of
1934, as adopted pursuant to Section&nbsp;302 of the
Sarbanes-Oxley Act of 2002</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">32.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of President and Chief Executive Officer
pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to
Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">32.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of Chief Financial Officer pursuant to 18
U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of
the Sarbanes-Oxley Act of 2002</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->51<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left">
<A name="C20581114"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>ONCOGENEX PHARMACEUTICALS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date:   August 4, 2011&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Michelle Burris
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Michelle Burris&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer<br>
(Principal Financial Officer)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C20581tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="86%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" colspan="3"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">31.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of President and Chief Executive Officer
pursuant to Rule&nbsp;13a-14(a) or 15d-14(a) of the Securities
Exchange Act of 1934, as adopted pursuant to Section&nbsp;302 of
the Sarbanes-Oxley Act of 2002</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">31.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of Chief Financial Officer pursuant to Rule
13a-14(a) or 15d-14(a) of the Securities Exchange Act of
1934, as adopted pursuant to Section&nbsp;302 of the
Sarbanes-Oxley Act of 2002</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">32.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of President and Chief Executive Officer
pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to
Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">32.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of Chief Financial Officer pursuant to 18
U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of
the Sarbanes-Oxley Act of 2002</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->53<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>c20581exv31w1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 31.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;31.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Certification Pursuant to Rule&nbsp;13a-14(a) or Rule&nbsp;15d-14(a) of the Securities Exchange Act of 1934</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">I, Scott Cormack, certify that:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">1. I have reviewed this quarterly report on Form 10-Q of OncoGenex Pharmaceuticals, Inc.;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this
report;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">3. Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and
internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and
15d-15(f)) for the registrant and have:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(a)&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and
procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(b)&nbsp;Designed such internal control over financial reporting, or caused such internal control
over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(c)&nbsp;Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(d)&nbsp;Disclosed in this report any change in the registrant&#146;s internal control over financial
reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth
fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant&#146;s internal control over financial reporting; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit
committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(a)&nbsp;all significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect the
registrant&#146;s ability to record, process, summarize and report financial information; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(b)&nbsp;any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrant&#146;s internal control over financial reporting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Date: August&nbsp;4, 2011
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Scott Cormack
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Scott Cormack&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">President and Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>c20581exv31w2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 31.2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;31.2</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Certification Pursuant to Rule&nbsp;13a-14(a) or Rule&nbsp;15d-14(a) of the Securities Exchange Act of 1934</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">I, Michelle Burris, certify that:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">1. I have reviewed this quarterly report on Form 10-Q of OncoGenex Pharmaceuticals, Inc.;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this
report;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">3. Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and
internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and
15d-15(f)) for the registrant and have:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(a)&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and
procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(b)&nbsp;Designed such internal control over financial reporting, or caused such internal control
over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(c)&nbsp;Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(d)&nbsp;Disclosed in this report any change in the registrant&#146;s internal control over financial
reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth
fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant&#146;s internal control over financial reporting; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit
committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(a)&nbsp;all significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect the
registrant&#146;s ability to record, process, summarize and report financial information; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(b)&nbsp;any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrant&#146;s internal control over financial reporting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Date: August&nbsp;4, 2011
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Michelle Burris
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Michelle Burris&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>c20581exv32w1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhbiti 32.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;32.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Certification pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">I, Scott Cormack, President and Chief Executive Officer of OncoGenex Pharmaceuticals, Inc.
(the &#147;Company&#148;), certify, pursuant to Rule&nbsp;13a-14(b) or Rule&nbsp;15d-14(b) of the Securities Exchange
Act of 1934 and 18 U.S.C. Section&nbsp;1350, that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(1)&nbsp;the Quarterly Report on Form 10-Q of the Company for the quarterly period ended June&nbsp;30,
2011 (the &#147;Report&#148;) fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934 (15 U.S.C. 78m or 780(d)); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(2)&nbsp;the information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Dated: August&nbsp;4, 2011
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Scott Cormack
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Scott Cormack&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">President and Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>c20581exv32w2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 32.2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;32.2</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Certification pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">I, Michelle Burris, Chief Financial Officer of OncoGenex Pharmaceuticals, Inc. (the
&#147;Company&#148;), certify, pursuant to Rule&nbsp;13a-14(b) or Rule&nbsp;15d-14(b) of the Securities Exchange Act of
1934 and 18 U.S.C. Section&nbsp;1350, that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(1)&nbsp;the Quarterly Report on Form 10-Q of the Company for the quarterly period ended June&nbsp;30,
2011 (the &#147;Report&#148;) fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934 (15 U.S.C. 78m or 780(d)); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">(2)&nbsp;the information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Dated: August&nbsp;4, 2011
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Michelle Burris
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Michelle Burris&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>ogxi-20110630.xml
<DESCRIPTION>EX-101 INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ogxi="http://oncogenex.com/2011-06-30" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="ogxi-20110630.xsd" />
<!-- Context Section -->
<context id="BalanceAsOf_01Aug2011">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000949858</identifier>
</entity>
<period>
<instant>2011-08-01</instant>
</period>
</context>
<context id="BalanceAsOf_30Jun2011">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000949858</identifier>
</entity>
<period>
<instant>2011-06-30</instant>
</period>
</context>
<context id="BalanceAsOf_31Dec2010">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000949858</identifier>
</entity>
<period>
<instant>2010-12-31</instant>
</period>
</context>
<context id="ThreeMonthsEnded_30Jun2011">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000949858</identifier>
</entity>
<period>
<startDate>2011-04-01</startDate>
<endDate>2011-06-30</endDate>
</period>
</context>
<context id="ThreeMonthsEnded_30Jun2010">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000949858</identifier>
</entity>
<period>
<startDate>2010-04-01</startDate>
<endDate>2010-06-30</endDate>
</period>
</context>
<context id="SixMonthsEnded_30Jun2011">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000949858</identifier>
</entity>
<period>
<startDate>2011-01-01</startDate>
<endDate>2011-06-30</endDate>
</period>
</context>
<context id="SixMonthsEnded_30Jun2010">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000949858</identifier>
</entity>
<period>
<startDate>2010-01-01</startDate>
<endDate>2010-06-30</endDate>
</period>
</context>
<context id="BalanceAsOf_31Dec2009">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000949858</identifier>
</entity>
<period>
<instant>2009-12-31</instant>
</period>
</context>
<context id="BalanceAsOf_30Jun2010">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000949858</identifier>
</entity>
<period>
<instant>2010-06-30</instant>
</period>
</context>
<!--Unit Section-->
 <unit id="USDEPS">
   <divide>
     <unitNumerator>
       <measure>iso4217:USD</measure>
     </unitNumerator>
     <unitDenominator>
       <measure>xbrli:shares</measure>
     </unitDenominator>
   </divide>
 </unit>
 <unit id="Shares">
   <measure>xbrli:shares</measure>
  </unit>
  <unit id="USD">
    <measure>iso4217:USD</measure>
  </unit>

<!-- Element Section -->
<!--Document Information-->
<dei:EntityRegistrantName contextRef="SixMonthsEnded_30Jun2011">ONCOGENEX PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="SixMonthsEnded_30Jun2011">0000949858</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="SixMonthsEnded_30Jun2011">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityWellKnownSeasonedIssuer contextRef="SixMonthsEnded_30Jun2011">No</dei:EntityWellKnownSeasonedIssuer>
<dei:EntityVoluntaryFilers contextRef="SixMonthsEnded_30Jun2011">No</dei:EntityVoluntaryFilers>
<dei:EntityCurrentReportingStatus contextRef="SixMonthsEnded_30Jun2011">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityFilerCategory contextRef="SixMonthsEnded_30Jun2011">Accelerated Filer</dei:EntityFilerCategory>
<dei:DocumentType contextRef="SixMonthsEnded_30Jun2011">10-Q</dei:DocumentType>
<dei:AmendmentFlag contextRef="SixMonthsEnded_30Jun2011">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate contextRef="SixMonthsEnded_30Jun2011">2011-06-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalPeriodFocus contextRef="SixMonthsEnded_30Jun2011">Q2</dei:DocumentFiscalPeriodFocus>
<dei:DocumentFiscalYearFocus contextRef="SixMonthsEnded_30Jun2011">2011</dei:DocumentFiscalYearFocus>
<dei:EntityPublicFloat contextRef="BalanceAsOf_30Jun2010" decimals="0" unitRef="USD">86062824</dei:EntityPublicFloat>
<dei:EntityCommonStockSharesOutstanding contextRef="BalanceAsOf_01Aug2011" decimals="INF" unitRef="Shares">9725489</dei:EntityCommonStockSharesOutstanding>
<!-- Instance Elements for BALANCE_SHEETS -->
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">20876000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">23533000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">502000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">502000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
<us-gaap:ShortTermInvestments contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">54536000</us-gaap:ShortTermInvestments>
<us-gaap:ShortTermInvestments contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">61574000</us-gaap:ShortTermInvestments>
<us-gaap:AccountsReceivableNetCurrent contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">1498000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">1224000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">1397000</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">2485000</us-gaap:PrepaidExpenseCurrent>
<us-gaap:AssetsCurrent contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">78809000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">89318000</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">207000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">87000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:OtherAssetsNoncurrent contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">509000</us-gaap:OtherAssetsNoncurrent>
<us-gaap:OtherAssetsNoncurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">513000</us-gaap:OtherAssetsNoncurrent>
<us-gaap:Assets contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">79525000</us-gaap:Assets>
<us-gaap:Assets contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">89918000</us-gaap:Assets>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">1643000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">893000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:DeferredRevenueCurrent contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">10000000</us-gaap:DeferredRevenueCurrent>
<us-gaap:DeferredRevenueCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">10000000</us-gaap:DeferredRevenueCurrent>
<us-gaap:CapitalLeaseObligationsCurrent contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">1384000</us-gaap:CapitalLeaseObligationsCurrent>
<us-gaap:CapitalLeaseObligationsCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">1314000</us-gaap:CapitalLeaseObligationsCurrent>
<us-gaap:WarrantsAndRightsOutstanding contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">14828000</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">15269000</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">27855000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">27476000</us-gaap:LiabilitiesCurrent>
<us-gaap:DeferredRevenueNoncurrent contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">9866000</us-gaap:DeferredRevenueNoncurrent>
<us-gaap:DeferredRevenueNoncurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">11622000</us-gaap:DeferredRevenueNoncurrent>
<us-gaap:CapitalLeaseObligationsNoncurrent contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">6606000</us-gaap:CapitalLeaseObligationsNoncurrent>
<us-gaap:CapitalLeaseObligationsNoncurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">6695000</us-gaap:CapitalLeaseObligationsNoncurrent>
<us-gaap:Liabilities contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">44327000</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">45793000</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies unitRef="USD" xsi:nil="true" contextRef="BalanceAsOf_30Jun2011" />
<us-gaap:CommitmentsAndContingencies unitRef="USD" xsi:nil="true" contextRef="BalanceAsOf_31Dec2010" />
<us-gaap:CommonStockValue contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">10000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">10000</us-gaap:CommonStockValue>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_30Jun2011" unitRef="USDEPS" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2010" unitRef="USDEPS" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_30Jun2011" unitRef="Shares" decimals="INF">25000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">25000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_30Jun2011" unitRef="Shares" decimals="INF">9718251</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">9693591</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_30Jun2011" unitRef="Shares" decimals="INF">9718251</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">9693591</us-gaap:CommonStockSharesOutstanding>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">108224000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">107579000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">-75644000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">-66069000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">2608000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">2605000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:StockholdersEquity contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">35198000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">44125000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">79525000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">89918000</us-gaap:LiabilitiesAndStockholdersEquity>
<!-- Instance Elements for STMNT_INCOME -->
<ogxi:RevenuesFromCollaborativeAgreements contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">1887000</ogxi:RevenuesFromCollaborativeAgreements>
<ogxi:RevenuesFromCollaborativeAgreements contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">1701000</ogxi:RevenuesFromCollaborativeAgreements>
<ogxi:RevenuesFromCollaborativeAgreements contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">3086000</ogxi:RevenuesFromCollaborativeAgreements>
<ogxi:RevenuesFromCollaborativeAgreements contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">6401000</ogxi:RevenuesFromCollaborativeAgreements>
<us-gaap:ResearchAndDevelopmentExpense contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">5409000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">3079000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">10262000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">9459000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">1471000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">1475000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">3042000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">2825000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:CostsAndExpenses contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">6880000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">4554000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">13304000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">12284000</us-gaap:CostsAndExpenses>
<us-gaap:OperatingIncomeLoss contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-4993000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-2853000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-10218000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-5883000</us-gaap:OperatingIncomeLoss>
<us-gaap:InvestmentIncomeInterest contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">63000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">14000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">119000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">19000</us-gaap:InvestmentIncomeInterest>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">87000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-7000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">83000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-26000</us-gaap:OtherNonoperatingIncomeExpense>
<ogxi:FairValueAdjustmentOfWarrants contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">1687000</ogxi:FairValueAdjustmentOfWarrants>
<ogxi:FairValueAdjustmentOfWarrants contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-441000</ogxi:FairValueAdjustmentOfWarrants>
<us-gaap:NonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-1537000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">7000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">643000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-7000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-6530000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-2846000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-9575000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-5890000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxExpenseBenefit contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-3000000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-3000000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-6530000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">154000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-9575000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-2890000</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USDEPS" decimals="2">0.67</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USDEPS" decimals="2">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="SixMonthsEnded_30Jun2011" unitRef="USDEPS" decimals="2">0.99</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="SixMonthsEnded_30Jun2010" unitRef="USDEPS" decimals="2">0.45</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="ThreeMonthsEnded_30Jun2011" unitRef="Shares" decimals="0">9718251</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="ThreeMonthsEnded_30Jun2010" unitRef="Shares" decimals="0">6400081</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="SixMonthsEnded_30Jun2011" unitRef="Shares" decimals="0">9715846</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="SixMonthsEnded_30Jun2010" unitRef="Shares" decimals="0">6366861</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="ThreeMonthsEnded_30Jun2011" unitRef="Shares" decimals="0">9718251</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="ThreeMonthsEnded_30Jun2010" unitRef="Shares" decimals="0">6529482</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="SixMonthsEnded_30Jun2011" unitRef="Shares" decimals="0">9715846</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="SixMonthsEnded_30Jun2010" unitRef="Shares" decimals="0">6366861</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<!-- Instance Elements for STMNT_CASH_FLOWS -->
<us-gaap:DepreciationDepletionAndAmortization contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">37000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">26000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:ShareBasedCompensation contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">554000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">311000</us-gaap:ShareBasedCompensation>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-440000</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">274000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-2696000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
<us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">502000</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-1091000</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">1619000</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">750000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-12786000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<ogxi:IncreaseDecreaseInLeaseObligation contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">19000</ogxi:IncreaseDecreaseInLeaseObligation>
<ogxi:IncreaseDecreaseInLeaseObligation contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">599000</ogxi:IncreaseDecreaseInLeaseObligation>
<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-1755000</us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-2393000</us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-9631000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-17756000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">91000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">521000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">91000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">521000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">51259000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
<us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">500000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
<us-gaap:PaymentsToAcquireShortTermInvestments contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">44222000</us-gaap:PaymentsToAcquireShortTermInvestments>
<us-gaap:PaymentsToAcquireShortTermInvestments contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">12291000</us-gaap:PaymentsToAcquireShortTermInvestments>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">68000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">27000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">6969000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-11818000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-86000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">13000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">2657000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">29040000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2009" unitRef="USD" decimals="-3">62051000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Jun2010" unitRef="USD" decimals="-3">33011000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<ogxi:PropertyAndEquipmentAcquiredUnderLeaseObligation contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">90000</ogxi:PropertyAndEquipmentAcquiredUnderLeaseObligation>
<!-- Begin Block Tagged Note -->
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="SixMonthsEnded_30Jun2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 1 - us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock--&gt;
   &lt;div align="left" style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;!-- xbrl,ns --&gt;
   &lt;!-- xbrl,nx --&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;&lt;b&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;/div&gt;
   &lt;div align="center" style="font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/div&gt;
   &lt;div align="center" style="font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;1. NATURE OF BUSINESS AND BASIS OF PRESENTATION&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;OncoGenex Pharmaceuticals, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;OncoGenex&amp;#8221;) is committed to the development and
   commercialization of new therapies that address treatment resistance in cancer patients. The
   Company was incorporated in the state of Delaware and, together with its subsidiaries, has a
   facility in Bothell, Washington and an office in Vancouver, British Columbia (Canada).
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;The unaudited financial statements have been prepared in accordance with generally accepted
   accounting principles in the United States for interim financial information and with the
   instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes
   required to be presented for complete financial statements. The accompanying unaudited consolidated
   financial statements reflect all adjustments (consisting only of normal recurring items) which are,
   in the opinion of management, necessary for a fair presentation of the results for the interim
   periods presented. The accompanying consolidated Balance Sheet at December&amp;#160;31, 2010 has been
   derived from the audited consolidated financial statements included in the Company&amp;#8217;s Annual Report
   on Form 10-K for the year then ended. The consolidated financial statements and related disclosures
   have been prepared with the assumption that users of the interim financial information have read or
   have access to the audited consolidated financial statements for the preceding fiscal year.
   Accordingly, these financial statements should be read in conjunction with the audited consolidated
   financial statements and the related notes thereto included in the Annual Report on Form 10-K for
   the year ended December&amp;#160;31, 2010 and filed with the United States Securities and Exchange
   Commission (&amp;#8220;SEC&amp;#8221;) on March&amp;#160;10, 2011.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;The consolidated financial statements include the accounts of OncoGenex and our wholly owned
   subsidiary, OncoGenex Technologies Inc. (&amp;#8220;OncoGenex Technologies&amp;#8221;). All intercompany
   balances and transactions have been eliminated.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="SixMonthsEnded_30Jun2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 2 - us-gaap:SignificantAccountingPoliciesTextBlock--&gt;
   &lt;div align="left" style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;2. ACCOUNTING POLICIES&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;Recently Adopted Accounting Policies&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;In April&amp;#160;2010, the Financial Accounting Standards Board, or FASB, issued ASU No.&amp;#160;2010 &amp;#8212; 17 &amp;#8212;
   Revenue Recognition &amp;#8212; Milestone Method (Topic 605): Milestone Method of Revenue Recognition. This
   standard provides guidance on defining a milestone and determining when it may be appropriate to
   apply the milestone method of revenue recognition for certain research and development
   transactions. Under this new standard, a company can recognize as revenue consideration that is
   contingent upon achievement of a milestone in the period in which it is achieved, only if the
   milestone meets all criteria to be considered substantive. This standard was effective for us on a
   prospective basis beginning in the quarter ended March&amp;#160;31, 2011. The adoption of this standard did
   not have a significant impact on our financial position or results of operations.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;In January&amp;#160;2010, the FASB issued amended guidance on fair value measurements and disclosures. The
   new guidance requires additional disclosures regarding fair value measurements, amends disclosures
   about post-retirement benefit plan assets, and provides clarification regarding the level of
   disaggregation of fair value disclosures by investment class. This guidance is effective for
   interim and annual reporting periods beginning after December&amp;#160;15, 2009, except for certain Level 3
   activity disclosure requirements that will be effective for reporting periods beginning after
   December&amp;#160;15, 2010. Accordingly, we adopted this amendment in the quarter ended March&amp;#160;31, 2010,
   while the additional Level 3 requirements were adopted
   in the quarter ended March&amp;#160;31, 2011. The adoption of this standard did not have a significant
   impact on our financial position or results of operations.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;In May&amp;#160;2011, the FASB issued ASU No.&amp;#160;2011-04, &amp;#8220;Fair Value Measurement.&amp;#8221; This ASU clarifies the
   concepts related to highest and best use and valuation premise, blockage factors and other premiums
   and discounts, the fair value measurement of financial instruments held in a portfolio and of those
   instruments classified as a component of shareowners&amp;#8217; equity. The guidance includes enhanced
   disclosure requirements about recurring Level 3 fair value measurements, the use of nonfinancial
   assets, and the level in the fair value hierarchy of assets and liabilities not recorded at fair
   value. The provisions of this ASU are effective prospectively for interim and annual periods
   beginning on or after December&amp;#160;15, 2011. Early application is prohibited. We are currently
   evaluating the impact of this new ASU.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;In June&amp;#160;2011, the FASB issued ASU No.&amp;#160;2011-05, &amp;#8220;Comprehensive Income.&amp;#8221; This ASU intends to enhance
   comparability and transparency of other comprehensive income components. The guidance provides an
   option to present total comprehensive income, the components of net income and the components of
   other comprehensive income in a single continuous statement or two separate but consecutive
   statements. This ASU eliminates the option to present other comprehensive income components as part
   of the statement of changes in shareowners&amp;#8217; equity. The provisions of this ASU will be applied
   retrospectively for interim and annual periods beginning after December&amp;#160;15, 2011. Early application
   is permitted. We are currently evaluating the impact of this new ASU.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<ogxi:CollaborationAgreementTextBlock contextRef="SixMonthsEnded_30Jun2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 3 - ogxi:CollaborationAgreementTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;3. COLLABORATION AGREEMENT&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;On December&amp;#160;20, 2009, the Company, through its wholly-owned subsidiary, OncoGenex Technologies,
   entered into a Collaboration Agreement with Teva Pharmaceutical Industries Ltd., or Teva, for the
   development and global commercialization of custirsen (and related compounds), a pharmaceutical
   compound designed to inhibit the production of clusterin, a protein we believe is associated with
   cancer treatment resistance, or the Licensed Product. Under the Collaboration Agreement, Teva paid
   the Company upfront payments in the aggregate amount of $50&amp;#160;million and has agreed to pay up to
   $370&amp;#160;million upon the achievement of developmental and commercial milestones and royalties at
   percentage rates ranging from the mid-teens to mid-twenties on net sales, depending on aggregate
   annual net sales of the Licensed Product.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;On the same date, the Company and Teva also entered into a stock purchase agreement, or Stock
   Purchase Agreement, pursuant to which Teva made an additional $10&amp;#160;million equity investment in the
   Company at a 20% premium to a thirty-day average closing price, resulting in the issuance of
   267,531 of our common shares purchased at a price of $37.38 per share. The 20% share premium was
   included as consideration for the custirsen license and has been included in collaboration revenue.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;In connection with the Collaboration Agreement and pursuant to the terms of agreements between the
   Company and Isis relating to custirsen, the Company paid Isis Pharmaceuticals, Inc., or Isis, $10
   million which was recorded as research and development expense in 2009. The Company also paid
   approximately $333,333 to the University of British Columbia, or UBC, pursuant to the terms of
   their license agreement relating to custirsen, which has been recorded as research and development
   expense in 2009. Pursuant to the terms of the third-party agreements, the Company anticipates that
   it would be required to pay third parties 31% of any milestone payments that are not based on a
   percentage of net sales of the Licensed Product. Pursuant to the terms of third-party agreements,
   the Company anticipates it will pay royalties to third-parties of 4.88% to 8.00% of net sales,
   unless the Company&amp;#8217;s royalties are adjusted for competition from generic compounds, in which case
   royalties to third parties will also be subject to adjustment on a country-by-country basis.
   Certain third-party royalties are tiered based on the royalty rate received by the Company. Minimum
   royalty rates payable by the Company assume certain third-party royalties are not paid
   at the time that the Licensed Product is marketed due to the expiration of patents held by such
   third parties. Maximum royalty rates assume all third-party royalty rates currently in effect
   continue in effect at the time the Licensed Product is marketed.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Teva has the exclusive worldwide right and license to develop and commercialize products containing
   custirsen and related compounds. The Company has an option to co-promote any Licensed Product in
   the United States and Canada.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Teva is responsible for all costs relating to product commercialization including costs incurred in
   relation to the Company&amp;#8217;s co-promotion option, except for start-up costs in advance of
   commercialization.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Teva and the Company have developed a Clinical Development Plan under which three phase 3 clinical
   trials will be initiated:
   &lt;/div&gt;
   &lt;div style="margin-top: 10pt"&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;
   The ongoing phase 3 clinical trial, referred to as the Synergy trial, or SYNERGY, to evaluate a survival benefit for
   custirsen in combination with first-line docetaxel treatment in patients with castrate resistant prostate cancer, or CRPC.
   Expected timing of results from the survival primary endpoint for the custirsen SYNERGY Phase 3 clinical trial remains
   unchanged at Q4 2013. During discussions regarding the Prostate Cancer SATURN trial, or SATURN, Special Protocol
   Assessment, or SPA, amendment, U.S. Food and Drug Administration, or FDA, stated that an application supported primarily
   by the results of SYNERGY alone would be acceptable for submission. We expect to increase patient enrollment in SYNERGY
   from 800 to approximately 1000 patients, and expand the number of clinical trial sites.
   &lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div style="margin-top: 10pt"&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;
   An ongoing phase 3 clinical trial, referred to as SATURN, to evaluate a durable pain palliation benefit for
   custirsen in combination with docetaxel as second-line chemotherapy in approximately 300 patients with CRPC. We have
   revised the custirsen SATURN Phase 3 trial protocol to expand the eligible patient population, and to align with the
   recently approved chemotherapy, cabazitaxel. We are awaiting final, written FDA agreement on the SPA amendment that will
   allow patients to receive either docetaxel re-treatment or cabazitaxel as second-line chemotherapy. Recruitment efforts
   are ongoing to enroll more patients in the SATURN study, which has had few patients accrued due to restrictive enrollment
   criteria regarding docetaxel retreatment and stable pain criteria. Expected timing of results for the pain palliation
   primary endpoint is now projected to be Q4 2013 rather than Q2 2013.
   &lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div style="margin-top: 10pt"&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;
   A phase 3 clinical trial to evaluate a survival benefit for custirsen in combination with first-line chemotherapy in
   patients with non-small cell lung cancer, or NSCLC. The initiation of the Phase 3 clinical trial evaluating custirsen
   in patients with NSCLC has been delayed as we determine the optimal chemotherapeutic combination. We believe NSCLC is
   a promising indication and remain committed to the advancement of custirsen in NSCLC.
   &lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Teva will be responsible for conducting any other studies and development work necessary to obtain
   required regulatory approvals. The Company may assume some of these activities if assigned by the
   joint steering committee. Teva will be responsible for all such costs. The joint steering committee
   will oversee the development and regulatory approval of any Licensed Product. The Company may
   terminate its participation in the joint steering committee at any time.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Funding responsibilities for the Clinical Development Plan will be allocated as follows:
   &lt;/div&gt;
   &lt;div style="margin-top: 10pt"&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;The Company will be required to spend $30&amp;#160;million in direct and indirect development
   costs, and&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div style="margin-top: 10pt"&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Teva will fund all other expenses under the Clinical Development Plan.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div style="margin-top: 10pt"&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;The Collaboration Agreement will remain in effect, on a country-by-country basis, until the
   expiration of the obligation of Teva to pay royalties on sales of the Licensed Product in such
   country (or earlier termination under its terms). After the completion of all three phase 3
   clinical trials set forth in the Clinical Development Plan, or upon early termination due to a
   material adverse change in the Company&amp;#8217;s patent rights related to custirsen or safety issues or
   &amp;#8220;futility&amp;#8221; as defined in the Collaboration Agreement, Teva may
   terminate the Collaboration Agreement at its sole discretion upon three months&amp;#8217; notice if notice is
   given prior to regulatory approval of a Licensed Product and upon six months&amp;#8217; notice if notice is
   given after such regulatory approval. If Teva terminates the Collaboration Agreement for any
   reasons other than an adverse change in custirsen patent rights, safety issues or &amp;#8220;futility&amp;#8221;
   determination as previously described, it will remain responsible for paying for any remaining
   costs of all three phase 3 clinical trials, except for specified development expenses that are the
   responsibility of the Company. Either party may terminate the Collaboration Agreement for an
   uncured material breach by the other party or upon the bankruptcy of either party. If the
   Collaboration Agreement is terminated by the Company for other than an uncured material breach by
   Teva, the Company will pay Teva a royalty on sales of Licensed Products. The percentage rates of
   such royalties (which are in the single digits) vary depending on whether termination occurs prior
   to the first regulatory approval in the United States or a primary European Market or after one of
   these approvals. These royalties would expire on a country-by-country basis on the earlier of ten
   years after the first commercial sale of a Licensed Product or certain thresholds related to
   generic competition.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;In the event of a change of control of the Company, within 90&amp;#160;days of the change of control, Teva
   may terminate the joint steering committee at its sole discretion, terminate the co-promotion
   option at its sole discretion if not then exercised by the Company or if exercised but not yet
   executed by the Company, or terminate the co-promotion option if in its commercially reasonable
   opinion co-promotion with the Company&amp;#8217;s successor would be materially detrimental to Teva&amp;#8217;s
   interests.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Upon entering into the Collaboration Agreement, the Company assessed whether withholdings taxes
   were owed to the Israeli Tax Authority, or ITA, resulting from the Collaboration Agreement. It was
   the Company&amp;#8217;s position that withholdings taxes were not owed, and a claim was issued to the ITA
   accordingly. For accounting purposes, management concluded that the withholdings tax claim was an
   uncertain tax position, and $3&amp;#160;million, which represented the potential withholdings tax
   obligation, once received from Teva was initially recorded as restricted cash pending the ITA
   review of our claim and a corresponding liability of $3&amp;#160;million was included in accounts payable
   and accrued liabilities. In June&amp;#160;2010, the Company received approval from the ITA for our request
   for a withholdings tax exemption on amounts received from Teva in relation to the Collaboration
   Agreement. Following receipt of this approval from the ITA the $3&amp;#160;million was released to the
   Company from escrow. Subsequently, the Company released the $3&amp;#160;million liability and recorded a $3
   million income tax recovery in the second quarter of 2010.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Revenue for the three and six months ended June&amp;#160;30, 2011 was $1.9&amp;#160;million, and $3.1&amp;#160;million which
   consists of partial recognition of deferred collaboration revenue representing OncoGenex&amp;#8217;s
   contribution to the custirsen phase 3 development plan under our Collaboration Agreement with Teva
   and custirsen manufacturing costs incurred by OncoGenex in the year ended December&amp;#160;31, 2010 that
   are reimbursable from Teva. At June&amp;#160;30, 2011, a remaining balance of $19.9&amp;#160;million of the up-front
   payment was recorded in deferred collaboration revenue. There was $1.7&amp;#160;million and $6.4&amp;#160;million in
   revenue recorded in the three and six months ended June&amp;#160;30, 2010 as a result of the Collaboration
   Agreement with Teva.
   &lt;/div&gt;
   &lt;/div&gt;
</ogxi:CollaborationAgreementTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:FairValueDisclosuresTextBlock contextRef="SixMonthsEnded_30Jun2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 4 - us-gaap:FairValueDisclosuresTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;4. FAIR VALUE MEASUREMENTS&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;With the adoption of Accounting Standards Codification, or ASC, 820 &amp;#8220;Fair Value Measurements and
   Disclosures&amp;#8221;, beginning January&amp;#160;1, 2008, assets and liabilities recorded at fair value in the
   balance sheets are categorized based upon the level of judgment associated with the inputs used to
   measure their fair value. For certain of the Company&amp;#8217;s financial instruments including cash and
   cash equivalents, amounts receivable, and accounts payable the carrying values approximate fair
   value due to their short-term nature.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those
   valuation techniques are observable or unobservable. In accordance with ASC 820, these inputs are
   summarized in the three broad levels listed below:
   &lt;/div&gt;
   &lt;div style="margin-top: 10pt"&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Level 1 &amp;#8212; Quoted prices in active markets for identical securities;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
       &lt;td style="font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Level 2 &amp;#8212; Other significant observable inputs that are observable through
   corroboration with market data (including quoted prices in active markets for similar
   securities); and&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div style="margin-top: 10pt"&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Level 3 &amp;#8212; Significant unobservable inputs that reflect management&amp;#8217;s best estimate of
   what market participants would use in pricing the asset or liability.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;As quoted prices in active markets are not readily available for certain financial instruments, the
   Company obtains estimates for the fair value of financial instruments through third party pricing
   service providers.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;In determining the appropriate levels, the Company performed a detailed analysis of the assets and
   liabilities that are subject to ASC 820.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;The Company invests its excess cash in accordance with investment guidelines that limit the credit
   exposure to any one financial institution other than securities issued by the U.S. Government. Our
   securities are not collateralized and mature within one year.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;A description of the valuation techniques applied to the Company&amp;#8217;s financial instruments measured
   at fair value on a recurring basis follows.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;Financial Instruments&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;Cash&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Significant amounts of cash are held on deposit with a large well established Canadian financial
   institution.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;Government and Agency Securities&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;u&gt;Government Securities&lt;/u&gt; U.S. and Canadian Government securities are valued using quoted
   market prices. Valuation adjustments are not applied. Accordingly, U.S. and Canadian government
   securities are categorized in Level 1 of the fair value hierarchy.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;u&gt;U.S. Agency Securities&lt;/u&gt; U.S. agency securities are comprised of two main categories
   consisting of callable and non-callable agency-issued debt securities. Non-callable agency-issued
   debt securities are generally valued using quoted market prices. Callable agency issued debt
   securities are valued by benchmarking model-derived prices to quoted market prices and trade data
   for identical or comparable securities. Actively traded non-callable agency issued debt securities
   are categorized in Level 1 of the fair value hierarchy. Callable agency issued debt securities are
   categorized in Level 2 of the fair value hierarchy.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;Corporate and Other Debt&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;u&gt;Corporate Bonds and Commercial Paper&lt;/u&gt; The fair value of corporate bonds and commercial
   paper is estimated using recently executed transactions, market price quotations (where
   observable), bond spreads or credit default swap spreads adjusted for any basis difference between
   cash and derivative instruments. The spread data used are for the same maturity as the bond. If the
   spread data does not reference the issuer, then data that reference a comparable issuer are used.
   When observable price quotations are not available, fair value is determined based on cash flow
   models with yield curves, bond or single name credit default swap spreads and recovery rates based
   on collateral values as significant inputs. Corporate bonds and commercial paper are generally
   categorized in Level 2 of the fair value hierarchy; in instances where prices, spreads or any of
   the other aforementioned key inputs are unobservable, they are categorized in Level 3 of the
   hierarchy.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;The following table presents information about our assets and liabilities that are measured at fair
   value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we
   utilized to determine such fair value:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="44%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;(in thousands)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Assets&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cash
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,824&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,824&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Money market securities
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;7,830&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;7,830&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Government securities
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;6,000&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;6,000&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Corporate bonds and commercial paper
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;60,260&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;60,260&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;15,654&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;60,260&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;75,914&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Liabilities&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Warrants
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;14,828&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;14,828&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Marketable securities consist of the following:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="44%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;(in thousands)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Gain&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Loss&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;2011&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cash
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,824&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,824&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Money market
   securities
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;7,329&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;7,329&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Government securities
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;5,998&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;6,000&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Corporate bonds and
   commercial paper
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;5,715&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;9&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(1&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;5,723&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Cash and cash
   equivalents&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;20,866&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;11&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;(1&lt;/b&gt;&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;20,876&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Money market
   securities
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;502&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;502&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Restricted cash&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;502&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;&amp;#8212;&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;&amp;#8212;&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;502&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Corporate bonds and
   commercial paper
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;54,578&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(45&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;54,536&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Short-term
   investments&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;54,578&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;3&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;(45&lt;/b&gt;&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;54,536&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;All securities included in cash, and cash equivalents have maturities of 90&amp;#160;days or less at the
   time of purchase. All securities included in short-term investments have maturities of within one
   year of the balance sheet date.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;There were no significant realized or unrealized gains or losses on the sales of marketable
   securities in the six months ended June&amp;#160;30, 2011 and no significant unrealized gains or losses are
   included in accumulated other comprehensive income as at June&amp;#160;30, 2011. Realized gains and losses
   are transferred out of accumulated other comprehensive income into interest income using the
   specific identification method.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;All of the marketable securities held as of June&amp;#160;30, 2011 had maturities of one year or less. The
   Company only invests in A (or equivalent) rated securities with maturities of one year or less.
   Given the quality of the investment portfolio, its short-term nature, and subsequent proceeds
   collected on sale of securities that
   reached maturity, the Company does not believe that there are any other than temporary impairments
   related to its investments in marketable securities at June&amp;#160;30, 2011.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;The Company has recorded a $14,828,000 warrant liability as of June&amp;#160;30, 2011. The Company
   reassesses the fair value of the common stock warrants at each reporting date utilizing a
   Black-Scholes pricing model. Inputs used in the pricing model include estimates of stock price
   volatility, expected warrant life and risk-free interest rate. The computation of expected
   volatility was based on the historical volatility of comparable companies from a representative
   peer group selected based on industry and market capitalization. See note 5(d) in the Notes to
   Financial Statements for further details on the inputs used in the Black-Scholes pricing model used
   to recalculate the warrant liability.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;The following table presents the changes in fair value of the Company&amp;#8217;s total Level 3 financial
   liabilities for the six months ended June&amp;#160;30, 2011:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="58%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Liability at&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Gain (loss) on&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Liability at June&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;warrants&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt; 30, 2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Warrant liability
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;15,269&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;441&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;14,828&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:FairValueDisclosuresTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="SixMonthsEnded_30Jun2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 5 - us-gaap:StockholdersEquityNoteDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;5. COMMON STOCK&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&amp;#091;a&amp;#093; Authorized&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;25,000,000 authorized common shares, par value of $0.001, and 5,000,000 preferred shares, par value
   of $0.001.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&amp;#091;b&amp;#093; Issued and Outstanding Shares&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;During the six month period ended June&amp;#160;30, 2011 the Company issued 24,660 common shares upon
   exercise of stock options (period ended June&amp;#160;30, 2010 &amp;#8212; 117,643) to satisfy stock option
   exercises.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&amp;#091;c&amp;#093; Stock options&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;2010 Performance Incentive Plan&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;At the 2011 Annual Meeting of Stockholders of the Company held on May&amp;#160;26, 2011, stockholders of the
   Company approved an amendment to the Company&amp;#8217;s 2010 Performance Incentive Plan. As a result of this
   amendment, the 2010 Plan was amended to provide for an increase in the total shares of common stock
   available for issuance under the 2010 Plan from 450,000 to 1,050,000. As at June&amp;#160;30, 2011 the
   Company has reserved, pursuant to various plans, 1,598,075 common shares for issuance upon exercise
   of stock options by employees, directors, officers and consultants of the Company, of which 777,359
   are reserved for options currently outstanding, and 820,716 are available for future option grants.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;Stock Option Summary&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Options vest in accordance with terms as determined by the board of directors of the Company, or
   the Board, typically over four years for employee grants and one to three years for Board option
   grants. The expiry date for each option is set by the Board, which is typically seven to ten years.
   The exercise price of the options is determined by the Board but generally will be at least equal
   to the fair value of the share at the grant date.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Stock option transactions and the number of stock options outstanding are summarized below:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Number &lt;br /&gt;
   of&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Optioned&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Common&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;#&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Balance, December&amp;#160;31, 2010&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;744,913&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;8.73&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Option grants
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;75,900&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;17.03&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Option expirations/cancellations
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(6,112&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;13.86&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Option exercises
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(24,660&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3.67&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Option forfeitures
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(12,682&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;12.66&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Balance, June&amp;#160;30, 2011&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;777,359&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;9.59&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;The fair value of each stock award is estimated on the grant date using the Black-Scholes
   option-pricing model based on the weighted-average assumptions noted in the following table:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Six months ended June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Risk-free interest rates
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2.39&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2.41&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected dividend yield
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;0&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;0&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected life
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="2" nowrap="nowrap" align="right"&gt;6 years&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="2" nowrap="nowrap" align="right"&gt;6 years&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected volatility
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;75&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;74&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;The expected life was calculated based on the simplified method as permitted by the SEC&amp;#8217;s Staff
   Accounting Bulletin 110, Share-Based Payment. The computation of expected volatility was based on
   the historical volatility of comparable companies from a representative peer group selected based
   on industry and market capitalization. The Company considers the use of these methods of
   calculating expected term and volatility appropriate because of the lack of sufficient historical
   exercise data following the reverse takeover of Sonus. The risk-free interest rate was based on a
   U.S. Treasury instrument whose term is consistent with the expected life of the stock options. In
   addition to the assumptions above, as required under ASC 718, management made an estimate of
   expected forfeitures and is recognizing compensation costs only for those equity awards expected to
   vest.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;The results for the periods set forth below included share-based compensation expense in the
   following expense categories of the consolidated statements of loss:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="44%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Three Months&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Six Months&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;(In thousands)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Research and development
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;122&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;74&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;243&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;142&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;General and administrative
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;161&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;70&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;311&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;169&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Total share-based compensation&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;283&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;144&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;554&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;311&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Options vest in accordance with terms as determined by the Board, typically over three or four
   years for employee grants and over one or three years for Board of Director option grants. The
   expiry date for each option is set by the Board with, which is typically seven to ten years.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;As at June&amp;#160;30, 2011 and December&amp;#160;31, 2010 the total unrecognized compensation expense related to
   stock options granted is $3,176,000 and $2,962,000 respectively, which is expected to be recognized
   into expense over a period of approximately four years.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;As of June&amp;#160;30, 2011 and December&amp;#160;31, 2010 a total of 2,364,660 and 2,332,214 options and warrants,
   respectively, have not been included in the calculation of potential common shares as their effect
   on diluted per share amounts would have been anti-dilutive.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&amp;#091;d&amp;#093; Stock Warrants&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;At June&amp;#160;30, 2011, there were exercisable warrants outstanding to purchase 1,587,301
   shares of common stock at an exercise price of $20 per share, expiring in October&amp;#160;2015.
   No warrants were exercised during the six months ended June&amp;#160;30, 2011 or six months ended
   June&amp;#160;30, 2010.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;The estimated fair value of warrants issued is reassessed at each balance sheet date
   using the Black-Scholes option pricing model. The following assumptions were used to
   value the warrants on the following balance sheet dates:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Six months ended June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Risk-free interest rates
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1.43&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected dividend yield
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;0&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected life
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td colspan="2" nowrap="nowrap" align="right"&gt;4.3 years&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected volatility
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;76&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="SixMonthsEnded_30Jun2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 6 - us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;6. RESTRUCTURING ACTIVITIES&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;On August&amp;#160;21, 2008, Sonus Pharmaceuticals, Inc., or Sonus, completed a transaction, or &amp;#8220;the
   Arrangement&amp;#8221;, with OncoGenex Technologies whereby Sonus acquired all of the outstanding preferred
   shares, common shares and convertible debentures of OncoGenex Technologies. Sonus then changed its
   name to OncoGenex Pharmaceuticals, Inc. Prior to the Arrangement, Sonus entered into a
   non-cancellable lease arrangement for office space located in Bothell, Washington, which is
   considered to be in excess of the Company&amp;#8217;s current requirements. The Company is currently in the
   process of evaluating opportunities to exit or sublet portions of the leased space and recorded an
   initial restructuring charge of $2,084,000 on August&amp;#160;21, 2008 as part of the purchase price
   allocation. The liability is computed as the present value of the difference between the remaining
   lease payments due less the estimate of net sublease income and expenses and has been accounted for
   in accordance with the then effective EITF No.&amp;#160;95-3, &amp;#8220;Recognition of Liabilities in Connection with
   a Purchase Business Combination&amp;#8221;. This represents the Company&amp;#8217;s best estimate of the liability.
   Subsequent changes in the liability due to changes in estimates of sublease assumptions are
   recognized as adjustments to restructuring charges.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;In June&amp;#160;2009, the Company revised its sublease income assumptions used to estimate the excess lease
   facility liability. These assumptions were subsequently revised again in December&amp;#160;2009 and
   September
   2010. These changes in estimate resulted in increases in the value of the excess lease liability of
   $494,000, $3,457,000, and $4,038,000 and a corresponding expense recorded in June&amp;#160;2009, December
   2009, and September&amp;#160;2010, respectively, to reflect these changes in estimate. The estimated value
   of the liability remaining with respect to excess facilities was $7,467,000 as of December&amp;#160;31,
   2010. In the six months ended June&amp;#160;30, 2011, with respect to excess facilities, $140,000 was
   amortized into income resulting in a remaining liability of $7,327,000 at June&amp;#160;30, 2011.
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="44%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Additional&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Liability at&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;of excess&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Liability&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Liability&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;December 31, 2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;lease facility&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Recorded&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;at June 30, 2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Current portion of
   excess lease
   facility
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,303&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(53&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,356&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Long-term portion
   of excess lease
   facility
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;6,164&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;193&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;5,971&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Total&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;7,467&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;140&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;&amp;#8212;&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;7,327&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="SixMonthsEnded_30Jun2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 7 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;7. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;Teva Pharmaceutical Industries Ltd.&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Under the Collaboration Agreement, Teva made upfront payments in the aggregate amount of $50
   million, may make up to $370&amp;#160;million in additional payments upon the achievement of developmental
   and commercial milestones and may be required in the future to pay royalties at percentage rates
   ranging from the mid-teens to mid-twenties on net sales. The Company is required to contribute $30
   million in direct and indirect costs towards the Clinical Development Plan. As of June&amp;#160;30, 2011,
   $10.1&amp;#160;million of these costs have been incurred by OncoGenex, resulting in a remaining funding
   responsibility of $19.9&amp;#160;million which has been recorded under Current and Long-term Deferred
   Collaboration Revenue as of June&amp;#160;30, 2011. Teva will fund all other expenses under the Clinical
   Development Plan. See note 3 in the Notes to Financial Statements for further details on our
   Collaboration Agreement with Teva.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;Isis Pharmaceuticals Inc. and University of British Columbia&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;To facilitate the execution and performance of the Collaboration Agreement with Teva, OncoGenex and
   Isis agreed to amend the Isis License Agreement and the Company and UBC agreed to amend the UBC
   License Agreement, in each case, effective December&amp;#160;19 and December&amp;#160;20, 2009, respectively.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;The amendment to the Isis License Agreement provides, among other things, that if the Company is
   the subject of a change of control with a third party, where the surviving company immediately
   following such change of control has the right to develop and sell the product, then (i)&amp;#160;a
   milestone payment of $20&amp;#160;million will be due and payable to Isis 21&amp;#160;days following the first
   commercial sale of the product in the United States; and (ii)&amp;#160;unless such surviving entity had
   previously sublicensed the product and a royalty rate payable to Isis by the Company has been
   established, the applicable royalty rate payable to Isis will thereafter be the maximum amount
   payable under the Isis License Agreement. Any non-royalty milestone amounts previously paid will be
   credited toward the $20&amp;#160;million milestone if not already paid. As a result of the $10&amp;#160;million
   milestone payment payable to Isis in relation to the Collaboration Agreement, the remaining amount
   owing in the event of change of control discussed above is a maximum of $10&amp;#160;million. As the Company
   has now licensed the product to Teva and established a royalty rate payable to Isis, no royalty
   rate adjustments would apply if Teva acquires the Company and is the surviving company. If the $30
   million in advanced reimbursement of development activities has not been spent by OncoGenex prior
   to the third anniversary of the Collaboration Agreement between OncoGenex and Teva, OncoGenex will
   pay Isis an amount equal to 30% of any un-spent portion less $3.5&amp;#160;million.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;In addition, we are required to pay to Isis 30% of all Non-Royalty Revenue we receive on custirsen
   sales. Isis has disclosed in its SEC filings that it is entitled to receive 30% of the up to $370
   million in milestone payments we may receive from Teva as part of the Collaboration Agreement;
   however, we believe that certain of the milestone payments related to sales targets may qualify as
   Royalty Revenue, and therefore be subject to the lesser payment obligations. No assurance can be
   provided that we will be entitled to receive these milestone payments or, if we are, that the
   applicable amount payable to Isis will be less than 30%.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Pursuant to license agreements the Company has with the UBC and Isis, the Company is obligated to
   pay milestone payments of up to CAD $1.6&amp;#160;million and $7.75&amp;#160;million, respectively, upon the
   achievement of specified product development milestones related to OGX-427 and OGX-225 and
   royalties on future product sales. We paid Isis and UBC $750,000 and CAD $100,000, respectively, in
   2010 upon the initiation of a phase 2 clinical trial of OGX-427 in patients with CRPC. We do not
   anticipate making any royalty payments to Isis in 2011.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Unless otherwise terminated, the Isis agreements for custirsen and OGX-427 will continue for each
   product until the later of 10&amp;#160;years after the date of the first commercial product sale, or the
   expiration of the last to expire of any patents required to be licensed in order to use or sell the
   product, unless OncoGenex Technologies abandons either custirsen or OGX-427 and Isis does not elect
   to unilaterally continue development. The Isis agreement for OGX-225 will continue into perpetuity
   unless OncoGenex Technologies abandons the product and Isis does not elect to unilaterally continue
   development.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;We are also obligated to pay to UBC certain patent costs and annual license maintenance fees for
   the extent of the patent life of CAD $8,000 per year relating to custirsen, OGX-427 and OGX-225.
   The UBC agreements have effective dates ranging from November&amp;#160;1, 2001 to April&amp;#160;5, 2005 and each
   agreement expires upon the later of 20&amp;#160;years from its effective date or the expiry of the last
   patent licensed thereunder, unless otherwise terminated.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;Bayer HealthCare LLC&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;On August&amp;#160;7, 2008, Sonus completed an exclusive in-licensing agreement with Bayer HealthCare LLC,
   or Bayer, for the right to develop, commercialize or sublicense a family of compounds known as
   caspase activators presently in pre-clinical research. Under terms of the agreement, Sonus was
   granted exclusive rights to develop two core compounds for all prophylactic and therapeutic uses in
   humans. Additionally, Sonus was granted rights to all other non-core compounds covered under the
   patents for use in oncology.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Under the terms of the agreement, Bayer received an upfront license fee of $450,000. OncoGenex will
   make annual payments to Bayer on the anniversary date (Anniversary Payments), with an initial
   payment of $100,000 paid in 2008. The payments increase by $25,000 each year until the initiation
   of the first phase 3 clinical trial, at which point the Anniversary Payments reset to $100,000 each
   year and increase by $25,000 until the Company achieves either the first New Drug Application, or
   NDA, filing in the United States or the European Union. OncoGenex is obligated to pay royalties on
   net future product sales in addition to aggregate milestone payments of up to $14,000,000 for
   clinical development and regulatory milestones. No milestone payments are triggered prior to the
   initiation of a phase 3 clinical trial. OncoGenex has the option to terminate this contract upon 60
   days written notice to Bayer.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;Lease Arrangements&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;The Company has an operating lease agreement for office space in Vancouver, Canada, which expires
   in September&amp;#160;2014.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Future minimum annual lease payments under the Vancouver lease are as follows (in thousands):
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="86%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;CAD&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;2011
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;53&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;2012
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;107&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;2013
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;107&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;2014
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;80&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Total&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;347&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;In November&amp;#160;2006, prior to the Arrangement , Sonus entered into a non-cancellable operating
   lease agreement for office space in Bothell, Washington, expiring in 2017 (note 6). In connection
   with the lease, Sonus was required to provide a cash security deposit of approximately $497,000,
   which is included in Other Long Term Assets. In addition, a standby letter of credit was issued in
   2010, and $502,000 was deposited in a restricted money market account as collateral. The Company is
   currently in the process of evaluating opportunities to exit or sublet portions of the leased space
   and has recorded a liability in the excess facilities lease charge of $7,327,000 as at June&amp;#160;30,
   2011 (note 6).
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;If the Company is unable to exit or sublet portions of this leased space, the future minimum annual
   lease payments are as follows (in thousands):
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="86%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;2011
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,027&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;2012
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2,117&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;2013
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2,180&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;2014
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2,246&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;2015
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2,313&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Remainder
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;4,837&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Total&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;14,720&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;Consolidated rent expense relating to both the Vancouver, Canada and Bothell, Washington
   offices for the periods ended June&amp;#160;30, 2011 and 2010 was $1,313,000 and $1,092,000 respectively.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;Guarantees and Indemnifications&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;OncoGenex indemnifies its officers and directors for certain events or occurrences, subject to
   certain limits, while the officer or director is or was serving at our request in such capacity.
   The term of the indemnification period is equal to the officer&amp;#8217;s or director&amp;#8217;s lifetime.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;The maximum amount of potential future indemnification is unlimited; however, we have obtained
   director and officer insurance that limits our exposure and may enable it to recover a portion of
   any future amounts paid. We believe that the fair value of these indemnification obligations is
   minimal. Accordingly, we have not recognized any liabilities relating to these obligations as of
   June&amp;#160;30, 2011.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;We have certain agreements with certain organizations with which we do business that contain
   indemnification provisions pursuant to which we typically agree to indemnify the party against
   certain types of third-party claims. We accrue for known indemnification issues when a loss is
   probable and can be reasonably estimated. There were no accruals for or expenses related to
   indemnification issues for any period presented.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="SixMonthsEnded_30Jun2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 8 - us-gaap:ComprehensiveIncomeNoteTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;8. COMPREHENSIVE LOSS&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="44%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Three Months&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Six Months&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;(In thousands)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Loss (income)&amp;#160;for the period
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6,530&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(154&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;9,575&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,890&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Unrealized gain on cash
   equivalents and marketable
   securities
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(14&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(14&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Unrealized loss on cash
   equivalents and short-term
   investments
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;46&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;46&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Comprehensive loss (income)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6,562&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(154&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;9,607&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,890&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:ComprehensiveIncomeNoteTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:SubsequentEventsTextBlock contextRef="SixMonthsEnded_30Jun2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 9 - us-gaap:SubsequentEventsTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;9. SUBSEQUENT EVENTS&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;The Company has performed an evaluation of events occurring subsequent to June&amp;#160;30, 2011. Based on
   our evaluation, no material events have occurred requiring financial statement disclosure.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:SubsequentEventsTextBlock>
<!-- End Block Tagged Note -->
<!--Footnote Section-->

</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ogxi-20110630.xsd
<DESCRIPTION>EX-101 SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
    xmlns:xbrli="http://www.xbrl.org/2003/instance"
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    targetNamespace="http://oncogenex.com/2011-06-30"
    xmlns:ogxi="http://oncogenex.com/2011-06-30"
    elementFormDefault="qualified"
    attributeFormDefault="unqualified"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xmlns:us-types="http://xbrl.sec.gov/us-types/2011-01-31"
    xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
    xmlns:num="http://www.xbrl.org/dtr/type/numeric">
<annotation>
<appinfo>
<link:roleType roleURI="http://oncogenex.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
  <link:definition>00 - Document - Document and Entity Information</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://oncogenex.com/role/BalanceSheets" id="BalanceSheets">
  <link:definition>01 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://oncogenex.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
  <link:definition>011 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://oncogenex.com/role/StatementsOfIncome" id="StatementsOfIncome">
  <link:definition>02 - Statement - Consolidated Statements of Loss (Unaudited)</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://oncogenex.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
  <link:definition>03 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>

<link:roleType roleURI="http://oncogenex.com/role/NatureOfBusinessAndBasisOfPresentation" id="NatureOfBusinessAndBasisOfPresentation">
  <link:definition>06001 - Disclosure - Nature of Business And Basis of Presentation</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://oncogenex.com/role/AccountingPolicies" id="AccountingPolicies">
  <link:definition>06002 - Disclosure - Accounting Policies</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://oncogenex.com/role/CollaborationAgreement" id="CollaborationAgreement">
  <link:definition>06003 - Disclosure - Collaboration Agreement</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://oncogenex.com/role/FairValueMeasurements" id="FairValueMeasurements">
  <link:definition>06004 - Disclosure - Fair Value Measurements</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://oncogenex.com/role/CommonStock" id="CommonStock">
  <link:definition>06005 - Disclosure - Common Stock</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://oncogenex.com/role/RestructuringActivities" id="RestructuringActivities">
  <link:definition>06006 - Disclosure - Restructuring Activities</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://oncogenex.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
  <link:definition>06007 - Disclosure - Commitments And Contingencies</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://oncogenex.com/role/ComprehensiveLoss" id="ComprehensiveLoss">
  <link:definition>06008 - Disclosure - Comprehensive Loss</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://oncogenex.com/role/SubsequentEvents" id="SubsequentEvents">
  <link:definition>06009 - Disclosure - Subsequent Events</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>

<link:linkbaseRef xlink:type="simple" xlink:href="ogxi-20110630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
<link:linkbaseRef xlink:type="simple" xlink:href="ogxi-20110630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links, all" />
<link:linkbaseRef xlink:type="simple" xlink:href="ogxi-20110630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links, all" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-types-2011-01-31.xsd" />
<import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd" />
<!-- elements -->
<element name="DocumentAndEntityInformationAbstract" id="ogxi_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true" />

<element name="RevenuesFromCollaborativeAgreements" id="ogxi_RevenuesFromCollaborativeAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
<element name="FairValueAdjustmentOfWarrants" id="ogxi_FairValueAdjustmentOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
<element name="WeightedAverageNumberOfCommonSharesAbstract" id="ogxi_WeightedAverageNumberOfCommonSharesAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
<element name="IncreaseDecreaseInLeaseObligation" id="ogxi_IncreaseDecreaseInLeaseObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
<element name="PropertyAndEquipmentAcquiredUnderLeaseObligation" id="ogxi_PropertyAndEquipmentAcquiredUnderLeaseObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
<element name="CollaborationAgreementTextBlock" id="ogxi_CollaborationAgreementTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
<element name="CollaborationAgreementAbstract" id="ogxi_CollaborationAgreementAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ogxi-20110630_cal.xml
<DESCRIPTION>EX-101 CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#DocumentAndEntityInformation" roleURI="http://oncogenex.com/role/DocumentAndEntityInformation" />
<calculationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" />
<roleRef roleURI="http://oncogenex.com/role/BalanceSheets" xlink:href="ogxi-20110630.xsd#BalanceSheets" xlink:type="simple" />
<roleRef roleURI="http://oncogenex.com/role/BalanceSheetsParenthetical" xlink:href="ogxi-20110630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />

<roleRef roleURI="http://oncogenex.com/role/StatementsOfIncome" xlink:href="ogxi-20110630.xsd#StatementsOfIncome" xlink:type="simple" />
<roleRef roleURI="http://oncogenex.com/role/StatementsOfCashFlows" xlink:href="ogxi-20110630.xsd#StatementsOfCashFlows" xlink:type="simple" />
<calculationLink xlink:role="http://oncogenex.com/role/BalanceSheets" xlink:title="01 - Statement - Consolidated Balance Sheets (Unaudited)" xlink:type="extended">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="1" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_ShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_ShortTermInvestments" order="3" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_AccountsReceivableNetCurrent" order="4" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_PrepaidExpenseCurrent" order="5" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_AssetsCurrent" order="6" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_PropertyPlantAndEquipmentNet" order="7" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_OtherAssetsNoncurrent" order="8" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccountsPayableAndAccruedLiabilitiesCurrent" order="9" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_DeferredRevenueCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_DeferredRevenueCurrent" order="10" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_CapitalLeaseObligationsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_CapitalLeaseObligationsCurrent" order="11" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_WarrantsAndRightsOutstanding" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_WarrantsAndRightsOutstanding" order="12" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_LiabilitiesCurrent" order="13" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_DeferredRevenueNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_DeferredRevenueNoncurrent" order="14" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_CapitalLeaseObligationsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_CapitalLeaseObligationsNoncurrent" order="15" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_Liabilities" order="16" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_CommonStockValue" order="17" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_AdditionalPaidInCapitalCommonStock" order="18" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_RetainedEarningsAccumulatedDeficit" order="19" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="20" use="optional" weight="1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_StockholdersEquity" order="21" use="optional" weight="1" />
</calculationLink>
<calculationLink xlink:role="http://oncogenex.com/role/StatementsOfIncome" xlink:title="02 - Statement - Consolidated Statements of Loss (Unaudited)" xlink:type="extended">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_RevenuesFromCollaborativeAgreements" xlink:label="ogxi_RevenuesFromCollaborativeAgreements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingIncomeLoss" xlink:to="ogxi_RevenuesFromCollaborativeAgreements" order="22" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_CostsAndExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CostsAndExpenses" xlink:to="loc_ResearchAndDevelopmentExpense" order="23" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CostsAndExpenses" xlink:to="loc_GeneralAndAdministrativeExpense" order="24" use="optional" weight="1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingIncomeLoss" xlink:to="loc_CostsAndExpenses" order="25" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_OperatingIncomeLoss" order="26" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_InvestmentIncomeInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="loc_InvestmentIncomeInterest" order="27" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="loc_OtherNonoperatingIncomeExpense" order="28" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_FairValueAdjustmentOfWarrants" xlink:label="ogxi_FairValueAdjustmentOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="ogxi_FairValueAdjustmentOfWarrants" order="29" use="optional" weight="-1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_NonoperatingIncomeExpense" order="30" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="31" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_IncomeTaxExpenseBenefit" order="32" use="optional" weight="-1" />
</calculationLink>
<calculationLink xlink:role="http://oncogenex.com/role/StatementsOfCashFlows" xlink:title="03 - Statement - Consolidated Statements of Cash Flows (Unaudited)" xlink:type="extended">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NetIncomeLoss" order="33" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_DepreciationDepletionAndAmortization" order="34" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ShareBasedCompensation" order="35" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_AdjustmentOfWarrantsGrantedForServices" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AdjustmentOfWarrantsGrantedForServices" order="36" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInAccountsReceivable" order="37" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="loc_IncreaseDecreaseInRestrictedCashForOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInRestrictedCashForOperatingActivities" order="38" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_IncreaseDecreaseInPrepaidExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInPrepaidExpense" order="39" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="40" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_IncreaseDecreaseInLeaseObligation" xlink:label="ogxi_IncreaseDecreaseInLeaseObligation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="ogxi_IncreaseDecreaseInLeaseObligation" order="41" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_IncreaseDecreaseInDeferredRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInDeferredRevenue" order="42" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="43" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="44" use="optional" weight="1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="45" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_ProceedsFromSaleOfShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ProceedsFromSaleOfShortTermInvestments" order="46" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_PaymentsToAcquireShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PaymentsToAcquireShortTermInvestments" order="47" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="48" use="optional" weight="-1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="49" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents" order="50" use="optional" weight="-1" />
</calculationLink>

<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#NatureOfBusinessAndBasisOfPresentation" roleURI="http://oncogenex.com/role/NatureOfBusinessAndBasisOfPresentation" />
<calculationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:title="06001 - Disclosure - Nature of Business And Basis of Presentation" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#AccountingPolicies" roleURI="http://oncogenex.com/role/AccountingPolicies" />
<calculationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/AccountingPolicies" xlink:title="06002 - Disclosure - Accounting Policies" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#CollaborationAgreement" roleURI="http://oncogenex.com/role/CollaborationAgreement" />
<calculationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/CollaborationAgreement" xlink:title="06003 - Disclosure - Collaboration Agreement" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#FairValueMeasurements" roleURI="http://oncogenex.com/role/FairValueMeasurements" />
<calculationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/FairValueMeasurements" xlink:title="06004 - Disclosure - Fair Value Measurements" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#CommonStock" roleURI="http://oncogenex.com/role/CommonStock" />
<calculationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/CommonStock" xlink:title="06005 - Disclosure - Common Stock" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#RestructuringActivities" roleURI="http://oncogenex.com/role/RestructuringActivities" />
<calculationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/RestructuringActivities" xlink:title="06006 - Disclosure - Restructuring Activities" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#CommitmentsAndContingencies" roleURI="http://oncogenex.com/role/CommitmentsAndContingencies" />
<calculationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/CommitmentsAndContingencies" xlink:title="06007 - Disclosure - Commitments And Contingencies" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#ComprehensiveLoss" roleURI="http://oncogenex.com/role/ComprehensiveLoss" />
<calculationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/ComprehensiveLoss" xlink:title="06008 - Disclosure - Comprehensive Loss" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#SubsequentEvents" roleURI="http://oncogenex.com/role/SubsequentEvents" />
<calculationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/SubsequentEvents" xlink:title="06009 - Disclosure - Subsequent Events" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ogxi-20110630_lab.xml
<DESCRIPTION>EX-101 LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />

<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">

<loc xlink:type="locator" xlink:label="ogxi_DocumentAndEntityInformationAbstract" xlink:href="ogxi-20110630.xsd#ogxi_DocumentAndEntityInformationAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogxi_DocumentAndEntityInformationAbstract" xlink:to="ogxi_DocumentAndEntityInformationAbstract_lbl" />
<label xlink:type="resource" xlink:label="ogxi_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document and Entity Information [Abstract]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents&#091;note 4&#093;</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investments &#091;note 4&#093;</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term Investments</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Amounts receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid Expense, Current</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current, Total</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other Assets, Noncurrent</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets, Total</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred Collaboration Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred Revenue, Current</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Current portion of long-term obligations &#091;note 6&#093;</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Capital Lease Obligations, Current</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrant liability &#091;note 4, note 5&#093;</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants and Rights Outstanding</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current, Total</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred Collaboration Revenue, net of current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred Revenue, Noncurrent</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Long-term obligation, less current portion &#091;note 6&#093;</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Capital Lease Obligations, Noncurrent</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities, Total</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies &#091;note 7&#093;</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders' equity:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common shares &#091;note 5&#093; $0.001 par value 25000000 shares authorized and 9,718,251 issued and outstanding at June 30, 2011 and 9,693,591 issued and outstanding at December 31, 2010</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Total</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders' equity</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity, Total</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and shareholders' equity</label>

<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_RevenuesFromCollaborativeAgreements" xlink:label="ogxi_RevenuesFromCollaborativeAgreements" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogxi_RevenuesFromCollaborativeAgreements" xlink:to="ogxi_RevenuesFromCollaborativeAgreements_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogxi_RevenuesFromCollaborativeAgreements_lbl" xml:lang="en-US">Revenues From Collaborative Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ogxi_RevenuesFromCollaborativeAgreements_lbl" xml:lang="en-US">COLLABORATION REVENUE</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogxi_RevenuesFromCollaborativeAgreements_lbl" xml:lang="en-US">COLLABORATION REVENUE</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">EXPENSES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and Expenses [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Costs and Expenses, Total</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total expenses</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSE)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</label>

<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_FairValueAdjustmentOfWarrants" xlink:label="ogxi_FairValueAdjustmentOfWarrants" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogxi_FairValueAdjustmentOfWarrants" xlink:to="ogxi_FairValueAdjustmentOfWarrants_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogxi_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair Value Adjustment Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ogxi_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Gain (loss) on warrants &#091;note 5&#093;</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogxi_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Gain (loss) on warrants &#091;note 5&#093;</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ogxi_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Gain (loss) on warrants &#091;note 5&#093;</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense), Total</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss for the period before income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss for the period before income taxes</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense (recovery) &#091;note 3&#093;</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss (income)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss (income)</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted loss (income) per common share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>

<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_WeightedAverageNumberOfCommonSharesAbstract" xlink:label="ogxi_WeightedAverageNumberOfCommonSharesAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogxi_WeightedAverageNumberOfCommonSharesAbstract" xlink:to="ogxi_WeightedAverageNumberOfCommonSharesAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ogxi_WeightedAverageNumberOfCommonSharesAbstract_lbl" xml:lang="en-US">Weighted average number of common shares:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogxi_WeightedAverageNumberOfCommonSharesAbstract_lbl" xml:lang="en-US">Weighted Average Number Of Common Shares Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogxi_WeightedAverageNumberOfCommonSharesAbstract_lbl" xml:lang="en-US">Weighted average number of common shares:</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">OPERATING ACTIVITIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Loss for the period</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Add items not involving cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation &#091;note 5(c)&#093;</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl" xml:lang="en-US">Change in value of warrants &#091;note 5&#093;&#093;</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl" xml:lang="en-US">Adjustment of Warrants Granted for Services</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in non-cash items</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Amounts receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Amounts receivable</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_lbl" xml:lang="en-US">Restricted cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_lbl" xml:lang="en-US">Increase (Decrease) in Restricted Cash for Operating Activities</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_lbl" xml:lang="en-US">Restricted cash</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>

<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_IncreaseDecreaseInLeaseObligation" xlink:label="ogxi_IncreaseDecreaseInLeaseObligation" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogxi_IncreaseDecreaseInLeaseObligation" xlink:to="ogxi_IncreaseDecreaseInLeaseObligation_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogxi_IncreaseDecreaseInLeaseObligation_lbl" xml:lang="en-US">Increase Decrease In Lease Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ogxi_IncreaseDecreaseInLeaseObligation_lbl" xml:lang="en-US">Lease obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogxi_IncreaseDecreaseInLeaseObligation_lbl" xml:lang="en-US">Lease obligation</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ogxi_IncreaseDecreaseInLeaseObligation_lbl" xml:lang="en-US">Lease obligation</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred collaboration revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Cash used in operating activities</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">FINANCING ACTIVITIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Proceeds from issuance of common stock under stock option and employee purchase plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Cash provided by financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Cash provided by financing activities</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">INVESTING ACTIVITIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xml:lang="en-US">Proceeds from sale of investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xml:lang="en-US">Proceeds from Sale of Short-term Investments</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Purchase of investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Payments to Acquire Short-term Investments</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Purchase of investments</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Cash provided by (used in) investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Cash provided by (used in) investing activities</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Decrease in cash and cash equivalents during the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Decrease in cash and cash equivalents during the period</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of the period</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, end of the period</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_PropertyAndEquipmentAcquiredUnderLeaseObligation" xlink:label="ogxi_PropertyAndEquipmentAcquiredUnderLeaseObligation" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogxi_PropertyAndEquipmentAcquiredUnderLeaseObligation" xlink:to="ogxi_PropertyAndEquipmentAcquiredUnderLeaseObligation_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogxi_PropertyAndEquipmentAcquiredUnderLeaseObligation_lbl" xml:lang="en-US">Property And Equipment Acquired Under Lease Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ogxi_PropertyAndEquipmentAcquiredUnderLeaseObligation_lbl" xml:lang="en-US">Property and equipment acquired under lease obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogxi_PropertyAndEquipmentAcquiredUnderLeaseObligation_lbl" xml:lang="en-US">Property and equipment acquired under lease obligation</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">NATURE OF BUSINESS AND BASIS OF PRESENTATION</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Nature of Business And Basis of Presentation [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Nature of Business And Basis of Presentation [Abstract]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ACCOUNTING POLICIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>

<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_CollaborationAgreementTextBlock" xlink:label="ogxi_CollaborationAgreementTextBlock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogxi_CollaborationAgreementTextBlock" xlink:to="ogxi_CollaborationAgreementTextBlock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogxi_CollaborationAgreementTextBlock_lbl" xml:lang="en-US">Collaboration Agreement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ogxi_CollaborationAgreementTextBlock_lbl" xml:lang="en-US">COLLABORATION AGREEMENT</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogxi_CollaborationAgreementTextBlock_lbl" xml:lang="en-US">COLLABORATION AGREEMENT</label>

<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_CollaborationAgreementAbstract" xlink:label="ogxi_CollaborationAgreementAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogxi_CollaborationAgreementAbstract" xlink:to="ogxi_CollaborationAgreementAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ogxi_CollaborationAgreementAbstract_lbl" xml:lang="en-US">Collaboration Agreement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogxi_CollaborationAgreementAbstract_lbl" xml:lang="en-US">Collaboration Agreement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogxi_CollaborationAgreementAbstract_lbl" xml:lang="en-US">COLLABORATION AGREEMENT</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">COMMON STOCK</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Common Stock and Comprehensive Loss [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Common Stock and Comprehensive Loss [Abstract]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">RESTRUCTURING ACTIVITIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US">Restructuring Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US">Restructuring Activities [Abstract]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments And Contingencies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments And Contingencies [Abstract]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl" xml:lang="en-US">COMPREHENSIVE LOSS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>

<loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
<label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
<loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
<label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
<loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
<label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
<loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
<label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
<loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
<label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
<loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
<label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</label>
<loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
<label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</label>
<loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
<label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
<loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
<label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
<loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
<label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</label>
<loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
<label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</label>
<loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
<label xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</label>
<loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
<label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
<loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
<label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Consolidated Statements of Loss [Abstract]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</label>

</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ogxi-20110630_pre.xml
<DESCRIPTION>EX-101 PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
<roleRef roleURI="http://oncogenex.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ogxi-20110630.xsd#DocumentAndEntityInformation" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#NatureOfBusinessAndBasisOfPresentation" roleURI="http://oncogenex.com/role/NatureOfBusinessAndBasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#AccountingPolicies" roleURI="http://oncogenex.com/role/AccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#CollaborationAgreement" roleURI="http://oncogenex.com/role/CollaborationAgreement" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#FairValueMeasurements" roleURI="http://oncogenex.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#CommonStock" roleURI="http://oncogenex.com/role/CommonStock" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#RestructuringActivities" roleURI="http://oncogenex.com/role/RestructuringActivities" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#CommitmentsAndContingencies" roleURI="http://oncogenex.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#ComprehensiveLoss" roleURI="http://oncogenex.com/role/ComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#SubsequentEvents" roleURI="http://oncogenex.com/role/SubsequentEvents" />
<presentationLink xlink:role="http://oncogenex.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" xlink:type="extended">
<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_DocumentAndEntityInformationAbstract" xlink:label="ogxi_DocumentAndEntityInformationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="5.03" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="5.05" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="5.04" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="5.01" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="5.02" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="5.08" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="5.09" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="5.10" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="5.11" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="5.12" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5.14" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="5.13" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="5.07" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="5.06" use="optional" />
</presentationLink>
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#BalanceSheets" roleURI="http://oncogenex.com/role/BalanceSheets" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#BalanceSheetsParenthetical" roleURI="http://oncogenex.com/role/BalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#StatementsOfIncome" roleURI="http://oncogenex.com/role/StatementsOfIncome" />
<roleRef xlink:type="simple" xlink:href="ogxi-20110630.xsd#StatementsOfCashFlows" roleURI="http://oncogenex.com/role/StatementsOfCashFlows" />
<presentationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/BalanceSheets" xlink:title="01 - Statement - Consolidated Balance Sheets (Unaudited)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_AssetsAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_AssetsAbstract" order="1." use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_AssetsCurrentAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_AssetsCurrentAbstract" order="2.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="3.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_RestrictedCashAndCashEquivalentsAtCarryingValue" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_ShortTermInvestments" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_ShortTermInvestments" order="5.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_AccountsReceivableNetCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_AccountsReceivableNetCurrent" order="6.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_PrepaidExpenseCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_PrepaidExpenseCurrent" order="7.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_AssetsCurrent" order="8.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_PropertyPlantAndEquipmentNet" order="9.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_OtherAssetsNoncurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_OtherAssetsNoncurrent" order="10.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_Assets" order="11.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract" order="12.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_LiabilitiesCurrentAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_LiabilitiesCurrentAbstract" order="13.2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccountsPayableAndAccruedLiabilitiesCurrent" order="14.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_DeferredRevenueCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_DeferredRevenueCurrent" order="15.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_CapitalLeaseObligationsCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_CapitalLeaseObligationsCurrent" order="16.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_WarrantsAndRightsOutstanding" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_WarrantsAndRightsOutstanding" order="17.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_LiabilitiesCurrent" order="18.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_DeferredRevenueNoncurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_DeferredRevenueNoncurrent" order="19.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_CapitalLeaseObligationsNoncurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_CapitalLeaseObligationsNoncurrent" order="20.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_Liabilities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_Liabilities" order="21.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_CommitmentsAndContingencies" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_CommitmentsAndContingencies" order="22.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_StockholdersEquityAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_StockholdersEquityAbstract" order="23.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockValue" order="24.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_AdditionalPaidInCapitalCommonStock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_AdditionalPaidInCapitalCommonStock" order="25.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_RetainedEarningsAccumulatedDeficit" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_RetainedEarningsAccumulatedDeficit" order="26.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="27.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_StockholdersEquity" order="28.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquity" order="29.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/BalanceSheetsParenthetical" xlink:title="011 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)" >
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract" order="12.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_StockholdersEquityAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_StockholdersEquityAbstract" order="23.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_CommonStockParOrStatedValuePerShare" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockParOrStatedValuePerShare" order="24.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_CommonStockSharesAuthorized" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockSharesAuthorized" order="24.2" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_CommonStockSharesIssued" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockSharesIssued" order="24.3" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_CommonStockSharesOutstanding" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockSharesOutstanding" order="24.4" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/StatementsOfIncome" xlink:title="02 - Statement - Consolidated Statements of Loss (Unaudited)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_RevenuesFromCollaborativeAgreements" xlink:label="ogxi_RevenuesFromCollaborativeAgreements" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="ogxi_RevenuesFromCollaborativeAgreements" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_CostsAndExpensesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_CostsAndExpensesAbstract" order="2.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_ResearchAndDevelopmentExpense" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_ResearchAndDevelopmentExpense" order="3.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_GeneralAndAdministrativeExpense" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_GeneralAndAdministrativeExpense" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_CostsAndExpenses" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_CostsAndExpenses" order="5.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_OperatingIncomeLoss" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_OperatingIncomeLoss" order="6.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_NonoperatingIncomeExpenseAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_NonoperatingIncomeExpenseAbstract" order="7.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_InvestmentIncomeInterest" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_InvestmentIncomeInterest" order="8.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_OtherNonoperatingIncomeExpense" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_OtherNonoperatingIncomeExpense" order="9.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_FairValueAdjustmentOfWarrants" xlink:label="ogxi_FairValueAdjustmentOfWarrants" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="ogxi_FairValueAdjustmentOfWarrants" order="10.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_NonoperatingIncomeExpense" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_NonoperatingIncomeExpense" order="11.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="12.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_IncomeTaxExpenseBenefit" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_IncomeTaxExpenseBenefit" order="13.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_NetIncomeLoss" order="14.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_EarningsPerShareBasicAndDiluted" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_EarningsPerShareBasicAndDiluted" order="15.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_WeightedAverageNumberOfCommonSharesAbstract" xlink:label="ogxi_WeightedAverageNumberOfCommonSharesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="ogxi_WeightedAverageNumberOfCommonSharesAbstract" order="16.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_WeightedAverageNumberOfSharesOutstandingBasic" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_WeightedAverageNumberOfCommonSharesAbstract" xlink:to="loc_WeightedAverageNumberOfSharesOutstandingBasic" order="17.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_WeightedAverageNumberOfDilutedSharesOutstanding" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_WeightedAverageNumberOfCommonSharesAbstract" xlink:to="loc_WeightedAverageNumberOfDilutedSharesOutstanding" order="18.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/StatementsOfCashFlows" xlink:title="03 - Statement - Consolidated Statements of Cash Flows (Unaudited)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NetIncomeLoss" order="2.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="3.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_DepreciationDepletionAndAmortization" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_DepreciationDepletionAndAmortization" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_ShareBasedCompensation" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ShareBasedCompensation" order="5.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_AdjustmentOfWarrantsGrantedForServices" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AdjustmentOfWarrantsGrantedForServices" order="6.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IncreaseDecreaseInOperatingCapitalAbstract" order="7.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_IncreaseDecreaseInAccountsReceivable" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInAccountsReceivable" order="8.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="loc_IncreaseDecreaseInRestrictedCashForOperatingActivities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInRestrictedCashForOperatingActivities" order="9.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_IncreaseDecreaseInPrepaidExpense" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInPrepaidExpense" order="10.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="11.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_IncreaseDecreaseInLeaseObligation" xlink:label="ogxi_IncreaseDecreaseInLeaseObligation" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="ogxi_IncreaseDecreaseInLeaseObligation" order="12.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_IncreaseDecreaseInDeferredRevenue" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInDeferredRevenue" order="13.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="14.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="15.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="16.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="17.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="18.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_ProceedsFromSaleOfShortTermInvestments" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_ProceedsFromSaleOfShortTermInvestments" order="19.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_PaymentsToAcquireShortTermInvestments" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquireShortTermInvestments" order="20.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="21.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="22.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents" order="23.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" order="24.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="25.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue_1" order="26.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_SupplementalCashFlowInformationAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_SupplementalCashFlowInformationAbstract" order="27.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_PropertyAndEquipmentAcquiredUnderLeaseObligation" xlink:label="ogxi_PropertyAndEquipmentAcquiredUnderLeaseObligation" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SupplementalCashFlowInformationAbstract" xlink:to="ogxi_PropertyAndEquipmentAcquiredUnderLeaseObligation" order="28.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:title="06001 - Disclosure - Nature of Business And Basis of Presentation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/AccountingPolicies" xlink:title="06002 - Disclosure - Accounting Policies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_SignificantAccountingPoliciesTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="loc_SignificantAccountingPoliciesTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/CollaborationAgreement" xlink:title="06003 - Disclosure - Collaboration Agreement">
<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_CollaborationAgreementAbstract" xlink:label="ogxi_CollaborationAgreementAbstract" />
<loc xlink:type="locator" xlink:href="ogxi-20110630.xsd#ogxi_CollaborationAgreementTextBlock" xlink:label="ogxi_CollaborationAgreementTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogxi_CollaborationAgreementAbstract" xlink:to="ogxi_CollaborationAgreementTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/FairValueMeasurements" xlink:title="06004 - Disclosure - Fair Value Measurements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_FairValueDisclosuresTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueDisclosuresAbstract" xlink:to="loc_FairValueDisclosuresTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/CommonStock" xlink:title="06005 - Disclosure - Common Stock">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_EquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityAbstract" xlink:to="loc_StockholdersEquityNoteDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/RestructuringActivities" xlink:title="06006 - Disclosure - Restructuring Activities">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_RestructuringAndRelatedActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RestructuringAndRelatedActivitiesAbstract" xlink:to="loc_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/CommitmentsAndContingencies" xlink:title="06007 - Disclosure - Commitments And Contingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_CommitmentsAndContingenciesDisclosureTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/ComprehensiveLoss" xlink:title="06008 - Disclosure - Comprehensive Loss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_EquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_ComprehensiveIncomeNoteTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityAbstract" xlink:to="loc_ComprehensiveIncomeNoteTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://oncogenex.com/role/SubsequentEvents" xlink:title="06009 - Disclosure - Subsequent Events">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_SubsequentEventsTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SubsequentEventsAbstract" xlink:to="loc_SubsequentEventsTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E6KAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">25,000,000<span></span></td>
        <td class="nump">25,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">9,718,251<span></span></td>
        <td class="nump">9,693,591<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">9,718,251<span></span></td>
        <td class="nump">9,693,591<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EURAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Loss (Unaudited) (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Consolidated Statements of Loss [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogxi_RevenuesFromCollaborativeAgreements', window );">COLLABORATION REVENUE</a></td>
        <td class="nump">$ 1,887<span></span></td>
        <td class="nump">$ 1,701<span></span></td>
        <td class="nump">$ 3,086<span></span></td>
        <td class="nump">$ 6,401<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>EXPENSES</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">5,409<span></span></td>
        <td class="nump">3,079<span></span></td>
        <td class="nump">10,262<span></span></td>
        <td class="nump">9,459<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">1,471<span></span></td>
        <td class="nump">1,475<span></span></td>
        <td class="nump">3,042<span></span></td>
        <td class="nump">2,825<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
        <td class="nump">6,880<span></span></td>
        <td class="nump">4,554<span></span></td>
        <td class="nump">13,304<span></span></td>
        <td class="nump">12,284<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
        <td class="nump">4,993<span></span></td>
        <td class="nump">2,853<span></span></td>
        <td class="nump">10,218<span></span></td>
        <td class="nump">5,883<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE)</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">63<span></span></td>
        <td class="nump">14<span></span></td>
        <td class="nump">119<span></span></td>
        <td class="nump">19<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other</a></td>
        <td class="nump">87<span></span></td>
        <td class="num">(7)<span></span></td>
        <td class="nump">83<span></span></td>
        <td class="num">(26)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogxi_FairValueAdjustmentOfWarrants', window );">Gain (loss) on warrants [note 5]</a></td>
        <td class="num">(1,687)<span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">441<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
        <td class="num">(1,537)<span></span></td>
        <td class="nump">7<span></span></td>
        <td class="nump">643<span></span></td>
        <td class="num">(7)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss for the period before income taxes</a></td>
        <td class="nump">6,530<span></span></td>
        <td class="nump">2,846<span></span></td>
        <td class="nump">9,575<span></span></td>
        <td class="nump">5,890<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (recovery) [note 3]</a></td>
        <td class="text"> <span></span></td>
        <td class="num">(3,000)<span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(3,000)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (income)</a></td>
        <td class="nump">$ 6,530<span></span></td>
        <td class="num">$ (154)<span></span></td>
        <td class="nump">$ 9,575<span></span></td>
        <td class="nump">$ 2,890<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss (income) per common share</a></td>
        <td class="nump">$ 0.67<span></span></td>
        <td class="num">$ (0.02)<span></span></td>
        <td class="nump">$ 0.99<span></span></td>
        <td class="nump">$ 0.45<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogxi_WeightedAverageNumberOfCommonSharesAbstract', window );"><strong>Weighted average number of common shares:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
        <td class="nump">9,718,251<span></span></td>
        <td class="nump">6,400,081<span></span></td>
        <td class="nump">9,715,846<span></span></td>
        <td class="nump">6,366,861<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
        <td class="nump">9,718,251<span></span></td>
        <td class="nump">6,529,482<span></span></td>
        <td class="nump">9,715,846<span></span></td>
        <td class="nump">6,366,861<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogxi_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain (loss) on warrants [note 5]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogxi_FairValueAdjustmentOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogxi</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogxi_RevenuesFromCollaborativeAgreements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>COLLABORATION REVENUE</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogxi_RevenuesFromCollaborativeAgreements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogxi</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogxi_WeightedAverageNumberOfCommonSharesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average number of common shares:</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogxi_WeightedAverageNumberOfCommonSharesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogxi</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs of sales and operating expenses for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 10<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Article 4<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 109<br> -Paragraph 45<br> -Subparagraph a, b<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 7<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 115<br> -Paragraph 14<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A7<br> -Appendix A<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 10, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 87-21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 19<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28, 29, 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 7<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 9<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141<br> -Paragraph 51<br> -Subparagraph g<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 2<br> -Paragraph 12, 13<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 86<br> -Paragraph 11, 12<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 07-4<br> -Paragraph 4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 40<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 171<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 40<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 07-4<br> -Paragraph 4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EAWAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Aug. 01, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogxi_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">ONCOGENEX PHARMACEUTICALS, INC.<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000949858<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Jun. 30,
         2011<span></span></td>
        <td class="text"><span></span></td>
        <td class="text"><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2011<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q2<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">$ 86,062,824<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">9,725,489<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogxi_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogxi_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogxi</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments And Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 7 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>7. COMMITMENTS AND CONTINGENCIES</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Teva Pharmaceutical Industries Ltd.</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Under the Collaboration Agreement, Teva made upfront payments in the aggregate amount of $50
   million, may make up to $370&#160;million in additional payments upon the achievement of developmental
   and commercial milestones and may be required in the future to pay royalties at percentage rates
   ranging from the mid-teens to mid-twenties on net sales. The Company is required to contribute $30
   million in direct and indirect costs towards the Clinical Development Plan. As of June&#160;30, 2011,
   $10.1&#160;million of these costs have been incurred by OncoGenex, resulting in a remaining funding
   responsibility of $19.9&#160;million which has been recorded under Current and Long-term Deferred
   Collaboration Revenue as of June&#160;30, 2011. Teva will fund all other expenses under the Clinical
   Development Plan. See note 3 in the Notes to Financial Statements for further details on our
   Collaboration Agreement with Teva.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Isis Pharmaceuticals Inc. and University of British Columbia</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">To facilitate the execution and performance of the Collaboration Agreement with Teva, OncoGenex and
   Isis agreed to amend the Isis License Agreement and the Company and UBC agreed to amend the UBC
   License Agreement, in each case, effective December&#160;19 and December&#160;20, 2009, respectively.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">The amendment to the Isis License Agreement provides, among other things, that if the Company is
   the subject of a change of control with a third party, where the surviving company immediately
   following such change of control has the right to develop and sell the product, then (i)&#160;a
   milestone payment of $20&#160;million will be due and payable to Isis 21&#160;days following the first
   commercial sale of the product in the United States; and (ii)&#160;unless such surviving entity had
   previously sublicensed the product and a royalty rate payable to Isis by the Company has been
   established, the applicable royalty rate payable to Isis will thereafter be the maximum amount
   payable under the Isis License Agreement. Any non-royalty milestone amounts previously paid will be
   credited toward the $20&#160;million milestone if not already paid. As a result of the $10&#160;million
   milestone payment payable to Isis in relation to the Collaboration Agreement, the remaining amount
   owing in the event of change of control discussed above is a maximum of $10&#160;million. As the Company
   has now licensed the product to Teva and established a royalty rate payable to Isis, no royalty
   rate adjustments would apply if Teva acquires the Company and is the surviving company. If the $30
   million in advanced reimbursement of development activities has not been spent by OncoGenex prior
   to the third anniversary of the Collaboration Agreement between OncoGenex and Teva, OncoGenex will
   pay Isis an amount equal to 30% of any un-spent portion less $3.5&#160;million.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt">In addition, we are required to pay to Isis 30% of all Non-Royalty Revenue we receive on custirsen
   sales. Isis has disclosed in its SEC filings that it is entitled to receive 30% of the up to $370
   million in milestone payments we may receive from Teva as part of the Collaboration Agreement;
   however, we believe that certain of the milestone payments related to sales targets may qualify as
   Royalty Revenue, and therefore be subject to the lesser payment obligations. No assurance can be
   provided that we will be entitled to receive these milestone payments or, if we are, that the
   applicable amount payable to Isis will be less than 30%.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Pursuant to license agreements the Company has with the UBC and Isis, the Company is obligated to
   pay milestone payments of up to CAD $1.6&#160;million and $7.75&#160;million, respectively, upon the
   achievement of specified product development milestones related to OGX-427 and OGX-225 and
   royalties on future product sales. We paid Isis and UBC $750,000 and CAD $100,000, respectively, in
   2010 upon the initiation of a phase 2 clinical trial of OGX-427 in patients with CRPC. We do not
   anticipate making any royalty payments to Isis in 2011.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Unless otherwise terminated, the Isis agreements for custirsen and OGX-427 will continue for each
   product until the later of 10&#160;years after the date of the first commercial product sale, or the
   expiration of the last to expire of any patents required to be licensed in order to use or sell the
   product, unless OncoGenex Technologies abandons either custirsen or OGX-427 and Isis does not elect
   to unilaterally continue development. The Isis agreement for OGX-225 will continue into perpetuity
   unless OncoGenex Technologies abandons the product and Isis does not elect to unilaterally continue
   development.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">We are also obligated to pay to UBC certain patent costs and annual license maintenance fees for
   the extent of the patent life of CAD $8,000 per year relating to custirsen, OGX-427 and OGX-225.
   The UBC agreements have effective dates ranging from November&#160;1, 2001 to April&#160;5, 2005 and each
   agreement expires upon the later of 20&#160;years from its effective date or the expiry of the last
   patent licensed thereunder, unless otherwise terminated.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Bayer HealthCare LLC</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">On August&#160;7, 2008, Sonus completed an exclusive in-licensing agreement with Bayer HealthCare LLC,
   or Bayer, for the right to develop, commercialize or sublicense a family of compounds known as
   caspase activators presently in pre-clinical research. Under terms of the agreement, Sonus was
   granted exclusive rights to develop two core compounds for all prophylactic and therapeutic uses in
   humans. Additionally, Sonus was granted rights to all other non-core compounds covered under the
   patents for use in oncology.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Under the terms of the agreement, Bayer received an upfront license fee of $450,000. OncoGenex will
   make annual payments to Bayer on the anniversary date (Anniversary Payments), with an initial
   payment of $100,000 paid in 2008. The payments increase by $25,000 each year until the initiation
   of the first phase 3 clinical trial, at which point the Anniversary Payments reset to $100,000 each
   year and increase by $25,000 until the Company achieves either the first New Drug Application, or
   NDA, filing in the United States or the European Union. OncoGenex is obligated to pay royalties on
   net future product sales in addition to aggregate milestone payments of up to $14,000,000 for
   clinical development and regulatory milestones. No milestone payments are triggered prior to the
   initiation of a phase 3 clinical trial. OncoGenex has the option to terminate this contract upon 60
   days written notice to Bayer.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Lease Arrangements</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">The Company has an operating lease agreement for office space in Vancouver, Canada, which expires
   in September&#160;2014.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Future minimum annual lease payments under the Vancouver lease are as follows (in thousands):
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="86%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000">CAD</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">2011
   </div></td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right">53</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">2012
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">107</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">2013
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">107</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">2014
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">80</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px"><b>Total</b>
   </div></td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right"><b>347</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">In November&#160;2006, prior to the Arrangement , Sonus entered into a non-cancellable operating
   lease agreement for office space in Bothell, Washington, expiring in 2017 (note 6). In connection
   with the lease, Sonus was required to provide a cash security deposit of approximately $497,000,
   which is included in Other Long Term Assets. In addition, a standby letter of credit was issued in
   2010, and $502,000 was deposited in a restricted money market account as collateral. The Company is
   currently in the process of evaluating opportunities to exit or sublet portions of the leased space
   and has recorded a liability in the excess facilities lease charge of $7,327,000 as at June&#160;30,
   2011 (note 6).
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">If the Company is unable to exit or sublet portions of this leased space, the future minimum annual
   lease payments are as follows (in thousands):
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="86%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">2011
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">1,027</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">2012
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">2,117</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">2013
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">2,180</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">2014
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">2,246</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">2015
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">2,313</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Remainder
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">4,837</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px"><b>Total</b>
   </div></td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right"><b>14,720</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Consolidated rent expense relating to both the Vancouver, Canada and Bothell, Washington
   offices for the periods ended June&#160;30, 2011 and 2010 was $1,313,000 and $1,092,000 respectively.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Guarantees and Indemnifications</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">OncoGenex indemnifies its officers and directors for certain events or occurrences, subject to
   certain limits, while the officer or director is or was serving at our request in such capacity.
   The term of the indemnification period is equal to the officer&#8217;s or director&#8217;s lifetime.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">The maximum amount of potential future indemnification is unlimited; however, we have obtained
   director and officer insurance that limits our exposure and may enable it to recover a portion of
   any future amounts paid. We believe that the fair value of these indemnification obligations is
   minimal. Accordingly, we have not recognized any liabilities relating to these obligations as of
   June&#160;30, 2011.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">We have certain agreements with certain organizations with which we do business that contain
   indemnification provisions pursuant to which we typically agree to indemnify the party against
   certain types of third-party claims. We accrue for known indemnification issues when a loss is
   probable and can be reasonably estimated. There were no accruals for or expenses related to
   indemnification issues for any period presented.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   </div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name FASB Interpretation (FIN)<br> -Number 14<br> -Paragraph 3<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 5<br> -Paragraph 9, 10, 11, 12<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration Agreement<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogxi_CollaborationAgreementAbstract', window );"><strong>Collaboration Agreement [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogxi_CollaborationAgreementTextBlock', window );">COLLABORATION AGREEMENT</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 3 - ogxi:CollaborationAgreementTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>3. COLLABORATION AGREEMENT</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">On December&#160;20, 2009, the Company, through its wholly-owned subsidiary, OncoGenex Technologies,
   entered into a Collaboration Agreement with Teva Pharmaceutical Industries Ltd., or Teva, for the
   development and global commercialization of custirsen (and related compounds), a pharmaceutical
   compound designed to inhibit the production of clusterin, a protein we believe is associated with
   cancer treatment resistance, or the Licensed Product. Under the Collaboration Agreement, Teva paid
   the Company upfront payments in the aggregate amount of $50&#160;million and has agreed to pay up to
   $370&#160;million upon the achievement of developmental and commercial milestones and royalties at
   percentage rates ranging from the mid-teens to mid-twenties on net sales, depending on aggregate
   annual net sales of the Licensed Product.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">On the same date, the Company and Teva also entered into a stock purchase agreement, or Stock
   Purchase Agreement, pursuant to which Teva made an additional $10&#160;million equity investment in the
   Company at a 20% premium to a thirty-day average closing price, resulting in the issuance of
   267,531 of our common shares purchased at a price of $37.38 per share. The 20% share premium was
   included as consideration for the custirsen license and has been included in collaboration revenue.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">In connection with the Collaboration Agreement and pursuant to the terms of agreements between the
   Company and Isis relating to custirsen, the Company paid Isis Pharmaceuticals, Inc., or Isis, $10
   million which was recorded as research and development expense in 2009. The Company also paid
   approximately $333,333 to the University of British Columbia, or UBC, pursuant to the terms of
   their license agreement relating to custirsen, which has been recorded as research and development
   expense in 2009. Pursuant to the terms of the third-party agreements, the Company anticipates that
   it would be required to pay third parties 31% of any milestone payments that are not based on a
   percentage of net sales of the Licensed Product. Pursuant to the terms of third-party agreements,
   the Company anticipates it will pay royalties to third-parties of 4.88% to 8.00% of net sales,
   unless the Company&#8217;s royalties are adjusted for competition from generic compounds, in which case
   royalties to third parties will also be subject to adjustment on a country-by-country basis.
   Certain third-party royalties are tiered based on the royalty rate received by the Company. Minimum
   royalty rates payable by the Company assume certain third-party royalties are not paid
   at the time that the Licensed Product is marketed due to the expiration of patents held by such
   third parties. Maximum royalty rates assume all third-party royalty rates currently in effect
   continue in effect at the time the Licensed Product is marketed.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Teva has the exclusive worldwide right and license to develop and commercialize products containing
   custirsen and related compounds. The Company has an option to co-promote any Licensed Product in
   the United States and Canada.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Teva is responsible for all costs relating to product commercialization including costs incurred in
   relation to the Company&#8217;s co-promotion option, except for start-up costs in advance of
   commercialization.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Teva and the Company have developed a Clinical Development Plan under which three phase 3 clinical
   trials will be initiated:
   </div>
   <div style="margin-top: 10pt">
   <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="4%" style="background: transparent">&#160;</td>
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>
   The ongoing phase 3 clinical trial, referred to as the Synergy trial, or SYNERGY, to evaluate a survival benefit for
   custirsen in combination with first-line docetaxel treatment in patients with castrate resistant prostate cancer, or CRPC.
   Expected timing of results from the survival primary endpoint for the custirsen SYNERGY Phase 3 clinical trial remains
   unchanged at Q4 2013. During discussions regarding the Prostate Cancer SATURN trial, or SATURN, Special Protocol
   Assessment, or SPA, amendment, U.S. Food and Drug Administration, or FDA, stated that an application supported primarily
   by the results of SYNERGY alone would be acceptable for submission. We expect to increase patient enrollment in SYNERGY
   from 800 to approximately 1000 patients, and expand the number of clinical trial sites.
   </td>
   </tr>
   </table>
   </div>
   <div style="margin-top: 10pt">
   <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="4%" style="background: transparent">&#160;</td>
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>
   An ongoing phase 3 clinical trial, referred to as SATURN, to evaluate a durable pain palliation benefit for
   custirsen in combination with docetaxel as second-line chemotherapy in approximately 300 patients with CRPC. We have
   revised the custirsen SATURN Phase 3 trial protocol to expand the eligible patient population, and to align with the
   recently approved chemotherapy, cabazitaxel. We are awaiting final, written FDA agreement on the SPA amendment that will
   allow patients to receive either docetaxel re-treatment or cabazitaxel as second-line chemotherapy. Recruitment efforts
   are ongoing to enroll more patients in the SATURN study, which has had few patients accrued due to restrictive enrollment
   criteria regarding docetaxel retreatment and stable pain criteria. Expected timing of results for the pain palliation
   primary endpoint is now projected to be Q4 2013 rather than Q2 2013.
   </td>
   </tr>
   </table>
   </div>
   <div style="margin-top: 10pt">
   <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="4%" style="background: transparent">&#160;</td>
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>
   A phase 3 clinical trial to evaluate a survival benefit for custirsen in combination with first-line chemotherapy in
   patients with non-small cell lung cancer, or NSCLC. The initiation of the Phase 3 clinical trial evaluating custirsen
   in patients with NSCLC has been delayed as we determine the optimal chemotherapeutic combination. We believe NSCLC is
   a promising indication and remain committed to the advancement of custirsen in NSCLC.
   </td>
   </tr>
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Teva will be responsible for conducting any other studies and development work necessary to obtain
   required regulatory approvals. The Company may assume some of these activities if assigned by the
   joint steering committee. Teva will be responsible for all such costs. The joint steering committee
   will oversee the development and regulatory approval of any Licensed Product. The Company may
   terminate its participation in the joint steering committee at any time.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Funding responsibilities for the Clinical Development Plan will be allocated as follows:
   </div>
   <div style="margin-top: 10pt">
   <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="4%" style="background: transparent">&#160;</td>
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>The Company will be required to spend $30&#160;million in direct and indirect development
   costs, and</td>
   </tr>
   </table>
   </div>
   <div style="margin-top: 10pt">
   <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="4%" style="background: transparent">&#160;</td>
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>Teva will fund all other expenses under the Clinical Development Plan.</td>
   </tr>
   </table>
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div style="margin-top: 10pt">
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">The Collaboration Agreement will remain in effect, on a country-by-country basis, until the
   expiration of the obligation of Teva to pay royalties on sales of the Licensed Product in such
   country (or earlier termination under its terms). After the completion of all three phase 3
   clinical trials set forth in the Clinical Development Plan, or upon early termination due to a
   material adverse change in the Company&#8217;s patent rights related to custirsen or safety issues or
   &#8220;futility&#8221; as defined in the Collaboration Agreement, Teva may
   terminate the Collaboration Agreement at its sole discretion upon three months&#8217; notice if notice is
   given prior to regulatory approval of a Licensed Product and upon six months&#8217; notice if notice is
   given after such regulatory approval. If Teva terminates the Collaboration Agreement for any
   reasons other than an adverse change in custirsen patent rights, safety issues or &#8220;futility&#8221;
   determination as previously described, it will remain responsible for paying for any remaining
   costs of all three phase 3 clinical trials, except for specified development expenses that are the
   responsibility of the Company. Either party may terminate the Collaboration Agreement for an
   uncured material breach by the other party or upon the bankruptcy of either party. If the
   Collaboration Agreement is terminated by the Company for other than an uncured material breach by
   Teva, the Company will pay Teva a royalty on sales of Licensed Products. The percentage rates of
   such royalties (which are in the single digits) vary depending on whether termination occurs prior
   to the first regulatory approval in the United States or a primary European Market or after one of
   these approvals. These royalties would expire on a country-by-country basis on the earlier of ten
   years after the first commercial sale of a Licensed Product or certain thresholds related to
   generic competition.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">In the event of a change of control of the Company, within 90&#160;days of the change of control, Teva
   may terminate the joint steering committee at its sole discretion, terminate the co-promotion
   option at its sole discretion if not then exercised by the Company or if exercised but not yet
   executed by the Company, or terminate the co-promotion option if in its commercially reasonable
   opinion co-promotion with the Company&#8217;s successor would be materially detrimental to Teva&#8217;s
   interests.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Upon entering into the Collaboration Agreement, the Company assessed whether withholdings taxes
   were owed to the Israeli Tax Authority, or ITA, resulting from the Collaboration Agreement. It was
   the Company&#8217;s position that withholdings taxes were not owed, and a claim was issued to the ITA
   accordingly. For accounting purposes, management concluded that the withholdings tax claim was an
   uncertain tax position, and $3&#160;million, which represented the potential withholdings tax
   obligation, once received from Teva was initially recorded as restricted cash pending the ITA
   review of our claim and a corresponding liability of $3&#160;million was included in accounts payable
   and accrued liabilities. In June&#160;2010, the Company received approval from the ITA for our request
   for a withholdings tax exemption on amounts received from Teva in relation to the Collaboration
   Agreement. Following receipt of this approval from the ITA the $3&#160;million was released to the
   Company from escrow. Subsequently, the Company released the $3&#160;million liability and recorded a $3
   million income tax recovery in the second quarter of 2010.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Revenue for the three and six months ended June&#160;30, 2011 was $1.9&#160;million, and $3.1&#160;million which
   consists of partial recognition of deferred collaboration revenue representing OncoGenex&#8217;s
   contribution to the custirsen phase 3 development plan under our Collaboration Agreement with Teva
   and custirsen manufacturing costs incurred by OncoGenex in the year ended December&#160;31, 2010 that
   are reimbursable from Teva. At June&#160;30, 2011, a remaining balance of $19.9&#160;million of the up-front
   payment was recorded in deferred collaboration revenue. There was $1.7&#160;million and $6.4&#160;million in
   revenue recorded in the three and six months ended June&#160;30, 2010 as a result of the Collaboration
   Agreement with Teva.
   </div>
   </div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogxi_CollaborationAgreementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>COLLABORATION AGREEMENT</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogxi_CollaborationAgreementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogxi</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogxi_CollaborationAgreementTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>COLLABORATION AGREEMENT</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogxi_CollaborationAgreementTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogxi</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 9 - us-gaap:SubsequentEventsTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>9. SUBSEQUENT EVENTS</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">The Company has performed an evaluation of events occurring subsequent to June&#160;30, 2011. Based on
   our evaluation, no material events have occurred requiring financial statement disclosure.
   </div>
   </div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Comprehensive Loss<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common Stock and Comprehensive Loss [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">COMPREHENSIVE LOSS</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 8 - us-gaap:ComprehensiveIncomeNoteTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>8. COMPREHENSIVE LOSS</b>
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="44%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Three Months</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Six Months</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Ended</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Ended</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>June 30,</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>June 30,</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000">(In thousands)</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td nowrap="nowrap" align="left">&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>$</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>$</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>$</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>$</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Loss (income)&#160;for the period
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">6,530</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(154</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">9,575</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2,890</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Unrealized gain on cash
   equivalents and marketable
   securities
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(14</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(14</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Unrealized loss on cash
   equivalents and short-term
   investments
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">46</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">46</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Comprehensive loss (income)
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">6,562</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(154</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">9,607</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2,890</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   </div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for comprehensive income.  Includes, but is not limited to,  the following:  1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. Components of comprehensive income include: (1) foreign currency translation adjustments; (2) gains (losses) on foreign currency transactions that are designated as, and are effective as, economic hedges of a net investment in a foreign entity; (3) gains (losses) on intercompany foreign currency transactions that are of a long-term-investment nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; (4) change in the market value of a futures contract that qualifies as a hedge of an asset reported at fair value; (5) unrealized holding gains (losses) on available-for-sale securities and that resulting from transfers of debt securities from the held-to-maturity category to the available-for-sale category; (6) a net loss recognized as an additional pension liability not yet recognized as net periodic pension cost; and (7)  the net gain (loss) and net prior service cost or credit for pension plans and other postretirement benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6920433&amp;loc=d3e998-108581<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e689-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e716-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e681-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Reclassification Adjustments<br> -URI http://asc.fasb.org/extlink&amp;oid=6522872<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 14-26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e640-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e653-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e709-108580<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNoteTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Nature of Business And Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business And Basis of Presentation [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF BUSINESS AND BASIS OF PRESENTATION</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 1 - us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-->
   <div align="left" style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <!-- xbrl,ns -->
   <!-- xbrl,nx -->
   <div align="center" style="font-size: 10pt; margin-top: 0pt"><b></b>
   </div>
   <div align="left">
   </div>
   <div align="center" style="font-size: 10pt"><b></b></div>
   <div align="center" style="font-size: 10pt"><b></b></div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>1. NATURE OF BUSINESS AND BASIS OF PRESENTATION</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">OncoGenex Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;OncoGenex&#8221;) is committed to the development and
   commercialization of new therapies that address treatment resistance in cancer patients. The
   Company was incorporated in the state of Delaware and, together with its subsidiaries, has a
   facility in Bothell, Washington and an office in Vancouver, British Columbia (Canada).
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">The unaudited financial statements have been prepared in accordance with generally accepted
   accounting principles in the United States for interim financial information and with the
   instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes
   required to be presented for complete financial statements. The accompanying unaudited consolidated
   financial statements reflect all adjustments (consisting only of normal recurring items) which are,
   in the opinion of management, necessary for a fair presentation of the results for the interim
   periods presented. The accompanying consolidated Balance Sheet at December&#160;31, 2010 has been
   derived from the audited consolidated financial statements included in the Company&#8217;s Annual Report
   on Form 10-K for the year then ended. The consolidated financial statements and related disclosures
   have been prepared with the assumption that users of the interim financial information have read or
   have access to the audited consolidated financial statements for the preceding fiscal year.
   Accordingly, these financial statements should be read in conjunction with the audited consolidated
   financial statements and the related notes thereto included in the Annual Report on Form 10-K for
   the year ended December&#160;31, 2010 and filed with the United States Securities and Exchange
   Commission (&#8220;SEC&#8221;) on March&#160;10, 2011.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">The consolidated financial statements include the accounts of OncoGenex and our wholly owned
   subsidiary, OncoGenex Technologies Inc. (&#8220;OncoGenex Technologies&#8221;). All intercompany
   balances and transactions have been eliminated.
   </div>
   </div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6970148&amp;loc=SL6228881-111685<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Name Statement of Position (SOP)<br> -Publisher AICPA<br> -Number 94-6<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name FASB Staff Position (FSP)<br> -Number FAS140-4/FIN46(R)-8<br> -Paragraph 8, C1, C7<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Name FASB Interpretation (FIN)<br> -Publisher FASB<br> -Number 46R<br> -Paragraph 4, 14, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 2-6<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 915<br> -SubTopic 235<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6359553&amp;loc=d3e288-107754<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0000950123-11-073065-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950123-11-073065-xbrl.zip
M4$L#!!0````(`"`P!3^QV/?3$%0``%ZC`@`1`!P`;V=X:2TR,#$Q,#8S,"YX
M;6Q55`D``UN_.TY;OSM.=7@+``$$)0X```0Y`0``Y%WK<^)&MO]^J^[_T.M;
MM3NI,D;BC<>3+8SQQ!L;O(;)))]2;:F!W@@UT<,V^>OO.=T2>B"0`#'.S4U5
M$BRU^OSZ]'EWJW7US[>%15Z8XW)A?SK3+[0SPFQ#F-R>?3KSW0IU#<[/_OG]
M?__7U=\J%?+S]=,]^<QLYE"/F>25>W-Y[8$ZOY&^6*X</IM[Y$/_._*\(D]/
MY$;8-K,LMB*52MC)-77A66&KWFH7>G#O[=FQ"."QW4]G<\];7E:KKZ^O%WCY
M0CBS:DW3ZE5NNQZU#7:F6EY:W/YM1W.\_0STPN9O&^U?Z[*UWNUVJ_)NV%3,
MWOBZI0"FS&#<;Q>&6$#7NE[16I6Z%C;FKFC4]/8NX*I%^`#P=D;I<OW`E+K/
MLG%P(Z"A5^KZ&COTQ_=@#=XUHP?BC5M5=3-L:K)4.Y<9%S/Q4H4;64A<GL5#
MZ%BO_OQP/S;F;$$K:SPPN81<(6\O77GKB4V)Y/6EMUJR3V<N7RPMQ"VOS1TV
M_72&[*\@::U5UR[>7/.,5$,)Z@O;8V\>&3/#`\$-Y,<(KG+ST]DUM9!TSQU-
M?]7TGC_#GA#(%;,][JWP%S?Q]Y0SATA8+#&FD`/]NQ_/OM?@GVZCVVEVKJK1
M8]A)->IOR1PN3-FS'+GWO>)<!YAW50VOX3-1RVH`>A?^NO8OWWY'_"CG1^'7
M;Y@!76GO@5^KZ#60W'WQ3T`(V0-<F+L#VV3F.TP"P'6\&["SP30TI!A%5R4,
M,]9`S5-X[<AQ?KO)2HQ3RQNG=M@XQ_SMSS6;^BEF<\LHWV\N=X_RP+G,L"U:
M]QULB]8]S+9DV?9WLHV%;3MXW2\V7WM<Z7#)E8^7<$A?QC>#Q[%R].3*Y"\`
M1/U!5*NAO\"843CA5;B^8-3U'?9]$!E=0B=7U?`B"9^N9CXN.[UAMEAP>TNW
M,ERZ=.?48>ZV?C=ZN*I&X%63Y$#'LKMPH+M)R:AGW4>26T$/.4Q(]!#$/@,+
MI,%.QSYPYT88OKQS9T^%LZ#K>;J"(.YR($7AB<VXZSDPUT.Z8"28X">,M[9;
MR-&P/_H\&`Y^)H\_])X>>OW!E\E=OW<_/B=WP_[%575;_TG:?<#F4.L.NG_[
M$1*"8L3CTKVUKY!0WW<<N'/+78-:OS#J#)1A*4BK$NKSKKZ2@_H*R<V/MGBU
MQS!EPF;FG>OZH+3%"`Y%?%!;^DH2_$E8O@WV='7++4C;#B*4ZB,U36K<3VPI
M'`_2P+%'/;\HG5]0_O/Z2M*3&/K`V)EPB@I%SS"8%>2@\ODXT42'(:U0.2:0
M;Q0D`N;QWZK?^,-AASVX8.+%6XO."O8XI9;+5)>)Q]$H)5`^2AN\G_#&HX:M
M?:79H:1;-;F%:T7G^=^U))&-?C:&%.G1/G3POUF4UOVLZ:BY?_2?+6[<6H)Z
M"0K9+I>8S.`+F)1/9_`'FEG96)KG3DMKU3JU1ERR8KVG=$8L%L(>>\+X33F(
MD>^A1\4RRE8<45H:PW$WO(TA";U-MUUK-CK=A&KM(!FFR7=!`A[Z#)>`8R#7
MO?O>L#_X=?S#8#`9!_XCJ#I<]JD[[]DF_F_PN\]?J(7/];P^=9P5=/T3M7R6
MRUH]Q<W8`"MUG-5.NP5V_:JZ%]D2<:XSTMTXZ\UZ_3B<3PS<(3?`4'T3SC:U
M6@+OGN1/@KP8KTM$/IZ#MYDP9W%GOT`O2O*/96RC64^*;!:5PU$48U)+;[8;
M>Z$`3RG`U[M/S&#`NF>+#9D7N.5C>:)#6)8`LXO8\:"*L4BOU1H'@7ITV))R
M<_"V9+;+RF)1O=M.H,FD<@2,@H:LT6GN!Z/GNLQS2^)"N]/1NLE)B7=_`-UB
MP^YTZWJG&-U'1T#B"RX>B'A@;=#2+%&;0%B.=W=I&=A.ZWA,!5ES&*21-V>.
M8N)0V$8YXM%,"4<FD2-0%'1`>GT_%.K>T;K1;=::&3*Z#Z6BVM#-U(8LR_Q(
M5V@I01+@BN,S\Y[39VYQC[.RC(+>:M0S#74!VJ5#+FQ/RD!\PZ8,+II/[(79
M?FFN1E/_1/"RZ1R#I*`+/@!)GRZY1ZU[1ETV@BQK)LM7I<E:O=-(Q?&[R)4!
MK""KZOJAP+Y"^$LQ$+;-)UQT+Y1S%H[L.K6DJ=A%[7A4!9G5K+6Z!Z$JWWK5
MVIUFTFSOUOGRC5&MW4@ET7M9G?+<=[?3:NW2]FSO>0"<@E*BMVJU_?%L4;SR
MV`1,2M<\<BB6!*]@:MGJ-@^'%Q.]8_G4:-1K[6URO3?-8H-O--LIU[Z%)E;=
MN,JRL20!5,'2,-M`#$D";RZ_M+GUZ<R#@."L"%.JIR44<6*#4%!'+*4"I2<]
M?[K[PTCO$7?L3?J1.B,'%R:8*9L],D<65/=E!*Y_I@JYWVL7&JY_[T&U-)#9
M+#LI2%6'[OG>7#C\#V;NQ<&@U)T&)W.C;=.:)G@TK@RFG1R77.0KA5?=MMZI
M-;.G,D[K*#C%6=1M=>O-[I%P#@UJ#V;1E@CR,&!E,FL+L)YI<G3,U'JDW+RS
M`[<=>_QXB][9J*GF$BT+8E'+WP8/?@3$)^91;C-S0!T;&.Q"'N\O?`LM'T2/
MW.!'AW^5=K/52'(QGVA9$(MQL8(A:O<(B+&[LGH&S%XZ;,YLE[^P.]L0"W8O
M7'?(O-%T0M^.SL%:VL;ZPS[T3P*]8/+6TIIE09?"/!>6R1P7Z[;>ZEC&UIMZ
M:F5GD\:A"`H&Y`T]517=C2`6KD.X7#Y'-JNT>13+07=H9;<(NNT[!,:3A^'D
MU[MA?_0P"/8'X&[\RR"!=F\=L>@+RZ+/PH&L\(7U9@YCFRN<.S91[S;GG6!Y
MHBC5\A'F.9RVIG\;A%OWQNS68*W3>E=\>=6&Q@'\BVT-8-0Q<%/`#3QI";E2
M%:QEEB*`S8:6]H,[2):,+8=U=:U]<FR'"9VNU5H;FSB^$;0<IG4;S0.9IEYV
MLW!MQUQP6^YN1=$L4]ST1EM/H,LA6CJ^/&O7:#>_!;Y#;5VC]H[H\B*]3NU@
MWO6%*\M_P:URG&NKTTD7+I)4CD>06VUM-LI!<*"=JH/(G!1`_AZE]'KD#@"C
M)>YTANPK2@-*$81*HYLJ>F=0*@5(7MY9ZS1+!7*86%3`?Z7"Z-/@R&-'L]/9
MBQW1UC]U_PX0.'"E''.1A+*-5GEX<GW1:?`<:$KT[C>%D\><_='(:L-0V"(I
M8V6&-ZF]9KLIEHTM3]F^`;;#1"MM`[XALEQ[W=H3FLSR;BEWY#)2S_R/K\1R
M-`UW<)031[?B=8.=]`Y`=:!7:33T/3"%/#VM1E;T9CTI^(4DZ[2J>#)`ATU<
M>GOBZ0'M9ZH*X8D"!E5;P6T$/CP01!3"=J_95#A!A7E"WY@[>(.$1#@FMZFS
MNO/80F[Y@"<=85F25HG11:4E([^$SSH9XC\58_)CXD;KK\R8`ZUIMYDJ1?S_
M8$M^RM!]1S6"QP/;<\UL-N4EJ4`]O<5B"[5]`1W(XT/@#)E7=M:^83$3-(XD
MGKL#MW$LZ;+TOCS2^9:X6Y#AX2IYN$_JFKK<P`HSMWPOM:FFZ/RG=FS5<+]6
MJQV!R:%9.KS=&\H`7D6[T&HGQU=,C+*8U^V^%[A<UFD7C>9!X+XRW/W.S-X+
M6/<9&_J+9^:,IAL;AV07^XOAYIXE+6,KU5X@3HQ^]XXK32Y`:EKG?=$7D.%M
MG&]"=/AGQ)[/]WJKU6F=D.^!=NS>I'=ZJ=\&X^0CR)^!9JW;Z-3>?02GEOYW
MPE^:!NS"G[=UI]\;__#K[?WH:_IXCQNV=`",S`#@M\7P!RY%+O"`GC_D]3*6
M9).EBB)43X$R?Q/>,2A#I\Q,W*P'"4!9W$LOCV83*@=*WF837=\32E9A\S/^
MEYFWPADSYX4;I:SB5N1NVL2.WR*44\FB@Z\WW3#U_SM[\["($I#6VNDUJWRR
MIX"97];O;I2<C@2:/,4%IF&]E-DS//ZR^?+681S>B;D(AF\SBCV/P#G%4)('
M?Y2S:M[5<V`GB98-,*]FT=I8%3T&7Y%W_DM@JZQV%%+%74"^S5#R[(I>:W>*
M&I:\T<A5M,W'4V^IEK&RWXU6[7+IE8LLSTQT]X6VG>VI5Z-+L0?MYD:%?C?5
MTB'F.KIZ-[VK90^(>'P46-]'1^!!L>;UZ@N$0W?V:3Q;I=NJZ^GJ8T'RIP.=
MJ_'M=K-5`FIH;C!FRC4,?%D0\YVP-O`%$#DP<7C&\0L:C.S8%$\T<J&9Y9OR
M`%)A_#9:R@60$F8GY?E."O=/Q9<\$U5[)\9L$;-;;@/)LG6S6T@Q,VB?#O&>
M\W(8Y/ALCJDE9S+GK,,#$V&]EMJV7XST:<#F1N_:L5#I2EZ;B)[QN\\==B*V
M-AJUU`DIA2B?!&K^3NFTC3T:ZM:S[LK8--39#78K[=,ASCU&J`3$6^R(FI&R
MS6ZKFWI)N3CUTV'.C8CT3FIO^6&H!],I,[S1=/!FS*D]8T_48R,[^XC<,L+/
M5.*V#_E3PLX]5JT4U-DMU"GGZ92AC#IAJYE4QGWHGQ)WG@GI:JE2;+G`]SQI
M6NOFV(^:UM0+P#W=Z>,%:^]U33\0IRP-A)8[;K0#HV[*H+O\HDFP4>8@\N&Z
MUC6;<9M<6W@LR(3.9LPD0^&QU$+6R)E1.UB4Z4,2("QNTF#!YA&R"B`F_QQ-
M@V"66O(@(^G<;KAK6`*_L#*!\2I2A0;__=\M[R-^:F74G_SR."!S;V&1QR_7
M]W=]<E:I5K_6^]7JS>2&_/S#Y.&>Z!<:F3B0MP0GD52K@^$9R?APWN2I^H9]
MZ?AP\+/BQ9Z\,#WS#%CP]YGW47XX)@"RE5LZJ9!3\2H%P^0OA,(LVI_.+#;U
MSHCKK2SVZ6P*+*Q,Z8);JTORCPE?@"<=LE?R)!;4_L>YO'#N@DV8?B0+ZL`X
M*OC\)=&X_9&<;0P5/[)S#NEI!A?4K;?TK1@R3"^9D\3F\C_8)=&UI;<&X(DE
MT%]ZDCIV\1S^J#XGNL;/!.WD0N'6NY%M`_(^O6[.[S8>;E+1+\BP-_GR-""C
M6W+]97PW'(S'I#>\(=>]\=T8KSX^#<:#X:0WN1L-#^'Y?LA&MB'P9=PW\CBG
MSH(:S/>X`;;LG("/NB`?O#DC?Z>+Y<?_Z4"^]!&K$=1>K:_H'XEPX@W6'<::
M?$<X!C1XF!_N$O,$P5[-Z)5S0FU3#@@;,0>5+USA%E-B@[[@VS5TB7&H-Z?0
MWC1!9^$/\)XRVR'P)P_V`H`M,/"'0Y;0!^KO!9G,F200X">OU(5VAG"60GU!
M!QY"4"[J/!*]819]Q</E`-HY0)XQA*`^]LHA/G/]9Y>;G#J`Z9S,H3LJ"4RI
M@97Z%79X+>`9RSHG7\%9@6OR8#S0'?P+%*9<0?T)H`K_A3GGY-H!2^?.`:3E
M+YXY)1_ZU*8F_>[B5-,/;`%?1GV3(P^FH>53;%#YZYR^,/+,F$V6N$+D*%Y1
M`WAG2G9+ELS4"]W6"N^P)?0F$5*UHH';1I8.\)LO+>:&O/YB2ZK2S*J-&QSU
ME2]B0'CT&2_).DG,"R83O]CF^(8JV(%4W4)3@E\LNB`]B0_H6JMS;+\BIB"V
M\'#2+=^$:;4LG&;$D:8Q%<*#ILR51!RFW#42>&;(!/05R"V!7[C";[:"Q&2Q
M3DJ=9(&4.61"Q&MC[8,"5F4RWV%3"Z)VB9:NE_9=\@$?YS)%(L(&KJ.:X"`L
M>`2/)L4;'+>O?T=>Y]R8$YBX\X!I<M!BR>U`O\`3T9DD>`ZZ9H!>46<EAT=!
MG+D3CGFMD/@\7/*M8+^-8J*<.DE"?3W/C7B5P8GX^$D0&)+QG#$8K`?:9S#<
M`:2,B-[2/M;U<X+AHE0U%$=)"2(H_H)SX8B%A)'%WFS6!H*PUOR49=/;'UW2
MLVT?GE*?[I($@0&AE/VX'ON*4?G#)@QC)37:?`0H:PZ3QUT1<QUA**G+T+I0
M]`EU77\AR[[*&/HN?@-M+<R[5$AV"S;3!*L=T4&5==W0+A=G83A^W#+$Y-ZP
MJ?PPE62(LEEI/72S586X<^%;)BJ81,=E(/X?WU:?]XN&OI?V((.5K"HF2Z66
MKH3!6-,"D)CLC8F65-:3+>=YEY1*.\*M^+0ES=T8U5155K!MF)6'3FK!7?P:
M.?D0<ZWC03_A5.'V`Q[?$I'7-4E>/ZF_**Q::L:"-6V4SRC8P"$+']SI7*#/
M$*]V,(]KMPKB$C6?,&-N"TO,D%TJ+LD*.1+MXJP"?V!92C4"$R2)/2NS$P@*
M9AHT<":1^C&+RV]C@EIO9VIT(?9"<,D)1Y@:0CJV-3$LGCJ.00(XA"!8SUS[
MZ$?`B(<K_V43PEHL(2S&@7=(\TI*-6H@]/W^Z,MP<C?\3!Y',!MW@_'I,XHU
M`-P>9WN@W3U38$!((C:3D,^GAW-GDQZ$GE9D)-$^2U]$UHH7AS;&+<;4@?#E
M6L#_SC&_N>V-K\\AB9&G`O?&7T":+I(=KE,@O?:1Z.WXGW(@X<8-8(H`N9->
M+?[(`_@*%_(#1AX@T1`F^3"!",T@+:WYW>7F73"F&3UBX,%5_.`&HP#?+$OK
M+IGY7,7K0-ED8+=QL)0LUEVC$30AEG46ZMXK!C3<`[:NT"_3)70%G,3\R!,J
MNE\N87J1DU$OBS5`)P#HQ(8L8V;FX'FJ&$'*T\<"PNMD4'G:F#6^(+)4!H0@
MC<1D,!S<.>`/[#EF?"&E/S!$6I.7D;(9O/"I`J:`1X8(#I2'$&J)L;\QY_"0
M3"<!?YPW08B@`EO\2P75^"EC-WP.105#<3Y=)RAQMN#'BS",-\#K0S<TR"="
M>"!8Z/OP"]00T:J9C&81TU4F"_AP4W+1=W$B5<X)$^,N@WO/%/("Z!@T0<YB
M@/QWGSI`-@A<4F%#$+7H09B.ZKJ.].,H3*Z<-.91*G`D;F1%"8>9,&3DA*X]
MB@R60AELU*0P;8"^Q?HMW).%*Z#\_Z(0U3FK3/4'K0Z5FBX49^):(G.?%UG%
M#KY%'865L7@]*BZ@;*X["/)&%VL5@;^*/P7W9]1107,VG7,%RMW(#>BS\#WD
MJE>!0):KYC#EZB7?)<0TF"(PV8,=LP"&11TY5W(R(OK("POU#V9%957<!:>)
M#4(YB$&,C^$9RQSA@C/V[[J!Y*[9P%."&^2@*DE1Q1`9=COAYY'7V6,DPW2*
MHKL9;>M-E%NM>T[8&Q8=$N;E7HZH'I0AY#+B*@8^G!\UI=(LO')03U#)I*+E
M`I,4MH'3M50MXC50,"PH(*-H^`WD?3154ZD\&"$KB+(C&0O&G1S?*W/6=.-5
M@++,PA:3H$B=P"Q@D'<+,83(BOZJF7<R^WCL?1Y</PUZ/V95S?^\L9T*K1(!
ME2-L^&VH^?XF8=4#35I5?=.J9H5*>D5KG,<KQG@<$%&+A0^1^;N(EYBE2<'.
M`A.FLOC0B:/JN^LD']SJG,_F>*8$FI=G_.&[*KQ!"Z9LVA*H<)>=DV>,\NF,
M8>'6$XZR[D+6>F4;?Q$8W<#HRV16C33;;DMS&2N^8(DRJ*0R2]5."5J4J112
M20T52KCQFF:P=0@-*@[7Q(!&Q3H03"@:+NX0Q,39<6,U*\+DT=9*92,CK!)R
M,,7V'"^8H9G/-(;*OT1UQ-"B;/53R`QDL2Q"VNO!*[[%/%'D:`+S$^L10B@'
MS8\L9:J'Y#-6;!L^&AF,\1PT5F"P\7%)1':AQBR]G2N3^-!0H>!@)3^RZ[&`
MR5HE*L\QCQ28>U4I6)M\9:]V>R0TF0/J8#$<(N30X7(LB(HY?^:R(OJ525#!
M=Z0L59%@@80&7CDTG=,H]H7!G#1<\FUVH%8WS],+1>NS^XDZ*B);IY'U&.:`
MX@;B&2X%+:FC)G\556BP%FH;4DJ4EAH)0EP2BC3%36G".ABBJH`<^#2@'12K
MX:<'DY_5J^)$U+5:F_)"FJ&$)QHH(MN!2G/@8FS`@GS$%[X;%=-0V+Q705PL
M`F/J]>S+#6\N:">*;YCLQ98<`K:N"U=N4.]/#[00^]#P`.6@^#V-ULA"4Z?*
MEG)-IX!%VJ*=8>0EU26P3A#:[J&EA:/%3-U4EM?%SM0:Y:9Z'JV:637"8C6H
M<BI_<C]*[&!Y8:\/EO_+UOOJI$**C/O_5/!7OR#]T?U][WKT)#<)D-[GI\'@
M83"<?(OM`AF*];_M?6ESVTB2Z%]!]+HCW!$0S4-G]]N-D&5UC_:Y;8\E3^]^
M>E$DBB+&(,#!(9GSZU\>=0$$*4HB)%+"AVZ+)%"5E969E95GOZNO88X?#3^D
M27'-WG*V\^^1G7\-&S]?;RAZ@_PS(+6$5]I#SVPB.UBN@#TK(0QPZ`0%IHK"
MEGW,@PY9\O`Y7SNNE`NQ%(;@74?)D`^`Q4B$$8P7IB`]O;>N\X[$90%GV"]H
MD9J5H#!G&3X`D^'MB+74,"9=0'G0DH`=V31-!/,`3<4T7`J4C!8G=$A$:&@B
MFU.6)9BFKQQ,/`L'/=3%1-#:<:*/X0C3.P.\,.",UK8FER'89^1B<JAQ@NDP
MBF(VAHM'#C_.M>N'[Z/*?`!_35&LX:K>''0MS0!#1=K?3L$3.!NA!8:"8;6)
M\<W@J.8M,M>Q=ZEDLG/V$K80Q[;;:(UQRO.:S$7$_K=<>ZWQ5H5W@92.39`\
MUV2?T<[E:1CLY5)RL`%]N,6$'4FF.-0$,A%A-$@@9Y)K9>`*-2K4-8).+?.P
M/E,7]J5!#J8S7,`QCRZ\$M,28FBW190E50;,J$O9K``M'6-FA240K+F!/Q*,
M7_0##@7!2YCPA-J5,IW2+%.!D1BQ:[YXTZO9;U8A7%L3TUDII`?#@D`._:SO
M;1X!#:=SFL_W`J`JP;5%/+STJ(@4Y`RV/3BVTE`E9VGUK7]XY!\,>J1R%J0Q
M31.E[60&'0'/3V,2M0^..H-C)"I^DO4?!(\^&B!O1:;N?<H;+;**R5I[V:WP
MB9A8#/.0H])U9X]*G*PLX4U>&P#B6%9\]<OD-=DD'7K`9]'K0+P@;(.=H03V
MDC7[#.]?H)&;Q"_I8XE%3IF>46CQP[7A;42Y^+./=*=-]D1R3*6WY$C0-\YL
MJ<_"DRI5'Y"/1R'OMH$8F<G(3W*D_`BGP'R@5KX9#`8^_*<Q\2T&=3?-D-P!
M'=6(,`+XV_LS?RD&M8B&B[4A$X/Z)1CCM1I*6F?!?$!7%_UEV;;2!^#$8`\O
M$W-GFZOR![8GG*E;BQ+,<$;>VN@0&XV%)P4-2C<4%,.#WL]$1#"2=;V8LXDC
M!X'WT(XP))ZU+A0K_-6M;K5X7K74VF4N')WN4D-E?,85V7.)1M:#A0S,?N?X
M^&?\Y;C3[?Y<@I6G*.*(8GF61#0YIQY9A#&DS(EED[GRT^&11S%]5/),J3>^
M]7R-A+)7+8)K=H.61+0/&P=*WS\QD@V%L@ED(_Q[=/%)YWO#^9[ZD[U8++#.
ME#W?Q6MY%?`'4H3940KYH2?F=)(C04L*$QO.7<1TO#_#.)P64V<A<W7VS[@$
M0^4-#KV2QL>P'"8D,<OQK.3E<%E@(JPC*=3J0+Q^EQ0.5DA-6,!D86HT4*07
M8TL$X+)B-%&DY:`>5B9^X,HJJU+@HQMR$73]D+WRP@K99N:X2PMIOZXL;/6:
M6FM^-98*-2`4NKS+J/2C">8V2:/@%HY_+\62:,H(RI(<2$+)X(IRBSYO=8?@
MU#%!/GS>-Z,WU-Y9RD<5Z>*Q8RT:)7LP\!1OT_C[X@['1K*5`]QP,@Y?;BX:
M#3%(BD`V0Y4)&9;"5M'-CLV$2@>>PD_-S2[4&?7J+?B,/!#HQ?$HC(]E@M7@
MB1B5T%=R2\(]+,WWX&*CIP`Q>.-JF0M@-8LV;:VT&W]C0O+QZ/?.(B`AO$8[
MK>$\3("%(P9OC'P.Y%B"$:^\&5I;1NH=%<(!:\F,;2_$$!`DO5]7KTLMI19R
M\V!.PAFX))_\YT\].`E_\H:HLZ1871#$<Q3-\$X17YO/V4R,].=EV$+3UQ[A
M]5=O,7\E)U<%(1V@6CX**-])^JOW'UPI^S<XET;?KU/DM5\=$[8SN*<G"/2*
M]G\VPZ]ZVUZ4")MYL&+(`0P9)[>IF/WG3_SO3PNI.C891MOI#ZMY,2OGZ/V\
M-ECF*Q0^27R=T(6L0D9,0GA#XSHTI#RPO+R<@VYR/==/X`7T?S^=?_WC?WWR
M(["MEKS117J#28(F/@*9L2(7Z<8$ZG4L[`UF##_E>P`(<$4RDKGX(2/'M`*O
MZ.02?AX4HEPI&VQTR<G+1.DD;)@A*,^^?CGK\/Q8:6M$'DLTU%]SR)0*JM<6
M!P,]W"NG&)4OXV`&N,IK;H4*`7C3J<$BC#V%0R'SE);(=GNZM?Y]'^WB@X[W
MH2!_'_H%BXRM].4HD2]Z16=L:KK$7*9/[B;0%[YW.9-D<X$7\@08@F<]S3+0
M3:W)X,NI;^,??.];Y[(#>D`2D'#ZD!;7GML=$`4JQN)]@+<(BD!I]'')S985
M,W2ORD#A#`YZGEVI<DZH@<:8B/">8.X8G,$B]&D"FJN*QB:O@*1M8P.>RAY6
ME`";@UT"-'WHT6ERVM'C;I=(N'0!Q.Q60TOL)X4IM'B.J1`J&P5+VPDW1.E&
M2#@LQ9_3RF=<S]VFX5;ZOBKI>QK?5_AJ#B]+V:!(B29F@@1C%'$%V?L*72MI
M8:9,@B(;L`@>3>0TX1Q`NI:466C@<!`/Q&(6N)74&J7$W829#*I"DR68EIG,
M6S,MM7"1EA<E;%C(JV1^GR6S(E*2B1Y*>%.M#4S-K`*A"6J\A[K+\>%X&(I_
MA[1NXW<4MR+,.:,FQEVX3=$O&:/T<^PYZK(+@M2)([.Q;'SYC*+DUJ('8%37
M84^&Y`&V2$_EGCWAT")@`5NU(1V,04Z+D-^#JR&(7W7.X%(T@9%_'P6D-TU2
M:2%25E>U$UE>!'/7)#41@3>6S@H$UT34=^14E0.E%5D!S-2F8VWM,>:NUBX6
M=R_++0GK%SLK3VF=_E0A>A636SFPT4F,&Y$F_U0#DEU$';YX]YZ0'P:.L[_W
M^4!NI7LKW1\EW9<(]754Y+6UXZIH9NHO2>,XB?>R*=W*@5J\J,";MM6)/UV>
M?3QC,X2Z)#IYIDNT62<:PT*J'"F5V6EX:]T.X#(_9^/VK30)#]($R6`.K;,F
M<ABX""`1K3VQ/':HI1UR-^B*[$L*M$;*9I>I8$26D^"5$<!$T[A89[QL7`@\
MTG"@[_-5HPN>#>C"Q@B<>*ZBBU":ZQ1'UUURFZ3?G5QC0$8R1)N5.B^5C1^D
M-IZO2:J/3A%5S%68FZ*,FAD&+C'1H,_#%JX**9Z0W>Y\!Z!9_DE2.<NE3-GR
MPSN#CKI5RT0J1J,KVW$8FF5#T3PT4((^'<E$5@TXJ%FE=F(LNATJBV=#"U$P
M\C*&6I`)F!P+;-JB.9=!2$Y+&`HMN(W9FWXOV!EN4*GC.?4!NMS49`+#0(D9
MT95/X&NHTF2M':D]ZP*=E&SJ>ABVM7["#*,QO#>#FL`"8(\`'ALQ)Z+,I@]5
M1R?Q.NGXK3;64N@#*-2<*&.,`J/:(W0^*@]ZIFSJ*X5A9U.TM\ONMK5XIH&B
M!\N##R-M6K5^47^U7]OW,-`W,II(V<-+>JBM1P??$/6H>`?K9493YZH0!8K(
MUMYA/?];.'&E2$%Y38W:0`%U1'ZH/E`<`Q9,H"AJ'<_.?8!(+2'?L>/TX?%+
MVCF:"N@6@;62XM5433<`BN>3%)7M0J5N^!RA@;8>4OU!949E2D6>KRK?PLYR
M]J.6$H2LFHWV73&6&%R&R0V9KHOB9#*,X0:`.0AN\@)H(91#[9:/614\N:BJ
MK8R0RKG$5!)QNF7*V%=1CXC[*05FNU'V<9)30:FQ^8OCRJ[#&RHB$Z*NE2Q5
M-A?)!P]$FC$+?]Q[/H[!)SVY9L:.=Z&I6N,C6XD04KQ5T0XTN5/^@+674`1A
ME2CL'I?(P%_8[SOVFB;5UT1UH:/21C=A4F1`L8&$'0J'F/\=E@5"]>X`#$PF
M/5Z->LJXZ<DO7,=A5>XJ^Y71TT(I8C7A:$[,DQ8V)25\KH6'B8@Y9YL@QX7@
M[6H]BN4E:==2@8J7X=<A[!C0@7*_),[XFO/Q^Z&(OZ?%+.?4'NF`0=1B@P#K
M`0@S"VDUSH>@*Y/+<B#9*4E1XGE5KT0!S,YS$S+C2N$J"ZG;X4)<L7+X,W<8
M>?[6U.DRM>@X+2@(KT$:_`(J63HOAQ;?3K@HG4N;R0A6EC'#L\AA0P-9;&K9
MO[8:&Q7_TC;,\P++F`HJ-_1=YC8!#MUF-N0PDY5K>B:=];%[C<XZN?I\U&9M
M?5`AC:IZ7UA\*5.3VU4Y0=ZX&4L$FI,;CNR539(H<$\%%E].S)L*AFLR;I:6
M>6,*3BCIA8:@A%J.5_C3)XL6+.#$N<L$8FZ4@(4!^/Q1!VB5FU=9!6H.(+_R
MNAOR0C.HJ*$EQQ<?%?@FG/4_<+^R15;%)*^Q^W.1TUMSJ4-.,?%MX3W.;U@*
MG88,AD8]+<\<DHGFZDA!Q5DM@TOCE49PPIH7%0U@931E`0S&B:PE"QT0(+=5
M3@)P(VZ(^[:R6G)?^>9J87PC'8L2Z,@\:6*9EN@ME;!'6![FFDQL&4SD'VS-
M[*$[A5=!90:26VO>O,A2(:/0NQ(_O-,BGR0I'#H<=7UUZH;>FXB')?#`(9";
M6/FE^IZN**!<8%48&3XD)X21?78"LZS#*1<$Y?Q6#?O5*5MU;?D&#$](2T4M
MBQ0FQ9P/6T214M(Y%-\$>U9A<2:UQZ863O"S7@G#^&:P8+G0'K)4VH*4Y(M*
M4-=!25B=DDG;7"SPCC)R0F-I`_B>2J51T0[/O%$*!E>=]S#<9>+IH\C%%NI%
M<+_3N1*T3(7G)&7E@][1>=US3I98-,VH"JTFI\$4DE.AN;PW.++R!SJ9XD`M
M-:G,W3)1FZ6;D]`0(2R&E88B)4L2K)NC..A87-A,$$JJ'B-*ORF#68-94@FK
MH80.N;/3QI+\[V3H9-,I##:SZ:;U(.._RU`)$TL*D.:)E3*E]",<!+78Y+;C
M71;##)>,'NLJPO002^:Q>\IV;4TY\#"?0,;J1EG&B#I\"#3WN=%YR,=LZI+`
M>JF&2E-"41?1TI9HUKO)&VQN/:HX2IF<!JK2(N'V3:]S4L.AS+J=7LV&(.\J
MK9_JN&8<VYWF'*EE"V914IL*P*C-ZK$2`.EDH?JR.6!('PCA.'6(S[DBJ9N&
M>X>8V5A/Y(,[TR\-0]IA02@66%>C2&N":^$$M]F?:OO7*ZYI,D,$E:X(IT-0
M>3E>2_-:QSO-EVP9)E6:JY>N`4E2J'=2LX]:M2IF>Y3KJ/R;<UZ\FQ\4QG?L
M%2G%`+*BF:/Z=,@WAYW].DNU%J^FJ%KJ%"^]+^%VN:(('\!6RUPJC.PVKYGB
MOD[:]69+6F(=&2HC8XMGOMQ*EOM.)<N5"]^%3`ACC=^',^_TXJOWC]./W\Z]
M/\]/+[]]I<SV)ZA;^9>I,>P4NJJM"WF6!*:,&NFRIY=GOG?<[]Y=U2@SE>Z=
MO7*,3;Y3QV*A<AV)O^ZQOZP\3K4TCJJLXZ3*:F&73;@<(1:X@'O*-:CE_S89
M5,8DHVO">?\L@FLV3):SSNFI,)X5,%:1V4NTJ@Z$/P,4%A16G[6>6[[:EA3Y
M^OI)3IH&:I^F9P!^D+85C%]1P?!@\+6F6%(A^1!4?6,8Q,P-+:P4&'*RLD+,
MZDW2?`_OG![<.6&Y;8)3A:.`+8@KM(D2#YQ2F2=;CBO'X@\A*MHVC<]8MRR1
M$?)UI:S:MRG@$!38E!O"HX4QMI_I7E!M7:#`U.7)U50PD++233&(_-_5HW:8
M)B)@%LF`"RF+<@BZTVT;EM`Z?>DK+IO6*Y7Y_7N1J,R$$==,$ARXRDF2J@E&
M@,H\FOLS4R-^8:HZWZ_ST0%^<1^/9W?AMW[TECX:H(]^B3X^<]2<4U37$69:
M"&J7CO.3JK6C;GIIFIBK!XDX)B^L]R&\M_88_=<:U)B%<)((/@4M/?[R6QL,
MT]+]8^A^4*)[IQ!:Z<`NT;QNAF--K26ED2I]8MO0*;=P8HLTOJC(WT1&4F@P
M&>H+KEZ!'*`-F:1<H^)@K%D;"[QYI#J5W<FPNO(`]E#!O#=Q(X!Y382N4KQK
MM6M_P2K($;F90:F-UW0N%TN+G>KJ7[8NP5RC6<F2]":T!1G31HN`NV7M:8^=
M6O:LPE7*QL@4>^:0[1+>%=3(!:@NFI-[<FP)Q5[HW)N8$=%.U0NE9C;:FD7#
MSX62,O)T8:Q`EO$MJ:9QEU-3"8MD2HSI5PO``I+LOABE,@A-S1<N&8N!.4@E
ML:Q00)BSD='QN-N#0_M8E/N.4C[_0`MPS";OST7UJ#%$32:U'+N,D3:.%[HI
M7;RT4Q1!L9V'FN!`%>OAU,&62ZXA7,AR5<&`>K915V=3-\1EM9@,=KHJ+[O*
M52QT8TO&$4(*XC;@7EAP:<*P2:%GYL=^K\U/YYY#VHJ`SG2R-P"E4=D5:J!!
M'CIF(>&!@G0-9(C)+9+2R,)L(E7YBU`X$E?Y>@V3-+]OEKF(8TZOJ7JN[3[U
M-%M85$"IS$\_LS`P94,0;\X;%8%`+('GM]5C59`#'_5T0G;(`*=BMISN>5JB
M*"ZM5.A?!./:@%$GFUP+FND[T-/BH:[$=:.[3KBD-=3OM8MK?J"Z'JP(3,$7
MN(3;Q./,);5*:=Q)IO\@\D?$:@:B#;.][!<TQ9Z2^H$<NCO9\3XM?5:%W0T7
M=MYVFJRA@>K^GY7']APXZK92C3C$AC?Q:(*#X=C3!,[%/=UK4&E?(-KKYM25
MJ@,JKRB,V]C>ZE6I+<$9TRXV3G6M8WJ_%I->/2:--^P!Q+@*214$*7MKS13]
M9Z-W/AUT(U="/]^B/P#\3RC=+`CO$RQG3A+$!J9]$:!4.@QXM:!'FV:T<*?5
M`]@P)>5VQ'J2H=7)-?6;%',3'^4V4/)+)$IDRQTV,.A0JFVUEZY??(+`RV9X
MCZ!80%8`T;TIT%^8W8J9^;E41`Y50M9,@G`\EEBK7>I*CM9:S^F`P$XBYZKC
M1J/@D$D>FNT5Y%A`TM:W#RI=2IH?11IPY#`"7`H4=8<($M,\0(-$1F6D\]3G
MB#1Z4%\SU4/"951^FB!!D)BF_\)7G>OJ`H+-4:-O8G[)-9/9!%2G@!WA:`QZ
M'1]I*'U4+NL\1`4$6/(&8XYHE\A&0X&B,2)FY4ZIJ`P*N.!85)J3]S]V-&SC
M#,G*'9[H-@X28R6I*C(M">L'2H[?*%XOYB+&6$9:I@K)&,AMZ9-N(B8055T]
M!%`,F0E@)V#&[W+N&/=+9@;5(GBI`!TH&&F"=<3:ZW3XD$PS,4NJG`('IV3E
M+LO4802C2I:X,LT%6M^'%MM]U-Z'?)/'-S))!<N:C"R]O-WR/E,JP+_Y$F?3
MQ"EJVPYYA[>GW(B^QI:YMDURP9JYPO#I&DB71!1<T>Q_0Q%9H2S'WCE,\CR9
MKK18[J]O^W-,DO=]Y1X61OW*R9/,TJZE7<MF9UGB>JN7$S^MPZJKS/_&W4#"
M9(]'@;%G/SQJ6*S=&33P6W*`)T4FL-7!:B/_6CA9`IF2EJB.@,"#+_KW@]/X
M,]3M9QU?QGT<&%NTMOX+7MO@1:X-XPP?O[`Z*:$C*9<?[=7C_WT2S.\^_NM<
MDO\Q&DDY'M?)FV5JJJMZ]@YF/Y2.`[H:H/;7/?RJC*E34@TMKA8TK:>CBO:Y
M]KF',>5:VO1C609](PUPQT*@P)N[GZ4D:WJXYQ_W]Y]0<#\*6"<6H05Y.TEB
M/>YZXL/JSR26<VU=K9CCMXD9C_SC07=7R&0'*7L'07X423S;45?K$=XZ=COT
M0>_?%4+80=K=09`?11);>?:MXP3:.L[<1<KI^OW#5IIL*X*7\&:-P5;QS:;M
M)0:R)IBM:@YS[5\E1%:L8>P8K#>%/</%_:6L8]N?VTX\/YNVVBQO+LWC8.EW
M5_;&HNC6[_<._,.#_74&:5R0;VQ-CI#?^35MQ1&[L9TY.O!/>AN@MJU4DLTJ
M/]KH%KO4!J1"^US[W`MP:?PETA3S]';BW'P9\OA%K**W[Q_WCU_M`NKXM1P7
M4.?S;SYWE0O'5A(>=!*)"0#6H:-M4.4K"GAKU]*NI>FU+%%C'AY4N9W:6G//
MW2,LKG0(_I$FF7/?:0'>&,!-J?;;PQ,/W<+3:9+FF+BQ"]NH@?X6IY(+&[10
M-PWUN4Z>?#S0&V>B5QRM?Y9D^9:3T<,6]H<(XQ>YL(_;?U8^;&&V>&LS(J*I
M4'T-)[T=B?B[=PF76^F^6`;[4:;M)IU;[7/M<T]MQGXNUU`Y):AEIO:YK7YN
M/69JCZ+VN?:Y+?*HMDEBKS"T=0=!?N%)8C30%J>N'/F#_LFNT,H.DO<.@OPH
MDGBV\VXW,L4._).3YPQ7N1>P_5T!=`>9['7DA]%X6Y\D=N`?]0YVA7">\K"^
MJY/$O0!_VUM_)GQD$SZLQY)%?[!A%FW3Q+8IO:I=1[N.+59I\35VE>LBRE0I
MF(9T&B`2?$WY$IK+`^IW_>/#PW4&:?P`WMB:-E'K;0-LT]CZWJZUOKK3W`SQ
MRR8QU"QU'FV`.M<7'OA+ZSUIGVN?V_*+[D[9=P^ZK16G!7DS!+&$&]L[;7N'
M:M>Q6^M87RUMZD[[569Y&HZPD=!(]_K;O4NLEJ8OY@9;/=':A6W[PC9"@NO+
M`_REO::VS[7/;?DU=8?]L?O^P='.1$D\V$7X`$`WZY#=7^'TWDZ/+!#&X'##
M7-I>7]OK4KN.W5K'^NIJ4]?7RTF2YGO8)9(/U3"^D:K?N-7&M^YDM9<&>\0^
M]T7H80O8JFYA#3A:U=F\O9[6A]/=H"&WZC84/CN-(K?B61B/HB+@UL)HY?)M
M%(<3P.%-Q(UI<8VO)6/OI&L7'X@Y=3V.9)9A8US=F3@/I]1)?%:DHXG(9,=;
M,7UF!98CJ^JFQL[3\$(2\RQS*5)=LFTH(NS,#(-)F6,/;=E8K_<KZOU\*ZFA
M=JDKM:Y!@B@I3$42[UJ$,:,IR3)<2:S:AT>\K*FI24<0EM#$3X8_O"G`-LD\
M&2/6_KN(I=V%0=?W,'67MK`"T@HPA.JW[NZ%&(V*:1%10W?N78V-QU,YD7'&
M#=+AL\1NW+#;]5!TO*_E&:FE,DU)TV$S9>H)/Y8I]E.F!LSC=6<.XSS!_P'V
MLUQ_R:WG;<-U.<+E>R$>D80(:JP\E?DD"=I>V36"03'1M+8XX@0[O0NBU"5T
M-Q%!A5.!115[LG#H>%=J=\ZPD3TV28^CN>)WHO-3[RT\:V7/+]07/G`!H<;S
M=\Q#<_P!!,.<\Z\"$).;+MM6OG@S$#ICW%+?"P$"1PC%.(-D@9@5PPQ@HA?2
M9"1ED"E+111)<A$`82$CXPP.J-@VG!X$[AM-I$'/G!J\&R0$"3P;)[DWE%$H
M@<JIW7A.`@;YA!!%S``_8&OP*1I.4D`<O!^F)"C5-,PYR!R$3RM'`;?U^[J<
M@QN4G&;I<"Q@SW14R8&ZO#=<;A1S#[Q;+KEK^K#/5U(?D98>5N,<I4VVV'9=
MD0':F7#?\F3T7<]&^,#-@M>1-E"BX#&BNJ_C1T&COX_$Z/O>Y6B2H/B>I2'6
M[`3Q',BHXUW$LP*&*C(6ISA9Z0DM;#VI2C_1PA@0?)!YY":!W:25^Y[\,6-"
MLU@92Z+--,R^[XU3*:T\1)9A?*#P+'(6?#"#'J4R/`R:8;]ZIF.$=A(",`"(
MB-S'8`0<4*1$0_1GC"0T3I,I;!Y@#*8':H/G;W@),PE$B[;$&9"<8A4S$5Q>
MBBP',L9EJ'"5D9B%.9X;!'/'NY1XO`+^#]X&OVA<?DH08WE"4_P>QG#DH['P
M$B:63.UC$`3C(B6>"8#FP\B<M^'BWJS82WJ.E9D$"55$(SJ=Z+T%"FV494PY
M6H]Y6"&;J1OTJ_B:585%0E=<83Q,1[\A]@#-GNIL[(TU$@G>R-:&)TS>0_EX
MY:5R#XY?4QG3=BW;N98EUJ?=+Z7YT:H"SU*:;]N?>RA>O\HIW-%`7#9C^'@1
MM/=!CN1T"/K$H.=ODVWOS@K"L+/>6[QY_P(JT"Y![G([JQO;1YV;JX]J3:L7
M"X52-V4C;;I.)6B`S]/2JNF%Z=OABUR<IY7W9OBKJ>*B3QRN\E?ULK=USK/>
M@=\_W)E:.?O[*_+MMPO4;>V!8[_X/^^*;.]:B-FO6"J8*@5_"+,1G/I%*K,K
M(.CW43+Z_E_PI)Z:O@``KJ_A,H\6%8!`_\[,N.P)/=4EVJLF202B)CO_5P$L
M@0_9><VTV%@'F>JK'/_G3Y?ACS_)CG".9H3_-^C"R8["YZ?_4HCY\/GLZG^_
MG'N3?!IY7[Z]_WAQYOVT]^[=7X.S=^\^7'WP_N=O5W]^]'J=KG>%#H00+44B
M>O?N_--/WD^3/)_]^N[=[>UMYW;02=+K=U=?W_W`L7KXLOIS+W?>[`1Y\--R
MF;2(A@-OS[LW$G;!"6".A(..=_;YSS\_?_(NKSZ?_5][,#1EX#(S,Q]U3WJ_
M"?WGX#?OM`"-*"T7]F\*E/X!FI_)!"W,M,98/!'`4+XW$XZ-[4VWT^WVV%5@
M7YZE4OFV%EXB2,V+C5D-:Y`Z=)!ZD64%6MT!ZL]%GN7P!UH7+PG:YO'\H4B5
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M'3O&&<;SW(@P(O4$1T`^(S!!S99I96;R_^P?L-B#J7M^ES_P*I8Y&!>0R,Y`
M..D`D3Y&C>"<A,4;`6Q:9-X,I@-!VO,/3H[][M%!A>/+D`+[&U;4$K?,_L.Y
M)Z>S*)E+%,]!F,I1GJ3P9S(>AR/<:@J'@4=A%\@[6*8:G\)1)N%HXAT='?F#
M@Q-&72K-.@@F/=^H@/,@SJ,YACMH@<OGQG&_ZQ_U#MG?6T+]N$!'M!K#NZ9[
M:!N^L$P$L>C[S,BZ+*;P]+QYN?-9;?`-AZ-@&`M<P8D,*5P!(PHR]%\'$O\,
M8_2#SCED*1%I@'1DR&^1R#@%@ER5^#1P_GR&SEDDI!M@QW%2I!0`P2R@:5H1
M"]$7ADB0.$)/L7WT/<]NSRY%7^0]EC]F83IG_S>-BWYQ18=AYF4RUXM08#$K
MP$\6ODQ2$`;,#/_0O$R[/+XZE\GGK9>MF26LPQ;#.RQR[UK&,J4I;L,H\H82
M!4T$(B['\!'ER50">-$E2@)#Q:KQFIN-%G-/9(Y[$B->)FX.`A$79%U>D%&.
MI"#AD!%-DTXZE%%R^\H]KD?]U^39>TEKJ;.+O`A/T2?F9/J<>N_,R,EXR\W'
MI57\)='^M95-Z;8%17SJ[U:SP5/0%\3U-KK2M@5#9W2EV*4]/5=Z5+NICW>&
M5:U?6[G[#UO:%]2R6QI9RD;_L>6[7@)VK02N^V_D"W'6&C2]YX0@W]/A.XX9
MJL?V78O(!CRZ:Y/!\I2TH_U]_Z3W+/F$&X#^N'.T`="7R)SF\VD_NU:WK:*/
MHP/_Y.$=&IX2TMY1I[OI.O7/*UX459!]C!(5LG<C%#-1Q)\:()2[4WL?M#=O
M#_U>;T7!Q8;*;#R"F`:=XTU7V'@R,6(<@SM$(.Q:W2$*&70.CUZBM!DGZ5B&
MZ`O:)?+I]?W#XYT2,/W.85O"9RT2V8I2*R]E'<]V-AE5W=R5ZMWU5HO?*CW8
M@*\\\(^_;#P+]">=38!>1T3;4';D:L$)2[YD]G2*6_3IAIG)AC9IR-8Q:XL[
ME+-U"3YVE>Z5$W=+^<RWRIFQ)]C\[8DL*Z;*PXKYQ287N))EVWI77Y%'\B6M
M97U-9-NMM(</M>379:QCKDLS8G8WD?N(3*^M:B6U92EL=Y_#.VM:_UI?;V2'
M[J3]SF!%EE3=A?3G+5[+JC2JM=;R;!>/<UW3!M[%(EV!-P]E%.P.(=W3*K:]
M5/38A:Q'0D\LJ`QY8:FD)HC*/6N6[(O33YN#7Y_PI'Q*\)Y?AM@R5;LC/X[N
M6=]\>P7(T7X#$F1;#!?2%2249F/*@`5E,T,63F?P4(B5_JC,)(;\SS"$/<]M
M#/OE^5DI%>@R%^,QP7LZ&H%8I'2E]T448>*2U^MU?<[)VWM/<WT1<TS_65G@
M;5EQ-YIE0P7>EA=W8Z/,>@7>W&*`F&@34H85@EAD.EH?_F!T8FH$#:XW`#%E
MUDQE&W$J9T64ES5+0VHS(4?"#NJA&8G"[0M,]@DQ7\MBA68Q^0F!R(5K&9I@
M?L\-`"J]7'R7E(.!^65)7*C4B255^<J5]KB2X+?.);R#R5D%EG2,`6,%98_=
M3A*<@"KB9HR<+*<?**5D@3)U:H.;/H"U"&D6-!]Q\@&G1+@&,#&$%?@>95_]
MJP@Q9973O$XOS[RCWK$/FQ>+:ZJM!W\&6'C0&.OTEAA8'#\5[4;(%1ZO8RZ?
MB%0EXXQ)=I1@W4\J`LJ%YG#%DM*HV2R8.=O+]?XPQ:9-?ZH14YPK:"OV<6HK
MI^G`=T`RE"]B"_U2#LP>4V-I5Q#EL4D5)!`M\>L?1[#WU\`LTN0K(87BQ9H+
MMMIBC/`SEA]ZY:;4_?W79'YLU]*NI35QKV_BUO>4(4MS5!RX2@J-OJU&U@K<
M:''?%-0O=G.I[,TN[>J&`'Y)&_HPU\+F_$\O>G$;)Y3-U6BL*<VX]=ZLUDVW
M:PMK=VQ;A,,S(KF$NPTD>[7`ML`NX9^7$I@@,RG2T82,C@$VMDAF:(!JP!^T
M]D;71)>OB(7?]/0/!W.5/V=[H.SO/V%OXT?L^?Z#]WS)<=>\7_4/KJY$O"2"
M:1B'69[:OCY;PTZ'3UA$^!'LM!-YFH/>3B"S]_`:U^MKCVUZSL:5WW8=[3J>
M(UW**+"1B+][ES,QDJ[NNB/<W3[7/K>YY];CGN<JVG)E:Q/7A"<0[,/R4K9`
M%370]X]WM59+;W]_1R$_.-A5R`=/TW;G>:(G'U$6N;[0,9<O3KCB,0%Y1]5C
MBLR+Z94EI8_'W@=5>+E28MOTJKYG&61:VKUJ(3>`^95UUQ$SR^MA.>7AL6T\
M1^XM"Q&S':<)\'+I8D*DI`C`-P._=W3(335@]C=]_^2P3Q]3B9W:T;(0S1VL
M.6%_6-O9PD'S4/]W#0-MLM"M([")/`9]_J#H1`HLU,6QF\3V\K;H=V!;*%S#
M`'U_<,B-+/`=^#3H^_W>OL$G?JL[D?D$>AEY$W$C51]Q&=LX/Y79;&)F.51X
MEF`L*?9-+M?0%Q1]&P*9C\<P-$T#OP9A5.!V`)9U\>PIQBIGWFU21`'/3?,"
M=.$>/0Y@/64'C$#_:3I@_+70MJTQ"EC&;+[JXWZ+_U,!Q2213<-QM\`W]FTH
MTM$$&S7T_(/C(W_0[3%GU79J0"87<4TA]3?]KMTJGT483@"T\!ED78D4`<P#
MWJ=/B07+!1ASM&JZM:QN!8TRM_HHS5+?9J71WMFVLD"Y"H%9K>HC0['*JFU\
M8%K!#[DP!B!32BY'0*`M*4F@CX9*3_AR"V\W_)HP3?W(=8@S@>=T&#?-R^T`
MBS"]]@#;ME;!KJYER6WT%86&M;4*VI":;0JI>2DA`3M?JZ#76>7C;BA)]!%F
M#7J+6N5M6%ZUY0CN1/[3ER/8`4)Y$44'%!;OE=&_WQD\=<F!'2"')K=\)TL0
MK"AU^EJ$1G/-N-=N#KW9QMQ?)>:0CW(RV9S&P5<VTIZBH3#,0YF]@A[=ATZ/
M[H?@8Q>ROLU%X+#C?3V_O/KZ[>SJV]>+3W]XIV=7%_^XN+HXO[3W@\:</+%W
M6EP76>Y8%,FXW3WVN22"]V4BTJD8R2)'3TCF8[/;#O:UY-]]\BU$$H6H<+LC
MTB.:Z_O=WW0V^BE:Q;@>@?FU]YO/3J7/\2C!\,4?WI4<3>(D2JXQ2?T6S;##
MN8)(C%2A`Q%%IO&D8X@US;L=XZM?M91S;]@;F>8A2HY`#@&@0IEIZ\'HJ/EA
MOM@;37`5@1>JUA*QF%*33OMJ+>*\+VF(_BPNY.#@0J.;[I=D^(=GN,A$G,1[
MND4!PAI1+V!AW^4^M=3VULLH1@:X0*C"J.\3F"F*?.\OD4T`/3ENC7;5T/BZ
M=(=QV(1HE1[)K-K-U,APK'RB^N'JLA-4+J!<$B1TF^8Z]0AF::('EV@NY5(@
MR6R6I'D1$U-[Y"(*<[)#%[#HW,-?N:FF*@$B*;J`UXO;B6ZF-*`VSLK/%)*+
M)'4E".Y;>JW,['[W>)_\6,ER-J`J,"+-];3&Q$_F>IH(R!#1;4JB1*$8<@43
M*OV!15YDH'PSGJK"4NYH&H1CH%B)-N&AS&_1$\-U2J8"5A%?TS2\[3.N()-Y
M08$XR'A4IZ"'%P.R"&?<,1H`8/PHEQO3/K9K9H\/EZWAVA\*;XN^WHEDJF>_
M$A:0.;^X^AVD=<=B[.1@;^"['/^5_7[::?51H06W%^8X2^)8DJ2@.1B3WA>-
MWO=HH<?E`34-PYBC1ZR\0$R3P5_A,UM*IT.T'+CXR=TM8L_%93',@(QQ7YBO
M,^UXLWN)^`:J='[7@V9<B49AO%2<)97*U6<\L=CH._@GD!KO(HQ81Y]MD^CJ
M27415WQ/P)PG?JD-?"IOR-T%(GF1`9Q=4>X:2Q1<CH=D$KU$((_%B#?>T@IR
M=V6'R?^3&?*)+!3B&G@7R631?XR@(Q<R[<E93K_3)_*FJ7EJ2$T5BF')KMO"
M&V(MR11W00X9JXH_;_9/2/3YZ-W?/SCBO\F]#]\/CHVW7X`$2]%5G?#A:H,'
ME+0-ZS=&KUJM"K_"X<QJ2RY,F+KL#2>V&&-=*E5#J@87JL^U\0[2ZFFZ*I-;
M0<KB3,W%APQA26TVZ1K`H6^._/W#(\8!<7=M#("S81?Q?;RK_MU@P+[T]KL$
M`0#$PG&*)^"_M6Z@")L)0KF'A;-2=\MQ08.^6M`R;_=Z3MP7ZX)L:_RT:VG7
MTKJ&U\CE_:J%K+V@/Z%I[:'-H_GXJ(1A[P#<JOBAB'8)Z@V2R(MEHX]&0Q'Y
M+NTMU6I%?6V7@#;(?J5`;YR+-E>9R"RWID31AC:J\7`6?4'R%CLS;R69/6R5
M?)G6EH$7N<2OZE[_(A>G[K[>8EN\38J5%Q*`=:8,_,KPCF8$&JYD6"J9RIIP
MG5==Y6_N?M:)P/('#^]>O3GZ?1CP;P_N&3VVB:)VCX)X`S[^9Z"0@]UK2?TQ
MB:_WJ+B\9DYM]]PAYCST>X=/6*KHD71R\I1RY+5QX8%_<O3@^C7K:_9M89BU
MC7R-'XWM.MIU[$98L+D]4&D+>V5XB@/5S+U6^<A5#;;1H?GXZ\XV+:FW_SQ&
MAL865#VXGWMA]],Z+*4-^AN@M#I1T%RP[T.B3#<;]WN63*<A!P7!_&<)=1*3
M\>AU1/P>.1&_]\/$+L0N6=[H>&>?__SSXNK/\T]7E][IIP_P^=/5Q:<_SC^=
M/4G`+XX0TF$F;T0E1-6[X)YO&`7S,0\Z-'W8)#3?J%,9QW!A<&N2<HF+T^M4
MJJA8@I/ZEA6S<9J@/4I'0*JH)R"C5%YC<!17M:!XEX,N@0B;'U$L\E3,X;_O
M.`K&V[P9''6M[%%/402-\3;:>8J9RN`7HTDH;SCD%B9QZA2KIG,<53R=8N$%
M&`'&!;F2Q"KF$F&@<B@J?%G!/RXP[IC*1\`#:3(7$04BB1RK0*#M4UQ+)_<1
MPWXQP(<:^^$`TS#8RZ6,*9J0/MQB=1!)E0<H&E1$<C$VU\"!48V`V#0<%H#$
M-X,2ZA#*@(KL<$.X6'W@[F]YPHW>:`NC,"8R^F#QXGV)1-SQ5M58X3"J-[UN
MI[>X(Z:'($]G"Y6$,8464\DA$W+M+X^&&A<4OL8(I&BV+'3"HWHGG9/%V3E*
MVH3*FI`W;K"G[:.(%FN0^>#&GI>I^BN6$"JD"BE;$H3%!'\+$!#,'...94AL
M_&YAN4:AG"9;1/NEI)(RTAMH6D-A2V3R>QB+F(CTTC9[PS#R<9'2;(',11@1
M">ER34MXE(/9$.Q&"\:0(+K(PH6,!(ZKQUWX%H?8V%%MZOL4.#F;(-C%=!B*
MYL795:*M;3:J5(X*0A?"!^P,*)Y27+6)K+\#I[Z34:!#1@D+`I\EYA533'C%
MT>B'C^&((C3M8$+]K)F?</7^K'8(^)[F6!C%I]A++*DR$AF6I3&AX(O!D;V3
M)963^D3F&`SJQGLV6CZ&ED9H4$D72Y`T2Q-,'<Y\/$8P'X'8(,>4B0SCC$$<
MAZ5L")T^08&?Q?"?*!6Q@)6*5>5R/R!6DXAW4^!@:4#9!%0M"T.'^>7T!M1,
MU5^31H8C)`BI!!;;<$WIF*S`#5B88**R"T@?QX6JLXFV(9,@0SCW(`E`R?4Y
MEO]M^(O=&*%E/A]8^O!3Y8AJ1",**#C,,"J>2%O,22F'J0F_?4>8!V*>53JP
MCL,TX_)4SG&)QY1)LV!0M=P"SL807Y)5V6\TX]O0A;^(*1>"T&/QB<<@"(.)
M8+Z986QV4F18SJT81DP"06D^#GGF0WC.;5^K2U/UXC05Z..!?6,97D!`ZLB`
M8]/%;`;ST/LK!R5\4K4I,89S!%%+1[OX$4Z+J=)L>!'J37L*U!,TG+H`'>8.
MZ8GM[NKR7PY"9B(,]*[RQL`A%G(1-SSC::9:4K##`G]@!3,1P2H"'I+.?J'.
M9;VY<-@O#+.$_JIX"F,N6^=TPUVJ.I92:%P4,ATJTL)#F2!;Y*H`KAL%5Y/"
M+KNH-`FS):0V+*Z#%NS0!TV(-!(GMUXMR<$RZ,RG'!U+/W>0H0\#Z@>46H@:
ML)-:PK7=D`#GN#,\!Z?.90O'09C5BZ*.=Z'V;%$M%,$-'F68>15.AT6:U6G&
MGC!W:(4&5>(.Q'^<E]0W3*E2.4AJ:UE@BIC/=9'.[SHV=?94Z<Q<.$>1S#4O
MJ<,TUI<'4(I!%,'\@^[/),X!046\Q]!J;QO)FC>#SL'B]B\_REYMWHZ^4\&9
MAVF+LG3SP"W0S*U1#D+H$\BMKXK\M=Y\2UDG$E4.;#\-A`ZGB!*\ZHI#PR"9
M!6PI4(DRP`V7YV=PZD1XFJO#/*=2E7A"1`R*'ER!07W,S6VQ2OP+H@IS@>B*
MIX>A^QES73F%<`GQ,L8GR2UV)R=<#66$]TV&=R33'#.*U"`U\]MZGHP.+\=4
M,O@!H4*R#L?`[*RT5'#K:QTQE:"AXLQ&I5&LB"0/YXW1"T!*70O5IOQ30CE1
M*2FV(^"EH4GT1)4JX`7<2J,UU&%=]8I?7%8"R`#YQ;2C-#&=2NH<KXI_:P_6
MH4F5!.!@>QM3.+^`%"P$ZYI*V+.6/:WF*!*5FN1*TL9A!UBREY5,C6M;8Q!Y
MI@Y18T6O9Z<?X&SJ'"Z>U93@==0Y6A1<U0PL;?1@-)<-'_A<.`ZQHJ@ZPUR!
M[U@]'(K\_,?_[.WWCP@"_+O?/S#W&6OS@#F5.42/K!C[+\D:BI+6?']Y<W30
M-8EJO.ANES/9RHL)64A0S59CS>'\8!W:)+P9Y9WVO9&V8^1IR+5=->S`?3-X
M@9D=M^[LZY<S@BU(\&!3-B"XEH8S/(VGXCMI'O'<'.5FLQR%9OWDJP>9V(CR
MZ39SBV5&N5@S;HMOM4>'1M$(8&2KV2Y</K'2B.RQA:VFK#F==@LX,.2[!FX\
M)J5[KH[$!9Q9PZ6\9R<EEZX$[G7`I0"?BT`[-9W-QO%DF4JC@U^D/K9Q#U@N
MVN,&)8%6PE"8IJ1$)Y@32KGFZJKD+@IX@7&XI#B!&`*2,!=4AG1EM,B#`5VR
M)TP'B60E2$:Z0B].'X>$,"HU;5#L<!5;[\I[15N@>:F\.90A.)/I3.:%COU9
M<Q75VU`-U$LAIGE<J)NBZK]8D1!1EI3$HU8G4#KH`Y/)0%D0Z7X7QZCC:?F,
M%P1X@@ZOL929281G`TZNA![AA8?"^E#X%8D<3I7%>KU(W>IVPN6`#27X=>*/
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MY;?HQTBE`R8N&6\3(,]FDWF$`(Z,IBMF9$%&T9]I#6%2P/T(U`V;=(;J@X'%
MP&%GM_9Y*M-2GG^$Y>V-P\"<*^I<0N@**E$`>L\(!7%SEE#K:5N&<"8AI8T3
MZ6F'FR:%L>2Z*?NL=77J;M3D8U,"UM5U>'3M1W,N]"1`WIXZWWQ1K_VBTN1%
MK$NY:.776":5NL>J(6E2W6,^*1TG(1=)0$O#F_X!/4Y6;)+65E^QVB"SC:N4
ML&8XJ&B&/GKHV$4T2\(XYXH^-0LAFB>.,P`;04Q0L&-M$4X+G3'5L")N=`T+
M(][N/Z3%-8A_NA+I$DPTRZ</I[ZZ_=9:5+4$/R^`420@''Y%4Y;=X,HUI.*J
M5$A#7V.=^NXZ5HEGC,=VU2WF38\K5"`F])%L=J!D8:+B/]?8'R%)G9L1WTQK
MID`!"5MX?4W,.7,J,M$D]1>#ZO:[V-'F=U4]GKJ$J',,;5@96Q0%*LAXS!ZR
M-8'LXK=IF&-+$5"NL'R39I76CK3LU/Y(7.)4SLJ>P+%7N;<#AP"?I*SHJ;(_
M):V\5(P+J/\?H%TF!=EUSD0L`J%+<"GU2]'=DO(H^XT="[\SMV*/6'(S*,VX
M7&G*>AK,,DP-,O)FLV\G\]Z&;O[B*V]I<'S8UGK8S23U>^46PAVPN1#'G<T=
M1)/6`OMO8>SMJA2[!Q%\\[E?@-K^4Z#V?NE1W:-F$?GT]#MX?4AN!I'[6X?(
MXP>W=%__F&MSS=J<H.T\\\S[@_VMSM-X=-S!HI6\W^T>^J4+OWN1].IK,"_4
M7S97/P)UG>M?;0UFMZ\?B,DC[RW%ZA[^0N4D1Z8\+LUB/,4TG6N2+`53L,,=
M8Q!A(B^3HR*EVK5REF1AOMA?\\W^"9?^Y$ET`T^W_>1G,C1A@+-WA0'.IUDF
ML=)S*;!#>%1]>S@'^'+E/^``,H)1=^BS;EA5:_2@V]<U+C60/*O@LK@A-6>8
M)K'$\/WTN\QUP6*\=XXPD()\4-7@=C8658I/-U!X6GE\N9ZR+4#MEH".W6JL
M3IU1IANG'+53HK.^`:Q&7L]22F/<4XUT]8I8AU6L1$^8E?#CNQD.92N#PSPE
MPUQK3VCM">W=>`-ZPCWKH'3[.WF[V+Z[<-_O]=K;\%.@>>/WN%=Z'^[[_?V&
MBR`]/<4>;"&:![W=LS=R)=M`5?+?)GSN^\>#30O:UI+36G)VSY+3V_>/^D_2
M3OAYC#EG<+]$@J3HDU2%+:HV)#;<$@AH4G93:V\[7=%KC#`$'AMK,A,?-Y-I
MF`2K.WC0@!1.3NU">BC9320Z?.R>L%WC2;)<<00*?_BC$!2?INH-7,`"IG$X
M5M%`3Q`GX<0+Z;DQ^H>B>A#)*0/&)00P3I""S56<+B7B42A2,F+3S0BS<6T>
M"AMUU--1.(5Q*8PBXEQ)-04.H">@L*64]BB3*>6UB1SSV<EJAHVA8"1.J15X
MW]?]H*Y4G)PV^81E3"H2H?PAG2[F0&#J^&#[*0>:TO<80YR'4]EH[G,Y?117
M,TLP]A##ZY51IKHT,O40<F7P6RD;B<*2DR%B7Y4W,&C&3=7H#V.="429.KQ/
MA'/@6:K=8HIA2+8IA;G*`\)H28RW,@5GE7EMKH$U>:N46?I7)4.*3$TB3$M]
MD++%)3JY2]I42*8I-".>4N<S(!2,^]2+QL!WMX57;)M"A3K+1<D@GM&=@:H]
MT"2/:;OSL!AY@EYSC!-A3M9DDU"67HM8-890/[$A^);R6H:Z$1MGH<'4(M0-
M]BI<@=;GC$:9.7E09K!\/L/PN6C.H'C4Q(B'F*OP^A2;`6#C+)T=KF"$5Z6V
M,*;!'C\XBD0XY=P@,1JE*B>%0Y,7R3HKN)$DVI:C)#-;#U`/.8$,B[=0\IJ'
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M1'X;D@W-J41:=B,VX$9>>]=K.FX=#!X<,K4YLKN7J*OIB]<[6-$VK*'&>`\'
M]\0_.#IX.@`>#FC?/S[9O8"Z;W$JJ6Y-X%V3-ROFW`<:$U,C``2.+2>G(Z80
MD$BAWU6"1*@2\#?+IXV1_RY1O_%Y/VDSNA;S&\'\>DS]Q,>NP_#DQEW)\-DD
M27-NS$"_A_&-5/61M^ID?GCX[8Z15(O4I^/3-I:U[;C8KF.WUK&^'HV_T#TY
M$O%W[Y)2C9TK\HYP=_M<^]SFGEN?>S;,(Z6P*M9+M65HJ_3,0__@L/^,,O:5
M6H`.'UZYYRD!W;@%J+F&K7?%,6XV8O2R&&:8,!#GYY2D\&)#14^<4-&EB]ZI
M&-&3CG?Y[?WE^=^_G7^Z\L[_@8U7B:C6#Q'=0,%0U?E/E?16M4>XOJQ.>Z&<
M%V[QIO&.$?++VD2^IR(;.H4)LRO,J-0:"F/6J7^%&I^S-T:J:R87C:%Z\J81
M9*8;0>KF.46Z*CNECBN7DLR:[/A[DN14VN222]_0#SC!CV$:P9__'U!+`P04
M````"``@,`4_R.W):=$)```L:0``%0`<`&]G>&DM,C`Q,3`V,S!?8V%L+GAM
M;%54"0`#6[\[3EN_.TYU>`L``00E#@``!#D!``#M74MSXS82OF_5_@>N<DD.
MLB0[F<13\:;D5\I5'DLESR2YI6`2LK!#`0I`RE)^_39`PI)(`(+D!Z&MO8QM
M$@UT?U^C"32;F)]_64S3:(ZY((R>M7I'W5:$:<P20A_/6KEH(Q$3TOKEW__\
MQ\__:K>C/\Y'M]&OF&*.,IQ$3R2;J&N?$/\:7;#9DI/'219]>_%=]+",1J/H
MDE&*TQ0OHW9;=W*.!,@R6O1V?-0K[Z6$?GV`>Q'H1,59:Y)ELX^=SM/3T]'B
M@:='C#]VCKO=DXYNV"I:?EP(LM'ZZ42W[77^^'1['T_P%+4)%1FB\4I*=F.2
MZYV>GG;476@JR$>AY&]9C#*%TE:](FL+^5=;-VO+2^W><?ND=[0024MBP%F*
M1W@<J>$_9LL9/FL),IVE4FUU;<+Q^*S%'A<$Y'N][H>3KI3^YI+%^133K$^3
M*YJ1;'E#QXQ/E<ZM2/;[973SK#P#DA^!Q\51S*8=>;?C[J`CM8M1&N>ING(+
MNFQHB1<9I@E.M)ZRS_V'*WLFF>RDVXW:D6Z__BNB250(1W5E-90>II^C5'K&
M_03C3&P#VMAXDZD7C3]$'&R;X(P`W#LI8Y2L:[:;;O<93'6)MAB,;^#V=*LG
MVB5>AM)ZOQ=(3*Y3]K25+:>001^SBV]S9K-/E-X+\2UZ5@-^OV!4L)0D*H26
MDE$A&GW[A:(\(7#GNY9Y>JE(R>*-FZF,38QO8E%JJP+0&(D'%84@I#\B-.M(
MC#HXS82^HE!K=WME,/JFO/QG7PC0ZR+GTK7T`"EZP*D:MGJ_\\[J24HA@L@?
M5W_E9(Y2274_NT"<+^$A]AM*<VQ0VU.NZA)]OFD9XK'N''[=\))Z\"];=$0^
M+0)5&WB>:ODQ9U,CI.5X;"?%&4\PAP=Z*\H%Z,1F<CP9%)ZP?$*K.^_-U0B+
MC),8?'M?UG;N(3S^=C:A9/(X)";O)XQGGS&?WM`YV*/"JX$N<[/P.#'K60)_
M$A+P_3AF.6@WPC$&CWE(\1W.','9V3P\(MSZEH1\'Q(A0XYGB"17BQFF`MN9
ML+0+CP*+HB7V/X2$?6&'=4W2*+HUS][$O(3S0TAP#CF;89XMA[`@5;LR>"C-
M9"R$.6CT:%?S@*!W*UHR\6-(3`Q@#\<+8^Y@LV$-*I9V`6%OT;`$_:>00+\E
MZ(&D)"/8L=LQ-6IJ#3!$2_F$!(^&*SS'B9<%.TDWXDEV,ZK+!"\;2E\[#<G7
M+O$8@WK)",\QS1W+!EO#0(FQJ:MWH]V02+A`,Y*A]!8C@0</*7E4MCNFSC:!
M0$G9IK8F)ZA<P>^P"49R.TR3D51"#/),IN_EBPD#->[F@1+C5EK3$M3&?\TH
M]].Q>="K:#N>#;V@]OB5(.I<`3K:AH:_0U5-0U`[>TO8=-+A(1,:+1XJ:WJ"
MVOROF03Q\SYC\=<)2T%1(?=WV=(=GBPB39/CM,00R%;<!)5)\&+#BO][SG$V
MG3*J-+&^**HU:<1)MKM%75'M&T'E-OI)0@HUAH@D-[2,/VO:FS:M'D*!TN*C
MNB8JJ'S("&>(4)Q<(4YA02I@BYU/);8X@4<YB8GI`>@C%"A1/JIKHH)*)JPI
MJM)MX%HSCB>8"C+'1?W%+1/B#F>#\6>T,.>$=NLA4`IWMD._6]V>EPA]46!J
MH:W;OK'O5*I>]B^$<=3^E-4PQZYJF)5XQ,:1)"N\BIC!3%8_0HA8>90I-V]J
MY1\:ZH5,\LJ?Y>9)7(.C7+`4QF-RE#GN/W*,3>_A_<4:\7,'F-*U_;77SAY4
MNN2""97>*=^FFORDWJ2!LAP,=,E:E$M`.F7JY5BIC[D(Q]6^$3>R`;U6=>/2
M63M/4'F@HLPZE6\WDBFA1&2%U]N9V2H1)#=;M=;L;$\/!1:]S-9K<^SIE'8#
MWK:RH`BS%,S*P;+21'A(G^,QX^4R"E9/6%PM@"FPAE#$ES<`D,H:@21@ERI0
M,LRQ,.T3WG2T1ESA'?![?JEN\CKM54$E@L`>MJFL/7@YVK[_7-!E@(4B3D>V
M-6W$"[<"KGW(KK=VI*"R1FH[MXLW;1,(FYUMVFN.7BEA9-EL7"/"52JQG_PG
M+YQE,-8O+4W;C"T"X6+NH[W&W)[[:3>U#'G'9\]VISP)JLCC#F?.;7KE?C,N
M:M)Q%:C?D%M-65"E'\^6E)YU#ON#L3';;&T9*HT&534%]KQ%^VVS=/6/XLI$
MW8E_HD[V$:E.PDO7R2\(0+TA9W,"PY\OOPB<W-#G170_ALVFK:)E%^'_AS;C
MG-@1_.<'S:;V>IH$E:&YQ#..8Z(`@-]3K'"E27_*>$;^WOB4>:-HQT?LP/CR
M,TK3&%2ES_T$<:P.)9`OC"`ZVXBS-3PPJFQF:'*"JO,Q+<9_E?_BY)KQ>\SG
M)#:&;E_!`R//URQ-9E#Y((CH7!::7>+BYPVM?_%G7N=YB!T8D7Y&:1KMV9B&
MDL45W3<_:P9/]%M?[=O1P7/M9Z9FWY[G"8/]S8]&O7BNBAP\HU6#-'<>^:(@
M(K#K8ZJ=8K*[HX/GV<],_:WZ*R7#+!G:NG:5.FY3EM9#Z(!(\C5)$V)/=84Q
M'2N?27C-O)K,`?'G:9&F+ZSR'N,)+D/,"4NJ-IE*?W82;Z9V8P\+US(XWOZ@
MZ;6G=YJ8G18+K@E%--XS=6@4;N"HAQCC1+U2N!$BER>0#<8J+R"^4*`"N`6B
M98D=3<SI`GF:@H!F:2X_5U3EIP-%F@F+-QXOI'#G<(ZU`RG>$@T]E\(KEWJ#
M:&*$6R,05H65Q8*B$F//:&(4;C*:W`.GTI>]S@?S%0QI?COH,LUOEUG:38-*
MT<&V1JGWF?5CF*,<^W+I)W=H5/I9I9D,*TM74]YZ$I(/GP[A0R?589IFUB,#
M]S_P-#6"IR$(*Y%U-1[C.!N,KQ;Q!-%'/$(9'E`S)@;WWDW\X/C=S3Q]N)\]
M6>6J07G1J>5W*,LY/"'/<T$H%K)2'A:[1`S&0U@-@WIE^L;C>&C?KE[])'/?
M@<LQRO*:#UUU,/0E$7'*!'0`?Q0]R8H:W5<$G46J-WG58,C^T)>)3)CM0Y:2
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MKXY/?8@:/*=5>%8RT89>S_^E#_SQ7U!+`P04````"``@,`4_!Q]:SLX;``"+
M;@$`%0`<`&]G>&DM,C`Q,3`V,S!?;&%B+GAM;%54"0`#6[\[3EN_.TYU>`L`
M`00E#@``!#D!``#5/6MSXS:2WZ_J_@-N<G7Q5,EC.W/)WF0WV9)E.='%(WDE
M>9*MK:T434$V+S2ID)3'WE]_>%$B1;SX$)K)AXPL=3>Z@6X`W6@T_O+7EZ<0
M/>,D#>+HNS<7[\[?(!SY\2J('KY[LTU/O=0/@C=__?[?_^TO_W%ZBGZYG-^@
M'W"$$R_#*_0YR![9=Q^]Y#<TBC>O2?#PF*&3T5MT_XKF<W051Q$.0_R*3D]S
M(I=>2G#CB%/[ZMV%^"T,HM_NR6^(\!2EW[UYS++-MV=GGS]_?O=RGX3OXN3A
M[*OS\_=G.>`;#OGM2QJ4H#^_SV$OSG[Y>+/P'_&3=QI$:>9%_AZ+DI'A77SX
M\.&,_4I`T^#;E.'?Q+Z7L5XR\H64$/2OTQSLE'YU>O'5Z?N+=R_IZ@WM@R0.
M\1RO$6O^V^QU@[][DP9/FY"RS;Y[3/!:SD.8)&<4_RS"#W1X*/T/E/[%-Y3^
M%^+K&^\>AV\0A;R;3Y3B?"C1$DAGCGA<QID7-F*TB$FYI7I%_[HA?)4XQB\9
MCE9XE?-,B6C&EK7!=$(0C?T2N9"J1YSDU%B;W[V)'UZ"7Z]B?_N$HVP8K<91
M%F2ODV@=)T],FX;W:99X?E;N.8I&>N;BXOR;]^>L7VH08F/$VA\F91Z]Q,_;
M(1\-`@N(,S\F-K/)3D/>IQQ]G<1/#:3+XAI(OX;W85&:DB@)3N-MXN.F_<V)
MDXF`8-*I#D>G=XM:JL"ZX_N\+>1%*\1;0X7FT#_R!O_Y%XYBI3TE^V&-K[WT
MGG%`YN0'S]N<4>TXPV&6YM\P?3D]OQ"SR1?BZU^':8JS]'`D1'^I@-SID)Y-
MJC!RB%P[D)5ZV(PH607OXQ3?%'G4=I-<A[X?+A;CY6(_W!VQ%[;FBP%)-=*]
M/HZV24)-U$8M*[!0VJE@NJJD!X"`NBKEI*(:`@I`9^WXX[`#)*#!=7CDI8]D
M=:'_C'_?!L]>2+A*A]G(2Y)7LG7^Y(7;PZ6I)JY[':\E5%'GK1!KK>8=F4`-
MQJHF09#8HN[3#WB/_E]?G'^X^',49QC]-_W\_L].S:83F=B'`OH`>1G**2!&
M`FJ[,L?$L@.?[.3;&%EM*N[-K:&@1<.K20+"!!NQ6%'</15FCDX-KG,)-%98
M68?=VM[B,4ZR)4Z>)M$SX9?Z-:FB5^2@[JU(QW+15&1P$/:@YJ.B,@ST-".P
M*-@#(^#UIYD`!6`P/]CWXRUI?XY]3"SN/L13G`F#4VU1M2@`7HB%""5G1`,/
MH?QF?JH[_R>&@9(=BELGI0''`@7M<0:(8('/[K<)WGC!:ORRP5&*]9JO@'6O
M\EJFB[HN!810<@TC%5T1L`ASX-2I;C=A5`"#ZW(I>&`38``/&AF#12`3<I6!
MRM"S`Q7DB\B+QS#@`D5V`:(!8ER7M;,31K/"\=*1NM3UJA!O<)*]WA(.V8D)
M\4<V=*-&EBSEQ*%#@5@CS"*4EPHU/,R*8>)',A]S%.9'XAQ^@"+L-HC;@O4!
M8DC\X&POP12#+2JS[!$GW'ZG1.NTBXL"UKWR:YDN:KT4$$+=-8Q4E(7!0BPZ
M]9G,EZ`]..SF2+L^P6V'U/L@N`V0=ID&V_$8MCK`.YQ:?>96_V\"[SX(@RS`
M*5F2%EGL__88ARN<I'2=R5X-A\[VZ.YMJ*YH12NSQ04YK:['7$7M;B;#R\G-
M9#D9+]!P>H46/P[GXQ]G-U?C^>)+-/[;W63Y=Z<FW%:>/?IN@T1V>]#GW@6V
M[!(X=`B@UF.1RJ&&AK:0_B9UU&:R@-"?](X\A'OKO=+P+3%@\DVRQ:NJ>(:X
ML14%N(.$&@+*SA4LT"&/&:S94\?P-YP$FX,]3@2%>RH@9Q$=B'5;$$L003)+
MA-K!7>$U)@RLYO@91UO#684*V+U9Z=DN6I`<$L)8=)Q4%"@'1J,X)'3BA"<Y
M"URGUM",;P$-KN`C;Q-0-PM[*9[=A\$#ZTC#HF)"@D@9M!&CG"NHPX!)$C1S
MI-I;H4V<,`N(URB,HP>>[!#OJ12S-;X!R19L(AQ'0@P+%=#`S>9G+TD\FG,5
MK>;THEDZVV;T4A>]KJ;H`3V*>Y.Q$:%H,#IX"',Q\U/1)X&RVSB]EG*8!HC]
M^S6`=327A7OE'`D5L'H0\M*O(?WP/^S<C'YX$]:[Z_*I+I278,VN;+\/&%7N
MLIM!G17CT:$&'MQET1\A*H%[X+@83^GTO@L[.J?;N,K9G7M?QEZ4'?/PAXZ*
MG:;1&BSP>N/7Z*W#B-0C[\:H8C<2;V:`0IRFNZDW]WWZZ>(8)=1X.?#65%@-
MS>LE\`[.L'4#WK-I=Q$]V*39[,[ZL"FKWX^.UY_XZ2G@-TSH':TXRH@[AB-?
M;4%:#(`UQRQ`:;51@X.L,R9VJO/O'H/?LRWB%!>5/T$L*JW%*>&`7>BKF_O2
MKVR7>ODM/<MHJ9WSL7CT$BP0OF1)O=GKMV[O]M5FN8#P99ZD,LRR)+C?9NR$
M,8O1K=>+0WUJH''$.-:69ZB`P2P%,E8/Y_\B#-2D7^5!.C42/R&E^EV:V47,
M%_WG^;OS\PNT\1+T3.F@K[X^9__E.-XV>XR3X%_$Y:5SZX?!GR[^9_#5UQ<H
M2-.M^#+>1V%I-8/_W488O3\?(*H.`NN;#^\'7W_085UA'S_=XP2]OV"8Y\Y7
M'?O^9'`#7JUA@"9,)LC=E^"<F/LL662T%AMC[18G;&8SRZS&!#5!DT`*JU2A
M`1NJGBVE[7)=VUDHE%DTXUY8"D%&<8(X.K<;1`@@1J$'EL/X2(>[N<[<'54,
M4$M1":"PD$-P8,N0LV.PB,H"!649];@7%L&1T%#"/;`5\.7,5NP<N@?:7V9<
MJ_D<M!=:7V3%3N.#@_T&A+;;<%W2]!YMDSA#YOP5/4H/%-Z0OZ*#[X7JFW,^
MI/H?RY(^((S`FO\#2^A!ULIPM0KHD8L7WGK!:A*)(YF"B(I.L$$$R*JW%J>4
M3&_$`LFAM^2JFF.^0T2T8LAI$"&?X[I-EN^`?XJ)"/\"=X"*A@17'S'S@@BO
MQEX2$=--A[Z_?=J&U*6YPNO`#U2A71M$B"J(MN*4"Q^:L&!J'=IQ);N7D0.B
M%8=T7.*P(>,Y(LHQT4E1%H'\%K#D6\X+NZ-/['>3X$<<I<$SGD1^_(1OXC2=
MXFRV7GHOJJFD+A60^UQ-!#VXTU6'!-"]KOHL:HTM9I4;_"(=,N%30JYO=G4L
M&"])4:*#."%T0DF]9856:+X;H=>?TTGK<ZE^G$;:G4*"E!E5<*'(WT@E1X_`
M)X_M3QP!\V8Z[?Y^%<\P9PHIT/I7+$-FOB8<X&PV#4_FU"QVX`ENZ@VED5?$
MZ$=NW+%'Q78&4#P;);+$TVMB'87D]V<\?$@PEE7YMD=S_-A4#5%V;TU9X'1N
MU3(#J,>,Q-?BF(BBHA(NVB-W;LJ:^:FE0*/9S<WP<C8?+B>S*9J//XVG=^/.
M^5^)![I8;K=3`5P?+:0L5U%4Z#4]^*4&ASA2T+->/DZ0PX*D^.F9J>C+^)?;
M\70Q=OLT6$T>&3A?8`4">.+>'*>8:!-]>N.*V&H8LTJA@CUE1$N+`_+:BUF(
M@[==U`A`+[F8&)*]>L)PF$*M]EBN'W!IQW@!*[<*J%F>/[T;TMH_JZ<@"JAA
MTK5*;PU&+/?V8"E(T2(,*!`V8<521;D$%B\J5<)S:A?MF2_C0=O&X4IGN2#V
M8<=CL].!29:0\:#P:4$>L;#DL+JM`8P<M.Q5QT71-_2M]R!ZV)]#*,220@(4
M1%<S7"J'7@4#*8:N8J,:`)LM%NAZ/ON(9K=C[G.Z]23L6=U!EL^<NK0U]:/O
M1^UFM[8WC:.XS+B8,@S.O06>>[NT%J9HI48D$+_?DJNJ72Q_',_19#J:?1RC
M$Q$.>.O4B)NR7L3;6;5`?0L>(M@_+\A9FT09)CVGL@\UN'NS,+%>M`85+,3"
MI>>EHC_YSQ#I%;59S<&%H@]0C@'Z,HW2=%5KG@$)Z*T:HQB51VN4&&"OUQ@X
MDK\0X_[]FD9L(NU4W]FAY+47).P*WG#U?UMN;K-U7EU1=DYC0'!\$&G%_NX(
M4@OM[O#1@HV*3E`<<5=RCX5F:Y3C.3]Q;"+%#UX0H9.0>B$HCM#GO(IG]3*Z
M^P-(5_)T[72!#U!/G+&Z.^U>.5^UG"Z(];;N&L:C9CRQ-Q"+%ZXL7I">5A,/
M"S!:>9P!<.T?YE$?GN5!2S-MB3PB+!1'Z25>QXG(M5YZ+S@=OQ"'-DY60>0E
MKY,,/[&*@@23]%K(NL+@8AZQ10@O]>@=6'9TC]8<C*]\9'$DY3O3%!&2B)@A
M(JT$\0K=LS9RF\QH*X[=<->]4(H^HS7/F\N;1?MV\ZX1\*SI`2HUCECKO#3H
MOGU%8,!I:/L/H%P0DST15*Q3ESC":^6U2"4TU"2K9+PZ059`X28W!2LJDR0*
MDI]LHI,$^S%IZ/5M<;?_'J#J8R-1"'A^J(Q.!`;81F>*,^,Y[0$,@#,B8[+D
M@!0!0)R.*@/5_3K.$/57T0F?]!Q[%Y8<EI=`^44IP,6K94>[-:[\DG->=.S2
M2P.?9A4&X393%BLR8KDW0$M!BB9I0($P4BN6*MK$H'@^*H<KZQ;=S]`+P;N"
ME4ZMNIE(N\OWNV)V`[074^!V%KC_&=-7C_!J2(;(>\#3+:V7.5N+RAJ\"ID\
M/:$^>N%<WTE4OX%LNQA_#5RG20O-F*L^?"4H((^30!&CP9Y,*=9WW54L[DXX
MY7E&AU()$HC3H.<;>;$742)/T'%_/``P=&Z7586`E>I6;$I33)PU:0`\^]=$
MR-([@'4(@#P,6)]!^>+L]@G`#KA632+$OL3L42`DEF:P%S3E\HI-@FU1PMI4
M>F-P)D$M3$Y%HD=&IV>Q^I[8X181SO!J<E[3]!KOA3N+SHR\]/$VB9^#%5Y=
MOMZE>#6)=LG)0S\+GGE%`4.";P-"('&>AN(>!(-J4H')"6[(9C4)BZ>=3W]`
MP]%R\FFRG#B^,=R9)#1P0RFAG!2Z?T4GE!H*HK=H1Q#M*2HRB8^=ME(G'"4Y
M_8"KGYKGU[`#'-+5[#!G&<\Q-<\@Q"6!EG$WL\_QFX6HW>JF*\N57X_;)L@\
MZ$8H6=E6%-"&Z&OB9'IYCL-G.K50!AP7G@62?]<L/Z2F\ZXXL\YBM&L<50\%
MR,_=S-(NGUS>)-@/6,R$?`XQ_4`O,C_1-TG_)8NEU$.%>(C97J3RF\QF/)CG
MF6WYDCQOO$?EE^0+.(X?9NY$".)XY,C\WKQ4'L?%-\7Y`E[1*J$X2G5&HP(&
M*,*I9;M4B%,*"5*,4\.)O,#EZ3V%9H5I<_!2)O2)_Q8@/:*>'!18R%$$A]\K
M[W/1?Z#_QZOK.%G@Y#GPE34C;)$A]ZTV8LEWGSI,F+<'[#FK5GIX)'_11#3Q
ME&"\UETF`+"B5M(5KN#$^RLX2.`SMS2G`)A^E]`GU:\P_[>PFQ4/*1C<RSH$
M0)+T:HIWD+=GB0WBO-5E3V%]*36_*(Y.F1?"W#+7>7SMQ,@)H).<Q%LJTMX7
M$F3`':&JI$/?C[=D3B`>'PZ>::*7=2?)4/M@8&J1]*95Q0/*C[7DJSK;/S$X
ME.P`@<W(FG.%`>7X:"Z1R&6@]TB#`FW\<TQFH\`GPM.(#ME.2`))UCUB1ZP/
M$T0=L?53A@VE?DPB]IS*BEL*5/?AT4X%4<PR!?E88)/NBF5AS+Y,/<<82NB9
MZ#;!]/DW_15I,UH?9A>Y*/IYI(S3CQE#QE-%H0003#''ACPKIH%<%&E94CAK
M;SD,T(:=[Y-NO5>Z]Z'!<-]/MJ07]D]:U-YTZ8GU81*H([:=5Z*CU(\)PYY3
MV5MD?)>\X;C\&(=C%Q\_Z8D_TT!"DX=S6Q!<$$4W,L%;7L>H"G5#_YG=A\&#
M,J?<`LEQ/25K,7;W+8P8[NHJ6;*BUJ$<$4TBQ%#1'M=Y?:6FTG#&X^,Q;KPJ
MT3WGSFHF'8=UR(W"%5[C),$K\;Z.]9Q<P>O#\J\01K_2'R#U8U&7,B7)7N!0
MR-^_B!1'*.%(P*NVG0B*!7HGV?Q0EK[F@BOZI0Z!/N=^RVS)'ANH.D`M[JJG
M9#0JM>49=FA?],N31*9ZE>_=79XW2"$SA\/6B[GD.HB\R._@7HF64&_F%@MQ
M+>88#94^W2LQLEDMY#J9#J>C_MTKJ2^)8;[9$>Q3QC)AU<=XQ6IT3=)T2SC$
M^373NVB%$[)=(:X-?78R6LD3[6Y))Z0$+-S2RVPL3W"V806^%!U^Y#;=&[Z3
M3BS.$4=M$&+KXD`@22R;M\D+\`6BU6+U`4H#;6GSXG.\V>5*XZ=-&+]BC#:D
M.Q[I?GY#&7`Z<\'WVJ30:^)B*^^O7<NLLU1)MX@U3]\Q$`P@Q@$2+/1_W])Z
M2>GW/J7=_J1'/I"2._EF>E-8P->[9;M??I"]2`WV)3WR@XXV=+V84_BC+AWX
M0EI"O9EC+,2UF&LT5/KD"QG9K,8&IY_&BQ[>L:\OB6'.V1'LJR^T\$*VE8J3
M;(F3I_W;2S9.C0X9UCLQBZ5R,]28T/Z"B3/#%C8EZ'3[&NSQP#;Q+459"%$8
M@=.,4$`3F52.S<I[9>TOXZ'_^S9(<!VKLL,%,*HZ0I5LR@81Q*3L&:NJ8>X#
M0]I1&_X%+JTY(+"MC.C81_!.Q@9X-B!3V`8GV2L-!63T]6GR[8:"V/:%AD`/
MY@6C>-K)08G=BQG"P)U6%3<"EP?3<D38&:.V/))I(Z<Q8+&M;,`?=Z_*!SI]
M''/@^NI6M_9X^NU&MW.?>Q2J4W)GCO><;'/_,MCYE_T*VMD+U\"![E'0SL$@
M.GYC8;W&?C9;CU]\=I5\3N;<6429)],G_8=.H<_$_U+[,O5(`+R^T$#$TE,,
M-?!!WF6HS5_U10-&@JZ"6!!!":&"?%%>(([8=3>V-+(/>$_2[8,-7<J:$T&4
M"I5QE,O(/HQE,KJU3KE@MZP(YF&>IJ+'ZI%P;YU-1"Q:9QU\".NLSY\D.5AD
MU@8:,T2K;4*7%%F55`>&V8&82NL;($X'25*,(?8&?1C2SJ3EA!>9EV3U91Z2
M35*2O!(FV?O3IH$]%'"`[O%#$-''=.A\[$#.<:1U*(\D)2;?:N1S6(1PN]F$
MF-WI"=G=]S#^/(G6<?+$TE8,)[36V`!E"NL)5JI;:(<*<@!;B[=J2<`"-M?*
M-<$G4\Z.@-MRAMT)PVR-XJ,"@1;GK(J[GGDXJ1A)$I&F%<M#L[CZ69^&XYN@
M387<70RM2\#=/=%FG,D.(WED<%@,>>:1T15BI.#OD78M;2D.BKQ<6IX'&8)?
M/NV)N&X7\%GRX$6BDO$HCM(X#%:>*))\2[HY[[#96J27>2'9VF5LWDRO@M0/
MXW2;X"5^R2X)F[\IINKNFW&_)3A65Q7W#EVW`>&@'D>&:MQWN+R;C]'L&EW>
M+2;3\6*!AM,K=#E<3!;TV]OY>#&>+H?+R6SJ=%OB2/YB,P-4:HA-/<6FJ+.P
M:PSM6T/[YM`_:(.(M?C//^1L9'`V.J+]!YMW=(Y*)X1!W)@..:_.*UY&S8%8
MS.4V#2*<IFR;1A_]2^FW);LZQFM'QYYBCBV_XPA$\!`%Z\"GY_.\=$\0/=R2
M#O$#G)JV);;(`/&'6F*5P@]6F"#/*-3@K%J0:C2:W4U9RO?M[&8R<IWPW8KY
M`C+:8Z,<O1=K;U4JTRMB&@2`=Q2,[)?>3E!"P[RY96!'59ZMK$0P:]'1>&\9
M:QL5"]\,'Q+,5C_5BF"'XCB29BG"+G!F@'<7)[-BI'K@42I5M$-3S(Z.@F`-
M19G=W`PO9W/F?:+A#_/Q^"-Q1MT'M8[$_E%L4['>6&'TPC)E*XX%N,N]F#4[
M]M;I=MGY0PG0T#Q-@G1EG=UL'*^](&'GV/M@DM'Q,N"XWSY:"5'<06H1(+PK
M"X:J)86&DSGZ-+RY&Z./X^'B;LX4R:UCU8AO@H,84B&"V0\W2B:.P9'2H_3#
M%G3.E`X>Q)TR,Z33J(_8HQ@\0`[D5!U9`L<A.EJJYC$.5SA)Z<EJ]CJ-,VQ_
M>%@#'R!05U>X4JS.%ADD7%>/.<DVY>-'LC]9+&>CG]R&ZEHR7L3_$G$*B)+H
MVW$99\VPNAP"`=R7D+)9NA%1@@!9,V0L2%P(5N^,U]YBF<7QTR;!CSA*:04O
M^AP[U(IQ5/[=JC5[$VGK9RQ9>1BMYCBD%S?W-Z3LEXYFI-R;2!N1BX;4A`[$
MVM*<S^H+6N/%<GXW6M[-`<L!=2E/D10S4D&L6`&H9PN147S#&E4#OX>VJ5O9
MK)%!%KV:W!ETU5BA"MX,NY3'\<T]LG0'O"()O5`2LP,T'/FUEL.Z1`!N[S42
MLW1_KQ8%D!M\#3B4>E>3)0O7L;S'T8PE1XRGSC,CNA%G3T1L3`MD^K;<64EL
M6/)JTNBI)>J6OEH$0):_!AQJ%7=845R@=1!&,.=&N'==)Y$?/V$:H[%8`@UH
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MNQU;DX3Y,*O@FHZXGE[[P1?T$6\`T180:0+1-AJIPI5(];O-R\)THP<*LFZ5
M0"M;K@%2H*;#KR'6?NQSXGD5J$[&?4G@NAMN3@UFE(N2'`XN_:WMF.YI=#B4
ME&BC\1M'69"]C@B-Q`LGT0J__(1?VP^D@JS;$=7*E@^M%*CI&&N(M1]L3AP)
MZHB11X1^FW%G"1$L'X*_RC;;9FGF1?2)M<Z40-L&B$982'V@'AJ,EKIBI-R=
MXA2R7P;Y*WR%YMKH$=].S/$F3C+V/J"7;=/.-$A!'41WM)(>:(T4MJ6^:&AV
MIREB=[AK!?%F6FC(=1#B9$1V&0]QTMGZ<D`40A^D<I75H`32;O0EI#H;=$8;
MY<1;#/4</P0T.A!E4^^I@TVAG"K$8,LE*X]V&:;=<,MH=3;>>^*(4F\QX)_B
M<!ME7L+5L[-IOT(68L@5LI7'_`"HW:!+B74VZCOJW-[;3.D_XS#\*8H_1POL
MI7&$5_217ZP);M<;?B5Y"#4PR%I6!P5P.[70$NU,/6@KI[_19E#>#N(-M5"4
MV^U]&/C78>QE72E'B22$0DAD*BM!`:#=P%<(=3;8G#)BI%L%?W@4D8>3KLEW
M'2P!&M(P82&EC(<QH@I@VX"1@F"'T2,1!1;Q0-9&!_I`@\I'T88"84A=J,@G
MUX0=6#=Z<$"N>RU@9P$'.N#ZPJ2HU5:HWW8;IX%-274K5(AKDO8BE6](FO&Z
M/_K6GAU;<R1)&<I+]6%:4(_\YM/G,S'NQ35=GL*T$\^@:$IH][IE8+RH3@I0
MMQJD94*O-(72K?&Z+_?U"A:1E^$W9M]H44"G)Z4(BFFI`@\V'2DXJ:-1NW<0
ME'K%/]\03KYG?Y$/]UZ*R1__#U!+`P04````"``@,`4_K[(]SAP0``!"Y```
M%0`<`&]G>&DM,C`Q,3`V,S!?<')E+GAM;%54"0`#6[\[3EN_.TYU>`L``00E
M#@``!#D!``#M75MSV[82?N],_P./^](^R++L-&TR33ORK>.I8VEDI^UYZE`D
M).&4(A20E*W^^K,`2?$&@*!UX:5Y26P9"^WNM[@M%KL__?*R=(PUHAXF[H>3
MP>G9B8%<B]C8G7\X";R>Z5D8G_SR\]=?_?2?7L_X\W)R;_R*7$1-']G&,_87
M_+./)OW;N"*K#<7SA6]\>_6=,=T8DXEQ35P7.0[:&+U>W,FEZ0$M<</>SD\'
MT=\<[/X]A;\9P)/KO7_Q\(>3A>^OWO?[S\_/I\\7IX3.^^=G9X/^GQ_O'ZT%
M6IH]['J^Z5KHQ(#V[SW^X3VQ3)\+E")_F5(G[N"BO_TN:0OV6R]NUF,?]0;G
MO8O!Z8MGGX0L:O1_$@O#/A"),WCW[EV?__6$Z8`2!TW0S&#_?YK<;2D(@#('
MO;^<6F399W_M7Q,K6"+7'[KVC>MC?W/GS@A=<LGA:UF7[_W-"GTX\?!RY:#X
MLP5%LP\G9/Z"0:K!X.SMQ1F3Z1MU?_TT=]4[?S#]@*+1[#+PL(L\#[X$S`![
MH]F8(@^^-?H:#;EUN]J1XZ%ED0#TX,['Q,$61IX6=R*R'3FY(HYC3@GE<@WG
M%"$&DQ8W,M(=.;HU,?W==`+T$9D>@,$ZU5./A')G#2V7Q'WTB?6WIEI2[7?\
M[@GR?!I88).`^=#R\1K[NL8BI=V#/K#/=0NCXXIP>X1Y79<O)?WNO*TH6B#7
MPVMT3SQMCO)4._+Q&$P]]#D`&6_6VN9;).)<K%(3SSU\:?35C&3G&1S[K).S
M,Z-GQ.W3/YJN;83$AG3^1R\^<FUD\Q7&(5;FCPY;+`DM4Q?[Y"\5P\,IV+)I
M^7%',.\@)^Q)DZZOS5ZD4K[D>L@ZG9-UWT:XSSAF/W#6>V>#:+G^!C[:\O`$
MW>9X+/ZY@.J09MDRJ15W`C]F@"YN!J(6_95)H;^>M<".'5//*%E6TE+$!1&Q
M3:B-Z(>3[T_/+DZ,P`.>R(I1F\ZAM3L$)FS&R*UCS@7JS?V]-?K-\9TH^/LC
M*SAF?HPH)L"_?0T[<(4=Y]JU1N$2_A/%OSFRXD/.)VB.&<.N_V`N17H7-VN-
MVL7L)UH?U*+U*Y""FLX=+%XOOZ&-5.V%=BW3>X'_1/'G1U;\54"9D+?8LTSG
MO\BD\JE&WK0UZI>+D"#P8RVF_P=RG-]<\NP^PD&)N,B^\[P`4>D0D+9O#18E
M<B2`O*L%D-^)`^=ZDVYNL8.H)P6BT*YE`!3XWRI^<%;/(A".T0E:$<K.H8^@
MQ4"N?UGSEL$@$R-!HYXEF5O%%4R1<T+E"W*N5<MTG^,^4?FQ%^/(%!)OU>,"
M9/9&@<^<WLQ)+Q\&2J*6`:(6)L&GGK/!.)@ZV+IUB)EW?DC:M$S[&=X391_;
MQ1`+$&[6PO/A+7PF6@H4;5NC?(4,R5[HAUI!8#MF/0A2+5L*0$J"1/UOQ>KO
MYQW"N[FJ+TV'77$^+A#2]%/G*'9TE6=Z&W-%+Y"/+29O569RY+LZ\4'%X1W2
M:'8'W\R<%CIN?`'9'CFY,KT%3)?/FG<*8DK5Q4+.K:]YW9`SBNS]PL#H&5M.
MX.<KXGK$P3:_YX\HC9#4^/:3:P8VAK]\IW^ED)YM9J8WY4,X\'ISTUR%4PYR
M?"_^)#_W1!__M65Q-+O%+C"%86HD'E;<0``WFF2OFSI?+\S0\T"="K;S#8X]
M=>JK+IDY17Q'$^;@M#!=@C`S!"<=^SZ46LHLYW2-Z)1XB+=EM)A0F,JA8Z8:
MPZ@#O>B<5@IBH5T=6(H-+HM:@=$(O//3XH&SQ>BQF9;=;<-_-Y\#O#8=-@,/
M_2N3T@T<*WB0@@!-3;KZT)489`RR)O\1Z!>G19]/!KA=+.#8TRV/ML`6+%NO
M!;]R#XTU@\J21`;QIDL&\;@@U']"='GGKD$?42Q2<?,@;-98:,7L)F>6[N`7
MQ=IY$V0A,-RI@QZ0'VE'M!`KFS<63S7;$:YONX3KF**5B>V;EQ5R/20'5-*N
ML4A*^(T@_*%+$&;T4;8I;C!D.3XCJ'[<+U0^\4VGMK%&5HCZFS&<\+EW#/8`
M*[9FP"0C''*JYLT[TZCYC>!\UZ61-_(7B(9*>2"N)1V!DG;-@U#":.Q3..L2
M>*&8TOFRB?#$G,5X#+HS-]YC<XH='I(/4P>_?EP0!\3TV#3B;Q1.'WW2MOCT
M]"6*+:%C'J.4`LJ=?JK&=2!>U90%J,L<@X.+TV)<1(MQCL];8W/##EN@+OB$
M!B!*01>*0Z86=<V6H'GPU!(E-H9..8BN(U8G:(W<0'$2E35L-L`RKF,L.^4L
MNC)7F&TED.FAT=3!<XZ'8B27$30;VS+N8XP[Y3CZPZ3L\0);XB;L(;HB4H[I
M2-V\V?BJ>8_1[91/26O];=\RJUI-.^1HRBTV2M^$HFV;-L\*,6*`.^5ZDJPY
M2J@U:-H$N88X<3Q%IQQ7*7VI)^5VP9EA/`:N0QXN9:*'XE@M30O1$EB5@L0P
MB]U7+1V?E9R737-7OA9F#2?EN3C"J;7.J]1+&6D$6Z%)/2[H*H,URV^,7:=\
M34/;QJ$08Q/;=VZTD\BD*BIZ&S6(FHVNC@0QWIWR1TV0;V(7V3<F=6'U\8:6
M%2P#A\7;P[D!6U@T,^L0-1MO'0EBO#OEFTH)RF^T,QFMPD<H+*_5`_)'LR?S
M17RU4*V'9EM"97%BL^B44ZNH+ZT-6=/!%7$<X]<AIU;9SO05D0'MVF*72Q.C
MOF=/5P%UX9O+P[V?R[UCC/J-'].]\C6=\6VFV^].C"_/Z[Z$[PBFX2_A.U\\
M(%\\(&4>$)A,1Y0/%IM[#L:(\O0A:J>(G*K96RXM$1+728><FX7T,,/`7X`H
M_R1KNQCJ8NO60%QD/8%6%([7%6AY.C@M6..6+8,T9CN!LYAHISMPJ@-TFI7$
M:D=@10$Z@&XQ9]5^T3W\N4B4325['CI7'8<2<H/,#.;RJ3/!2"C`EB?%'E':
M4G]02=*L1_$BWBV87:J"PQIM*SCD;V?UR>H8-"4Z92-&7X!M+I$..0&OB,=O
MHJ.7H:J4,/*F#456S70WDXM,``10(,NK<`TV[1#^Y#"27GBMHVQ?![)E)IE*
M)*%BO8MY1,+Z5PY[#V$OL<LSIK-92HYO*463$2YEOHNI0?+*T9B)FXUBD=O#
M9`2I\S9FM&)UZ6!_G=P>"G`3MFKPXBGD=\]I/]Z%X+EHSK;D3S5B^$!<DA4X
MLEC%GDB#IL'X:G"_S1#2J5U2DI\H%/O.]1$@)#YKR9K6`:RVC<80R]D_3$*1
M!F2@D.I(-".7$+0"XS(AFI5K1.)YV)9G'-K_"T*+'<WBIV8BGT,)0>.1TQ%B
MWYE&LHMMT];9*NMK"P`NX;^#64N2;6+H1V./&P*0/-I'$M>[1#-"HQ"[)_,%
M>3<OH#=0!79-NKF#[0I_L`24((S#E:98F0_X;0W>M1U4[B0$HVO;^ZTZHA%X
MB5PT$X8Z2ULVWB@$/">I4AJQ^N]I"4&^\J"=^WN#<<MQNN]<)LT9?G'4?1P0
MP@JG6\QUBYW`%UZKEU(T&-92WAN6Z$2R*?\#L00/R!Y"O^8</03+*:*C673!
M',:!*(HO5R+O_VPT$L[JDB0)3CKE-)'HH!!BP&U=,)XKTM=2K.<5!K]-BU)-
MO$[F29'H()KU=.)N*O?0$3.1"WB@A"RUQ^ND"@Y%748A.Q?Z(3NL#X-WTI#*
M0%NA])XL")K7L)5F7(PI66-`\G+SR4/VG;N]^AE:/EZ'X=^*:Y!7=%+S\P4I
M4JF=>669MA%"G5KX6W#:>KT5JP]BAW&#U/;./_8Q<_</Z(N[@I[(!%GP.^;E
M'1(E/)'=)X;#?V4[K>WP>MF&/W5J*KI&P+R%.=#PLX,XXJX]7+):U?_PSP5F
MJ$=62X;S(XW))#&<CB:Z&%<5^V&0S9[[(]>3&8NLX;_!/&2R=[*&D^#*]5?V
M+[)O"7U$=(TM8?B=+N&_P6!T=='%8E&@1LJR+5ZC\/^4XJ)<0NHW'-K$_P9#
MJJ*/K@:EY350K+^F94@BLIKN2BJ.#[DQB&3:<P1;(\YH1<FS]3)A4A4,*BVS
MT.NH[8:B)^6>0^(::CK9JG]:1I(G:;LYY.7I9$2=?+I4%5"IM):H.VJ[E>A)
M>:"(O3W?V1>ERZ4$%]W4:Q"U!V-=B0X;Z]:8N2!7"T!KV!=HVH.^ID!=C8O3
M/(;M=(G75J][%0D/5%6LSO!LB?A1(K?=KGJ5G;3TJE<I4Q+`URDG!.C`0LCF
MH>4L'Q!+%QD',7UR06286D&I+#.&:XN]Q:S@L0?-G(`%L/`T-".N&M&D<^#O
M:]`\I3',4J6C#ZF43A9@T]?Z3I-:6TVJBH0'"DULX-(7OH[=<>E3=M+2I4\I
M4Q*1V-FE[]%T^(Q+J/^$Z#)Y15VVAJD(&S1S:!B^:#%22=?)NG)C<\/%>R)#
MZW.`*=(U"3VZEEJ$GG#[KC;7"/=*07;0(QP?_0W;</DLRPU\RA-1Z5B%@K@C
MIJ&0<-]%[1IA'_HJW&F#T5;[J")A4@VO,]O0F]D,6;`MNWFQ%J8[1Q.PU)'+
M-,**`<)_;'BL89$5KRK5R)N^]:PFC3IG?$NW%V)AQPCDL?,^;($]5"-ONCU4
MD^9`E?AJ+8DJ5,`09DQ*-S`Y2LLJZM&U$_^"&`<JR;?B=@;\4K^+\/\UZ(@!
M,$$.5*4O-($;MZZ]XV.P6CE<6:83*^O.G1&Z-$7U==(AZ[J433<!;4&2BGP-
M\4%)HC'B\T_ZZ!,=C6SNRM<(SJC>1RTP5[/>;:!&=>D.5,VOEA?1#Z8?4#2:
M708>=I''\N2R!`'>:#9.?<U6:=$3Z;=G9ZS.VS7V+(=XT`'\$O;$7D7'?1G0
MF<%[8Y]F^CMV7D8Z-]WH=5'RG#M\>93F*U55+'GHK9CW]M3OT=-4[L)V`OH3
M&-NE(R[/O/^OJ&-.V:O=;--E[ETU1RL,<?CY*(J$A-W6&/1BI?Q4J;GG/#_W
M)%3&ENSX18YSC*N>)2L:'WW7A^<NGF&+^4<+;*F&N"YA+:^'2M'8[O@TI>C0
M&$L5F`$PX@(S@G%VD1]G&4HC(=TU9EC,D2JU5QG%SF',XB^0C0<]DEIR!>GI
M=KL=+A6B0P-AF_WX(VSQP<(SMZFI<?`F/PX8H<$IC0SID:?N+?\)<ZI51]W\
MV.N.B!O5<E/2OHY51D?_\3I3PGZ'1E6J_)]@+'U?7%-8<R-L?^S[L+)JR,(*
MR,?<G!6*+CX0'^D=P2K0UC%XJI9OEC+?H:'#'X\&EA]0X55]:AB]S0^C#*F1
MHCVRQ69%<.T)<E@XA%:`8P7:8P_$4M;TQN3KNJEC>%;&,546[Q4B=F@0LP4-
MAT%H[#:)Y\>')A)?Q@^B]3`BYP[4;`<U5"V6R)(PK:S968F^CJ+,I>RIQG/5
M#NJID_<*#-.UG*L(V*UQ#/TMD.OA=2;U9&KT_B@8O0D1+^G\94];''2)BL(,
M/FQO5S+,2DB:MX,MY[E#8^4QF'KH<P#]W:PE3I1W^:&2T!@1T='C';),*P,<
M9$V/'Z21Y41Y`I2WK>>&7JWO)`A#RG:]0Z;/V)R:'H)?OO[J_U!+`P04````
M"``@,`4_VR1T<-<%``"E)```$0`<`&]G>&DM,C`Q,3`V,S`N>'-D550)``-;
MOSM.6[\[3G5X"P`!!"4.```$.0$``.5:77/3.!1]9X;_H/43S*SCI('NMD/*
MI"EE.A-H)X6%-T:Q;Q(MMA0D.4W^_5[)=OP1.TW:98%-'UI9NN?HWB-9DJ_Z
MZO4R"LD"I&*"]YQ.J^T0X+X(&)_VG%BY5/F,.:_/GCYY]9OKDL_GHR%Y"QPD
MU1"0.Z9GMNX=E5_)0,Q7DDUGFCP;/"?C%1F-R(7@',(05L1U,Y)SJA`K>,)V
MU.JD;<J?040)>L15SYEI/3_UO+N[N]9=MR7DU#MJMSO>YW?#6VOG/'U"\,=:
MGR[',F0EC*G)4%V/<:4I]Z$$"AG_N@5CFL?H:KFC#5#J7.?DY,2SK:F]IG(*
M^CV-0,VI#VN,0'FGJ."RY8L(>^ITW/:QVVV7NA'3)=L5`2%$P/6ED-$%3&@<
MZI[S+:8AFS`(')(84:TE&\<:2F8QSPVK<@9Z[4!1EY=>TI@1)P"<*7HU!U6&
M*/!;4['PLM;4]X[;[93A'&=)'-6/1:"E9]`>&KEH!9+Y%?3]T!1F9AGE7&BJ
M<;[;I_F<\8DP13-VIU*$\`$AQ!0^CJX:!L&T>A?"CXWR?1Z\X9KIU14RR<AR
M.X0%/6>KQ9F)(>DU@`GCS/K4;A.79+ABD?*`)"2DP/+*JQ+DK#&^9M?\S);G
M$A2R6,P0*U)<:E*/R4EW1?@T]..PL9/T.=/X0:*?T]"\R+<S`*T2E<M5#;+B
M(D-N,7Y(=1T(KD3(`KN.I0PDH2#//G(:!PQ;GA^VOC=48E`ST`Q[KA&[W-ZD
M_`.E)\]*](<W%&O-U/7D"ILC2(:@IKY!^J-MRN<T1$S(4*C#GOA%50=4S2Y#
M<:<V!<^;&C3O[JZYX2*6['^D_$.T?T]U+.%Z<AXKQD$IW"_QD,A0[IM"D,E@
M[&C;,#K';;L37##EAT(A$3XDC&9`,DZ"I,2RFMHB[R\^./L/3=_W18S'#CZ]
MP5GL,TC?B9KZ9LF/JI+G:)+!#T[9@0A#.A;2=M*?2K`+0Z)N0UNSPMVJPB4&
MLJ8X.)4O*9-_T3"&=T"--';Q342N;VK6^$558T-`+`,I4AR<Q@,118+?:N%_
MS:9O7M&LY\O-.6M@Q.(.3L01*"UC'[<B7!7[OF8+]#!;;9L:F\4]KHI;HB`Y
MQ\$);689T_9-Q6T>CV=F&P*>;VW;#)H%_Z-N-J<T]CQ1(CI$U3&6&7#%%F`^
M-M9:5ZJ;%?ZS1N$<;+]@#D[6VWBLX%N,L;Q9Y#O;1FVSJ"=547,L2<"_N*:9
MJN:72>>.8$)LGO;4I`9[CF+1/,0OZZ1N)F'2<TSZU37)RO9QM_T%NVPMHS`S
M,=Q;TL9V6"I>IOUF#%3Z&R0;:61O+L4<I%FB\U1TYCG3!C[(>R&F&_4[H2'Z
MZ9V1QT>-P[EOU-49\)W"+GZ/_?MQXZEYW[@1`N%W#'AH^&LB]0K9:Z^<U\8P
MA=2$;UP_;+D;(<D%S%#XEF8+Q#RY&<XU56[GR.UV6DL5&.?V<R"/>C\',MQC
M'-BX(MC)ARK*>'!B/.@<9QZ0![A0O.#8SPW!WS_,DPE58\M5>T?3X(1UH(B<
M4CJW0`]"K=9<;LZUMS-KRL?[8FKV=:5T?Q4`V]F5*L84&CHW=Z'IY9U*KT#3
M1^O0]NNC_AB/\]1/\P5F"?NRFWFR#MH+TU.LPQ/IE8;(;)88&.[]"(P-XJT4
M\3PS9&B"BY(MXV+%1/#!T@2Q3%-S-.V@Y^!7!E)Q9O(/9O5*GKUD*RX'.`(\
M8<2@+J6("@F+!:SS%:H0WT[6Q?#P8Q(TE:N=`ZPZO2W@I&V<7%_T'%]"P'2Z
M]I2C7.<9^L'?L;)?!->33U1*6H[O'KL?%5D`XX;`/H&Y[8>@OP!)IX!+T!CD
M]23]^I]1W*=KINE>J.JT>L3LW4>"FF"O.`XQ[C87D/R]XD/SYWH<LFDA/6U#
MW,'V)YRG-\E!9&76CV\QF]NUQ,<20C[R`&1SP/M#?\+XZY.N'V"IS\-U:LN&
M>Z]E$EWR;PVG.JO_KZ9JO7LUK^)]AC_R[?.271:+_P!02P$"'@,4````"``@
M,`4_L=CWTQ!4``!>HP(`$0`8```````!````I($`````;V=X:2TR,#$Q,#8S
M,"YX;6Q55`4``UN_.TYU>`L``00E#@``!#D!``!02P$"'@,4````"``@,`4_
MR.W):=$)```L:0``%0`8```````!````I(%;5```;V=X:2TR,#$Q,#8S,%]C
M86PN>&UL550%``-;OSM.=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`(#`%
M/P<?6L[.&P``BVX!`!4`&````````0```*2!>UX``&]G>&DM,C`Q,3`V,S!?
M;&%B+GAM;%54!0`#6[\[3G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`"`P
M!3^OLCW.'!```$+D```5`!@```````$```"D@9AZ``!O9WAI+3(P,3$P-C,P
M7W!R92YX;6Q55`4``UN_.TYU>`L``00E#@``!#D!``!02P$"'@,4````"``@
M,`4_VR1T<-<%``"E)```$0`8```````!````I($#BP``;V=X:2TR,#$Q,#8S
M,"YX<V155`4``UN_.TYU>`L``00E#@``!#D!``!02P4&``````4`!0"_`0``
&)9$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 4 - us-gaap:FairValueDisclosuresTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>4. FAIR VALUE MEASUREMENTS</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">With the adoption of Accounting Standards Codification, or ASC, 820 &#8220;Fair Value Measurements and
   Disclosures&#8221;, beginning January&#160;1, 2008, assets and liabilities recorded at fair value in the
   balance sheets are categorized based upon the level of judgment associated with the inputs used to
   measure their fair value. For certain of the Company&#8217;s financial instruments including cash and
   cash equivalents, amounts receivable, and accounts payable the carrying values approximate fair
   value due to their short-term nature.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt">ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those
   valuation techniques are observable or unobservable. In accordance with ASC 820, these inputs are
   summarized in the three broad levels listed below:
   </div>
   <div style="margin-top: 10pt">
   <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="4%" style="background: transparent">&#160;</td>
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>Level 1 &#8212; Quoted prices in active markets for identical securities;</td>
   </tr>
   <tr>
       <td style="font-size: 8pt">&#160;</td>
   </tr>
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="4%" style="background: transparent">&#160;</td>
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>Level 2 &#8212; Other significant observable inputs that are observable through
   corroboration with market data (including quoted prices in active markets for similar
   securities); and</td>
   </tr>
   </table>
   </div>
   <div style="margin-top: 10pt">
   <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="4%" style="background: transparent">&#160;</td>
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>Level 3 &#8212; Significant unobservable inputs that reflect management&#8217;s best estimate of
   what market participants would use in pricing the asset or liability.</td>
   </tr>
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">As quoted prices in active markets are not readily available for certain financial instruments, the
   Company obtains estimates for the fair value of financial instruments through third party pricing
   service providers.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">In determining the appropriate levels, the Company performed a detailed analysis of the assets and
   liabilities that are subject to ASC 820.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">The Company invests its excess cash in accordance with investment guidelines that limit the credit
   exposure to any one financial institution other than securities issued by the U.S. Government. Our
   securities are not collateralized and mature within one year.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">A description of the valuation techniques applied to the Company&#8217;s financial instruments measured
   at fair value on a recurring basis follows.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Financial Instruments</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Cash</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Significant amounts of cash are held on deposit with a large well established Canadian financial
   institution.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Government and Agency Securities</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><u>Government Securities</u> U.S. and Canadian Government securities are valued using quoted
   market prices. Valuation adjustments are not applied. Accordingly, U.S. and Canadian government
   securities are categorized in Level 1 of the fair value hierarchy.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><u>U.S. Agency Securities</u> U.S. agency securities are comprised of two main categories
   consisting of callable and non-callable agency-issued debt securities. Non-callable agency-issued
   debt securities are generally valued using quoted market prices. Callable agency issued debt
   securities are valued by benchmarking model-derived prices to quoted market prices and trade data
   for identical or comparable securities. Actively traded non-callable agency issued debt securities
   are categorized in Level 1 of the fair value hierarchy. Callable agency issued debt securities are
   categorized in Level 2 of the fair value hierarchy.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Corporate and Other Debt</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><u>Corporate Bonds and Commercial Paper</u> The fair value of corporate bonds and commercial
   paper is estimated using recently executed transactions, market price quotations (where
   observable), bond spreads or credit default swap spreads adjusted for any basis difference between
   cash and derivative instruments. The spread data used are for the same maturity as the bond. If the
   spread data does not reference the issuer, then data that reference a comparable issuer are used.
   When observable price quotations are not available, fair value is determined based on cash flow
   models with yield curves, bond or single name credit default swap spreads and recovery rates based
   on collateral values as significant inputs. Corporate bonds and commercial paper are generally
   categorized in Level 2 of the fair value hierarchy; in instances where prices, spreads or any of
   the other aforementioned key inputs are unobservable, they are categorized in Level 3 of the
   hierarchy.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt">The following table presents information about our assets and liabilities that are measured at fair
   value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we
   utilized to determine such fair value:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="44%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000">(in thousands)</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Level 1</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Level 2</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Level 3</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px"><b>Assets</b>
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Cash
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">1,824</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">1,824</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Money market securities
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">7,830</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">7,830</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Government securities
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">6,000</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">6,000</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Corporate bonds and commercial paper
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">60,260</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">60,260</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right"><b>15,654</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right"><b>60,260</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right"><b>75,914</b></td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px"><b>Liabilities</b>
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Warrants
   </div></td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right">14,828</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right">14,828</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Marketable securities consist of the following:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="44%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Gross</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Gross</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Amortized</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Unrealized</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Unrealized</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Estimated</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000">(in thousands)</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Cost</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Gain</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Loss</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Fair Value</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px"><b>2011</b>
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Cash
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">1,824</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">1,824</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Money market
   securities
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">7,329</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">7,329</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Government securities
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">5,998</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">2</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">6,000</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Corporate bonds and
   commercial paper
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">5,715</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">9</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">$</td>
       <td align="right">(1</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">5,723</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px"><b>Cash and cash
   equivalents</b>
   </div></td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right"><b>20,866</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right"><b>11</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left"><b>$</b></td>
       <td align="right"><b>(1</b></td>
       <td nowrap="nowrap"><b>)</b></td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right"><b>20,876</b></td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Money market
   securities
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">502</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">502</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px"><b>Restricted cash</b>
   </div></td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right"><b>502</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right"><b>&#8212;</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right"><b>&#8212;</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right"><b>502</b></td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Corporate bonds and
   commercial paper
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">54,578</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">3</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">$</td>
       <td align="right">(45</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">54,536</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px"><b>Short-term
   investments</b>
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right"><b>54,578</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right"><b>3</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left"><b>$</b></td>
       <td align="right"><b>(45</b></td>
       <td nowrap="nowrap"><b>)</b></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right"><b>54,536</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">All securities included in cash, and cash equivalents have maturities of 90&#160;days or less at the
   time of purchase. All securities included in short-term investments have maturities of within one
   year of the balance sheet date.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">There were no significant realized or unrealized gains or losses on the sales of marketable
   securities in the six months ended June&#160;30, 2011 and no significant unrealized gains or losses are
   included in accumulated other comprehensive income as at June&#160;30, 2011. Realized gains and losses
   are transferred out of accumulated other comprehensive income into interest income using the
   specific identification method.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt">All of the marketable securities held as of June&#160;30, 2011 had maturities of one year or less. The
   Company only invests in A (or equivalent) rated securities with maturities of one year or less.
   Given the quality of the investment portfolio, its short-term nature, and subsequent proceeds
   collected on sale of securities that
   reached maturity, the Company does not believe that there are any other than temporary impairments
   related to its investments in marketable securities at June&#160;30, 2011.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">The Company has recorded a $14,828,000 warrant liability as of June&#160;30, 2011. The Company
   reassesses the fair value of the common stock warrants at each reporting date utilizing a
   Black-Scholes pricing model. Inputs used in the pricing model include estimates of stock price
   volatility, expected warrant life and risk-free interest rate. The computation of expected
   volatility was based on the historical volatility of comparable companies from a representative
   peer group selected based on industry and market capitalization. See note 5(d) in the Notes to
   Financial Statements for further details on the inputs used in the Black-Scholes pricing model used
   to recalculate the warrant liability.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">The following table presents the changes in fair value of the Company&#8217;s total Level 3 financial
   liabilities for the six months ended June&#160;30, 2011:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="58%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Liability at</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Remaining</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>December 31,</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Gain (loss) on</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Liability at June</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"><b>(In thousands)</b></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>warrants</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b> 30, 2011</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Warrant liability
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">15,269</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">441</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">14,828</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   </div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19296-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 159<br> -Paragraph 17-22, 27, 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 107<br> -Paragraph 15C, 15D<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13504-108611<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 107<br> -Paragraph 15A<br> -Subparagraph a-d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13537-108611<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 133<br> -Paragraph 44A, 44B<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19207-110258<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 107<br> -Paragraph 3, 10, 14, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 107<br> -Paragraph 15B<br> -Subparagraph a, b<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 157<br> -Paragraph 32, 33, 34<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Common Stock<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common Stock and Comprehensive Loss [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">COMMON STOCK</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 5 - us-gaap:StockholdersEquityNoteDisclosureTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>5. COMMON STOCK</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>&#091;a&#093; Authorized</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">25,000,000 authorized common shares, par value of $0.001, and 5,000,000 preferred shares, par value
   of $0.001.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>&#091;b&#093; Issued and Outstanding Shares</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">During the six month period ended June&#160;30, 2011 the Company issued 24,660 common shares upon
   exercise of stock options (period ended June&#160;30, 2010 &#8212; 117,643) to satisfy stock option
   exercises.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>&#091;c&#093; Stock options</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>2010 Performance Incentive Plan</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">At the 2011 Annual Meeting of Stockholders of the Company held on May&#160;26, 2011, stockholders of the
   Company approved an amendment to the Company&#8217;s 2010 Performance Incentive Plan. As a result of this
   amendment, the 2010 Plan was amended to provide for an increase in the total shares of common stock
   available for issuance under the 2010 Plan from 450,000 to 1,050,000. As at June&#160;30, 2011 the
   Company has reserved, pursuant to various plans, 1,598,075 common shares for issuance upon exercise
   of stock options by employees, directors, officers and consultants of the Company, of which 777,359
   are reserved for options currently outstanding, and 820,716 are available for future option grants.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Stock Option Summary</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Options vest in accordance with terms as determined by the board of directors of the Company, or
   the Board, typically over four years for employee grants and one to three years for Board option
   grants. The expiry date for each option is set by the Board, which is typically seven to ten years.
   The exercise price of the options is determined by the Board but generally will be at least equal
   to the fair value of the share at the grant date.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Stock option transactions and the number of stock options outstanding are summarized below:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="72%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Number <br />
   of</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Weighted</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Optioned</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Average</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Common</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Exercise</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Shares</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Price</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>#</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>$</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px"><b>Balance, December&#160;31, 2010</b>
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right"><b>744,913</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right"><b>8.73</b></td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Option grants
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">75,900</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">17.03</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Option expirations/cancellations
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(6,112</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">13.86</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Option exercises
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(24,660</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">3.67</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Option forfeitures
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(12,682</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">12.66</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px"><b>Balance, June&#160;30, 2011</b>
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right"><b>777,359</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right"><b>9.59</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">The fair value of each stock award is estimated on the grant date using the Black-Scholes
   option-pricing model based on the weighted-average assumptions noted in the following table:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="72%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Six months ended June 30,</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Risk-free interest rates
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">2.39</td>
       <td nowrap="nowrap">%</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">2.41</td>
       <td nowrap="nowrap">%</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Expected dividend yield
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">0</td>
       <td nowrap="nowrap">%</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">0</td>
       <td nowrap="nowrap">%</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Expected life
   </div></td>
       <td>&#160;</td>
       <td colspan="2" nowrap="nowrap" align="right">6 years</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td colspan="2" nowrap="nowrap" align="right">6 years</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Expected volatility
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">75</td>
       <td nowrap="nowrap">%</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">74</td>
       <td nowrap="nowrap">%</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">The expected life was calculated based on the simplified method as permitted by the SEC&#8217;s Staff
   Accounting Bulletin 110, Share-Based Payment. The computation of expected volatility was based on
   the historical volatility of comparable companies from a representative peer group selected based
   on industry and market capitalization. The Company considers the use of these methods of
   calculating expected term and volatility appropriate because of the lack of sufficient historical
   exercise data following the reverse takeover of Sonus. The risk-free interest rate was based on a
   U.S. Treasury instrument whose term is consistent with the expected life of the stock options. In
   addition to the assumptions above, as required under ASC 718, management made an estimate of
   expected forfeitures and is recognizing compensation costs only for those equity awards expected to
   vest.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt">The results for the periods set forth below included share-based compensation expense in the
   following expense categories of the consolidated statements of loss:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="44%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Three Months</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Six Months</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Ended</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Ended</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>June 30,</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>June 30,</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000">(In thousands)</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td nowrap="nowrap" align="left">&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>$</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>$</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>$</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>$</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Research and development
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">122</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">74</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">243</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">142</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">General and administrative
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">161</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">70</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">311</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">169</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px"><b>Total share-based compensation</b>
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right"><b>283</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right"><b>144</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right"><b>554</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right"><b>311</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">Options vest in accordance with terms as determined by the Board, typically over three or four
   years for employee grants and over one or three years for Board of Director option grants. The
   expiry date for each option is set by the Board with, which is typically seven to ten years.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">As at June&#160;30, 2011 and December&#160;31, 2010 the total unrecognized compensation expense related to
   stock options granted is $3,176,000 and $2,962,000 respectively, which is expected to be recognized
   into expense over a period of approximately four years.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">As of June&#160;30, 2011 and December&#160;31, 2010 a total of 2,364,660 and 2,332,214 options and warrants,
   respectively, have not been included in the calculation of potential common shares as their effect
   on diluted per share amounts would have been anti-dilutive.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>&#091;d&#093; Stock Warrants</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">At June&#160;30, 2011, there were exercisable warrants outstanding to purchase 1,587,301
   shares of common stock at an exercise price of $20 per share, expiring in October&#160;2015.
   No warrants were exercised during the six months ended June&#160;30, 2011 or six months ended
   June&#160;30, 2010.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">The estimated fair value of warrants issued is reassessed at each balance sheet date
   using the Black-Scholes option pricing model. The following assumptions were used to
   value the warrants on the following balance sheet dates:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="72%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Six months ended June 30,</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Risk-free interest rates
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">1.43</td>
       <td nowrap="nowrap">%</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Expected dividend yield
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">0</td>
       <td nowrap="nowrap">%</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Expected life
   </div></td>
       <td>&#160;</td>
   <td colspan="2" nowrap="nowrap" align="right">4.3 years</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Expected volatility
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">76</td>
       <td nowrap="nowrap">%</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   </div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 5<br> -Paragraph 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Article 4<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 4<br> -Section 08<br> -Paragraph d<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 43<br> -Chapter 1<br> -Section B<br> -Paragraph 7, 11A<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Restructuring Activities<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring Activities [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING ACTIVITIES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 6 - us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>6. RESTRUCTURING ACTIVITIES</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">On August&#160;21, 2008, Sonus Pharmaceuticals, Inc., or Sonus, completed a transaction, or &#8220;the
   Arrangement&#8221;, with OncoGenex Technologies whereby Sonus acquired all of the outstanding preferred
   shares, common shares and convertible debentures of OncoGenex Technologies. Sonus then changed its
   name to OncoGenex Pharmaceuticals, Inc. Prior to the Arrangement, Sonus entered into a
   non-cancellable lease arrangement for office space located in Bothell, Washington, which is
   considered to be in excess of the Company&#8217;s current requirements. The Company is currently in the
   process of evaluating opportunities to exit or sublet portions of the leased space and recorded an
   initial restructuring charge of $2,084,000 on August&#160;21, 2008 as part of the purchase price
   allocation. The liability is computed as the present value of the difference between the remaining
   lease payments due less the estimate of net sublease income and expenses and has been accounted for
   in accordance with the then effective EITF No.&#160;95-3, &#8220;Recognition of Liabilities in Connection with
   a Purchase Business Combination&#8221;. This represents the Company&#8217;s best estimate of the liability.
   Subsequent changes in the liability due to changes in estimates of sublease assumptions are
   recognized as adjustments to restructuring charges.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt">In June&#160;2009, the Company revised its sublease income assumptions used to estimate the excess lease
   facility liability. These assumptions were subsequently revised again in December&#160;2009 and
   September
   2010. These changes in estimate resulted in increases in the value of the excess lease liability of
   $494,000, $3,457,000, and $4,038,000 and a corresponding expense recorded in June&#160;2009, December
   2009, and September&#160;2010, respectively, to reflect these changes in estimate. The estimated value
   of the liability remaining with respect to excess facilities was $7,467,000 as of December&#160;31,
   2010. In the six months ended June&#160;30, 2011, with respect to excess facilities, $140,000 was
   amortized into income resulting in a remaining liability of $7,327,000 at June&#160;30, 2011.
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="44%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Remaining</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Amortization</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Additional</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Remaining</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Liability at</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>of excess</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Liability</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Liability</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"><b>(In thousands)</b></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>December 31, 2010</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>lease facility</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Recorded</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>at June 30, 2011</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Current portion of
   excess lease
   facility
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">1,303</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">$</td>
       <td align="right">(53</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">1,356</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Long-term portion
   of excess lease
   facility
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">6,164</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">193</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">5,971</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px"><b>Total</b>
   </div></td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right"><b>7,467</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right"><b>140</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left"><b>$</b></td>
       <td align="right"><b>&#8212;</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right"><b>7,327</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   </div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringAndRelatedActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 146<br> -Paragraph 20<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140864-122747<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ECJAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) (USD $)<br>In Thousands</strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
        <td class="nump">$ 9,575<span></span></td>
        <td class="nump">$ 2,890<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Add items not involving cash</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">37<span></span></td>
        <td class="nump">26<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation [note 5(c)]</a></td>
        <td class="nump">554<span></span></td>
        <td class="nump">311<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Change in value of warrants [note 5]]</a></td>
        <td class="num">(440)<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in non-cash items</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Amounts receivable</a></td>
        <td class="num">(274)<span></span></td>
        <td class="nump">2,696<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities', window );">Restricted cash</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(502)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
        <td class="nump">1,091<span></span></td>
        <td class="num">(1,619)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
        <td class="nump">750<span></span></td>
        <td class="num">(12,786)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogxi_IncreaseDecreaseInLeaseObligation', window );">Lease obligation</a></td>
        <td class="num">(19)<span></span></td>
        <td class="num">(599)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred collaboration revenue</a></td>
        <td class="num">(1,755)<span></span></td>
        <td class="num">(2,393)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
        <td class="num">(9,631)<span></span></td>
        <td class="num">(17,756)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under stock option and employee purchase plans</a></td>
        <td class="nump">91<span></span></td>
        <td class="nump">521<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
        <td class="nump">91<span></span></td>
        <td class="nump">521<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale of investments</a></td>
        <td class="nump">51,259<span></span></td>
        <td class="nump">500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of investments</a></td>
        <td class="num">(44,222)<span></span></td>
        <td class="num">(12,291)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(68)<span></span></td>
        <td class="num">(27)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash provided by (used in) investing activities</a></td>
        <td class="nump">6,969<span></span></td>
        <td class="num">(11,818)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
        <td class="num">(86)<span></span></td>
        <td class="nump">13<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Decrease in cash and cash equivalents during the period</a></td>
        <td class="nump">2,657<span></span></td>
        <td class="nump">29,040<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of the period</a></td>
        <td class="nump">23,533<span></span></td>
        <td class="nump">62,051<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of the period</a></td>
        <td class="nump">20,876<span></span></td>
        <td class="nump">33,011<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogxi_PropertyAndEquipmentAcquiredUnderLeaseObligation', window );">Property and equipment acquired under lease obligation</a></td>
        <td class="nump">$ 90<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogxi_IncreaseDecreaseInLeaseObligation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Lease obligation</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogxi_IncreaseDecreaseInLeaseObligation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogxi</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogxi_PropertyAndEquipmentAcquiredUnderLeaseObligation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Property and equipment acquired under lease obligation</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogxi_PropertyAndEquipmentAcquiredUnderLeaseObligation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogxi</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment for noncash service expenses paid for by granting of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentOfWarrantsGrantedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7<br> -Footnote 1<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 8, 9<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7, 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effect of exchange rate changes on cash balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 25<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as operating activities. This may include cash restricted for regulatory purposes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A7<br> -Appendix A<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 10, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 87-21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 19<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28, 29, 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 17<br> -Subparagraph c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15, 17<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 159<br> -Section Appendix C<br> -Paragraph 5<br> -Subparagraph c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 123R<br> -Paragraph A240<br> -Subparagraph i<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 19<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15, 16<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 159<br> -Section Appendix C<br> -Paragraph 5<br> -Subparagraph c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">ACCOUNTING POLICIES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 2 - us-gaap:SignificantAccountingPoliciesTextBlock-->
   <div align="left" style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>2. ACCOUNTING POLICIES</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>Recently Adopted Accounting Policies</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">In April&#160;2010, the Financial Accounting Standards Board, or FASB, issued ASU No.&#160;2010 &#8212; 17 &#8212;
   Revenue Recognition &#8212; Milestone Method (Topic 605): Milestone Method of Revenue Recognition. This
   standard provides guidance on defining a milestone and determining when it may be appropriate to
   apply the milestone method of revenue recognition for certain research and development
   transactions. Under this new standard, a company can recognize as revenue consideration that is
   contingent upon achievement of a milestone in the period in which it is achieved, only if the
   milestone meets all criteria to be considered substantive. This standard was effective for us on a
   prospective basis beginning in the quarter ended March&#160;31, 2011. The adoption of this standard did
   not have a significant impact on our financial position or results of operations.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">In January&#160;2010, the FASB issued amended guidance on fair value measurements and disclosures. The
   new guidance requires additional disclosures regarding fair value measurements, amends disclosures
   about post-retirement benefit plan assets, and provides clarification regarding the level of
   disaggregation of fair value disclosures by investment class. This guidance is effective for
   interim and annual reporting periods beginning after December&#160;15, 2009, except for certain Level 3
   activity disclosure requirements that will be effective for reporting periods beginning after
   December&#160;15, 2010. Accordingly, we adopted this amendment in the quarter ended March&#160;31, 2010,
   while the additional Level 3 requirements were adopted
   in the quarter ended March&#160;31, 2011. The adoption of this standard did not have a significant
   impact on our financial position or results of operations.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>Recent Accounting Pronouncements</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">In May&#160;2011, the FASB issued ASU No.&#160;2011-04, &#8220;Fair Value Measurement.&#8221; This ASU clarifies the
   concepts related to highest and best use and valuation premise, blockage factors and other premiums
   and discounts, the fair value measurement of financial instruments held in a portfolio and of those
   instruments classified as a component of shareowners&#8217; equity. The guidance includes enhanced
   disclosure requirements about recurring Level 3 fair value measurements, the use of nonfinancial
   assets, and the level in the fair value hierarchy of assets and liabilities not recorded at fair
   value. The provisions of this ASU are effective prospectively for interim and annual periods
   beginning on or after December&#160;15, 2011. Early application is prohibited. We are currently
   evaluating the impact of this new ASU.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt">In June&#160;2011, the FASB issued ASU No.&#160;2011-05, &#8220;Comprehensive Income.&#8221; This ASU intends to enhance
   comparability and transparency of other comprehensive income components. The guidance provides an
   option to present total comprehensive income, the components of net income and the components of
   other comprehensive income in a single continuous statement or two separate but consecutive
   statements. This ASU eliminates the option to present other comprehensive income components as part
   of the statement of changes in shareowners&#8217; equity. The provisions of this ASU will be applied
   retrospectively for interim and annual periods beginning after December&#160;15, 2011. Early application
   is permitted. We are currently evaluating the impact of this new ASU.
   </div>
   </div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 22<br> -Paragraph 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E6GAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (USD $)<br>In Thousands</strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents[note 4]</a></td>
        <td class="nump">$ 20,876<span></span></td>
        <td class="nump">$ 23,533<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
        <td class="nump">502<span></span></td>
        <td class="nump">502<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments [note 4]</a></td>
        <td class="nump">54,536<span></span></td>
        <td class="nump">61,574<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Amounts receivable</a></td>
        <td class="nump">1,498<span></span></td>
        <td class="nump">1,224<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">1,397<span></span></td>
        <td class="nump">2,485<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">78,809<span></span></td>
        <td class="nump">89,318<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">207<span></span></td>
        <td class="nump">87<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">509<span></span></td>
        <td class="nump">513<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">79,525<span></span></td>
        <td class="nump">89,918<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
        <td class="nump">1,643<span></span></td>
        <td class="nump">893<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred Collaboration Revenue</a></td>
        <td class="nump">10,000<span></span></td>
        <td class="nump">10,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations [note 6]</a></td>
        <td class="nump">1,384<span></span></td>
        <td class="nump">1,314<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability [note 4, note 5]</a></td>
        <td class="nump">14,828<span></span></td>
        <td class="nump">15,269<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">27,855<span></span></td>
        <td class="nump">27,476<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred Collaboration Revenue, net of current</a></td>
        <td class="nump">9,866<span></span></td>
        <td class="nump">11,622<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Long-term obligation, less current portion [note 6]</a></td>
        <td class="nump">6,606<span></span></td>
        <td class="nump">6,695<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">44,327<span></span></td>
        <td class="nump">45,793<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies [note 7]</a></td>
        <td class="text">&nbsp;<span></span></td>
        <td class="text">&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares [note 5] $0.001 par value 25000000 shares authorized and 9,718,251 issued and outstanding at June 30, 2011 and 9,693,591 issued and outstanding at December 31, 2010</a></td>
        <td class="nump">10<span></span></td>
        <td class="nump">10<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">108,224<span></span></td>
        <td class="nump">107,579<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(75,644)<span></span></td>
        <td class="num">(66,069)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
        <td class="nump">2,608<span></span></td>
        <td class="nump">2,605<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
        <td class="nump">35,198<span></span></td>
        <td class="nump">44,125<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
        <td class="nump">$ 79,525<span></span></td>
        <td class="nump">$ 89,918<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a(1)<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 4<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3-4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e653-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 14, 17, 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name FASB Staff Position (FSP)<br> -Number FAS115-1/124-1<br> -Paragraph 15D<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e637-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e681-108580<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 12<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Topic 210<br> -SubTopic 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br> -Section S99<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Concepts (CON)<br> -Number 6<br> -Paragraph 25<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 18<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Section 45<br> -SubTopic 10<br> -Topic 210<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 9<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid within one year (or one operating cycle, if longer) of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 13<br> -Paragraph 7, 10, 13<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 13<br> -Paragraph 7, 10, 13<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 22<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7<br> -Footnote 1<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 8, 9<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7, 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 17<br> -Article 9<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 19<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 25<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 5<br> -Paragraph 8, 9<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 43<br> -Chapter 3<br> -Section A<br> -Paragraph 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 43<br> -Chapter 3<br> -Section A<br> -Paragraph 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 48<br> -Paragraph 6<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 32<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 25<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 21<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 17<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6386993&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 43<br> -Section A<br> -Paragraph 4<br> -Chapter 3<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6787-107765<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 8<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 12<br> -Paragraph 5<br> -Subparagraph b, c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Audit and Accounting Guide (AAG)<br> -Number AAG-BRD<br> -Chapter 4<br> -Paragraph 80<br> -Subparagraph Exhibit 4-8, 3<br> -IssueDate 2006-05-01<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 1<br> -Subparagraph g<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A3<br> -Appendix A<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of warrants and rights outstanding. "Equity warrants and rights outstanding" represents derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 4<br> -Section 08<br> -Paragraph i<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 00-27<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 98-5<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.3.0.11</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ReportType />
  <ContextCount>9</ContextCount>
  <ElementCount>85</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>true</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncogenex.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>01 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncogenex.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>011 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncogenex.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>02 - Statement - Consolidated Statements of Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncogenex.com/role/StatementsOfIncome</Role>
      <ShortName>Consolidated Statements of Loss (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>03 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncogenex.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>06001 - Disclosure - Nature of Business And Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncogenex.com/role/NatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of Business And Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>06002 - Disclosure - Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncogenex.com/role/AccountingPolicies</Role>
      <ShortName>Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>06003 - Disclosure - Collaboration Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncogenex.com/role/CollaborationAgreement</Role>
      <ShortName>Collaboration Agreement</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>06004 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncogenex.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>06005 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncogenex.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>06006 - Disclosure - Restructuring Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncogenex.com/role/RestructuringActivities</Role>
      <ShortName>Restructuring Activities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>06007 - Disclosure - Commitments And Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncogenex.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments And Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>06008 - Disclosure - Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncogenex.com/role/ComprehensiveLoss</Role>
      <ShortName>Comprehensive Loss</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>06009 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncogenex.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 01 - Statement - Consolidated Balance Sheets (Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jun. 30, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">Process Flow-Through: 011 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 02 - Statement - Consolidated Statements of Loss (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 03 - Statement - Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>ogxi-20110630.xml</File>
    <File>ogxi-20110630.xsd</File>
    <File>ogxi-20110630_cal.xml</File>
    <File>ogxi-20110630_lab.xml</File>
    <File>ogxi-20110630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>29
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S7U5N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U5N,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED
M871E9%]3=&%T96UE;G1S7V]F7TQO<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYA='5R
M95]O9E]"=7-I;F5S<U]!;F1?0F%S:7-?;SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D%C8V]U;G1I;F=?4&]L:6-I97,\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,#<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VQL86)O<F%T:6]N
M7T%G<F5E;65N=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D9A:7)?5F%L=65?365A<W5R96UE;G1S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`Y+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0V]M;6]N7U-T;V-K/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#$P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4F5S=')U8W1U<FEN9U]!8W1I
M=FET:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#$Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M0V]M;6ET;65N='-?06YD7T-O;G1I;F=E;F-I97,\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3(N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUP<F5H96YS:79E7TQO<W,\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,3,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6)S97%U96YT
M7T5V96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE
M<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z
M06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T
M<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T
M96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC
M96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\
M8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@
M36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V)B.#8R9#8U7V)F-#!?-&0U
M9E]B8S%D7SAB,3DS83-E9#4Y-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]B8C@V,F0V-5]B9C0P7S1D-69?8F,Q9%\X8C$Y,V$S960U.30O5V]R
M:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%05=!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N
M("A54T0@)FYB<W`[)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N
M+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!
M=6<N(#`Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO
M;B!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/D].0T]'14Y%6"!02$%234%#155424-!3%,L
M($E.0RX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X($ME>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^,#`P,#DT.3@U.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@5'EP93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3`M43QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@
M4&5R:6]D($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y*=6X@,S`L#0H)"3(P,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#YF86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%EE
M87(@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(P,3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1O8W5M96YT($9I<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/E$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I<V-A;"!996%R($5N9"!$
M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XM+3$R+3,Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;G1I='D@5V5L;"UK;F]W;B!396%S;VYE9"!)<W-U97(\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/DYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@5F]L=6YT87)Y($9I;&5R
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^3F\\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#
M=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/EEE<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A=&5G;W)Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!8V-E;&5R871E9"!&:6QE<CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT
M:71Y(%!U8FQI8R!&;&]A=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)FYB<W`[)"`X-BPP-C(L.#(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V]M;6]N(%-T;V-K+"!3
M:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDL-S(U+#0X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?8F(X-C)D-C5?8F8T,%\T9#5F7V)C,61?.&(Q.3-A,V5D-3DT
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)B.#8R9#8U7V)F-#!?
M-&0U9E]B8S%D7SAB,3DS83-E9#4Y-"]7;W)K<VAE971S+U-H965T,#(N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$4V1T%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O
M;&ED871E9"!"86QA;F-E(%-H965T<R`H56YA=61I=&5D*2`H55-$("9N8G-P
M.R0I/&)R/DEN(%1H;W5S86YD<SPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A
M<V@@97%U:79A;&5N='-;;F]T92`T73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)FYB<W`[)"`R,"PX-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#(S+#4S,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I
M8W1E9"!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-H;W)T+71E<FT@:6YV97-T;65N=',@6VYO=&4@-%T\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4T+#4S-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Q+#4W-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO=6YT<R!R
M96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0Y
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,C(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#,Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L-#@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!A<W-E=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<X+#@P.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Y+#,Q.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O<&5R='D@86YD(&5Q=6EP;65N="P@;F5T/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,3,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<Y+#4R-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Y+#DQ.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#=7)R96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@;&EA8FEL
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C0S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#DS
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$969E<G)E9"!#;VQL86)O<F%T:6]N(%)E=F5N=64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!P;W)T
M:6]N(&]F(&QO;F<M=&5R;2!O8FQI9V%T:6]N<R!;;F]T92`V73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS.#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,Q-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!L
M:6%B:6QI='D@6VYO=&4@-"P@;F]T92`U73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,30L.#(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,34L,C8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!L:6%B
M:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L.#4U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C<L-#<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$969E<G)E9"!#;VQL86)O<F%T:6]N(%)E=F5N=64L(&YE="!O
M9B!C=7)R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#@V
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$Q+#8R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&]N9RUT97)M(&]B;&EG871I;VXL(&QE<W,@8W5R<F5N="!P
M;W)T:6]N(%MN;W1E(#9=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV+#8P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8L-CDU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0T+#,R-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U+#<Y,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@
M86YD(&-O;G1I;F=E;F-I97,@6VYO=&4@-UT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R96AO;&1E
M<G,G(&5Q=6ET>3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-H87)E<R!;;F]T92`U72`F;F)S<#LD,"XP,#$@
M<&%R('9A;'5E(#(U,#`P,#`P('-H87)E<R!A=71H;W)I>F5D(&%N9"`Y+#<Q
M."PR-3$@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!A="!*=6YE(#,P+"`R,#$Q
M(&%N9"`Y+#8Y,RPU.3$@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!A="!$96-E
M;6)E<B`S,2P@,C`Q,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^061D:71I;VYA;"!P86ED+6EN(&-A<&ET86P\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P."PR,C0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#<L-3<Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E
M9"!D969I8VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W-2PV
M-#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-C8L,#8Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-C=6UU;&%T960@;W1H97(@8V]M<')E:&5N<VEV92!I
M;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C`X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPV
M,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!S:&%R96AO;&1E<G,G(&5Q=6ET>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S4L,3DX/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L,3(U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL
M:71I97,@86YD('-H87)E:&]L9&5R<R<@97%U:71Y/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#<Y+#4R-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@.#DL.3$X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P139+
M04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N<V]L:61A=&5D($)A;&%N
M8V4@4VAE971S("A5;F%U9&ET960I("A087)E;G1H971I8V%L*2`H55-$("9N
M8G-P.R0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R96AO;&1E<G,G(&5Q=6ET>3H\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B9N8G-P.R0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#`N,#`Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL
M('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R
M97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#<Q
M."PR-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY+#8Y,RPU.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&]U='-T86YD
M:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#<Q."PR-3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M+#8Y,RPU.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V)B.#8R9#8U7V)F-#!?-&0U9E]B8S%D7SAB,3DS83-E9#4Y-`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B8C@V,F0V-5]B9C0P7S1D-69?
M8F,Q9%\X8C$Y,V$S960U.30O5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%55)!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYS;VQI9&%T
M960@4W1A=&5M96YT<R!O9B!,;W-S("A5;F%U9&ET960I("A54T0@)FYB<W`[
M)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T83PO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R
M,#$P/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L
M(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S
M,"P@,C`Q,#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!,;W-S(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0T],3$%"3U)!5$E/3B!2159%3E5%/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XF;F)S<#LD(#$L.#@W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`Q+#<P,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@
M,RPP.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XF;F)S<#LD(#8L-#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D584$5.4T53/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N
M9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PT,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#`W.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P+#(V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDL-#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A
M=&EV93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT-S$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0W
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,L,#0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPX,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-BPX.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT+#4U-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#,P-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#(X-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQ/4U,@
M1E)/32!/4$52051)3TY3/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#DY,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L.#4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3`L,C$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-2PX.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3U1(15(@24Y#3TU%
M("A%6%!%3E-%*3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G1E<F5S="!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#(V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V%I;B`H;&]S<RD@;VX@=V%R<F%N
M=',@6VYO=&4@-5T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L
M-C@W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L(&]T:&5R(&EN8V]M92`H97AP96YS92D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-3,W*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-#,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@
M9F]R('1H92!P97)I;V0@8F5F;W)E(&EN8V]M92!T87AE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BPU,S`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@T-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL-3<U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PX.3`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN
M8V]M92!T87@@97AP96YS92`H<F5C;W9E<GDI(%MN;W1E(#-=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#`P,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#`P,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S
M<R`H:6YC;VUE*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB
M<W`[)"`V+#4S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)FYB<W`[)"`H,34T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@.2PU-S4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#(L
M.#DP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y"87-I8R!A;F0@9&EL=71E9"!L;W-S("AI;F-O;64I('!E<B!C;VUM
M;VX@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P
M.R0@,"XV-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)FYB<W`[)"`H,"XP,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#`N.3D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#`N-#4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^5V5I9VAT960@879E<F%G92!N=6UB97(@;V8@8V]M;6]N('-H
M87)E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0F%S:6,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL-S$X
M+#(U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8L-#`P+#`X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDL-S$U+#@T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,S8V+#@V,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&EL=71E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PW,3@L,C4Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPU,CDL-#@R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.2PW,34L.#0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-BPS-C8L.#8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14-*04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@0V%S:"!&;&]W<R`H56YA=61I
M=&5D*2`H55-$("9N8G-P.R0I/&)R/DEN(%1H;W5S86YD<SPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C8@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/4$52051)3D<@
M04-4259)5$E%4SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,;W-S(&9O<B!T:&4@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XF;F)S<#LD(#DL-3<U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`R+#@Y,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY!9&0@:71E;7,@;F]T(&EN=F]L=FEN9R!C87-H/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A
M;F0@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX@6VYO=&4@-2AC*5T\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E
M(&EN('9A;'5E(&]F('=A<G)A;G1S(%MN;W1E(#5=73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-#0P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#:&%N9V5S(&EN(&YO
M;BUC87-H(&ET96US/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%M;W5N=',@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,C<T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L-CDV/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(&-A<V@\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,#(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X
M<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`Y,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L
M-C$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!L:6%B:6QI=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(L-S@V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&5A<V4@;V)L:6=A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-3DY*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5F97)R960@8V]L;&%B;W)A=&EO;B!R979E;G5E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#<U-2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#,Y,RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#DL-C,Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$W+#<U-BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1DE.
M04Y#24Y'($%#5$E6251)15,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM
M;VX@<W1O8VL@=6YD97(@<W1O8VL@;W!T:6]N(&%N9"!E;7!L;WEE92!P=7)C
M:&%S92!P;&%N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY)
M3E9%4U1)3D<@04-4259)5$E%4SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('-A;&4@;V8@:6YV97-T
M;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q+#(U.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4'5R8VAA<V4@;V8@:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#0T+#(R,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q,BPR.3$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!P<F]P
M97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#87-H('!R;W9I9&5D(&)Y("AU<V5D(&EN*2!I;G9E
M<W1I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-BPY-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q,2PX,3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%9F9E8W0@;V8@97AC:&%N9V4@<F%T92!C:&%N
M9V5S(&]N(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#@V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5C<F5A<V4@:6X@8V%S:"!A
M;F0@8V%S:"!E<75I=F%L96YT<R!D=7)I;F<@=&AE('!E<FEO9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPV-3<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PP-#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD
M(&-A<V@@97%U:79A;&5N=',L(&)E9VEN;FEN9R!O9B!T:&4@<&5R:6]D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPU,S,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,BPP-3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A
M<V@@86YD(&-A<V@@97%U:79A;&5N=',L(&5N9"!O9B!T:&4@<&5R:6]D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PX-S8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,RPP,3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4W5P<&QE;65N=&%L(&-A<V@@9FQO=R!I;F9O<FUA=&EO;CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T
M>2!A;F0@97%U:7!M96YT(&%C<75I<F5D('5N9&5R(&QE87-E(&]B;&EG871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@.3`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V)B.#8R
M9#8U7V)F-#!?-&0U9E]B8S%D7SAB,3DS83-E9#4Y-`T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]B8C@V,F0V-5]B9C0P7S1D-69?8F,Q9%\X8C$Y
M,V$S960U.30O5V]R:W-H965T<R]3:&5E=#`V+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D@^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F%T=7)E(&]F($)U<VEN97-S($%N
M9"!"87-I<R!O9B!0<F5S96YT871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.871U<F4@;V8@0G5S:6YE<W,@
M06YD($)A<VES(&]F(%!R97-E;G1A=&EO;B!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DY!5%5212!/1B!"
M55-)3D534R!!3D0@0D%325,@3T8@4%)%4T5.5$%424]./"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B
M+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P
M.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N
M86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@
M,2`M('5S+6=A87`Z3W)G86YI>F%T:6]N0V]N<V]L:61A=&EO;D%N9%!R97-E
M;G1A=&EO;D]F1FEN86YC:6%L4W1A=&5M96YT<T1I<V-L;W-U<F5497AT0FQO
M8VLM+3X-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@;6%R9VEN+6QE
M9G0Z(#!I;CL@)SX-"B`@(#PA+2T@>&)R;"QN<R`M+3X-"B`@(#PA+2T@>&)R
M;"QN>"`M+3X-"B`@(#QD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`P<'0G/CQB/CPO8CX-"B`@(#PO
M9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0^#0H@("`\+V1I=CX-"B`@(#QD
M:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SX\
M8CX\+V(^/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P="<^/&(^/"]B/CPO9&EV/@T*("`@/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P
M.B`Q,'!T)SX\8CXQ+B!.05154D4@3T8@0E5324Y%4U,@04Y$($)!4TE3($]&
M(%!215-%3E1!5$E/3CPO8CX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q
M,'!T)SY/;F-O1V5N97@@4&AA<FUA8V5U=&EC86QS+"!);F,N("AT:&4@)B,X
M,C(P.T-O;7!A;GDF(S@R,C$[(&]R("8C.#(R,#M/;F-O1V5N97@F(S@R,C$[
M*2!I<R!C;VUM:71T960@=&\@=&AE(&1E=F5L;W!M96YT(&%N9`T*("`@8V]M
M;65R8VEA;&EZ871I;VX@;V8@;F5W('1H97)A<&EE<R!T:&%T(&%D9')E<W,@
M=')E871M96YT(')E<VES=&%N8V4@:6X@8V%N8V5R('!A=&EE;G1S+B!4:&4-
M"B`@($-O;7!A;GD@=V%S(&EN8V]R<&]R871E9"!I;B!T:&4@<W1A=&4@;V8@
M1&5L87=A<F4@86YD+"!T;V=E=&AE<B!W:71H(&ET<R!S=6)S:61I87)I97,L
M(&AA<R!A#0H@("!F86-I;&ET>2!I;B!";W1H96QL+"!787-H:6YG=&]N(&%N
M9"!A;B!O9F9I8V4@:6X@5F%N8V]U=F5R+"!"<FET:7-H($-O;'5M8FEA("A#
M86YA9&$I+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/E1H92!U
M;F%U9&ET960@9FEN86YC:6%L('-T871E;65N=',@:&%V92!B965N('!R97!A
M<F5D(&EN(&%C8V]R9&%N8V4@=VET:"!G96YE<F%L;'D@86-C97!T960-"B`@
M(&%C8V]U;G1I;F<@<')I;F-I<&QE<R!I;B!T:&4@56YI=&5D(%-T871E<R!F
M;W(@:6YT97)I;2!F:6YA;F-I86P@:6YF;W)M871I;VX@86YD('=I=&@@=&AE
M#0H@("!I;G-T<G5C=&EO;G,@=&\@1F]R;2`Q,"U1+B!!8V-O<F1I;F=L>2P@
M=&AE>2!D;R!N;W0@:6YC;'5D92!A;&P@;V8@=&AE(&EN9F]R;6%T:6]N(&%N
M9"!F;V]T;F]T97,-"B`@(')E<75I<F5D('1O(&)E('!R97-E;G1E9"!F;W(@
M8V]M<&QE=&4@9FEN86YC:6%L('-T871E;65N=',N(%1H92!A8V-O;7!A;GEI
M;F<@=6YA=61I=&5D(&-O;G-O;&ED871E9`T*("`@9FEN86YC:6%L('-T871E
M;65N=',@<F5F;&5C="!A;&P@861J=7-T;65N=',@*&-O;G-I<W1I;F<@;VYL
M>2!O9B!N;W)M86P@<F5C=7)R:6YG(&ET96US*2!W:&EC:"!A<F4L#0H@("!I
M;B!T:&4@;W!I;FEO;B!O9B!M86YA9V5M96YT+"!N96-E<W-A<GD@9F]R(&$@
M9F%I<B!P<F5S96YT871I;VX@;V8@=&AE(')E<W5L=',@9F]R('1H92!I;G1E
M<FEM#0H@("!P97)I;V1S('!R97-E;G1E9"X@5&AE(&%C8V]M<&%N>6EN9R!C
M;VYS;VQI9&%T960@0F%L86YC92!3:&5E="!A="!$96-E;6)E<B8C,38P.S,Q
M+"`R,#$P(&AA<R!B965N#0H@("!D97)I=F5D(&9R;VT@=&AE(&%U9&ET960@
M8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN8VQU9&5D(&EN
M('1H92!#;VUP86YY)B,X,C$W.W,@06YN=6%L(%)E<&]R=`T*("`@;VX@1F]R
M;2`Q,"U+(&9O<B!T:&4@>65A<B!T:&5N(&5N9&5D+B!4:&4@8V]N<V]L:61A
M=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%N9"!R96QA=&5D(&1I<V-L;W-U
M<F5S#0H@("!H879E(&)E96X@<')E<&%R960@=VET:"!T:&4@87-S=6UP=&EO
M;B!T:&%T('5S97)S(&]F('1H92!I;G1E<FEM(&9I;F%N8VEA;"!I;F9O<FUA
M=&EO;B!H879E(')E860@;W(-"B`@(&AA=F4@86-C97-S('1O('1H92!A=61I
M=&5D(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!F;W(@=&AE
M('!R96-E9&EN9R!F:7-C86P@>65A<BX-"B`@($%C8V]R9&EN9VQY+"!T:&5S
M92!F:6YA;F-I86P@<W1A=&5M96YT<R!S:&]U;&0@8F4@<F5A9"!I;B!C;VYJ
M=6YC=&EO;B!W:71H('1H92!A=61I=&5D(&-O;G-O;&ED871E9`T*("`@9FEN
M86YC:6%L('-T871E;65N=',@86YD('1H92!R96QA=&5D(&YO=&5S('1H97)E
M=&\@:6YC;'5D960@:6X@=&AE($%N;G5A;"!297!O<G0@;VX@1F]R;2`Q,"U+
M(&9O<@T*("`@=&AE('EE87(@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q
M,"!A;F0@9FEL960@=VET:"!T:&4@56YI=&5D(%-T871E<R!396-U<FET:65S
M(&%N9"!%>&-H86YG90T*("`@0V]M;6ES<VEO;B`H)B,X,C(P.U-%0R8C.#(R
M,3LI(&]N($UA<F-H)B,Q-C`[,3`L(#(P,3$N#0H@("`\+V1I=CX-"B`@(#QD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R
M9VEN+71O<#H@,3!P="<^5&AE(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A
M=&5M96YT<R!I;F-L=61E('1H92!A8V-O=6YT<R!O9B!/;F-O1V5N97@@86YD
M(&]U<B!W:&]L;'D@;W=N960-"B`@('-U8G-I9&EA<GDL($]N8V]'96YE>"!4
M96-H;F]L;V=I97,@26YC+B`H)B,X,C(P.T]N8V]'96YE>"!496-H;F]L;V=I
M97,F(S@R,C$[*2X@06QL(&EN=&5R8V]M<&%N>0T*("`@8F%L86YC97,@86YD
M('1R86YS86-T:6]N<R!H879E(&)E96X@96QI;6EN871E9"X-"B`@(#PO9&EV
M/@T*("`@/"]D:78^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V)B.#8R9#8U7V)F-#!?-&0U9E]B8S%D7SAB,3DS83-E9#4Y
M-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B8C@V,F0V-5]B9C0P
M7S1D-69?8F,Q9%\X8C$Y,V$S960U.30O5V]R:W-H965T<R]3:&5E=#`W+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%,D@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^06-C;W5N
M=&EN9R!0;VQI8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M0T-/54Y424Y'(%!/3$E#2453/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A4
M34P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]4
M4B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@
M(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@,B`M('5S+6=A87`Z4VEG
M;FEF:6-A;G1!8V-O=6YT:6YG4&]L:6-I97-497AT0FQO8VLM+3X-"B`@(#QD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@;6%R9VEN+6QE9G0Z(#!I;CL@)SX-
M"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^,BX@04-#3U5.5$E.1R!03TQ)0TE%
M4SPO8CX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\8CY296-E
M;G1L>2!!9&]P=&5D($%C8V]U;G1I;F<@4&]L:6-I97,\+V(^#0H@("`\+V1I
M=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^26X@07!R:6PF(S$V,#LR,#$P+"!T
M:&4@1FEN86YC:6%L($%C8V]U;G1I;F<@4W1A;F1A<F1S($)O87)D+"!O<B!&
M05-"+"!I<W-U960@05-5($YO+B8C,38P.S(P,3`@)B,X,C$R.R`Q-R`F(S@R
M,3([#0H@("!2979E;G5E(%)E8V]G;FET:6]N("8C.#(Q,CL@36EL97-T;VYE
M($UE=&AO9"`H5&]P:6,@-C`U*3H@36EL97-T;VYE($UE=&AO9"!O9B!2979E
M;G5E(%)E8V]G;FET:6]N+B!4:&ES#0H@("!S=&%N9&%R9"!P<F]V:61E<R!G
M=6ED86YC92!O;B!D969I;FEN9R!A(&UI;&5S=&]N92!A;F0@9&5T97)M:6YI
M;F<@=VAE;B!I="!M87D@8F4@87!P<F]P<FEA=&4@=&\-"B`@(&%P<&QY('1H
M92!M:6QE<W1O;F4@;65T:&]D(&]F(')E=F5N=64@<F5C;V=N:71I;VX@9F]R
M(&-E<G1A:6X@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT#0H@("!T<F%N<V%C
M=&EO;G,N(%5N9&5R('1H:7,@;F5W('-T86YD87)D+"!A(&-O;7!A;GD@8V%N
M(')E8V]G;FEZ92!A<R!R979E;G5E(&-O;G-I9&5R871I;VX@=&AA="!I<PT*
M("`@8V]N=&EN9V5N="!U<&]N(&%C:&EE=F5M96YT(&]F(&$@;6EL97-T;VYE
M(&EN('1H92!P97)I;V0@:6X@=VAI8V@@:70@:7,@86-H:65V960L(&]N;'D@
M:68@=&AE#0H@("!M:6QE<W1O;F4@;65E=',@86QL(&-R:71E<FEA('1O(&)E
M(&-O;G-I9&5R960@<W5B<W1A;G1I=F4N(%1H:7,@<W1A;F1A<F0@=V%S(&5F
M9F5C=&EV92!F;W(@=7,@;VX@80T*("`@<')O<W!E8W1I=F4@8F%S:7,@8F5G
M:6YN:6YG(&EN('1H92!Q=6%R=&5R(&5N9&5D($UA<F-H)B,Q-C`[,S$L(#(P
M,3$N(%1H92!A9&]P=&EO;B!O9B!T:&ES('-T86YD87)D(&1I9`T*("`@;F]T
M(&AA=F4@82!S:6=N:69I8V%N="!I;7!A8W0@;VX@;W5R(&9I;F%N8VEA;"!P
M;W-I=&EO;B!O<B!R97-U;'1S(&]F(&]P97)A=&EO;G,N#0H@("`\+V1I=CX-
M"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+71O<#H@,3!P="<^26X@2F%N=6%R>28C,38P.S(P,3`L('1H
M92!&05-"(&ES<W5E9"!A;65N9&5D(&=U:61A;F-E(&]N(&9A:7(@=F%L=64@
M;65A<W5R96UE;G1S(&%N9"!D:7-C;&]S=7)E<RX@5&AE#0H@("!N97<@9W5I
M9&%N8V4@<F5Q=6ER97,@861D:71I;VYA;"!D:7-C;&]S=7)E<R!R96=A<F1I
M;F<@9F%I<B!V86QU92!M96%S=7)E;65N=',L(&%M96YD<R!D:7-C;&]S=7)E
M<PT*("`@86)O=70@<&]S="UR971I<F5M96YT(&)E;F5F:70@<&QA;B!A<W-E
M=',L(&%N9"!P<F]V:61E<R!C;&%R:69I8V%T:6]N(')E9V%R9&EN9R!T:&4@
M;&5V96P@;V8-"B`@(&1I<V%G9W)E9V%T:6]N(&]F(&9A:7(@=F%L=64@9&ES
M8VQO<W5R97,@8GD@:6YV97-T;65N="!C;&%S<RX@5&AI<R!G=6ED86YC92!I
M<R!E9F9E8W1I=F4@9F]R#0H@("!I;G1E<FEM(&%N9"!A;FYU86P@<F5P;W)T
M:6YG('!E<FEO9',@8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R)B,Q-C`[,34L
M(#(P,#DL(&5X8V5P="!F;W(@8V5R=&%I;B!,979E;"`S#0H@("!A8W1I=FET
M>2!D:7-C;&]S=7)E(')E<75I<F5M96YT<R!T:&%T('=I;&P@8F4@969F96-T
M:79E(&9O<B!R97!O<G1I;F<@<&5R:6]D<R!B96=I;FYI;F<@869T97(-"B`@
M($1E8V5M8F5R)B,Q-C`[,34L(#(P,3`N($%C8V]R9&EN9VQY+"!W92!A9&]P
M=&5D('1H:7,@86UE;F1M96YT(&EN('1H92!Q=6%R=&5R(&5N9&5D($UA<F-H
M)B,Q-C`[,S$L(#(P,3`L#0H@("!W:&EL92!T:&4@861D:71I;VYA;"!,979E
M;"`S(')E<75I<F5M96YT<R!W97)E(&%D;W!T960-"B`@(&EN('1H92!Q=6%R
M=&5R(&5N9&5D($UA<F-H)B,Q-C`[,S$L(#(P,3$N(%1H92!A9&]P=&EO;B!O
M9B!T:&ES('-T86YD87)D(&1I9"!N;W0@:&%V92!A('-I9VYI9FEC86YT#0H@
M("!I;7!A8W0@;VX@;W5R(&9I;F%N8VEA;"!P;W-I=&EO;B!O<B!R97-U;'1S
M(&]F(&]P97)A=&EO;G,N#0H@("`\+V1I=CX-"B`@(#PA+2T@1F]L:6\@+2T^
M#0H@("`\(2TM("]&;VQI;R`M+3X-"B`@(#PO9&EV/@T*("`@/"$M+2!004=%
M0E)%04L@+2T^#0H@("`\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@;6%R9VEN+6QE9G0Z(#!I;CL@
M)SX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^4F5C96YT($%C8V]U;G1I;F<@
M4')O;F]U;F-E;65N=',\+V(^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@
M,3!P="<^26X@36%Y)B,Q-C`[,C`Q,2P@=&AE($9!4T(@:7-S=65D($%352!.
M;RXF(S$V,#LR,#$Q+3`T+"`F(S@R,C`[1F%I<B!686QU92!-96%S=7)E;65N
M="XF(S@R,C$[(%1H:7,@05-5(&-L87)I9FEE<R!T:&4-"B`@(&-O;F-E<'1S
M(')E;&%T960@=&\@:&EG:&5S="!A;F0@8F5S="!U<V4@86YD('9A;'5A=&EO
M;B!P<F5M:7-E+"!B;&]C:V%G92!F86-T;W)S(&%N9"!O=&AE<B!P<F5M:75M
M<PT*("`@86YD(&1I<V-O=6YT<RP@=&AE(&9A:7(@=F%L=64@;65A<W5R96UE
M;G0@;V8@9FEN86YC:6%L(&EN<W1R=6UE;G1S(&AE;&0@:6X@82!P;W)T9F]L
M:6\@86YD(&]F('1H;W-E#0H@("!I;G-T<G5M96YT<R!C;&%S<VEF:65D(&%S
M(&$@8V]M<&]N96YT(&]F('-H87)E;W=N97)S)B,X,C$W.R!E<75I='DN(%1H
M92!G=6ED86YC92!I;F-L=61E<R!E;FAA;F-E9`T*("`@9&ES8VQO<W5R92!R
M97%U:7)E;65N=',@86)O=70@<F5C=7)R:6YG($QE=F5L(#,@9F%I<B!V86QU
M92!M96%S=7)E;65N=',L('1H92!U<V4@;V8@;F]N9FEN86YC:6%L#0H@("!A
M<W-E=',L(&%N9"!T:&4@;&5V96P@:6X@=&AE(&9A:7(@=F%L=64@:&EE<F%R
M8VAY(&]F(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@;F]T(')E8V]R9&5D(&%T
M(&9A:7(-"B`@('9A;'5E+B!4:&4@<')O=FES:6]N<R!O9B!T:&ES($%352!A
M<F4@969F96-T:79E('!R;W-P96-T:79E;'D@9F]R(&EN=&5R:6T@86YD(&%N
M;G5A;"!P97)I;V1S#0H@("!B96=I;FYI;F<@;VX@;W(@869T97(@1&5C96UB
M97(F(S$V,#LQ-2P@,C`Q,2X@16%R;'D@87!P;&EC871I;VX@:7,@<')O:&EB
M:71E9"X@5V4@87)E(&-U<G)E;G1L>0T*("`@979A;'5A=&EN9R!T:&4@:6UP
M86-T(&]F('1H:7,@;F5W($%352X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P
M.B`Q,'!T)SY);B!*=6YE)B,Q-C`[,C`Q,2P@=&AE($9!4T(@:7-S=65D($%3
M52!.;RXF(S$V,#LR,#$Q+3`U+"`F(S@R,C`[0V]M<')E:&5N<VEV92!);F-O
M;64N)B,X,C(Q.R!4:&ES($%352!I;G1E;F1S('1O(&5N:&%N8V4-"B`@(&-O
M;7!A<F%B:6QI='D@86YD('1R86YS<&%R96YC>2!O9B!O=&AE<B!C;VUP<F5H
M96YS:79E(&EN8V]M92!C;VUP;VYE;G1S+B!4:&4@9W5I9&%N8V4@<')O=FED
M97,@86X-"B`@(&]P=&EO;B!T;R!P<F5S96YT('1O=&%L(&-O;7!R96AE;G-I
M=F4@:6YC;VUE+"!T:&4@8V]M<&]N96YT<R!O9B!N970@:6YC;VUE(&%N9"!T
M:&4@8V]M<&]N96YT<R!O9@T*("`@;W1H97(@8V]M<')E:&5N<VEV92!I;F-O
M;64@:6X@82!S:6YG;&4@8V]N=&EN=6]U<R!S=&%T96UE;G0@;W(@='=O('-E
M<&%R871E(&)U="!C;VYS96-U=&EV90T*("`@<W1A=&5M96YT<RX@5&AI<R!!
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M+"`R,#$Q+B!%87)L>2!A<'!L:6-A=&EO;@T*("`@:7,@<&5R;6ET=&5D+B!7
M92!A<F4@8W5R<F5N=&QY(&5V86QU871I;F<@=&AE(&EM<&%C="!O9B!T:&ES
M(&YE=R!!4U4N#0H@("`\+V1I=CX-"B`@(#PO9&EV/@T*/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)(/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D-O;&QA8F]R871I;VX@06=R965M96YT/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]L;&%B
M;W)A=&EO;B!!9W)E96UE;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#3TQ,04)/4D%424].($%'4D5%
M345.5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U19
M4$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET
M:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X
M:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L
M;V-K(%1A9V=E9"!.;W1E(#,@+2!O9WAI.D-O;&QA8F]R871I;VY!9W)E96UE
M;G1497AT0FQO8VLM+3X-"B`@(#QD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF.R!M87)G:6XM;&5F=#H@
M,&EN.R`G/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\8CXS+B!#3TQ,04)/4D%4
M24].($%'4D5%345.5#PO8CX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q
M,'!T)SY/;B!$96-E;6)E<B8C,38P.S(P+"`R,#`Y+"!T:&4@0V]M<&%N>2P@
M=&AR;W5G:"!I=',@=VAO;&QY+6]W;F5D('-U8G-I9&EA<GDL($]N8V]'96YE
M>"!496-H;F]L;V=I97,L#0H@("!E;G1E<F5D(&EN=&\@82!#;VQL86)O<F%T
M:6]N($%G<F5E;65N="!W:71H(%1E=F$@4&AA<FUA8V5U=&EC86P@26YD=7-T
M<FEE<R!,=&0N+"!O<B!4979A+"!F;W(@=&AE#0H@("!D979E;&]P;65N="!A
M;F0@9VQO8F%L(&-O;6UE<F-I86QI>F%T:6]N(&]F(&-U<W1I<G-E;B`H86YD
M(')E;&%T960@8V]M<&]U;F1S*2P@82!P:&%R;6%C975T:6-A;`T*("`@8V]M
M<&]U;F0@9&5S:6=N960@=&\@:6YH:6)I="!T:&4@<')O9'5C=&EO;B!O9B!C
M;'5S=&5R:6XL(&$@<')O=&5I;B!W92!B96QI979E(&ES(&%S<V]C:6%T960@
M=VET:`T*("`@8V%N8V5R('1R96%T;65N="!R97-I<W1A;F-E+"!O<B!T:&4@
M3&EC96YS960@4')O9'5C="X@56YD97(@=&AE($-O;&QA8F]R871I;VX@06=R
M965M96YT+"!4979A('!A:60-"B`@('1H92!#;VUP86YY('5P9G)O;G0@<&%Y
M;65N=',@:6X@=&AE(&%G9W)E9V%T92!A;6]U;G0@;V8@)FYB<W`[)#4P)B,Q
M-C`[;6EL;&EO;B!A;F0@:&%S(&%G<F5E9"!T;R!P87D@=7`@=&\-"B`@("9N
M8G-P.R0S-S`F(S$V,#MM:6QL:6]N('5P;VX@=&AE(&%C:&EE=F5M96YT(&]F
M(&1E=F5L;W!M96YT86P@86YD(&-O;6UE<F-I86P@;6EL97-T;VYE<R!A;F0@
M<F]Y86QT:65S(&%T#0H@("!P97)C96YT86=E(')A=&5S(')A;F=I;F<@9G)O
M;2!T:&4@;6ED+71E96YS('1O(&UI9"UT=V5N=&EE<R!O;B!N970@<V%L97,L
M(&1E<&5N9&EN9R!O;B!A9V=R96=A=&4-"B`@(&%N;G5A;"!N970@<V%L97,@
M;V8@=&AE($QI8V5N<V5D(%!R;V1U8W0N#0H@("`\+V1I=CX-"B`@(#QD:78@
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M;VUP86YY(&%T(&$@,C`E('!R96UI=6T@=&\@82!T:&ER='DM9&%Y(&%V97)A
M9V4@8VQO<VEN9R!P<FEC92P@<F5S=6QT:6YG(&EN('1H92!I<W-U86YC92!O
M9@T*("`@,C8W+#4S,2!O9B!O=7(@8V]M;6]N('-H87)E<R!P=7)C:&%S960@
M870@82!P<FEC92!O9B`F;F)S<#LD,S<N,S@@<&5R('-H87)E+B!4:&4@,C`E
M('-H87)E('!R96UI=6T@=V%S#0H@("!I;F-L=61E9"!A<R!C;VYS:61E<F%T
M:6]N(&9O<B!T:&4@8W5S=&ER<V5N(&QI8V5N<V4@86YD(&AA<R!B965N(&EN
M8VQU9&5D(&EN(&-O;&QA8F]R871I;VX@<F5V96YU92X-"B`@(#PO9&EV/@T*
M("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!M87)G:6XM=&]P.B`Q,'!T)SY);B!C;VYN96-T:6]N('=I=&@@=&AE($-O
M;&QA8F]R871I;VX@06=R965M96YT(&%N9"!P=7)S=6%N="!T;R!T:&4@=&5R
M;7,@;V8@86=R965M96YT<R!B971W965N('1H90T*("`@0V]M<&%N>2!A;F0@
M27-I<R!R96QA=&EN9R!T;R!C=7-T:7)S96XL('1H92!#;VUP86YY('!A:60@
M27-I<R!0:&%R;6%C975T:6-A;',L($EN8RXL(&]R($ES:7,L("9N8G-P.R0Q
M,`T*("`@;6EL;&EO;B!W:&EC:"!W87,@<F5C;W)D960@87,@<F5S96%R8V@@
M86YD(&1E=F5L;W!M96YT(&5X<&5N<V4@:6X@,C`P.2X@5&AE($-O;7!A;GD@
M86QS;R!P86ED#0H@("!A<'!R;WAI;6%T96QY("9N8G-P.R0S,S,L,S,S('1O
M('1H92!5;FEV97)S:71Y(&]F($)R:71I<V@@0V]L=6UB:6$L(&]R(%5"0RP@
M<'5R<W5A;G0@=&\@=&AE('1E<FUS(&]F#0H@("!T:&5I<B!L:6-E;G-E(&%G
M<F5E;65N="!R96QA=&EN9R!T;R!C=7-T:7)S96XL('=H:6-H(&AA<R!B965N
M(')E8V]R9&5D(&%S(')E<V5A<F-H(&%N9"!D979E;&]P;65N=`T*("`@97AP
M96YS92!I;B`R,#`Y+B!0=7)S=6%N="!T;R!T:&4@=&5R;7,@;V8@=&AE('1H
M:7)D+7!A<G1Y(&%G<F5E;65N=',L('1H92!#;VUP86YY(&%N=&EC:7!A=&5S
M('1H870-"B`@(&ET('=O=6QD(&)E(')E<75I<F5D('1O('!A>2!T:&ER9"!P
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M=&EE<R!O9B`T+C@X)2!T;R`X+C`P)2!O9B!N970@<V%L97,L#0H@("!U;FQE
M<W,@=&AE($-O;7!A;GDF(S@R,3<[<R!R;WEA;'1I97,@87)E(&%D:G5S=&5D
M(&9O<B!C;VUP971I=&EO;B!F<F]M(&=E;F5R:6,@8V]M<&]U;F1S+"!I;B!W
M:&EC:"!C87-E#0H@("!R;WEA;'1I97,@=&\@=&AI<F0@<&%R=&EE<R!W:6QL
M(&%L<V\@8F4@<W5B:F5C="!T;R!A9&IU<W1M96YT(&]N(&$@8V]U;G1R>2UB
M>2UC;W5N=')Y(&)A<VES+@T*("`@0V5R=&%I;B!T:&ER9"UP87)T>2!R;WEA
M;'1I97,@87)E('1I97)E9"!B87-E9"!O;B!T:&4@<F]Y86QT>2!R871E(')E
M8V5I=F5D(&)Y('1H92!#;VUP86YY+B!-:6YI;75M#0H@("!R;WEA;'1Y(')A
M=&5S('!A>6%B;&4@8GD@=&AE($-O;7!A;GD@87-S=6UE(&-E<G1A:6X@=&AI
M<F0M<&%R='D@<F]Y86QT:65S(&%R92!N;W0@<&%I9`T*("`@870@=&AE('1I
M;64@=&AA="!T:&4@3&EC96YS960@4')O9'5C="!I<R!M87)K971E9"!D=64@
M=&\@=&AE(&5X<&ER871I;VX@;V8@<&%T96YT<R!H96QD(&)Y('-U8V@-"B`@
M('1H:7)D('!A<G1I97,N($UA>&EM=6T@<F]Y86QT>2!R871E<R!A<W-U;64@
M86QL('1H:7)D+7!A<G1Y(')O>6%L='D@<F%T97,@8W5R<F5N=&QY(&EN(&5F
M9F5C=`T*("`@8V]N=&EN=64@:6X@969F96-T(&%T('1H92!T:6UE('1H92!,
M:6-E;G-E9"!0<F]D=6-T(&ES(&UA<FME=&5D+@T*("`@/"]D:78^#0H@("`\
M(2TM($9O;&EO("TM/@T*("`@/"$M+2`O1F]L:6\@+2T^#0H@("`\+V1I=CX-
M"B`@(#PA+2T@4$%'14)214%+("TM/@T*("`@/&1I=B!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I
M;BUL969T.B`P:6X[("<^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/E1E=F$@:&%S
M('1H92!E>&-L=7-I=F4@=V]R;&1W:61E(')I9VAT(&%N9"!L:6-E;G-E('1O
M(&1E=F5L;W`@86YD(&-O;6UE<F-I86QI>F4@<')O9'5C=',@8V]N=&%I;FEN
M9PT*("`@8W5S=&ER<V5N(&%N9"!R96QA=&5D(&-O;7!O=6YD<RX@5&AE($-O
M;7!A;GD@:&%S(&%N(&]P=&EO;B!T;R!C;RUP<F]M;W1E(&%N>2!,:6-E;G-E
M9"!0<F]D=6-T(&EN#0H@("!T:&4@56YI=&5D(%-T871E<R!A;F0@0V%N861A
M+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/E1E=F$@:7,@<F5S
M<&]N<VEB;&4@9F]R(&%L;"!C;W-T<R!R96QA=&EN9R!T;R!P<F]D=6-T(&-O
M;6UE<F-I86QI>F%T:6]N(&EN8VQU9&EN9R!C;W-T<R!I;F-U<G)E9"!I;@T*
M("`@<F5L871I;VX@=&\@=&AE($-O;7!A;GDF(S@R,3<[<R!C;RUP<F]M;W1I
M;VX@;W!T:6]N+"!E>&-E<'0@9F]R('-T87)T+75P(&-O<W1S(&EN(&%D=F%N
M8V4@;V8-"B`@(&-O;6UE<F-I86QI>F%T:6]N+@T*("`@/"]D:78^#0H@("`\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA
M<F=I;BUT;W`Z(#$P<'0G/E1E=F$@86YD('1H92!#;VUP86YY(&AA=F4@9&5V
M96QO<&5D(&$@0VQI;FEC86P@1&5V96QO<&UE;G0@4&QA;B!U;F1E<B!W:&EC
M:"!T:')E92!P:&%S92`S(&-L:6YI8V%L#0H@("!T<FEA;',@=VEL;"!B92!I
M;FET:6%T960Z#0H@("`\+V1I=CX-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN
M+71O<#H@,3!P="<^#0H@("`\=&%B;&4@=VED=&@],T0Q,#`E(&)O<F1E<CTS
M1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*("`@/'1R('9A
M;&EG;CTS1'1O<"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&-O;&]R.B`C
M,#`P,#`P.R!B86-K9W)O=6YD.B!T<F%N<W!A<F5N="<^#0H@("`@("`@/'1D
M('=I9'1H/3-$-"4@<W1Y;&4],T0G8F%C:V=R;W5N9#H@=')A;G-P87)E;G0G
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,R4@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$;&5F=#X\8CXF(S@R,C8[/"]B/CPO=&0^#0H@("`@
M("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^#0H@
M("!4:&4@;VYG;VEN9R!P:&%S92`S(&-L:6YI8V%L('1R:6%L+"!R969E<G)E
M9"!T;R!A<R!T:&4@4WEN97)G>2!T<FEA;"P@;W(@4UE.15)'62P@=&\@979A
M;'5A=&4@82!S=7)V:79A;"!B96YE9FET(&9O<B`-"B`@(&-U<W1I<G-E;B!I
M;B!C;VUB:6YA=&EO;B!W:71H(&9I<G-T+6QI;F4@9&]C971A>&5L('1R96%T
M;65N="!I;B!P871I96YT<R!W:71H(&-A<W1R871E(')E<VES=&%N="!P<F]S
M=&%T92!C86YC97(L(&]R($-24$,N(`T*("`@17AP96-T960@=&EM:6YG(&]F
M(')E<W5L=',@9G)O;2!T:&4@<W5R=FEV86P@<')I;6%R>2!E;F1P;VEN="!F
M;W(@=&AE(&-U<W1I<G-E;B!364Y%4D=9(%!H87-E(#,@8VQI;FEC86P@=')I
M86P@<F5M86EN<R`-"B`@('5N8VAA;F=E9"!A="!1-"`R,#$S+B!$=7)I;F<@
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M<F]L;&UE;G0@:6X@4UE.15)'62`-"B`@(&9R;VT@.#`P('1O(&%P<')O>&EM
M871E;'D@,3`P,"!P871I96YT<RP@86YD(&5X<&%N9"!T:&4@;G5M8F5R(&]F
M(&-L:6YI8V%L('1R:6%L('-I=&5S+@T*("`@/"]T9#X-"B`@(#PO='(^#0H@
M("`\+W1A8FQE/@T*("`@/"]D:78^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I
M;BUT;W`Z(#$P<'0G/@T*("`@/'1A8FQE('=I9'1H/3-$,3`P)2!B;W)D97(]
M,T0P(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B`@(#QT<B!V
M86QI9VX],T1T;W`@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!C;VQO<CH@
M(S`P,#`P,#L@8F%C:V=R;W5N9#H@=')A;G-P87)E;G0G/@T*("`@("`@(#QT
M9"!W:61T:#TS1#0E('-T>6QE/3-$)V)A8VMG<F]U;F0Z('1R86YS<&%R96YT
M)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#,E(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1&QE9G0^/&(^)B,X,C(V.SPO8CX\+W1D/@T*("`@
M("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/@T*
M("`@06X@;VYG;VEN9R!P:&%S92`S(&-L:6YI8V%L('1R:6%L+"!R969E<G)E
M9"!T;R!A<R!305154DXL('1O(&5V86QU871E(&$@9'5R86)L92!P86EN('!A
M;&QI871I;VX@8F5N969I="!F;W(@#0H@("!C=7-T:7)S96X@:6X@8V]M8FEN
M871I;VX@=VET:"!D;V-E=&%X96P@87,@<V5C;VYD+6QI;F4@8VAE;6]T:&5R
M87!Y(&EN(&%P<')O>&EM871E;'D@,S`P('!A=&EE;G1S('=I=&@@0U)00RX@
M5V4@:&%V92`-"B`@(')E=FES960@=&AE(&-U<W1I<G-E;B!305154DX@4&AA
M<V4@,R!T<FEA;"!P<F]T;V-O;"!T;R!E>'!A;F0@=&AE(&5L:6=I8FQE('!A
M=&EE;G0@<&]P=6QA=&EO;BP@86YD('1O(&%L:6=N('=I=&@@=&AE(`T*("`@
M<F5C96YT;'D@87!P<F]V960@8VAE;6]T:&5R87!Y+"!C86)A>FET87AE;"X@
M5V4@87)E(&%W86ET:6YG(&9I;F%L+"!W<FET=&5N($9$02!A9W)E96UE;G0@
M;VX@=&AE(%-002!A;65N9&UE;G0@=&AA="!W:6QL(`T*("`@86QL;W<@<&%T
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M92!E;G)O;&QM96YT(`T*("`@8W)I=&5R:6$@<F5G87)D:6YG(&1O8V5T87AE
M;"!R971R96%T;65N="!A;F0@<W1A8FQE('!A:6X@8W)I=&5R:6$N($5X<&5C
M=&5D('1I;6EN9R!O9B!R97-U;'1S(&9O<B!T:&4@<&%I;B!P86QL:6%T:6]N
M(`T*("`@<')I;6%R>2!E;F1P;VEN="!I<R!N;W<@<')O:F5C=&5D('1O(&)E
M(%$T(#(P,3,@<F%T:&5R('1H86X@43(@,C`Q,RX-"B`@(#PO=&0^#0H@("`\
M+W1R/@T*("`@/"]T86)L93X-"B`@(#PO9&EV/@T*("`@/&1I=B!S='EL93TS
M1"=M87)G:6XM=&]P.B`Q,'!T)SX-"B`@(#QT86)L92!W:61T:#TS1#$P,"4@
M8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0H@
M("`\='(@=F%L:6=N/3-$=&]P('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M8V]L;W(Z(",P,#`P,#`[(&)A8VMG<F]U;F0Z('1R86YS<&%R96YT)SX-"B`@
M("`@("`\=&0@=VED=&@],T0T)2!S='EL93TS1"=B86-K9W)O=6YD.B!T<F%N
M<W!A<F5N="<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0S)2!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1L969T/CQB/B8C.#(R-CL\+V(^/"]T
M9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#X-"B`@($$@<&AA<V4@,R!C;&EN:6-A;"!T<FEA;"!T;R!E=F%L=6%T
M92!A('-U<G9I=F%L(&)E;F5F:70@9F]R(&-U<W1I<G-E;B!I;B!C;VUB:6YA
M=&EO;B!W:71H(&9I<G-T+6QI;F4@8VAE;6]T:&5R87!Y(&EN(`T*("`@<&%T
M:65N=',@=VET:"!N;VXM<VUA;&P@8V5L;"!L=6YG(&-A;F-E<BP@;W(@3E-#
M3$,N(%1H92!I;FET:6%T:6]N(&]F('1H92!0:&%S92`S(&-L:6YI8V%L('1R
M:6%L(&5V86QU871I;F<@8W5S=&ER<V5N(`T*("`@:6X@<&%T:65N=',@=VET
M:"!.4T-,0R!H87,@8F5E;B!D96QA>65D(&%S('=E(&1E=&5R;6EN92!T:&4@
M;W!T:6UA;"!C:&5M;W1H97)A<&5U=&EC(&-O;6)I;F%T:6]N+B!792!B96QI
M979E($Y30TQ#(&ES(`T*("`@82!P<F]M:7-I;F<@:6YD:6-A=&EO;B!A;F0@
M<F5M86EN(&-O;6UI='1E9"!T;R!T:&4@861V86YC96UE;G0@;V8@8W5S=&ER
M<V5N(&EN($Y30TQ#+@T*("`@/"]T9#X-"B`@(#PO='(^#0H@("`\+W1A8FQE
M/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/E1E=F$@=VEL;"!B
M92!R97-P;VYS:6)L92!F;W(@8V]N9'5C=&EN9R!A;GD@;W1H97(@<W1U9&EE
M<R!A;F0@9&5V96QO<&UE;G0@=V]R:R!N96-E<W-A<GD@=&\@;V)T86EN#0H@
M("!R97%U:7)E9"!R96=U;&%T;W)Y(&%P<')O=F%L<RX@5&AE($-O;7!A;GD@
M;6%Y(&%S<W5M92!S;VUE(&]F('1H97-E(&%C=&EV:71I97,@:68@87-S:6=N
M960@8GD@=&AE#0H@("!J;VEN="!S=&5E<FEN9R!C;VUM:71T964N(%1E=F$@
M=VEL;"!B92!R97-P;VYS:6)L92!F;W(@86QL('-U8V@@8V]S=',N(%1H92!J
M;VEN="!S=&5E<FEN9R!C;VUM:71T964-"B`@('=I;&P@;W9E<G-E92!T:&4@
M9&5V96QO<&UE;G0@86YD(')E9W5L871O<GD@87!P<F]V86P@;V8@86YY($QI
M8V5N<V5D(%!R;V1U8W0N(%1H92!#;VUP86YY(&UA>0T*("`@=&5R;6EN871E
M(&ET<R!P87)T:6-I<&%T:6]N(&EN('1H92!J;VEN="!S=&5E<FEN9R!C;VUM
M:71T964@870@86YY('1I;64N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@
M,3!P="<^1G5N9&EN9R!R97-P;VYS:6)I;&ET:65S(&9O<B!T:&4@0VQI;FEC
M86P@1&5V96QO<&UE;G0@4&QA;B!W:6QL(&)E(&%L;&]C871E9"!A<R!F;VQL
M;W=S.@T*("`@/"]D:78^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M(#$P<'0G/@T*("`@/'1A8FQE('=I9'1H/3-$,3`P)2!B;W)D97(],T0P(&-E
M;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B`@(#QT<B!V86QI9VX]
M,T1T;W`@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!C;VQO<CH@(S`P,#`P
M,#L@8F%C:V=R;W5N9#H@=')A;G-P87)E;G0G/@T*("`@("`@(#QT9"!W:61T
M:#TS1#0E('-T>6QE/3-$)V)A8VMG<F]U;F0Z('1R86YS<&%R96YT)SXF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#,E(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1&QE9G0^/&(^)B,X,C(V.SPO8CX\+W1D/@T*("`@("`@(#QT
M9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/E1H92!#;VUP
M86YY('=I;&P@8F4@<F5Q=6ER960@=&\@<W!E;F0@)FYB<W`[)#,P)B,Q-C`[
M;6EL;&EO;B!I;B!D:7)E8W0@86YD(&EN9&ER96-T(&1E=F5L;W!M96YT#0H@
M("!C;W-T<RP@86YD/"]T9#X-"B`@(#PO='(^#0H@("`\+W1A8FQE/@T*("`@
M/"]D:78^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#$P<'0G/@T*
M("`@/'1A8FQE('=I9'1H/3-$,3`P)2!B;W)D97(],T0P(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T)SX-"B`@(#QT<B!V86QI9VX],T1T;W`@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!C;VQO<CH@(S`P,#`P,#L@8F%C:V=R
M;W5N9#H@=')A;G-P87)E;G0G/@T*("`@("`@(#QT9"!W:61T:#TS1#0E('-T
M>6QE/3-$)V)A8VMG<F]U;F0Z('1R86YS<&%R96YT)SXF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!W:61T:#TS1#,E(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&QE9G0^/&(^)B,X,C(V.SPO8CX\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS
M1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/E1E=F$@=VEL;"!F=6YD(&%L
M;"!O=&AE<B!E>'!E;G-E<R!U;F1E<B!T:&4@0VQI;FEC86P@1&5V96QO<&UE
M;G0@4&QA;BX\+W1D/@T*("`@/"]T<CX-"B`@(#PO=&%B;&4^#0H@("`\+V1I
M=CX-"B`@(#PA+2T@1F]L:6\@+2T^#0H@("`\(2TM("]&;VQI;R`M+3X-"B`@
M(#PO9&EV/@T*("`@/"$M+2!004=%0E)%04L@+2T^#0H@("`\9&EV('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I
M9CL@;6%R9VEN+6QE9G0Z(#!I;CL@)SX-"B`@(#QD:78@<W1Y;&4],T0G;6%R
M9VEN+71O<#H@,3!P="<^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P
M="<^5&AE($-O;&QA8F]R871I;VX@06=R965M96YT('=I;&P@<F5M86EN(&EN
M(&5F9F5C="P@;VX@82!C;W5N=')Y+6)Y+6-O=6YT<GD@8F%S:7,L('5N=&EL
M('1H90T*("`@97AP:7)A=&EO;B!O9B!T:&4@;V)L:6=A=&EO;B!O9B!4979A
M('1O('!A>2!R;WEA;'1I97,@;VX@<V%L97,@;V8@=&AE($QI8V5N<V5D(%!R
M;V1U8W0@:6X@<W5C:`T*("`@8V]U;G1R>2`H;W(@96%R;&EE<B!T97)M:6YA
M=&EO;B!U;F1E<B!I=',@=&5R;7,I+B!!9G1E<B!T:&4@8V]M<&QE=&EO;B!O
M9B!A;&P@=&AR964@<&AA<V4@,PT*("`@8VQI;FEC86P@=')I86QS('-E="!F
M;W)T:"!I;B!T:&4@0VQI;FEC86P@1&5V96QO<&UE;G0@4&QA;BP@;W(@=7!O
M;B!E87)L>2!T97)M:6YA=&EO;B!D=64@=&\@80T*("`@;6%T97)I86P@861V
M97)S92!C:&%N9V4@:6X@=&AE($-O;7!A;GDF(S@R,3<[<R!P871E;G0@<FEG
M:'1S(')E;&%T960@=&\@8W5S=&ER<V5N(&]R('-A9F5T>2!I<W-U97,@;W(-
M"B`@("8C.#(R,#MF=71I;&ET>28C.#(R,3L@87,@9&5F:6YE9"!I;B!T:&4@
M0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0L(%1E=F$@;6%Y#0H@("!T97)M:6YA
M=&4@=&AE($-O;&QA8F]R871I;VX@06=R965M96YT(&%T(&ET<R!S;VQE(&1I
M<V-R971I;VX@=7!O;B!T:')E92!M;VYT:',F(S@R,3<[(&YO=&EC92!I9B!N
M;W1I8V4@:7,-"B`@(&=I=F5N('!R:6]R('1O(')E9W5L871O<GD@87!P<F]V
M86P@;V8@82!,:6-E;G-E9"!0<F]D=6-T(&%N9"!U<&]N('-I>"!M;VYT:',F
M(S@R,3<[(&YO=&EC92!I9B!N;W1I8V4@:7,-"B`@(&=I=F5N(&%F=&5R('-U
M8V@@<F5G=6QA=&]R>2!A<'!R;W9A;"X@268@5&5V82!T97)M:6YA=&5S('1H
M92!#;VQL86)O<F%T:6]N($%G<F5E;65N="!F;W(@86YY#0H@("!R96%S;VYS
M(&]T:&5R('1H86X@86X@861V97)S92!C:&%N9V4@:6X@8W5S=&ER<V5N('!A
M=&5N="!R:6=H=',L('-A9F5T>2!I<W-U97,@;W(@)B,X,C(P.V9U=&EL:71Y
M)B,X,C(Q.PT*("`@9&5T97)M:6YA=&EO;B!A<R!P<F5V:6]U<VQY(&1E<V-R
M:6)E9"P@:70@=VEL;"!R96UA:6X@<F5S<&]N<VEB;&4@9F]R('!A>6EN9R!F
M;W(@86YY(')E;6%I;FEN9PT*("`@8V]S=',@;V8@86QL('1H<F5E('!H87-E
M(#,@8VQI;FEC86P@=')I86QS+"!E>&-E<'0@9F]R('-P96-I9FEE9"!D979E
M;&]P;65N="!E>'!E;G-E<R!T:&%T(&%R92!T:&4-"B`@(')E<W!O;G-I8FEL
M:71Y(&]F('1H92!#;VUP86YY+B!%:71H97(@<&%R='D@;6%Y('1E<FUI;F%T
M92!T:&4@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0@9F]R(&%N#0H@("!U;F-U
M<F5D(&UA=&5R:6%L(&)R96%C:"!B>2!T:&4@;W1H97(@<&%R='D@;W(@=7!O
M;B!T:&4@8F%N:W)U<'1C>2!O9B!E:71H97(@<&%R='DN($EF('1H90T*("`@
M0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0@:7,@=&5R;6EN871E9"!B>2!T:&4@
M0V]M<&%N>2!F;W(@;W1H97(@=&AA;B!A;B!U;F-U<F5D(&UA=&5R:6%L(&)R
M96%C:"!B>0T*("`@5&5V82P@=&AE($-O;7!A;GD@=VEL;"!P87D@5&5V82!A
M(')O>6%L='D@;VX@<V%L97,@;V8@3&EC96YS960@4')O9'5C=',N(%1H92!P
M97)C96YT86=E(')A=&5S(&]F#0H@("!S=6-H(')O>6%L=&EE<R`H=VAI8V@@
M87)E(&EN('1H92!S:6YG;&4@9&EG:71S*2!V87)Y(&1E<&5N9&EN9R!O;B!W
M:&5T:&5R('1E<FUI;F%T:6]N(&]C8W5R<R!P<FEO<@T*("`@=&\@=&AE(&9I
M<G-T(')E9W5L871O<GD@87!P<F]V86P@:6X@=&AE(%5N:71E9"!3=&%T97,@
M;W(@82!P<FEM87)Y($5U<F]P96%N($UA<FME="!O<B!A9G1E<B!O;F4@;V8-
M"B`@('1H97-E(&%P<')O=F%L<RX@5&AE<V4@<F]Y86QT:65S('=O=6QD(&5X
M<&ER92!O;B!A(&-O=6YT<GDM8GDM8V]U;G1R>2!B87-I<R!O;B!T:&4@96%R
M;&EE<B!O9B!T96X-"B`@('EE87)S(&%F=&5R('1H92!F:7)S="!C;VUM97)C
M:6%L('-A;&4@;V8@82!,:6-E;G-E9"!0<F]D=6-T(&]R(&-E<G1A:6X@=&AR
M97-H;VQD<R!R96QA=&5D('1O#0H@("!G96YE<FEC(&-O;7!E=&ET:6]N+@T*
M("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/DEN('1H92!E=F5N="!O
M9B!A(&-H86YG92!O9B!C;VYT<F]L(&]F('1H92!#;VUP86YY+"!W:71H:6X@
M.3`F(S$V,#MD87ES(&]F('1H92!C:&%N9V4@;V8@8V]N=')O;"P@5&5V80T*
M("`@;6%Y('1E<FUI;F%T92!T:&4@:F]I;G0@<W1E97)I;F<@8V]M;6ET=&5E
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M<R!C;VUM97)C:6%L;'D@<F5A<V]N86)L90T*("`@;W!I;FEO;B!C;RUP<F]M
M;W1I;VX@=VET:"!T:&4@0V]M<&%N>28C.#(Q-SMS('-U8V-E<W-O<B!W;W5L
M9"!B92!M871E<FEA;&QY(&1E=')I;65N=&%L('1O(%1E=F$F(S@R,3<[<PT*
M("`@:6YT97)E<W1S+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G
M/E5P;VX@96YT97)I;F<@:6YT;R!T:&4@0V]L;&%B;W)A=&EO;B!!9W)E96UE
M;G0L('1H92!#;VUP86YY(&%S<V5S<V5D('=H971H97(@=VET:&AO;&1I;F=S
M('1A>&5S#0H@("!W97)E(&]W960@=&\@=&AE($ES<F%E;&D@5&%X($%U=&AO
M<FET>2P@;W(@251!+"!R97-U;'1I;F<@9G)O;2!T:&4@0V]L;&%B;W)A=&EO
M;B!!9W)E96UE;G0N($ET('=A<PT*("`@=&AE($-O;7!A;GDF(S@R,3<[<R!P
M;W-I=&EO;B!T:&%T('=I=&AH;VQD:6YG<R!T87AE<R!W97)E(&YO="!O=V5D
M+"!A;F0@82!C;&%I;2!W87,@:7-S=65D('1O('1H92!)5$$-"B`@(&%C8V]R
M9&EN9VQY+B!&;W(@86-C;W5N=&EN9R!P=7)P;W-E<RP@;6%N86=E;65N="!C
M;VYC;'5D960@=&AA="!T:&4@=VET:&AO;&1I;F=S('1A>"!C;&%I;2!W87,@
M86X-"B`@('5N8V5R=&%I;B!T87@@<&]S:71I;VXL(&%N9"`F;F)S<#LD,R8C
M,38P.VUI;&QI;VXL('=H:6-H(')E<')E<V5N=&5D('1H92!P;W1E;G1I86P@
M=VET:&AO;&1I;F=S('1A>`T*("`@;V)L:6=A=&EO;BP@;VYC92!R96-E:79E
M9"!F<F]M(%1E=F$@=V%S(&EN:71I86QL>2!R96-O<F1E9"!A<R!R97-T<FEC
M=&5D(&-A<V@@<&5N9&EN9R!T:&4@251!#0H@("!R979I97<@;V8@;W5R(&-L
M86EM(&%N9"!A(&-O<G)E<W!O;F1I;F<@;&EA8FEL:71Y(&]F("9N8G-P.R0S
M)B,Q-C`[;6EL;&EO;B!W87,@:6YC;'5D960@:6X@86-C;W5N=',@<&%Y86)L
M90T*("`@86YD(&%C8W)U960@;&EA8FEL:71I97,N($EN($IU;F4F(S$V,#LR
M,#$P+"!T:&4@0V]M<&%N>2!R96-E:79E9"!A<'!R;W9A;"!F<F]M('1H92!)
M5$$@9F]R(&]U<B!R97%U97-T#0H@("!F;W(@82!W:71H:&]L9&EN9W,@=&%X
M(&5X96UP=&EO;B!O;B!A;6]U;G1S(')E8V5I=F5D(&9R;VT@5&5V82!I;B!R
M96QA=&EO;B!T;R!T:&4@0V]L;&%B;W)A=&EO;@T*("`@06=R965M96YT+B!&
M;VQL;W=I;F<@<F5C96EP="!O9B!T:&ES(&%P<')O=F%L(&9R;VT@=&AE($E4
M02!T:&4@)FYB<W`[)#,F(S$V,#MM:6QL:6]N('=A<R!R96QE87-E9"!T;R!T
M:&4-"B`@($-O;7!A;GD@9G)O;2!E<V-R;W<N(%-U8G-E<75E;G1L>2P@=&AE
M($-O;7!A;GD@<F5L96%S960@=&AE("9N8G-P.R0S)B,Q-C`[;6EL;&EO;B!L
M:6%B:6QI='D@86YD(')E8V]R9&5D(&$@)FYB<W`[)#,-"B`@(&UI;&QI;VX@
M:6YC;VUE('1A>"!R96-O=F5R>2!I;B!T:&4@<V5C;VYD('%U87)T97(@;V8@
M,C`Q,"X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SY2979E;G5E
M(&9O<B!T:&4@=&AR964@86YD('-I>"!M;VYT:',@96YD960@2G5N928C,38P
M.S,P+"`R,#$Q('=A<R`F;F)S<#LD,2XY)B,Q-C`[;6EL;&EO;BP@86YD("9N
M8G-P.R0S+C$F(S$V,#MM:6QL:6]N('=H:6-H#0H@("!C;VYS:7-T<R!O9B!P
M87)T:6%L(')E8V]G;FET:6]N(&]F(&1E9F5R<F5D(&-O;&QA8F]R871I;VX@
M<F5V96YU92!R97!R97-E;G1I;F<@3VYC;T=E;F5X)B,X,C$W.W,-"B`@(&-O
M;G1R:6)U=&EO;B!T;R!T:&4@8W5S=&ER<V5N('!H87-E(#,@9&5V96QO<&UE
M;G0@<&QA;B!U;F1E<B!O=7(@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0@=VET
M:"!4979A#0H@("!A;F0@8W5S=&ER<V5N(&UA;G5F86-T=7)I;F<@8V]S=',@
M:6YC=7)R960@8GD@3VYC;T=E;F5X(&EN('1H92!Y96%R(&5N9&5D($1E8V5M
M8F5R)B,Q-C`[,S$L(#(P,3`@=&AA=`T*("`@87)E(')E:6UB=7)S86)L92!F
M<F]M(%1E=F$N($%T($IU;F4F(S$V,#LS,"P@,C`Q,2P@82!R96UA:6YI;F<@
M8F%L86YC92!O9B`F;F)S<#LD,3DN.28C,38P.VUI;&QI;VX@;V8@=&AE('5P
M+69R;VYT#0H@("!P87EM96YT('=A<R!R96-O<F1E9"!I;B!D969E<G)E9"!C
M;VQL86)O<F%T:6]N(')E=F5N=64N(%1H97)E('=A<R`F;F)S<#LD,2XW)B,Q
M-C`[;6EL;&EO;B!A;F0@)FYB<W`[)#8N-"8C,38P.VUI;&QI;VX@:6X-"B`@
M(')E=F5N=64@<F5C;W)D960@:6X@=&AE('1H<F5E(&%N9"!S:7@@;6]N=&AS
M(&5N9&5D($IU;F4F(S$V,#LS,"P@,C`Q,"!A<R!A(')E<W5L="!O9B!T:&4@
M0V]L;&%B;W)A=&EO;@T*("`@06=R965M96YT('=I=&@@5&5V82X-"B`@(#PO
M9&EV/@T*("`@/"]D:78^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V)B.#8R9#8U7V)F-#!?-&0U9E]B8S%D7SAB,3DS83-E
M9#4Y-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B8C@V,F0V-5]B
M9C0P7S1D-69?8F,Q9%\X8C$Y,V$S960U.30O5V]R:W-H965T<R]3:&5E=#`Y
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%,D@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1F%I
M<B!686QU92!-96%S=7)E;65N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E($UE87-U<F5M96YT
M<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9!25(@5D%,544@345!4U5214U%3E13/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B
M+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P
M.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N
M86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@
M-"`M('5S+6=A87`Z1F%I<E9A;'5E1&ES8VQO<W5R97-497AT0FQO8VLM+3X-
M"B`@(#QD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M
M86XG+%1I;65S+'-E<FEF.R!M87)G:6XM;&5F=#H@,&EN.R`G/@T*("`@/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM=&]P.B`Q,'!T)SX\8CXT+B!&04E2(%9!3%5%($U%05-54D5-14Y44SPO
M8CX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SY7:71H('1H92!A
M9&]P=&EO;B!O9B!!8V-O=6YT:6YG(%-T86YD87)D<R!#;V1I9FEC871I;VXL
M(&]R($%30RP@.#(P("8C.#(R,#M&86ER(%9A;'5E($UE87-U<F5M96YT<R!A
M;F0-"B`@($1I<V-L;W-U<F5S)B,X,C(Q.RP@8F5G:6YN:6YG($IA;G5A<GDF
M(S$V,#LQ+"`R,#`X+"!A<W-E=',@86YD(&QI86)I;&ET:65S(')E8V]R9&5D
M(&%T(&9A:7(@=F%L=64@:6X@=&AE#0H@("!B86QA;F-E('-H965T<R!A<F4@
M8V%T96=O<FEZ960@8F%S960@=7!O;B!T:&4@;&5V96P@;V8@:G5D9VUE;G0@
M87-S;V-I871E9"!W:71H('1H92!I;G!U=',@=7-E9"!T;PT*("`@;65A<W5R
M92!T:&5I<B!F86ER('9A;'5E+B!&;W(@8V5R=&%I;B!O9B!T:&4@0V]M<&%N
M>28C.#(Q-SMS(&9I;F%N8VEA;"!I;G-T<G5M96YT<R!I;F-L=61I;F<@8V%S
M:"!A;F0-"B`@(&-A<V@@97%U:79A;&5N=',L(&%M;W5N=',@<F5C96EV86)L
M92P@86YD(&%C8V]U;G1S('!A>6%B;&4@=&AE(&-A<G)Y:6YG('9A;'5E<R!A
M<'!R;WAI;6%T92!F86ER#0H@("!V86QU92!D=64@=&\@=&AE:7(@<VAO<G0M
M=&5R;2!N871U<F4N#0H@("`\+V1I=CX-"B`@(#PA+2T@1F]L:6\@+2T^#0H@
M("`\(2TM("]&;VQI;R`M+3X-"B`@(#PO9&EV/@T*("`@/"$M+2!004=%0E)%
M04L@+2T^#0H@("`\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@;6%R9VEN+6QE9G0Z(#!I;CL@)SX-
M"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+71O<#H@,3!P="<^05-#(#@R,"!S<&5C:69I97,@82!H:65R
M87)C:'D@;V8@=F%L=6%T:6]N('1E8VAN:7%U97,@8F%S960@;VX@=VAE=&AE
M<B!T:&4@:6YP=71S('1O('1H;W-E#0H@("!V86QU871I;VX@=&5C:&YI<75E
M<R!A<F4@;V)S97)V86)L92!O<B!U;F]B<V5R=F%B;&4N($EN(&%C8V]R9&%N
M8V4@=VET:"!!4T,@.#(P+"!T:&5S92!I;G!U=',@87)E#0H@("!S=6UM87)I
M>F5D(&EN('1H92!T:')E92!B<F]A9"!L979E;',@;&ES=&5D(&)E;&]W.@T*
M("`@/"]D:78^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#$P<'0G
M/@T*("`@/'1A8FQE('=I9'1H/3-$,3`P)2!B;W)D97(],T0P(&-E;&QP861D
M:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B`@(#QT<B!V86QI9VX],T1T;W`@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!C;VQO<CH@(S`P,#`P,#L@8F%C
M:V=R;W5N9#H@=')A;G-P87)E;G0G/@T*("`@("`@(#QT9"!W:61T:#TS1#0E
M('-T>6QE/3-$)V)A8VMG<F]U;F0Z('1R86YS<&%R96YT)SXF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!W:61T:#TS1#,E(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&QE9G0^/&(^)B,X,C(V.SPO8CX\+W1D/@T*("`@("`@(#QT9"!W:61T
M:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/DQE=F5L(#$@)B,X,C$R
M.R!1=6]T960@<')I8V5S(&EN(&%C=&EV92!M87)K971S(&9O<B!I9&5N=&EC
M86P@<V5C=7)I=&EE<SL\+W1D/@T*("`@/"]T<CX-"B`@(#QT<CX-"B`@("`@
M("`\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G/B8C,38P.SPO=&0^#0H@
M("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1'1O<"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&-O;&]R.B`C,#`P,#`P.R!B86-K9W)O=6YD.B!T<F%N<W!A
M<F5N="<^#0H@("`@("`@/'1D('=I9'1H/3-$-"4@<W1Y;&4],T0G8F%C:V=R
M;W5N9#H@=')A;G-P87)E;G0G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I
M9'1H/3-$,R4@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$;&5F=#X\8CXF(S@R
M,C8[/"]B/CPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^3&5V96P@,B`F(S@R,3([($]T:&5R('-I9VYI9FEC
M86YT(&]B<V5R=F%B;&4@:6YP=71S('1H870@87)E(&]B<V5R=F%B;&4@=&AR
M;W5G:`T*("`@8V]R<F]B;W)A=&EO;B!W:71H(&UA<FME="!D871A("AI;F-L
M=61I;F<@<75O=&5D('!R:6-E<R!I;B!A8W1I=F4@;6%R:V5T<R!F;W(@<VEM
M:6QA<@T*("`@<V5C=7)I=&EE<RD[(&%N9#PO=&0^#0H@("`\+W1R/@T*("`@
M/"]T86)L93X-"B`@(#PO9&EV/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM
M=&]P.B`Q,'!T)SX-"B`@(#QT86)L92!W:61T:#TS1#$P,"4@8F]R9&5R/3-$
M,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0H@("`\='(@=F%L
M:6=N/3-$=&]P('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@8V]L;W(Z(",P
M,#`P,#`[(&)A8VMG<F]U;F0Z('1R86YS<&%R96YT)SX-"B`@("`@("`\=&0@
M=VED=&@],T0T)2!S='EL93TS1"=B86-K9W)O=6YD.B!T<F%N<W!A<F5N="<^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0S)2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1L969T/CQB/B8C.#(R-CL\+V(^/"]T9#X-"B`@("`@
M("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#Y,979E
M;"`S("8C.#(Q,CL@4VEG;FEF:6-A;G0@=6YO8G-E<G9A8FQE(&EN<'5T<R!T
M:&%T(')E9FQE8W0@;6%N86=E;65N="8C.#(Q-SMS(&)E<W0@97-T:6UA=&4@
M;V8-"B`@('=H870@;6%R:V5T('!A<G1I8VEP86YT<R!W;W5L9"!U<V4@:6X@
M<')I8VEN9R!T:&4@87-S970@;W(@;&EA8FEL:71Y+CPO=&0^#0H@("`\+W1R
M/@T*("`@/"]T86)L93X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T
M)SY!<R!Q=6]T960@<')I8V5S(&EN(&%C=&EV92!M87)K971S(&%R92!N;W0@
M<F5A9&EL>2!A=F%I;&%B;&4@9F]R(&-E<G1A:6X@9FEN86YC:6%L(&EN<W1R
M=6UE;G1S+"!T:&4-"B`@($-O;7!A;GD@;V)T86EN<R!E<W1I;6%T97,@9F]R
M('1H92!F86ER('9A;'5E(&]F(&9I;F%N8VEA;"!I;G-T<G5M96YT<R!T:')O
M=6=H('1H:7)D('!A<G1Y('!R:6-I;F<-"B`@('-E<G9I8V4@<')O=FED97)S
M+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/DEN(&1E=&5R;6EN
M:6YG('1H92!A<'!R;W!R:6%T92!L979E;',L('1H92!#;VUP86YY('!E<F9O
M<FUE9"!A(&1E=&%I;&5D(&%N86QY<VES(&]F('1H92!A<W-E=',@86YD#0H@
M("!L:6%B:6QI=&EE<R!T:&%T(&%R92!S=6)J96-T('1O($%30R`X,C`N#0H@
M("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^5&AE($-O;7!A;GD@:6YV
M97-T<R!I=',@97AC97-S(&-A<V@@:6X@86-C;W)D86YC92!W:71H(&EN=F5S
M=&UE;G0@9W5I9&5L:6YE<R!T:&%T(&QI;6ET('1H92!C<F5D:70-"B`@(&5X
M<&]S=7)E('1O(&%N>2!O;F4@9FEN86YC:6%L(&EN<W1I='5T:6]N(&]T:&5R
M('1H86X@<V5C=7)I=&EE<R!I<W-U960@8GD@=&AE(%4N4RX@1V]V97)N;65N
M="X@3W5R#0H@("!S96-U<FET:65S(&%R92!N;W0@8V]L;&%T97)A;&EZ960@
M86YD(&UA='5R92!W:71H:6X@;VYE('EE87(N#0H@("`\+V1I=CX-"B`@(#QD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R
M9VEN+71O<#H@,3!P="<^02!D97-C<FEP=&EO;B!O9B!T:&4@=F%L=6%T:6]N
M('1E8VAN:7%U97,@87!P;&EE9"!T;R!T:&4@0V]M<&%N>28C.#(Q-SMS(&9I
M;F%N8VEA;"!I;G-T<G5M96YT<R!M96%S=7)E9`T*("`@870@9F%I<B!V86QU
M92!O;B!A(')E8W5R<FEN9R!B87-I<R!F;VQL;W=S+@T*("`@/"]D:78^#0H@
M("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&UA<F=I;BUT;W`Z(#$P<'0G/CQI/D9I;F%N8VEA;"!);G-T<G5M96YT<SPO
M:3X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\:3Y#87-H/"]I
M/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/E-I9VYI9FEC86YT
M(&%M;W5N=',@;V8@8V%S:"!A<F4@:&5L9"!O;B!D97!O<VET('=I=&@@82!L
M87)G92!W96QL(&5S=&%B;&ES:&5D($-A;F%D:6%N(&9I;F%N8VEA;`T*("`@
M:6YS=&ET=71I;VXN#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^
M/&D^1V]V97)N;65N="!A;F0@06=E;F-Y(%-E8W5R:71I97,\+VD^#0H@("`\
M+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/'4^1V]V97)N;65N="!396-U
M<FET:65S/"]U/B!5+E,N(&%N9"!#86YA9&EA;B!';W9E<FYM96YT('-E8W5R
M:71I97,@87)E('9A;'5E9"!U<VEN9R!Q=6]T960-"B`@(&UA<FME="!P<FEC
M97,N(%9A;'5A=&EO;B!A9&IU<W1M96YT<R!A<F4@;F]T(&%P<&QI960N($%C
M8V]R9&EN9VQY+"!5+E,N(&%N9"!#86YA9&EA;B!G;W9E<FYM96YT#0H@("!S
M96-U<FET:65S(&%R92!C871E9V]R:7IE9"!I;B!,979E;"`Q(&]F('1H92!F
M86ER('9A;'5E(&AI97)A<F-H>2X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P
M.B`Q,'!T)SX\=3Y5+E,N($%G96YC>2!396-U<FET:65S/"]U/B!5+E,N(&%G
M96YC>2!S96-U<FET:65S(&%R92!C;VUP<FES960@;V8@='=O(&UA:6X@8V%T
M96=O<FEE<PT*("`@8V]N<VES=&EN9R!O9B!C86QL86)L92!A;F0@;F]N+6-A
M;&QA8FQE(&%G96YC>2UI<W-U960@9&5B="!S96-U<FET:65S+B!.;VXM8V%L
M;&%B;&4@86=E;F-Y+6ES<W5E9`T*("`@9&5B="!S96-U<FET:65S(&%R92!G
M96YE<F%L;'D@=F%L=65D('5S:6YG('%U;W1E9"!M87)K970@<')I8V5S+B!#
M86QL86)L92!A9V5N8WD@:7-S=65D(&1E8G0-"B`@('-E8W5R:71I97,@87)E
M('9A;'5E9"!B>2!B96YC:&UA<FMI;F<@;6]D96PM9&5R:79E9"!P<FEC97,@
M=&\@<75O=&5D(&UA<FME="!P<FEC97,@86YD('1R861E(&1A=&$-"B`@(&9O
M<B!I9&5N=&EC86P@;W(@8V]M<&%R86)L92!S96-U<FET:65S+B!!8W1I=F5L
M>2!T<F%D960@;F]N+6-A;&QA8FQE(&%G96YC>2!I<W-U960@9&5B="!S96-U
M<FET:65S#0H@("!A<F4@8V%T96=O<FEZ960@:6X@3&5V96P@,2!O9B!T:&4@
M9F%I<B!V86QU92!H:65R87)C:'DN($-A;&QA8FQE(&%G96YC>2!I<W-U960@
M9&5B="!S96-U<FET:65S(&%R90T*("`@8V%T96=O<FEZ960@:6X@3&5V96P@
M,B!O9B!T:&4@9F%I<B!V86QU92!H:65R87)C:'DN#0H@("`\+V1I=CX-"B`@
M(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+71O<#H@,3!P="<^/&D^0V]R<&]R871E(&%N9"!/=&AE<B!$96)T
M/"]I/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQU/D-O<G!O
M<F%T92!";VYD<R!A;F0@0V]M;65R8VEA;"!087!E<CPO=3X@5&AE(&9A:7(@
M=F%L=64@;V8@8V]R<&]R871E(&)O;F1S(&%N9"!C;VUM97)C:6%L#0H@("!P
M87!E<B!I<R!E<W1I;6%T960@=7-I;F<@<F5C96YT;'D@97AE8W5T960@=')A
M;G-A8W1I;VYS+"!M87)K970@<')I8V4@<75O=&%T:6]N<R`H=VAE<F4-"B`@
M(&]B<V5R=F%B;&4I+"!B;VYD('-P<F5A9',@;W(@8W)E9&ET(&1E9F%U;'0@
M<W=A<"!S<')E861S(&%D:G5S=&5D(&9O<B!A;GD@8F%S:7,@9&EF9F5R96YC
M92!B971W965N#0H@("!C87-H(&%N9"!D97)I=F%T:79E(&EN<W1R=6UE;G1S
M+B!4:&4@<W!R96%D(&1A=&$@=7-E9"!A<F4@9F]R('1H92!S86UE(&UA='5R
M:71Y(&%S('1H92!B;VYD+B!)9B!T:&4-"B`@('-P<F5A9"!D871A(&1O97,@
M;F]T(')E9F5R96YC92!T:&4@:7-S=65R+"!T:&5N(&1A=&$@=&AA="!R969E
M<F5N8V4@82!C;VUP87)A8FQE(&ES<W5E<B!A<F4@=7-E9"X-"B`@(%=H96X@
M;V)S97)V86)L92!P<FEC92!Q=6]T871I;VYS(&%R92!N;W0@879A:6QA8FQE
M+"!F86ER('9A;'5E(&ES(&1E=&5R;6EN960@8F%S960@;VX@8V%S:"!F;&]W
M#0H@("!M;V1E;',@=VET:"!Y:65L9"!C=7)V97,L(&)O;F0@;W(@<VEN9VQE
M(&YA;64@8W)E9&ET(&1E9F%U;'0@<W=A<"!S<')E861S(&%N9"!R96-O=F5R
M>2!R871E<R!B87-E9`T*("`@;VX@8V]L;&%T97)A;"!V86QU97,@87,@<VEG
M;FEF:6-A;G0@:6YP=71S+B!#;W)P;W)A=&4@8F]N9',@86YD(&-O;6UE<F-I
M86P@<&%P97(@87)E(&=E;F5R86QL>0T*("`@8V%T96=O<FEZ960@:6X@3&5V
M96P@,B!O9B!T:&4@9F%I<B!V86QU92!H:65R87)C:'D[(&EN(&EN<W1A;F-E
M<R!W:&5R92!P<FEC97,L('-P<F5A9',@;W(@86YY(&]F#0H@("!T:&4@;W1H
M97(@869O<F5M96YT:6]N960@:V5Y(&EN<'5T<R!A<F4@=6YO8G-E<G9A8FQE
M+"!T:&5Y(&%R92!C871E9V]R:7IE9"!I;B!,979E;"`S(&]F('1H90T*("`@
M:&EE<F%R8VAY+@T*("`@/"]D:78^#0H@("`\(2TM($9O;&EO("TM/@T*("`@
M/"$M+2`O1F]L:6\@+2T^#0H@("`\+V1I=CX-"B`@(#PA+2T@4$%'14)214%+
M("TM/@T*("`@/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I;BUL969T.B`P:6X[("<^#0H@
M("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&UA<F=I;BUT;W`Z(#$P<'0G/E1H92!F;VQL;W=I;F<@=&%B;&4@<')E<V5N
M=',@:6YF;W)M871I;VX@86)O=70@;W5R(&%S<V5T<R!A;F0@;&EA8FEL:71I
M97,@=&AA="!A<F4@;65A<W5R960@870@9F%I<@T*("`@=F%L=64@;VX@82!R
M96-U<G)I;F<@8F%S:7,L(&%N9"!I;F1I8V%T97,@=&AE(&9A:7(@=F%L=64@
M:&EE<F%R8VAY(&]F('1H92!V86QU871I;VX@=&5C:&YI<75E<R!W90T*("`@
M=71I;&EZ960@=&\@9&5T97)M:6YE('-U8V@@9F%I<B!V86QU93H-"B`@(#PO
M9&EV/@T*("`@/&1I=B!A;&EG;CTS1&-E;G1E<CX-"B`@(#QT86)L92!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G(&-E;&QS
M<&%C:6YG/3-$,"!B;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#$P,"4^#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9"!W:61T:#TS1#0T)3XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!W:61T:#TS1#DE/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H
M/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0S)3XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#,E
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1L969T('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SXH:6X@=&AO
M=7-A;F1S*3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^
M/&(^3&5V96P@,3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/DQE=F5L(#(\+V(^
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P
M>"!S;VQI9"`C,#`P,#`P)SX\8CY,979E;"`S/"]B/CPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N
M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P
M,"<^/&(^,C`Q,3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM
M($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@("`@(#QT9#X-
M"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E
M;G0Z+3$U<'@G/CQB/D%S<V5T<SPO8CX-"B`@(#PO9&EV/CPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS
M1&)O='1O;3X-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY#87-H#0H@("`\+V1I
M=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^,2PX,C0\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^
M)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T
M9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@
M(#QT9"!A;&EG;CTS1')I9VAT/C$L.#(T/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@("`@(#QT9#X-"B`@
M(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z
M+3$U<'@G/DUO;F5Y(&UA<FME="!S96-U<FET:65S#0H@("`\+V1I=CX\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^
M-RPX,S`\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[
M)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@
M("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT/C<L.#,P/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@
M(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X
M="UI;F1E;G0Z+3$U<'@G/D=O=F5R;FUE;G0@<V5C=7)I=&EE<PT*("`@/"]D
M:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT/C8L,#`P/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T
M/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B8C.#(Q
M,CL\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO
M=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1R:6=H=#XV+#`P,#PO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@
M("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT
M.BTQ-7!X)SY#;W)P;W)A=&4@8F]N9',@86YD(&-O;6UE<F-I86P@<&%P97(-
M"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@
M86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I
M9VAT/C8P+#(V,#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF
M;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D
M/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C8P+#(V,#PO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,7!X)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE
M/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V
M,#L-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P
M)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P
M.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R
M/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^#0H@("`\
M9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ
M-7!X)SXF(S$V,#L-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#X\8CXF;F)S<#LD/"]B
M/CPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^/&(^,34L-C4T/"]B
M/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#X\8CXF;F)S<#LD
M/"]B/CPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^/&(^-C`L,C8P
M/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#X\8CXF;F)S
M<#LD/"]B/CPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#X\8CXF;F)S<#LD
M/"]B/CPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^/&(^-S4L.3$T
M/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*
M("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD.B`C
M8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SX\8CY,:6%B:6QI=&EE
M<SPO8CX-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\
M=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M
M:6YD96YT.BTQ-7!X)SY787)R86YT<PT*("`@/"]D:78^/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/CQB
M/B9N8G-P.R0\+V(^/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF
M(S@R,3([/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/CQB/B9N
M8G-P.R0\+V(^/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R
M,3([/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/CQB/B9N8G-P
M.R0\+V(^/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XQ-"PX,C@\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^/&(^)FYB<W`[)#PO
M8CX\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C$T+#@R.#PO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%
M;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^#0H@("`\+V1I=CX-"B`@
M(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+71O<#H@,3!P="<^36%R:V5T86)L92!S96-U<FET:65S(&-O;G-I
M<W0@;V8@=&AE(&9O;&QO=VEN9SH-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG
M;CTS1&-E;G1E<CX-"B`@(#QT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G(&-E;&QS<&%C:6YG/3-$,"!B;W)D97(]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@("`\(2TM($)E
M9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@("`@(#QT9"!W:61T:#TS1#0T)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$
M,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED
M=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#DE/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$
M.24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED
M=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^
M/&(^1W)O<W,\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/D=R;W-S/"]B/CPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E
M;G1E<B!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/D%M;W)T
M:7IE9#PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&(^56YR96%L:7IE9#PO8CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C
M96YT97(@8V]L<W!A;CTS1#(^/&(^56YR96%L:7IE9#PO8CX\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L
M<W!A;CTS1#(^/&(^17-T:6UA=&5D/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1L969T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(#%P>"!S;VQI9"`C,#`P,#`P)SXH:6X@=&AO=7-A;F1S*3PO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^0V]S=#PO8CX\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED
M(",P,#`P,#`G/CQB/D=A:6X\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CY,;W-S
M/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^1F%I<B!686QU93PO8CX\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD
M(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^
M#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/CPA+2T@0FQA;FL@4W!A8V4@+2T^
M#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ
M-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[#0H@("`\+V1I=CX\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^
M#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ
M-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^/&(^,C`Q,3PO8CX-"B`@(#PO9&EV
M/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@
M/'1R('9A;&EG;CTS1&)O='1O;3X\(2TM($)L86YK(%-P86-E("TM/@T*("`@
M("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@
M=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@/"]D:78^/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/D-A<V@-"B`@(#PO
M9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX]
M,T1R:6=H=#XQ+#@R-#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F
M=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R
M,3([/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\
M+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B8C.#(Q,CL\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0^,2PX,C0\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@("`@/'1D/@T*
M("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N
M=#HM,35P>"<^36]N97D@;6%R:V5T(`T*("`@<V5C=7)I=&EE<PT*("`@/"]D
M:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT/C<L,S(Y/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T
M/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B8C.#(Q
M,CL\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO
M=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1R:6=H=#XW+#,R.3PO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X-
M"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U
M<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY';W9E<FYM96YT('-E8W5R:71I97,-
M"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@
M86QI9VX],T1R:6=H=#XU+#DY.#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N
M/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H
M=#XR/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\
M+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B8C.#(Q,CL\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0^-BPP,#`\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@("`@/'1D/@T*
M("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N
M=#HM,35P>"<^0V]R<&]R871E(&)O;F1S(&%N9"`-"B`@(&-O;6UE<F-I86P@
M<&%P97(-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1R:6=H=#XU+#<Q-3PO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX]
M,T1R:6=H=#XY/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX]
M,T1R:6=H=#XH,3PO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XI
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I
M9VAT/C4L-S(S/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@G/@T*("`@("`@
M(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X
M="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@/"]D:78^/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O
M<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A
M;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4]
M,T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A
M;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SX\8CY#87-H
M(&%N9"!C87-H(`T*("`@97%U:79A;&5N=',\+V(^#0H@("`\+V1I=CX\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0^/&(^)FYB<W`[)#PO8CX\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT/CQB/C(P+#@V-CPO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0^/&(^)FYB<W`[)#PO8CX\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT/CQB/C$Q/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^/&(^)FYB<W`[)#PO8CX\+W1D/@T*
M("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/CQB/B@Q/"]B/CPO=&0^#0H@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<#X\8CXI/"]B/CPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#X\8CXF
M;F)S<#LD/"]B/CPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^/&(^
M,C`L.#<V/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X\(2TM($)L86YK(%-P86-E
M("TM/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@/"]D:78^
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\
M='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E
M9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/DUO;F5Y(&UA<FME="`-"B`@
M('-E8W5R:71I97,-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-
M"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XU,#(\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L
M:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N
M/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H
M=#XF(S@R,3([/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N
M8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C4P,CPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,7!X)SX-"B`@("`@("`\=&0^#0H@("`\9&EV
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X
M)SXF(S$V,#L-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C
M,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D
M97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C
M;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^
M#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ
M-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^/&(^4F5S=')I8W1E9"!C87-H/"]B
M/@T*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@86QI9VX],T1L969T/CQB/B9N8G-P.R0\+V(^/"]T9#X-"B`@
M("`@("`\=&0@86QI9VX],T1R:6=H=#X\8CXU,#(\+V(^/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@86QI9VX],T1L969T/CQB/B9N8G-P.R0\+V(^/"]T9#X-"B`@
M("`@("`\=&0@86QI9VX],T1R:6=H=#X\8CXF(S@R,3([/"]B/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#X\8CXF;F)S<#LD/"]B/CPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^/&(^)B,X,C$R.SPO8CX\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^/&(^)FYB<W`[)#PO8CX\
M+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/CQB/C4P,CPO8CX\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V
M86QI9VX],T1B;W1T;VT^/"$M+2!";&%N:R!3<&%C92`M+3X-"B`@("`@("`\
M=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M
M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`@("`\
M=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M
M:6YD96YT.BTQ-7!X)SY#;W)P;W)A=&4@8F]N9',@86YD(`T*("`@8V]M;65R
M8VEA;"!P87!E<@T*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*
M("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C4T+#4W.#PO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@
M86QI9VX],T1R:6=H=#XS/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@
M86QI9VX],T1R:6=H=#XH-#4\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N
M;W=R87`^*3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1R:6=H=#XU-"PU,S8\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#%P>"<^
M#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ
M-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[#0H@("`\+V1I=CX\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B
M;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H
M="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@
M("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#X-"B`@(#QD:78@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G
M/CQB/E-H;W)T+71E<FT@#0H@("!I;G9E<W1M96YT<SPO8CX-"B`@(#PO9&EV
M/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L
M:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R
M:6=H=#X\8CXU-"PU-S@\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX]
M,T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M/CQB/C,\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$;&5F=#X\8CXF;F)S<#LD/"]B/CPO=&0^#0H@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^/&(^*#0U/"]B/CPO=&0^#0H@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<#X\8CXI/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-
M"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#X\8CXU-"PU,S8\+V(^/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N
M9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X-"B`@(#PO9&EV/@T*("`@
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M
M87)G:6XM=&]P.B`Q,'!T)SY!;&P@<V5C=7)I=&EE<R!I;F-L=61E9"!I;B!C
M87-H+"!A;F0@8V%S:"!E<75I=F%L96YT<R!H879E(&UA='5R:71I97,@;V8@
M.3`F(S$V,#MD87ES(&]R(&QE<W,@870@=&AE#0H@("!T:6UE(&]F('!U<F-H
M87-E+B!!;&P@<V5C=7)I=&EE<R!I;F-L=61E9"!I;B!S:&]R="UT97)M(&EN
M=F5S=&UE;G1S(&AA=F4@;6%T=7)I=&EE<R!O9B!W:71H:6X@;VYE#0H@("!Y
M96%R(&]F('1H92!B86QA;F-E('-H965T(&1A=&4N#0H@("`\+V1I=CX-"B`@
M(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+71O<#H@,3!P="<^5&AE<F4@=V5R92!N;R!S:6=N:69I8V%N="!R
M96%L:7IE9"!O<B!U;G)E86QI>F5D(&=A:6YS(&]R(&QO<W-E<R!O;B!T:&4@
M<V%L97,@;V8@;6%R:V5T86)L90T*("`@<V5C=7)I=&EE<R!I;B!T:&4@<VEX
M(&UO;G1H<R!E;F1E9"!*=6YE)B,Q-C`[,S`L(#(P,3$@86YD(&YO('-I9VYI
M9FEC86YT('5N<F5A;&EZ960@9V%I;G,@;W(@;&]S<V5S(&%R90T*("`@:6YC
M;'5D960@:6X@86-C=6UU;&%T960@;W1H97(@8V]M<')E:&5N<VEV92!I;F-O
M;64@87,@870@2G5N928C,38P.S,P+"`R,#$Q+B!296%L:7IE9"!G86EN<R!A
M;F0@;&]S<V5S#0H@("!A<F4@=')A;G-F97)R960@;W5T(&]F(&%C8W5M=6QA
M=&5D(&]T:&5R(&-O;7!R96AE;G-I=F4@:6YC;VUE(&EN=&\@:6YT97)E<W0@
M:6YC;VUE('5S:6YG('1H90T*("`@<W!E8VEF:6,@:61E;G1I9FEC871I;VX@
M;65T:&]D+@T*("`@/"]D:78^#0H@("`\(2TM($9O;&EO("TM/@T*("`@/"$M
M+2`O1F]L:6\@+2T^#0H@("`\+V1I=CX-"B`@(#PA+2T@4$%'14)214%+("TM
M/@T*("`@/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I;BUL969T.B`P:6X[("<^#0H@("`\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA
M<F=I;BUT;W`Z(#$P<'0G/D%L;"!O9B!T:&4@;6%R:V5T86)L92!S96-U<FET
M:65S(&AE;&0@87,@;V8@2G5N928C,38P.S,P+"`R,#$Q(&AA9"!M871U<FET
M:65S(&]F(&]N92!Y96%R(&]R(&QE<W,N(%1H90T*("`@0V]M<&%N>2!O;FQY
M(&EN=F5S=',@:6X@02`H;W(@97%U:79A;&5N="D@<F%T960@<V5C=7)I=&EE
M<R!W:71H(&UA='5R:71I97,@;V8@;VYE('EE87(@;W(@;&5S<RX-"B`@($=I
M=F5N('1H92!Q=6%L:71Y(&]F('1H92!I;G9E<W1M96YT('!O<G1F;VQI;RP@
M:71S('-H;W)T+71E<FT@;F%T=7)E+"!A;F0@<W5B<V5Q=65N="!P<F]C965D
M<PT*("`@8V]L;&5C=&5D(&]N('-A;&4@;V8@<V5C=7)I=&EE<R!T:&%T#0H@
M("!R96%C:&5D(&UA='5R:71Y+"!T:&4@0V]M<&%N>2!D;V5S(&YO="!B96QI
M979E('1H870@=&AE<F4@87)E(&%N>2!O=&AE<B!T:&%N('1E;7!O<F%R>2!I
M;7!A:7)M96YT<PT*("`@<F5L871E9"!T;R!I=',@:6YV97-T;65N=',@:6X@
M;6%R:V5T86)L92!S96-U<FET:65S(&%T($IU;F4F(S$V,#LS,"P@,C`Q,2X-
M"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SY4:&4@0V]M<&%N>2!H
M87,@<F5C;W)D960@82`F;F)S<#LD,30L.#(X+#`P,"!W87)R86YT(&QI86)I
M;&ET>2!A<R!O9B!*=6YE)B,Q-C`[,S`L(#(P,3$N(%1H92!#;VUP86YY#0H@
M("!R96%S<V5S<V5S('1H92!F86ER('9A;'5E(&]F('1H92!C;VUM;VX@<W1O
M8VL@=V%R<F%N=',@870@96%C:"!R97!O<G1I;F<@9&%T92!U=&EL:7II;F<@
M80T*("`@0FQA8VLM4V-H;VQE<R!P<FEC:6YG(&UO9&5L+B!);G!U=',@=7-E
M9"!I;B!T:&4@<')I8VEN9R!M;V1E;"!I;F-L=61E(&5S=&EM871E<R!O9B!S
M=&]C:R!P<FEC90T*("`@=F]L871I;&ET>2P@97AP96-T960@=V%R<F%N="!L
M:69E(&%N9"!R:7-K+69R964@:6YT97)E<W0@<F%T92X@5&AE(&-O;7!U=&%T
M:6]N(&]F(&5X<&5C=&5D#0H@("!V;VQA=&EL:71Y('=A<R!B87-E9"!O;B!T
M:&4@:&ES=&]R:6-A;"!V;VQA=&EL:71Y(&]F(&-O;7!A<F%B;&4@8V]M<&%N
M:65S(&9R;VT@82!R97!R97-E;G1A=&EV90T*("`@<&5E<B!G<F]U<"!S96QE
M8W1E9"!B87-E9"!O;B!I;F1U<W1R>2!A;F0@;6%R:V5T(&-A<&ET86QI>F%T
M:6]N+B!3964@;F]T92`U*&0I(&EN('1H92!.;W1E<R!T;PT*("`@1FEN86YC
M:6%L(%-T871E;65N=',@9F]R(&9U<G1H97(@9&5T86EL<R!O;B!T:&4@:6YP
M=71S('5S960@:6X@=&AE($)L86-K+5-C:&]L97,@<')I8VEN9R!M;V1E;"!U
M<V5D#0H@("!T;R!R96-A;&-U;&%T92!T:&4@=V%R<F%N="!L:6%B:6QI='DN
M#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^5&AE(&9O;&QO=VEN
M9R!T86)L92!P<F5S96YT<R!T:&4@8VAA;F=E<R!I;B!F86ER('9A;'5E(&]F
M('1H92!#;VUP86YY)B,X,C$W.W,@=&]T86P@3&5V96P@,R!F:6YA;F-I86P-
M"B`@(&QI86)I;&ET:65S(&9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE
M)B,Q-C`[,S`L(#(P,3$Z#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1C
M96YT97(^#0H@("`\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)R!C96QL<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*("`@/"$M+2!"96=I;B!4
M86)L92!(96%D("TM/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@
M("`\=&0@=VED=&@],T0U."4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED
M=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$
M,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED
M=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#DE/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V
M86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY,:6%B:6QI='D@870\
M+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/E)E;6%I;FEN9SPO8CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT
M<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R
M(&-O;'-P86X],T0R/CQB/D1E8V5M8F5R(#,Q+#PO8CX\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A
M;CTS1#(^/&(^1V%I;B`H;&]S<RD@;VX\+V(^/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R
M/CQB/DQI86)I;&ET>2!A="!*=6YE/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1L969T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CXH26X@=&AO=7-A;F1S*3PO8CX\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/C(P,3`\+V(^
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P
M>"!S;VQI9"`C,#`P,#`P)SX\8CYW87)R86YT<SPO8CX\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P
M,#`G/CQB/B`S,"P@,C`Q,3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@
M("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@("`@
M(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X
M="UI;F1E;G0Z+3$U<'@G/E=A<G)A;G0@;&EA8FEL:71Y#0H@("`\+V1I=CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^,34L,C8Y/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N
M8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C0T,3PO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@
M("`@("`\=&0@86QI9VX],T1R:6=H=#XQ-"PX,C@\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($)O
M9'D@+2T^#0H@("`\+W1A8FQE/@T*("`@/"]D:78^#0H@("`\+V1I=CX-"CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8F(X-C)D
M-C5?8F8T,%\T9#5F7V)C,61?.&(Q.3-A,V5D-3DT#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V)B.#8R9#8U7V)F-#!?-&0U9E]B8S%D7SAB,3DS
M83-E9#4Y-"]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R2#X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM;VX@4W1O8VL\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM;VX@
M4W1O8VL@86YD($-O;7!R96AE;G-I=F4@3&]S<R!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-/34U/3B!3
M5$]#2SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U19
M4$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET
M:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X
M:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L
M;V-K(%1A9V=E9"!.;W1E(#4@+2!U<RUG86%P.E-T;V-K:&]L9&5R<T5Q=6ET
M>4YO=&5$:7-C;&]S=7)E5&5X=$)L;V-K+2T^#0H@("`\9&EV('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@
M;6%R9VEN+6QE9G0Z(#!I;CL@)SX-"B`@(#QD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^
M-2X@0T]-34].(%-43T-+/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N
M/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z
M(#$P<'0G/CQB/B8C,#DQ.V$F(S`Y,SL@075T:&]R:7IE9#PO8CX-"B`@(#PO
M9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SXR-2PP,#`L,#`P(&%U=&AO<FEZ
M960@8V]M;6]N('-H87)E<RP@<&%R('9A;'5E(&]F("9N8G-P.R0P+C`P,2P@
M86YD(#4L,#`P+#`P,"!P<F5F97)R960@<VAA<F5S+"!P87(@=F%L=64-"B`@
M(&]F("9N8G-P.R0P+C`P,2X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q
M,'!T)SX\8CXF(S`Y,3MB)B,P.3,[($ES<W5E9"!A;F0@3W5T<W1A;F1I;F<@
M4VAA<F5S/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/D1U
M<FEN9R!T:&4@<VEX(&UO;G1H('!E<FEO9"!E;F1E9"!*=6YE)B,Q-C`[,S`L
M(#(P,3$@=&AE($-O;7!A;GD@:7-S=65D(#(T+#8V,"!C;VUM;VX@<VAA<F5S
M('5P;VX-"B`@(&5X97)C:7-E(&]F('-T;V-K(&]P=&EO;G,@*'!E<FEO9"!E
M;F1E9"!*=6YE)B,Q-C`[,S`L(#(P,3`@)B,X,C$R.R`Q,3<L-C0S*2!T;R!S
M871I<V9Y('-T;V-K(&]P=&EO;@T*("`@97AE<F-I<V5S+@T*("`@/"]D:78^
M#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQB/B8C,#DQ.V,F(S`Y,SL@4W1O8VL@
M;W!T:6]N<SPO8CX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\
M:3XR,#$P(%!E<F9O<FUA;F-E($EN8V5N=&EV92!0;&%N/"]I/@T*("`@/"]D
M:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/D%T('1H92`R,#$Q($%N;G5A;"!-
M965T:6YG(&]F(%-T;V-K:&]L9&5R<R!O9B!T:&4@0V]M<&%N>2!H96QD(&]N
M($UA>28C,38P.S(V+"`R,#$Q+"!S=&]C:VAO;&1E<G,@;V8@=&AE#0H@("!#
M;VUP86YY(&%P<')O=F5D(&%N(&%M96YD;65N="!T;R!T:&4@0V]M<&%N>28C
M.#(Q-SMS(#(P,3`@4&5R9F]R;6%N8V4@26YC96YT:79E(%!L86XN($%S(&$@
M<F5S=6QT(&]F('1H:7,-"B`@(&%M96YD;65N="P@=&AE(#(P,3`@4&QA;B!W
M87,@86UE;F1E9"!T;R!P<F]V:61E(&9O<B!A;B!I;F-R96%S92!I;B!T:&4@
M=&]T86P@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:PT*("`@879A:6QA8FQE(&9O
M<B!I<W-U86YC92!U;F1E<B!T:&4@,C`Q,"!0;&%N(&9R;VT@-#4P+#`P,"!T
M;R`Q+#`U,"PP,#`N($%S(&%T($IU;F4F(S$V,#LS,"P@,C`Q,2!T:&4-"B`@
M($-O;7!A;GD@:&%S(')E<V5R=F5D+"!P=7)S=6%N="!T;R!V87)I;W5S('!L
M86YS+"`Q+#4Y."PP-S4@8V]M;6]N('-H87)E<R!F;W(@:7-S=6%N8V4@=7!O
M;B!E>&5R8VES90T*("`@;V8@<W1O8VL@;W!T:6]N<R!B>2!E;7!L;WEE97,L
M(&1I<F5C=&]R<RP@;V9F:6-E<G,@86YD(&-O;G-U;'1A;G1S(&]F('1H92!#
M;VUP86YY+"!O9B!W:&EC:"`W-S<L,S4Y#0H@("!A<F4@<F5S97)V960@9F]R
M(&]P=&EO;G,@8W5R<F5N=&QY(&]U='-T86YD:6YG+"!A;F0@.#(P+#<Q-B!A
M<F4@879A:6QA8FQE(&9O<B!F=71U<F4@;W!T:6]N(&=R86YT<RX-"B`@(#PO
M9&EV/@T*("`@/"$M+2!&;VQI;R`M+3X-"B`@(#PA+2T@+T9O;&EO("TM/@T*
M("`@/"]D:78^#0H@("`\(2TM(%!!1T5"4D5!2R`M+3X-"B`@(#QD:78@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E
M<FEF.R!M87)G:6XM;&5F=#H@,&EN.R`G/@T*("`@/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T
M)SX\:3Y3=&]C:R!/<'1I;VX@4W5M;6%R>3PO:3X-"B`@(#PO9&EV/@T*("`@
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M
M87)G:6XM=&]P.B`Q,'!T)SY/<'1I;VYS('9E<W0@:6X@86-C;W)D86YC92!W
M:71H('1E<FUS(&%S(&1E=&5R;6EN960@8GD@=&AE(&)O87)D(&]F(&1I<F5C
M=&]R<R!O9B!T:&4@0V]M<&%N>2P@;W(-"B`@('1H92!";V%R9"P@='EP:6-A
M;&QY(&]V97(@9F]U<B!Y96%R<R!F;W(@96UP;&]Y964@9W)A;G1S(&%N9"!O
M;F4@=&\@=&AR964@>65A<G,@9F]R($)O87)D(&]P=&EO;@T*("`@9W)A;G1S
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M<VAA<F4@870@=&AE(&=R86YT(&1A=&4N#0H@("`\+V1I=CX-"B`@(#QD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+71O<#H@,3!P="<^4W1O8VL@;W!T:6]N('1R86YS86-T:6]N<R!A;F0@=&AE
M(&YU;6)E<B!O9B!S=&]C:R!O<'1I;VYS(&]U='-T86YD:6YG(&%R92!S=6UM
M87)I>F5D(&)E;&]W.@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$8V5N
M=&5R/@T*("`@/'1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<@8V5L;'-P86-I;F<],T0P(&)O<F1E<CTS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`@(#PA+2T@0F5G:6X@5&%B
M;&4@2&5A9"`M+3X-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@
M/'1D('=I9'1H/3-$-S(E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H
M/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#DE/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@/"]T
M<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS
M1&)O='1O;3X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/DYU;6)E<B`\8G(@+SX-"B`@(&]F
M/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY796EG:'1E9#PO8CX\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P
M86X],T0R/CQB/D]P=&EO;F5D/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY!
M=F5R86=E/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&(^0V]M;6]N/"]B/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C
M;VQS<&%N/3-$,CX\8CY%>&5R8VES93PO8CX\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CY3:&%R
M97,\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CY0<FEC93PO8CX\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X]
M,T0R/CQB/B,\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/B9N8G-P.R0\+V(^
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\
M(2TM($5N9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!"
M;V1Y("TM/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K
M9W)O=6YD.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE
M/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SX\8CY"
M86QA;F-E+"!$96-E;6)E<B8C,38P.S,Q+"`R,#$P/"]B/@T*("`@/"]D:78^
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#X\8CXW-#0L.3$S
M/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^/&(^."XW,SPO8CX\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T
M;VT^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F
M=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^3W!T:6]N(&=R86YT<PT*("`@
M/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XW-2PY
M,#`\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!A;&EG;CTS1')I9VAT/C$W+C`S/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD
M:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U
M<'@G/D]P=&EO;B!E>'!I<F%T:6]N<R]C86YC96QL871I;VYS#0H@("`\+V1I
M=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1L969T/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0^*#8L,3$R/"]T9#X-"B`@("`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT/C$S+C@V/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#X-
M"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E
M;G0Z+3$U<'@G/D]P=&EO;B!E>&5R8VES97,-"B`@(#PO9&EV/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1R:6=H=#XH,C0L-C8P/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P/BD\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C,N
M-C<\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@
M(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C
M965F9B<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM
M;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^3W!T:6]N(&9O<F9E:71U
M<F5S#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1L969T/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^*#$R+#8X,CPO=&0^
M#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1R:6=H=#XQ,BXV-CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,7!X)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@(#PO
M9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS
M1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@
M(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X
M="UI;F1E;G0Z+3$U<'@G/CQB/D)A;&%N8V4L($IU;F4F(S$V,#LS,"P@,C`Q
M,3PO8CX-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^/&(^-S<W+#,U.3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/CQB/CDN-3D\+V(^
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\
M(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X-"B`@(#PO9&EV
M/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SY4:&4@9F%I<B!V86QU92!O9B!E86-H
M('-T;V-K(&%W87)D(&ES(&5S=&EM871E9"!O;B!T:&4@9W)A;G0@9&%T92!U
M<VEN9R!T:&4@0FQA8VLM4V-H;VQE<PT*("`@;W!T:6]N+7!R:6-I;F<@;6]D
M96P@8F%S960@;VX@=&AE('=E:6=H=&5D+6%V97)A9V4@87-S=6UP=&EO;G,@
M;F]T960@:6X@=&AE(&9O;&QO=VEN9R!T86)L93H-"B`@(#PO9&EV/@T*("`@
M/&1I=B!A;&EG;CTS1&-E;G1E<CX-"B`@(#QT86)L92!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G(&-E;&QS<&%C:6YG/3-$
M,"!B;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@
M("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@("`@(#QT9"!W:61T:#TS1#<R)3XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Y
M)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T
M:#TS1#DE/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q
M-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$-B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^4VEX(&UO
M;G1H<R!E;F1E9"!*=6YE(#,P+#PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CXR,#$Q/"]B
M/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q
M<'@@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,#PO8CX\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE
M860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G
M/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E)I<VLM9G)E92!I;G1E<F5S="!R
M871E<PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$;&5F=#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C(N,SD\+W1D/@T*
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`^)3PO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H
M=#XR+C0Q/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/B4\+W1D
M/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@
M/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT
M+6EN9&5N=#HM,35P>"<^17AP96-T960@9&EV:61E;F0@>6EE;&0-"B`@(#PO
M9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@86QI9VX],T1R:6=H=#XP/"]T9#X-"B`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P/B4\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1L969T/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,#PO=&0^#0H@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XE/"]T9#X-"B`@(#PO='(^#0H@("`\
M='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E
M9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/D5X<&5C=&5D(&QI9F4-"B`@
M(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT
M/C8@>65A<G,\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#XV('EE87)S/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/D5X<&5C=&5D('9O;&%T
M:6QI='D-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XW-3PO=&0^#0H@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XE/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$;&5F=#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M/C<T/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/B4\+W1D/@T*
M("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A
M8FQE/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/E1H92!E>'!E
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M=6UP=&EO;G,@86)O=F4L(&%S(')E<75I<F5D('5N9&5R($%30R`W,3@L(&UA
M;F%G96UE;G0@;6%D92!A;B!E<W1I;6%T92!O9@T*("`@97AP96-T960@9F]R
M9F5I='5R97,@86YD(&ES(')E8V]G;FEZ:6YG(&-O;7!E;G-A=&EO;B!C;W-T
M<R!O;FQY(&9O<B!T:&]S92!E<75I='D@87=A<F1S(&5X<&5C=&5D('1O#0H@
M("!V97-T+@T*("`@/"]D:78^#0H@("`\(2TM($9O;&EO("TM/@T*("`@/"$M
M+2`O1F]L:6\@+2T^#0H@("`\+V1I=CX-"B`@(#PA+2T@4$%'14)214%+("TM
M/@T*("`@/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I;BUL969T.B`P:6X[("<^#0H@("`\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA
M<F=I;BUT;W`Z(#$P<'0G/E1H92!R97-U;'1S(&9O<B!T:&4@<&5R:6]D<R!S
M970@9F]R=&@@8F5L;W<@:6YC;'5D960@<VAA<F4M8F%S960@8V]M<&5N<V%T
M:6]N(&5X<&5N<V4@:6X@=&AE#0H@("!F;VQL;W=I;F<@97AP96YS92!C871E
M9V]R:65S(&]F('1H92!C;VYS;VQI9&%T960@<W1A=&5M96YT<R!O9B!L;W-S
M.@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$8V5N=&5R/@T*("`@/'1A
M8FQE('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<@8V5L;'-P86-I;F<],T0P(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$,3`P)3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-
M"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D('=I9'1H/3-$
M-#0E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!W:61T:#TS1#DE/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I
M9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0S)3XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS
M1#,E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I
M9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#DE/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@(#PO='(^
M#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B
M;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<B!C;VQS<&%N/3-$-CX\8CY4:')E92!-;VYT:',\+V(^/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R
M(&-O;'-P86X],T0V/CQB/E-I>"!-;VYT:',\+V(^/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$-CX\
M8CY%;F1E9#PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#8^/&(^16YD960\+V(^/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C
M;VQS<&%N/3-$-B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@
M(S`P,#`P,"<^/&(^2G5N92`S,"P\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0V('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CY*
M=6YE(#,P+#PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG
M;CTS1&)O='1O;3X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$;&5F="!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P
M,#`P,"<^*$EN('1H;W5S86YD<RD\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT
M97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O
M;&ED(",P,#`P,#`G/CQB/C(P,3$\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CXR
M,#$P/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,3PO8CX\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P
M,#`P,#`G/CQB/C(P,3`\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N
M=&5R(&-O;'-P86X],T0R/CQB/B9N8G-P.R0\+V(^/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X]
M,T0R/CQB/B9N8G-P.R0\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/B9N8G-P
M.R0\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/B9N8G-P.R0\+V(^/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N
M9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM
M/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD
M.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY297-E87)C:"!A
M;F0@9&5V96QO<&UE;G0-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^,3(R/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XW-#PO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^,C0S/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1R:6=H=#XQ-#(\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@
M("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X
M.R!T97AT+6EN9&5N=#HM,35P>"<^1V5N97)A;"!A;F0@861M:6YI<W1R871I
M=F4-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^,38Q/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1R:6=H=#XW,#PO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,S$Q/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX]
M,T1R:6=H=#XQ-CD\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#%P>"<^#0H@("`@
M("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T
M97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[#0H@("`\+V1I=CX\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M
M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG
M:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS
M<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P
M>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL
M93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@
M=F%L:6=N/3-$8F]T=&]M/CPA+2T@0FQA;FL@4W!A8V4@+2T^#0H@("`@("`@
M/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT
M+6EN9&5N=#HM,35P>"<^)B,Q-C`[#0H@("`\+V1I=CX\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@("`@
M/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT
M+6EN9&5N=#HM,35P>"<^/&(^5&]T86P@<VAA<F4M8F%S960@8V]M<&5N<V%T
M:6]N/"]B/@T*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX]
M,T1R:6=H=#X\8CXR.#,\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#X\8CXQ-#0\+V(^/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1R:6=H=#X\8CXU-30\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#X\8CXS,3$\+V(^
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\
M(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X-"B`@(#PO9&EV
M/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SY/<'1I;VYS('9E<W0@:6X@86-C;W)D
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M("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/D%S(&%T($IU;F4F(S$V
M,#LS,"P@,C`Q,2!A;F0@1&5C96UB97(F(S$V,#LS,2P@,C`Q,"!T:&4@=&]T
M86P@=6YR96-O9VYI>F5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T960@
M=&\-"B`@('-T;V-K(&]P=&EO;G,@9W)A;G1E9"!I<R`F;F)S<#LD,RPQ-S8L
M,#`P(&%N9"`F;F)S<#LD,BPY-C(L,#`P(')E<W!E8W1I=F5L>2P@=VAI8V@@
M:7,@97AP96-T960@=&\@8F4@<F5C;V=N:7IE9`T*("`@:6YT;R!E>'!E;G-E
M(&]V97(@82!P97)I;V0@;V8@87!P<F]X:6UA=&5L>2!F;W5R('EE87)S+@T*
M("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/D%S(&]F($IU;F4F(S$V
M,#LS,"P@,C`Q,2!A;F0@1&5C96UB97(F(S$V,#LS,2P@,C`Q,"!A('1O=&%L
M(&]F(#(L,S8T+#8V,"!A;F0@,BPS,S(L,C$T(&]P=&EO;G,@86YD('=A<G)A
M;G1S+`T*("`@<F5S<&5C=&EV96QY+"!H879E(&YO="!B965N(&EN8VQU9&5D
M(&EN('1H92!C86QC=6QA=&EO;B!O9B!P;W1E;G1I86P@8V]M;6]N('-H87)E
M<R!A<R!T:&5I<B!E9F9E8W0-"B`@(&]N(&1I;'5T960@<&5R('-H87)E(&%M
M;W5N=',@=V]U;&0@:&%V92!B965N(&%N=&DM9&EL=71I=F4N#0H@("`\+V1I
M=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^)B,P.3$[9"8C,#DS.R!3=&]C
M:R!787)R86YT<SPO8CX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T
M)SY!="!*=6YE)B,Q-C`[,S`L(#(P,3$L('1H97)E('=E<F4@97AE<F-I<V%B
M;&4@=V%R<F%N=',@;W5T<W1A;F1I;F<@=&\@<'5R8VAA<V4@,2PU.#<L,S`Q
M#0H@("!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%T(&%N(&5X97)C:7-E('!R
M:6-E(&]F("9N8G-P.R0R,"!P97(@<VAA<F4L(&5X<&ER:6YG(&EN($]C=&]B
M97(F(S$V,#LR,#$U+@T*("`@3F\@=V%R<F%N=',@=V5R92!E>&5R8VES960@
M9'5R:6YG('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4F(S$V,#LS,"P@,C`Q
M,2!O<B!S:7@@;6]N=&AS(&5N9&5D#0H@("!*=6YE)B,Q-C`[,S`L(#(P,3`N
M#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^5&AE(&5S=&EM871E
M9"!F86ER('9A;'5E(&]F('=A<G)A;G1S(&ES<W5E9"!I<R!R96%S<V5S<V5D
M(&%T(&5A8V@@8F%L86YC92!S:&5E="!D871E#0H@("!U<VEN9R!T:&4@0FQA
M8VLM4V-H;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E;"X@5&AE(&9O;&QO=VEN
M9R!A<W-U;7!T:6]N<R!W97)E('5S960@=&\-"B`@('9A;'5E('1H92!W87)R
M86YT<R!O;B!T:&4@9F]L;&]W:6YG(&)A;&%N8V4@<VAE970@9&%T97,Z#0H@
M("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1C96YT97(^#0H@("`\=&%B;&4@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)R!C
M96QL<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0Q,#`E/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@
M/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0@=VED=&@],T0W,B4^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@]
M,T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#,E/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W
M:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A
M;CTS1#8@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P
M,#`G/CQB/E-I>"!M;VYT:',@96YD960@2G5N92`S,"P\+V(^/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N
M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P
M,"<^/&(^,C`Q,3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/C(P,3`\+V(^/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM
M($5N9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y
M("TM/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O
M=6YD.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY2:7-K+69R
M964@:6YT97)E<W0@<F%T97,-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H
M=#XQ+C0S/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/B4\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B8C.#(Q,CL\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI
M9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M
M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^17AP96-T960@
M9&EV:61E;F0@>6EE;&0-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XP
M/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/B4\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B8C.#(Q,CL\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@("`@
M/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT
M+6EN9&5N=#HM,35P>"<^17AP96-T960@;&EF90T*("`@/"]D:78^/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#QT9"!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#XT+C,@>65A<G,\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT/B8C.#(Q,CL\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D
M/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN
M9&5N=#HM,35P>"<^17AP96-T960@=F]L871I;&ET>0T*("`@/"]D:78^/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$;&5F=#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!A;&EG;CTS1')I9VAT/C<V/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P/B4\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B8C
M.#(Q,CL\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-
M"B`@(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A8FQE/@T*("`@
M/"]D:78^#0H@("`\+V1I=CX-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?8F(X-C)D-C5?8F8T,%\T9#5F7V)C,61?.&(Q.3-A
M,V5D-3DT#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)B.#8R9#8U
M7V)F-#!?-&0U9E]B8S%D7SAB,3DS83-E9#4Y-"]7;W)K<VAE971S+U-H965T
M,3$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$4R2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY2
M97-T<G5C='5R:6YG($%C=&EV:71I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-T<G5C='5R:6YG($%C=&EV
M:71I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y215-44E5#5%5224Y'($%#5$E6251)15,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"
M3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@
M(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS
M:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@
M3F]T92`V("T@=7,M9V%A<#I297-T<G5C='5R:6YG06YD4F5L871E9$%C=&EV
M:71I97-$:7-C;&]S=7)E5&5X=$)L;V-K+2T^#0H@("`\9&EV('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@
M;6%R9VEN+6QE9G0Z(#!I;CL@)SX-"B`@(#QD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^
M-BX@4D535%)50U154DE.1R!!0U1)5DE42453/"]B/@T*("`@/"]D:78^#0H@
M("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&UA<F=I;BUT;W`Z(#$P<'0G/D]N($%U9W5S="8C,38P.S(Q+"`R,#`X+"!3
M;VYU<R!0:&%R;6%C975T:6-A;',L($EN8RXL(&]R(%-O;G5S+"!C;VUP;&5T
M960@82!T<F%N<V%C=&EO;BP@;W(@)B,X,C(P.W1H90T*("`@07)R86YG96UE
M;G0F(S@R,C$[+"!W:71H($]N8V]'96YE>"!496-H;F]L;V=I97,@=VAE<F5B
M>2!3;VYU<R!A8W%U:7)E9"!A;&P@;V8@=&AE(&]U='-T86YD:6YG('!R969E
M<G)E9`T*("`@<VAA<F5S+"!C;VUM;VX@<VAA<F5S(&%N9"!C;VYV97)T:6)L
M92!D96)E;G1U<F5S(&]F($]N8V]'96YE>"!496-H;F]L;V=I97,N(%-O;G5S
M('1H96X@8VAA;F=E9"!I=',-"B`@(&YA;64@=&\@3VYC;T=E;F5X(%!H87)M
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M96-O<F1E9"!A;@T*("`@:6YI=&EA;"!R97-T<G5C='5R:6YG(&-H87)G92!O
M9B`F;F)S<#LD,BPP.#0L,#`P(&]N($%U9W5S="8C,38P.S(Q+"`R,#`X(&%S
M('!A<G0@;V8@=&AE('!U<F-H87-E('!R:6-E#0H@("!A;&QO8V%T:6]N+B!4
M:&4@;&EA8FEL:71Y(&ES(&-O;7!U=&5D(&%S('1H92!P<F5S96YT('9A;'5E
M(&]F('1H92!D:69F97)E;F-E(&)E='=E96X@=&AE(')E;6%I;FEN9PT*("`@
M;&5A<V4@<&%Y;65N=',@9'5E(&QE<W,@=&AE(&5S=&EM871E(&]F(&YE="!S
M=6)L96%S92!I;F-O;64@86YD(&5X<&5N<V5S(&%N9"!H87,@8F5E;B!A8V-O
M=6YT960@9F]R#0H@("!I;B!A8V-O<F1A;F-E('=I=&@@=&AE('1H96X@969F
M96-T:79E($5)5$8@3F\N)B,Q-C`[.34M,RP@)B,X,C(P.U)E8V]G;FET:6]N
M(&]F($QI86)I;&ET:65S(&EN($-O;FYE8W1I;VX@=VET:`T*("`@82!0=7)C
M:&%S92!"=7-I;F5S<R!#;VUB:6YA=&EO;B8C.#(R,3LN(%1H:7,@<F5P<F5S
M96YT<R!T:&4@0V]M<&%N>28C.#(Q-SMS(&)E<W0@97-T:6UA=&4@;V8@=&AE
M(&QI86)I;&ET>2X-"B`@(%-U8G-E<75E;G0@8VAA;F=E<R!I;B!T:&4@;&EA
M8FEL:71Y(&1U92!T;R!C:&%N9V5S(&EN(&5S=&EM871E<R!O9B!S=6)L96%S
M92!A<W-U;7!T:6]N<R!A<F4-"B`@(')E8V]G;FEZ960@87,@861J=7-T;65N
M=',@=&\@<F5S=')U8W1U<FEN9R!C:&%R9V5S+@T*("`@/"]D:78^#0H@("`\
M(2TM($9O;&EO("TM/@T*("`@/"$M+2`O1F]L:6\@+2T^#0H@("`\+V1I=CX-
M"B`@(#PA+2T@4$%'14)214%+("TM/@T*("`@/&1I=B!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I
M;BUL969T.B`P:6X[("<^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/DEN($IU;F4F
M(S$V,#LR,#`Y+"!T:&4@0V]M<&%N>2!R979I<V5D(&ET<R!S=6)L96%S92!I
M;F-O;64@87-S=6UP=&EO;G,@=7-E9"!T;R!E<W1I;6%T92!T:&4@97AC97-S
M(&QE87-E#0H@("!F86-I;&ET>2!L:6%B:6QI='DN(%1H97-E(&%S<W5M<'1I
M;VYS('=E<F4@<W5B<V5Q=65N=&QY(')E=FES960@86=A:6X@:6X@1&5C96UB
M97(F(S$V,#LR,#`Y(&%N9`T*("`@4V5P=&5M8F5R#0H@("`R,#$P+B!4:&5S
M92!C:&%N9V5S(&EN(&5S=&EM871E(')E<W5L=&5D(&EN(&EN8W)E87-E<R!I
M;B!T:&4@=F%L=64@;V8@=&AE(&5X8V5S<R!L96%S92!L:6%B:6QI='D@;V8-
M"B`@("9N8G-P.R0T.30L,#`P+"`F;F)S<#LD,RPT-3<L,#`P+"!A;F0@)FYB
M<W`[)#0L,#,X+#`P,"!A;F0@82!C;W)R97-P;VYD:6YG(&5X<&5N<V4@<F5C
M;W)D960@:6X@2G5N928C,38P.S(P,#DL($1E8V5M8F5R#0H@("`R,#`Y+"!A
M;F0@4V5P=&5M8F5R)B,Q-C`[,C`Q,"P@<F5S<&5C=&EV96QY+"!T;R!R969L
M96-T('1H97-E(&-H86YG97,@:6X@97-T:6UA=&4N(%1H92!E<W1I;6%T960@
M=F%L=64-"B`@(&]F('1H92!L:6%B:6QI='D@<F5M86EN:6YG('=I=&@@<F5S
M<&5C="!T;R!E>&-E<W,@9F%C:6QI=&EE<R!W87,@)FYB<W`[)#<L-#8W+#`P
M,"!A<R!O9B!$96-E;6)E<B8C,38P.S,Q+`T*("`@,C`Q,"X@26X@=&AE('-I
M>"!M;VYT:',@96YD960@2G5N928C,38P.S,P+"`R,#$Q+"!W:71H(')E<W!E
M8W0@=&\@97AC97-S(&9A8VEL:71I97,L("9N8G-P.R0Q-#`L,#`P('=A<PT*
M("`@86UO<G1I>F5D(&EN=&\@:6YC;VUE(')E<W5L=&EN9R!I;B!A(')E;6%I
M;FEN9R!L:6%B:6QI='D@;V8@)FYB<W`[)#<L,S(W+#`P,"!A="!*=6YE)B,Q
M-C`[,S`L(#(P,3$N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1C96YT
M97(^#0H@("`\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)R!C96QL<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*("`@/"$M+2!"96=I;B!486)L
M92!(96%D("TM/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\
M=&0@=VED=&@],T0T-"4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@]
M,T0S)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W
M:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@]
M,T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#DE/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W
M:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$.24^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D
M/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G
M('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/E)E;6%I;FEN9SPO
M8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1C96YT97(@8V]L<W!A;CTS1#(^/&(^06UO<G1I>F%T:6]N/"]B/CPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E
M<B!C;VQS<&%N/3-$,CX\8CY!9&1I=&EO;F%L/"]B/CPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N
M/3-$,CX\8CY296UA:6YI;F<\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY,:6%B:6QI
M='D@870\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/F]F(&5X8V5S<SPO8CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C
M96YT97(@8V]L<W!A;CTS1#(^/&(^3&EA8FEL:71Y/"]B/CPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS
M<&%N/3-$,CX\8CY,:6%B:6QI='D\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M,7!X('-O;&ED(",P,#`P,#`G/CQB/BA);B!T:&]U<V%N9',I/"]B/CPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^1&5C96UB97(@
M,S$L(#(P,3`\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CYL96%S92!F86-I;&ET
M>3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/E)E8V]R9&5D/"]B/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C
M;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@
M(S`P,#`P,"<^/&(^870@2G5N92`S,"P@,C`Q,3PO8CX\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE
M($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\
M='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E
M9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/D-U<G)E;G0@<&]R=&EO;B!O
M9B`-"B`@(&5X8V5S<R!L96%S92`-"B`@(&9A8VEL:71Y#0H@("`\+V1I=CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^,2PS,#,\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT/B@U,SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XI
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I
M9VAT/B8C.#(Q,CL\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^
M)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,2PS-38\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT
M<B!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL
M93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^3&]N
M9RUT97)M('!O<G1I;VX@#0H@("!O9B!E>&-E<W,@;&5A<V4@#0H@("!F86-I
M;&ET>0T*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@
M(#QT9"!A;&EG;CTS1')I9VAT/C8L,38T/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT/C$Y,SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF
M;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D
M/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C4L.3<Q/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q<'@G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P
M.PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C
M;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S
M='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X]
M,T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O
M;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=B86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X
M)SX\8CY4;W1A;#PO8CX-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#X\8CXF;F)S<#LD
M/"]B/CPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^/&(^-RPT-C<\
M+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/CQB/B9N8G-P
M.R0\+V(^/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#X\8CXQ-#`\
M+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/CQB/B9N8G-P
M.R0\+V(^/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#X\8CXF(S@R
M,3([/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S
M<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#X\8CXW+#,R-SPO
M8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@
M(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A8FQE/@T*("`@/"]D
M:78^#0H@("`\+V1I=CX-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?8F(X-C)D-C5?8F8T,%\T9#5F7V)C,61?.&(Q.3-A,V5D
M-3DT#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)B.#8R9#8U7V)F
M-#!?-&0U9E]B8S%D7SAB,3DS83-E9#4Y-"]7;W)K<VAE971S+U-H965T,3(N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4R2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM
M:71M96YT<R!!;F0@0V]N=&EN9V5N8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#
M;VYT:6YG96YC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0T]-34E4345.5%,@04Y$($-/3E1)3D=%
M3D-)15,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-4
M65!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I
M=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O
M>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!"
M;&]C:R!486=G960@3F]T92`W("T@=7,M9V%A<#I#;VUM:71M96YT<T%N9$-O
M;G1I;F=E;F-I97-$:7-C;&]S=7)E5&5X=$)L;V-K+2T^#0H@("`\9&EV('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UE<RQS
M97)I9CL@;6%R9VEN+6QE9G0Z(#!I;CL@)SX-"B`@(#QD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P
M="<^/&(^-RX@0T]-34E4345.5%,@04Y$($-/3E1)3D=%3D-)15,\+V(^#0H@
M("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&D^5&5V82!0:&%R;6%C
M975T:6-A;"!);F1U<W1R:65S($QT9"X\+VD^#0H@("`\+V1I=CX-"B`@(#QD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R
M9VEN+71O<#H@,3!P="<^56YD97(@=&AE($-O;&QA8F]R871I;VX@06=R965M
M96YT+"!4979A(&UA9&4@=7!F<F]N="!P87EM96YT<R!I;B!T:&4@86=G<F5G
M871E(&%M;W5N="!O9B`F;F)S<#LD-3`-"B`@(&UI;&QI;VXL(&UA>2!M86ME
M('5P('1O("9N8G-P.R0S-S`F(S$V,#MM:6QL:6]N(&EN(&%D9&ET:6]N86P@
M<&%Y;65N=',@=7!O;B!T:&4@86-H:65V96UE;G0@;V8@9&5V96QO<&UE;G1A
M;`T*("`@86YD(&-O;6UE<F-I86P@;6EL97-T;VYE<R!A;F0@;6%Y(&)E(')E
M<75I<F5D(&EN('1H92!F=71U<F4@=&\@<&%Y(')O>6%L=&EE<R!A="!P97)C
M96YT86=E(')A=&5S#0H@("!R86YG:6YG(&9R;VT@=&AE(&UI9"UT965N<R!T
M;R!M:60M='=E;G1I97,@;VX@;F5T('-A;&5S+B!4:&4@0V]M<&%N>2!I<R!R
M97%U:7)E9"!T;R!C;VYT<FEB=71E("9N8G-P.R0S,`T*("`@;6EL;&EO;B!I
M;B!D:7)E8W0@86YD(&EN9&ER96-T(&-O<W1S('1O=V%R9',@=&AE($-L:6YI
M8V%L($1E=F5L;W!M96YT(%!L86XN($%S(&]F($IU;F4F(S$V,#LS,"P@,C`Q
M,2P-"B`@("9N8G-P.R0Q,"XQ)B,Q-C`[;6EL;&EO;B!O9B!T:&5S92!C;W-T
M<R!H879E(&)E96X@:6YC=7)R960@8GD@3VYC;T=E;F5X+"!R97-U;'1I;F<@
M:6X@82!R96UA:6YI;F<@9G5N9&EN9PT*("`@<F5S<&]N<VEB:6QI='D@;V8@
M)FYB<W`[)#$Y+CDF(S$V,#MM:6QL:6]N('=H:6-H(&AA<R!B965N(')E8V]R
M9&5D('5N9&5R($-U<G)E;G0@86YD($QO;F<M=&5R;2!$969E<G)E9`T*("`@
M0V]L;&%B;W)A=&EO;B!2979E;G5E(&%S(&]F($IU;F4F(S$V,#LS,"P@,C`Q
M,2X@5&5V82!W:6QL(&9U;F0@86QL(&]T:&5R(&5X<&5N<V5S('5N9&5R('1H
M92!#;&EN:6-A;`T*("`@1&5V96QO<&UE;G0@4&QA;BX@4V5E(&YO=&4@,R!I
M;B!T:&4@3F]T97,@=&\@1FEN86YC:6%L(%-T871E;65N=',@9F]R(&9U<G1H
M97(@9&5T86EL<R!O;B!O=7(-"B`@($-O;&QA8F]R871I;VX@06=R965M96YT
M('=I=&@@5&5V82X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\
M:3Y)<VES(%!H87)M86-E=71I8V%L<R!);F,N(&%N9"!5;FEV97)S:71Y(&]F
M($)R:71I<V@@0V]L=6UB:6$\+VD^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O
M<#H@,3!P="<^5&\@9F%C:6QI=&%T92!T:&4@97AE8W5T:6]N(&%N9"!P97)F
M;W)M86YC92!O9B!T:&4@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0@=VET:"!4
M979A+"!/;F-O1V5N97@@86YD#0H@("!)<VES(&%G<F5E9"!T;R!A;65N9"!T
M:&4@27-I<R!,:6-E;G-E($%G<F5E;65N="!A;F0@=&AE($-O;7!A;GD@86YD
M(%5"0R!A9W)E960@=&\@86UE;F0@=&AE(%5"0PT*("`@3&EC96YS92!!9W)E
M96UE;G0L(&EN(&5A8V@@8V%S92P@969F96-T:79E($1E8V5M8F5R)B,Q-C`[
M,3D@86YD($1E8V5M8F5R)B,Q-C`[,C`L(#(P,#DL(')E<W!E8W1I=F5L>2X-
M"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SY4:&4@86UE;F1M96YT
M('1O('1H92!)<VES($QI8V5N<V4@06=R965M96YT('!R;W9I9&5S+"!A;6]N
M9R!O=&AE<B!T:&EN9W,L('1H870@:68@=&AE($-O;7!A;GD@:7,-"B`@('1H
M92!S=6)J96-T(&]F(&$@8VAA;F=E(&]F(&-O;G1R;VP@=VET:"!A('1H:7)D
M('!A<G1Y+"!W:&5R92!T:&4@<W5R=FEV:6YG(&-O;7!A;GD@:6UM961I871E
M;'D-"B`@(&9O;&QO=VEN9R!S=6-H(&-H86YG92!O9B!C;VYT<F]L(&AA<R!T
M:&4@<FEG:'0@=&\@9&5V96QO<"!A;F0@<V5L;"!T:&4@<')O9'5C="P@=&AE
M;B`H:2DF(S$V,#MA#0H@("!M:6QE<W1O;F4@<&%Y;65N="!O9B`F;F)S<#LD
M,C`F(S$V,#MM:6QL:6]N('=I;&P@8F4@9'5E(&%N9"!P87EA8FQE('1O($ES
M:7,@,C$F(S$V,#MD87ES(&9O;&QO=VEN9R!T:&4@9FER<W0-"B`@(&-O;6UE
M<F-I86P@<V%L92!O9B!T:&4@<')O9'5C="!I;B!T:&4@56YI=&5D(%-T871E
M<SL@86YD("AI:2DF(S$V,#MU;FQE<W,@<W5C:"!S=7)V:79I;F<@96YT:71Y
M(&AA9`T*("`@<')E=FEO=7-L>2!S=6)L:6-E;G-E9"!T:&4@<')O9'5C="!A
M;F0@82!R;WEA;'1Y(')A=&4@<&%Y86)L92!T;R!)<VES(&)Y('1H92!#;VUP
M86YY(&AA<R!B965N#0H@("!E<W1A8FQI<VAE9"P@=&AE(&%P<&QI8V%B;&4@
M<F]Y86QT>2!R871E('!A>6%B;&4@=&\@27-I<R!W:6QL('1H97)E869T97(@
M8F4@=&AE(&UA>&EM=6T@86UO=6YT#0H@("!P87EA8FQE('5N9&5R('1H92!)
M<VES($QI8V5N<V4@06=R965M96YT+B!!;GD@;F]N+7)O>6%L='D@;6EL97-T
M;VYE(&%M;W5N=',@<')E=FEO=7-L>2!P86ED('=I;&P@8F4-"B`@(&-R961I
M=&5D('1O=V%R9"!T:&4@)FYB<W`[)#(P)B,Q-C`[;6EL;&EO;B!M:6QE<W1O
M;F4@:68@;F]T(&%L<F5A9'D@<&%I9"X@07,@82!R97-U;'0@;V8@=&AE("9N
M8G-P.R0Q,"8C,38P.VUI;&QI;VX-"B`@(&UI;&5S=&]N92!P87EM96YT('!A
M>6%B;&4@=&\@27-I<R!I;B!R96QA=&EO;B!T;R!T:&4@0V]L;&%B;W)A=&EO
M;B!!9W)E96UE;G0L('1H92!R96UA:6YI;F<@86UO=6YT#0H@("!O=VEN9R!I
M;B!T:&4@979E;G0@;V8@8VAA;F=E(&]F(&-O;G1R;VP@9&ES8W5S<V5D(&%B
M;W9E(&ES(&$@;6%X:6UU;2!O9B`F;F)S<#LD,3`F(S$V,#MM:6QL:6]N+B!!
M<R!T:&4@0V]M<&%N>0T*("`@:&%S(&YO=R!L:6-E;G-E9"!T:&4@<')O9'5C
M="!T;R!4979A(&%N9"!E<W1A8FQI<VAE9"!A(')O>6%L='D@<F%T92!P87EA
M8FQE('1O($ES:7,L(&YO(')O>6%L='D-"B`@(')A=&4@861J=7-T;65N=',@
M=V]U;&0@87!P;'D@:68@5&5V82!A8W%U:7)E<R!T:&4@0V]M<&%N>2!A;F0@
M:7,@=&AE('-U<G9I=FEN9R!C;VUP86YY+B!)9B!T:&4@)FYB<W`[)#,P#0H@
M("!M:6QL:6]N(&EN(&%D=F%N8V5D(')E:6UB=7)S96UE;G0@;V8@9&5V96QO
M<&UE;G0@86-T:79I=&EE<R!H87,@;F]T(&)E96X@<W!E;G0@8GD@3VYC;T=E
M;F5X('!R:6]R#0H@("!T;R!T:&4@=&AI<F0@86YN:79E<G-A<GD@;V8@=&AE
M($-O;&QA8F]R871I;VX@06=R965M96YT(&)E='=E96X@3VYC;T=E;F5X(&%N
M9"!4979A+"!/;F-O1V5N97@@=VEL;`T*("`@<&%Y($ES:7,@86X@86UO=6YT
M(&5Q=6%L('1O(#,P)2!O9B!A;GD@=6XM<W!E;G0@<&]R=&EO;B!L97-S("9N
M8G-P.R0S+C4F(S$V,#MM:6QL:6]N+@T*("`@/"]D:78^#0H@("`\(2TM($9O
M;&EO("TM/@T*("`@/"$M+2`O1F]L:6\@+2T^#0H@("`\+V1I=CX-"B`@(#PA
M+2T@4$%'14)214%+("TM/@T*("`@/&1I=B!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I;BUL969T
M.B`P:6X[("<^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/DEN(&%D9&ET:6]N+"!W
M92!A<F4@<F5Q=6ER960@=&\@<&%Y('1O($ES:7,@,S`E(&]F(&%L;"!.;VXM
M4F]Y86QT>2!2979E;G5E('=E(')E8V5I=F4@;VX@8W5S=&ER<V5N#0H@("!S
M86QE<RX@27-I<R!H87,@9&ES8VQO<V5D(&EN(&ET<R!314,@9FEL:6YG<R!T
M:&%T(&ET(&ES(&5N=&ET;&5D('1O(')E8V5I=F4@,S`E(&]F('1H92!U<"!T
M;R`F;F)S<#LD,S<P#0H@("!M:6QL:6]N(&EN(&UI;&5S=&]N92!P87EM96YT
M<R!W92!M87D@<F5C96EV92!F<F]M(%1E=F$@87,@<&%R="!O9B!T:&4@0V]L
M;&%B;W)A=&EO;B!!9W)E96UE;G0[#0H@("!H;W=E=F5R+"!W92!B96QI979E
M('1H870@8V5R=&%I;B!O9B!T:&4@;6EL97-T;VYE('!A>6UE;G1S(')E;&%T
M960@=&\@<V%L97,@=&%R9V5T<R!M87D@<75A;&EF>2!A<PT*("`@4F]Y86QT
M>2!2979E;G5E+"!A;F0@=&AE<F5F;W)E(&)E('-U8FIE8W0@=&\@=&AE(&QE
M<W-E<B!P87EM96YT(&]B;&EG871I;VYS+B!.;R!A<W-U<F%N8V4@8V%N(&)E
M#0H@("!P<F]V:61E9"!T:&%T('=E('=I;&P@8F4@96YT:71L960@=&\@<F5C
M96EV92!T:&5S92!M:6QE<W1O;F4@<&%Y;65N=',@;W(L(&EF('=E(&%R92P@
M=&AA="!T:&4-"B`@(&%P<&QI8V%B;&4@86UO=6YT('!A>6%B;&4@=&\@27-I
M<R!W:6QL(&)E(&QE<W,@=&AA;B`S,"4N#0H@("`\+V1I=CX-"B`@(#QD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+71O<#H@,3!P="<^4'5R<W5A;G0@=&\@;&EC96YS92!A9W)E96UE;G1S('1H
M92!#;VUP86YY(&AA<R!W:71H('1H92!50D,@86YD($ES:7,L('1H92!#;VUP
M86YY(&ES(&]B;&EG871E9"!T;PT*("`@<&%Y(&UI;&5S=&]N92!P87EM96YT
M<R!O9B!U<"!T;R!#040@)FYB<W`[)#$N-B8C,38P.VUI;&QI;VX@86YD("9N
M8G-P.R0W+C<U)B,Q-C`[;6EL;&EO;BP@<F5S<&5C=&EV96QY+"!U<&]N('1H
M90T*("`@86-H:65V96UE;G0@;V8@<W!E8VEF:65D('!R;V1U8W0@9&5V96QO
M<&UE;G0@;6EL97-T;VYE<R!R96QA=&5D('1O($]'6"TT,C<@86YD($]'6"TR
M,C4@86YD#0H@("!R;WEA;'1I97,@;VX@9G5T=7)E('!R;V1U8W0@<V%L97,N
M(%=E('!A:60@27-I<R!A;F0@54)#("9N8G-P.R0W-3`L,#`P(&%N9"!#040@
M)FYB<W`[)#$P,"PP,#`L(')E<W!E8W1I=F5L>2P@:6X-"B`@(#(P,3`@=7!O
M;B!T:&4@:6YI=&EA=&EO;B!O9B!A('!H87-E(#(@8VQI;FEC86P@=')I86P@
M;V8@3T=8+30R-R!I;B!P871I96YT<R!W:71H($-24$,N(%=E(&1O(&YO=`T*
M("`@86YT:6-I<&%T92!M86MI;F<@86YY(')O>6%L='D@<&%Y;65N=',@=&\@
M27-I<R!I;B`R,#$Q+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G
M/E5N;&5S<R!O=&AE<G=I<V4@=&5R;6EN871E9"P@=&AE($ES:7,@86=R965M
M96YT<R!F;W(@8W5S=&ER<V5N(&%N9"!/1U@M-#(W('=I;&P@8V]N=&EN=64@
M9F]R(&5A8V@-"B`@('!R;V1U8W0@=6YT:6P@=&AE(&QA=&5R(&]F(#$P)B,Q
M-C`[>65A<G,@869T97(@=&AE(&1A=&4@;V8@=&AE(&9I<G-T(&-O;6UE<F-I
M86P@<')O9'5C="!S86QE+"!O<B!T:&4-"B`@(&5X<&ER871I;VX@;V8@=&AE
M(&QA<W0@=&\@97AP:7)E(&]F(&%N>2!P871E;G1S(')E<75I<F5D('1O(&)E
M(&QI8V5N<V5D(&EN(&]R9&5R('1O('5S92!O<B!S96QL('1H90T*("`@<')O
M9'5C="P@=6YL97-S($]N8V]'96YE>"!496-H;F]L;V=I97,@86)A;F1O;G,@
M96ET:&5R(&-U<W1I<G-E;B!O<B!/1U@M-#(W(&%N9"!)<VES(&1O97,@;F]T
M(&5L96-T#0H@("!T;R!U;FEL871E<F%L;'D@8V]N=&EN=64@9&5V96QO<&UE
M;G0N(%1H92!)<VES(&%G<F5E;65N="!F;W(@3T=8+3(R-2!W:6QL(&-O;G1I
M;G5E(&EN=&\@<&5R<&5T=6ET>0T*("`@=6YL97-S($]N8V]'96YE>"!496-H
M;F]L;V=I97,@86)A;F1O;G,@=&AE('!R;V1U8W0@86YD($ES:7,@9&]E<R!N
M;W0@96QE8W0@=&\@=6YI;&%T97)A;&QY(&-O;G1I;G5E#0H@("!D979E;&]P
M;65N="X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SY792!A<F4@
M86QS;R!O8FQI9V%T960@=&\@<&%Y('1O(%5"0R!C97)T86EN('!A=&5N="!C
M;W-T<R!A;F0@86YN=6%L(&QI8V5N<V4@;6%I;G1E;F%N8V4@9F5E<R!F;W(-
M"B`@('1H92!E>'1E;G0@;V8@=&AE('!A=&5N="!L:69E(&]F($-!1"`F;F)S
M<#LD."PP,#`@<&5R('EE87(@<F5L871I;F<@=&\@8W5S=&ER<V5N+"!/1U@M
M-#(W(&%N9"!/1U@M,C(U+@T*("`@5&AE(%5"0R!A9W)E96UE;G1S(&AA=F4@
M969F96-T:79E(&1A=&5S(')A;F=I;F<@9G)O;2!.;W9E;6)E<B8C,38P.S$L
M(#(P,#$@=&\@07!R:6PF(S$V,#LU+"`R,#`U(&%N9"!E86-H#0H@("!A9W)E
M96UE;G0@97AP:7)E<R!U<&]N('1H92!L871E<B!O9B`R,"8C,38P.WEE87)S
M(&9R;VT@:71S(&5F9F5C=&EV92!D871E(&]R('1H92!E>'!I<GD@;V8@=&AE
M(&QA<W0-"B`@('!A=&5N="!L:6-E;G-E9"!T:&5R975N9&5R+"!U;FQE<W,@
M;W1H97)W:7-E('1E<FUI;F%T960N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O
M<#H@,3!P="<^/&D^0F%Y97(@2&5A;'1H0V%R92!,3$,\+VD^#0H@("`\+V1I
M=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^3VX@075G=7-T)B,Q-C`[-RP@,C`P
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M86YD('1H97)A<&5U=&EC('5S97,@:6X-"B`@(&AU;6%N<RX@061D:71I;VYA
M;&QY+"!3;VYU<R!W87,@9W)A;G1E9"!R:6=H=',@=&\@86QL(&]T:&5R(&YO
M;BUC;W)E(&-O;7!O=6YD<R!C;W9E<F5D('5N9&5R('1H90T*("`@<&%T96YT
M<R!F;W(@=7-E(&EN(&]N8V]L;V=Y+@T*("`@/"]D:78^#0H@("`\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT
M;W`Z(#$P<'0G/E5N9&5R('1H92!T97)M<R!O9B!T:&4@86=R965M96YT+"!"
M87EE<B!R96-E:79E9"!A;B!U<&9R;VYT(&QI8V5N<V4@9F5E(&]F("9N8G-P
M.R0T-3`L,#`P+B!/;F-O1V5N97@@=VEL;`T*("`@;6%K92!A;FYU86P@<&%Y
M;65N=',@=&\@0F%Y97(@;VX@=&AE(&%N;FEV97)S87)Y(&1A=&4@*$%N;FEV
M97)S87)Y(%!A>6UE;G1S*2P@=VET:"!A;B!I;FET:6%L#0H@("!P87EM96YT
M(&]F("9N8G-P.R0Q,#`L,#`P('!A:60@:6X@,C`P."X@5&AE('!A>6UE;G1S
M(&EN8W)E87-E(&)Y("9N8G-P.R0R-2PP,#`@96%C:"!Y96%R('5N=&EL('1H
M92!I;FET:6%T:6]N#0H@("!O9B!T:&4@9FER<W0@<&AA<V4@,R!C;&EN:6-A
M;"!T<FEA;"P@870@=VAI8V@@<&]I;G0@=&AE($%N;FEV97)S87)Y(%!A>6UE
M;G1S(')E<V5T('1O("9N8G-P.R0Q,#`L,#`P(&5A8V@-"B`@('EE87(@86YD
M(&EN8W)E87-E(&)Y("9N8G-P.R0R-2PP,#`@=6YT:6P@=&AE($-O;7!A;GD@
M86-H:65V97,@96ET:&5R('1H92!F:7)S="!.97<@1')U9R!!<'!L:6-A=&EO
M;BP@;W(-"B`@($Y$02P@9FEL:6YG(&EN('1H92!5;FET960@4W1A=&5S(&]R
M('1H92!%=7)O<&5A;B!5;FEO;BX@3VYC;T=E;F5X(&ES(&]B;&EG871E9"!T
M;R!P87D@<F]Y86QT:65S(&]N#0H@("!N970@9G5T=7)E('!R;V1U8W0@<V%L
M97,@:6X@861D:71I;VX@=&\@86=G<F5G871E(&UI;&5S=&]N92!P87EM96YT
M<R!O9B!U<"!T;R`F;F)S<#LD,30L,#`P+#`P,"!F;W(-"B`@(&-L:6YI8V%L
M(&1E=F5L;W!M96YT(&%N9"!R96=U;&%T;W)Y(&UI;&5S=&]N97,N($YO(&UI
M;&5S=&]N92!P87EM96YT<R!A<F4@=')I9V=E<F5D('!R:6]R('1O('1H90T*
M("`@:6YI=&EA=&EO;B!O9B!A('!H87-E(#,@8VQI;FEC86P@=')I86PN($]N
M8V]'96YE>"!H87,@=&AE(&]P=&EO;B!T;R!T97)M:6YA=&4@=&AI<R!C;VYT
M<F%C="!U<&]N(#8P#0H@("!D87ES('=R:71T96X@;F]T:6-E('1O($)A>65R
M+@T*("`@/"]D:78^#0H@("`\(2TM($9O;&EO("TM/@T*("`@/"$M+2`O1F]L
M:6\@+2T^#0H@("`\+V1I=CX-"B`@(#PA+2T@4$%'14)214%+("TM/@T*("`@
M/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L
M5&EM97,L<V5R:68[(&UA<F=I;BUL969T.B`P:6X[("<^#0H@("`\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT
M;W`Z(#$P<'0G/CQI/DQE87-E($%R<F%N9V5M96YT<SPO:3X-"B`@(#PO9&EV
M/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SY4:&4@0V]M<&%N>2!H87,@86X@;W!E
M<F%T:6YG(&QE87-E(&%G<F5E;65N="!F;W(@;V9F:6-E('-P86-E(&EN(%9A
M;F-O=79E<BP@0V%N861A+"!W:&EC:"!E>'!I<F5S#0H@("!I;B!397!T96UB
M97(F(S$V,#LR,#$T+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G
M/D9U='5R92!M:6YI;75M(&%N;G5A;"!L96%S92!P87EM96YT<R!U;F1E<B!T
M:&4@5F%N8V]U=F5R(&QE87-E(&%R92!A<R!F;VQL;W=S("AI;B!T:&]U<V%N
M9',I.@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$8V5N=&5R/@T*("`@
M/'1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<@8V5L;'-P86-I;F<],T0P(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M
M+3X-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D('=I9'1H
M/3-$.#8E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,R4^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!W:61T:#TS1#DE/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS
M<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P
M,#`P,"<^0T%$/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^#0H@("`\(2TM($5N9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I
M;B!486)L92!";V1Y("TM/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\
M9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ
M-7!X)SXR,#$Q#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^/&(^)FYB<W`[)#PO8CX\
M+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C4S/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/C(P,3(-"B`@(#PO9&EV
M/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L
M:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R
M:6=H=#XQ,#<\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T
M<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N
M9#H@(V-C965F9B<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M
M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^,C`Q,PT*("`@
M/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT/C$P-SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^
M#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD
M96YT.BTQ-7!X)SXR,#$T#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO
M=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^.#`\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#%P>"<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS
M1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[
M#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R
M:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^
M#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z
M("-C8V5E9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/CQB/E1O=&%L/"]B
M/@T*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@86QI9VX],T1L969T/CQB/B9N8G-P.R0\+V(^/"]T9#X-"B`@
M("`@("`\=&0@86QI9VX],T1R:6=H=#X\8CXS-#<\+V(^/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L
M92!";V1Y("TM/@T*("`@/"]T86)L93X-"B`@(#PO9&EV/@T*("`@/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM
M=&]P.B`Q,'!T)SY);B!.;W9E;6)E<B8C,38P.S(P,#8L('!R:6]R('1O('1H
M92!!<G)A;F=E;65N="`L(%-O;G5S(&5N=&5R960@:6YT;R!A(&YO;BUC86YC
M96QL86)L92!O<&5R871I;F<-"B`@(&QE87-E(&%G<F5E;65N="!F;W(@;V9F
M:6-E('-P86-E(&EN($)O=&AE;&PL(%=A<VAI;F=T;VXL(&5X<&ER:6YG(&EN
M(#(P,3<@*&YO=&4@-BDN($EN(&-O;FYE8W1I;VX-"B`@('=I=&@@=&AE(&QE
M87-E+"!3;VYU<R!W87,@<F5Q=6ER960@=&\@<')O=FED92!A(&-A<V@@<V5C
M=7)I='D@9&5P;W-I="!O9B!A<'!R;WAI;6%T96QY("9N8G-P.R0T.3<L,#`P
M+`T*("`@=VAI8V@@:7,@:6YC;'5D960@:6X@3W1H97(@3&]N9R!497)M($%S
M<V5T<RX@26X@861D:71I;VXL(&$@<W1A;F1B>2!L971T97(@;V8@8W)E9&ET
M('=A<R!I<W-U960@:6X-"B`@(#(P,3`L(&%N9"`F;F)S<#LD-3`R+#`P,"!W
M87,@9&5P;W-I=&5D(&EN(&$@<F5S=')I8W1E9"!M;VYE>2!M87)K970@86-C
M;W5N="!A<R!C;VQL871E<F%L+B!4:&4@0V]M<&%N>2!I<PT*("`@8W5R<F5N
M=&QY(&EN('1H92!P<F]C97-S(&]F(&5V86QU871I;F<@;W!P;W)T=6YI=&EE
M<R!T;R!E>&ET(&]R('-U8FQE="!P;W)T:6]N<R!O9B!T:&4@;&5A<V5D('-P
M86-E#0H@("!A;F0@:&%S(')E8V]R9&5D(&$@;&EA8FEL:71Y(&EN('1H92!E
M>&-E<W,@9F%C:6QI=&EE<R!L96%S92!C:&%R9V4@;V8@)FYB<W`[)#<L,S(W
M+#`P,"!A<R!A="!*=6YE)B,Q-C`[,S`L#0H@("`R,#$Q("AN;W1E(#8I+@T*
M("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/DEF('1H92!#;VUP86YY
M(&ES('5N86)L92!T;R!E>&ET(&]R('-U8FQE="!P;W)T:6]N<R!O9B!T:&ES
M(&QE87-E9"!S<&%C92P@=&AE(&9U='5R92!M:6YI;75M(&%N;G5A;`T*("`@
M;&5A<V4@<&%Y;65N=',@87)E(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ
M#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1C96YT97(^#0H@("`\=&%B
M;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)R!C96QL<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0Q,#`E/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*
M("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0@=VED=&@],T0X
M-B4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0S)3XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED
M=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A
M8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@
M("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C
M8V5E9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/C(P,3$-"B`@(#PO9&EV
M/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L
M:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R
M:6=H=#XQ+#`R-SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^#0H@
M("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT
M.BTQ-7!X)SXR,#$R#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,BPQ,3<\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@("`@
M/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT
M+6EN9&5N=#HM,35P>"<^,C`Q,PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P
M.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C(L,3@P/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/C(P,30-"B`@
M(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1R:6=H=#XR+#(T-CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T
M>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXR
M,#$U#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^,BPS,3,\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@
M("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X
M.R!T97AT+6EN9&5N=#HM,35P>"<^4F5M86EN9&5R#0H@("`\+V1I=CX\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^
M-"PX,S<\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-
M"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#%P>"<^#0H@("`@("`@/'1D
M/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN
M9&5N=#HM,35P>"<^)B,Q-C`[#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L
M<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q
M<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@("`@(#QT9#X-"B`@
M(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z
M+3$U<'@G/CQB/E1O=&%L/"]B/@T*("`@/"]D:78^/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/CQB/B9N
M8G-P.R0\+V(^/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#X\8CXQ
M-"PW,C`\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X-
M"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SY#;VYS;VQI9&%T960@
M<F5N="!E>'!E;G-E(')E;&%T:6YG('1O(&)O=&@@=&AE(%9A;F-O=79E<BP@
M0V%N861A(&%N9"!";W1H96QL+"!787-H:6YG=&]N#0H@("!O9F9I8V5S(&9O
M<B!T:&4@<&5R:6]D<R!E;F1E9"!*=6YE)B,Q-C`[,S`L(#(P,3$@86YD(#(P
M,3`@=V%S("9N8G-P.R0Q+#,Q,RPP,#`@86YD("9N8G-P.R0Q+#`Y,BPP,#`@
M<F5S<&5C=&EV96QY+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G
M/CQI/D=U87)A;G1E97,@86YD($EN9&5M;FEF:6-A=&EO;G,\+VD^#0H@("`\
M+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^3VYC;T=E;F5X(&EN9&5M;FEF
M:65S(&ET<R!O9F9I8V5R<R!A;F0@9&ER96-T;W)S(&9O<B!C97)T86EN(&5V
M96YT<R!O<B!O8V-U<G)E;F-E<RP@<W5B:F5C="!T;PT*("`@8V5R=&%I;B!L
M:6UI=',L('=H:6QE('1H92!O9F9I8V5R(&]R(&1I<F5C=&]R(&ES(&]R('=A
M<R!S97)V:6YG(&%T(&]U<B!R97%U97-T(&EN('-U8V@@8V%P86-I='DN#0H@
M("!4:&4@=&5R;2!O9B!T:&4@:6YD96UN:69I8V%T:6]N('!E<FEO9"!I<R!E
M<75A;"!T;R!T:&4@;V9F:6-E<B8C.#(Q-SMS(&]R(&1I<F5C=&]R)B,X,C$W
M.W,@;&EF971I;64N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^
M5&AE(&UA>&EM=6T@86UO=6YT(&]F('!O=&5N=&EA;"!F=71U<F4@:6YD96UN
M:69I8V%T:6]N(&ES('5N;&EM:71E9#L@:&]W979E<BP@=V4@:&%V92!O8G1A
M:6YE9`T*("`@9&ER96-T;W(@86YD(&]F9FEC97(@:6YS=7)A;F-E('1H870@
M;&EM:71S(&]U<B!E>'!O<W5R92!A;F0@;6%Y(&5N86)L92!I="!T;R!R96-O
M=F5R(&$@<&]R=&EO;B!O9@T*("`@86YY(&9U='5R92!A;6]U;G1S('!A:60N
M(%=E(&)E;&EE=F4@=&AA="!T:&4@9F%I<B!V86QU92!O9B!T:&5S92!I;F1E
M;6YI9FEC871I;VX@;V)L:6=A=&EO;G,@:7,-"B`@(&UI;FEM86PN($%C8V]R
M9&EN9VQY+"!W92!H879E(&YO="!R96-O9VYI>F5D(&%N>2!L:6%B:6QI=&EE
M<R!R96QA=&EN9R!T;R!T:&5S92!O8FQI9V%T:6]N<R!A<R!O9@T*("`@2G5N
M928C,38P.S,P+"`R,#$Q+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P
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M871I;VX@:7-S=65S(&9O<B!A;GD@<&5R:6]D('!R97-E;G1E9"X-"B`@(#PO
M9&EV/@T*("`@/"$M+2!&;VQI;R`M+3X-"B`@(#PA+2T@+T9O;&EO("TM/@T*
M("`@/"]D:78^#0H@("`\(2TM(%!!1T5"4D5!2R`M+3X-"B`@(#QD:78@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E
M<FEF.R!M87)G:6XM;&5F=#H@,&EN.R`G/@T*("`@/"]D:78^#0H\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V)B.#8R9#8U7V)F
M-#!?-&0U9E]B8S%D7SAB,3DS83-E9#4Y-`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]B8C@V,F0V-5]B9C0P7S1D-69?8F,Q9%\X8C$Y,V$S960U
M.30O5V]R:W-H965T<R]3:&5E=#$S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D@^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^0V]M<')E:&5N<VEV92!,;W-S/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6]N
M(%-T;V-K(&%N9"!#;VUP<F5H96YS:79E($QO<W,@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#3TU04D5(
M14Y3259%($Q/4U,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA
M+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@
M5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL
M,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"
M96=I;B!";&]C:R!486=G960@3F]T92`X("T@=7,M9V%A<#I#;VUP<F5H96YS
M:79E26YC;VUE3F]T951E>'1";&]C:RTM/@T*("`@/&1I=B!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA
M<F=I;BUL969T.B`P:6X[("<^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQB/C@N
M($-/35!214A%3E-)5D4@3$]34SPO8CX-"B`@(#PO9&EV/@T*("`@/&1I=B!A
M;&EG;CTS1&-E;G1E<CX-"B`@(#QT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G(&-E;&QS<&%C:6YG/3-$,"!B;W)D
M97(],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@("`\(2TM
M($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@("`@(#QT9"!W:61T:#TS1#0T)3XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H
M/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Y)3XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#DE
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H
M/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E
M/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#8^/&(^
M5&AR964@36]N=&AS/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$-CX\8CY3:7@@36]N
M=&AS/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R
M/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1C96YT97(@8V]L<W!A;CTS1#8^/&(^16YD960\+V(^/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P
M86X],T0V/CQB/D5N9&5D/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#8@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/DIU;F4@,S`L/"]B
M/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<B!C;VQS<&%N/3-$-B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q
M<'@@<V]L:60@(S`P,#`P,"<^/&(^2G5N92`S,"P\+V(^/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/BA);B!T:&]U<V%N9',I/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CXR,#$Q/"]B
M/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q
M<'@@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,#PO8CX\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G
M/CQB/C(P,3$\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CXR,#$P/"]B/CPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1L969T/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CXF;F)S
M<#LD/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CXF;F)S<#LD/"]B/CPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E
M<B!C;VQS<&%N/3-$,CX\8CXF;F)S<#LD/"]B/CPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$
M,CX\8CXF;F)S<#LD/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA
M+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@(#QT<B!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@("`@/'1D
M/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN
M9&5N=#HM,35P>"<^3&]S<R`H:6YC;VUE*28C,38P.V9O<B!T:&4@<&5R:6]D
M#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M/C8L-3,P/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$;&5F=#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I
M9VAT/B@Q-30\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`^*3PO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^.2PU-S4\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT/C(L.#DP/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#X-
M"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E
M;G0Z+3$U<'@G/E5N<F5A;&EZ960@9V%I;B!O;B!C87-H(`T*("`@97%U:79A
M;&5N=',@86YD(&UA<FME=&%B;&4@#0H@("!S96-U<FET:65S#0H@("`\+V1I
M=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1L969T/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0^*#$T/"]T9#X-"B`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P/BD\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I
M9VAT/B8C.#(Q,CL\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1L969T/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N
M/3-$<FEG:'0^*#$T/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M/BD\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B8C.#(Q,CL\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT
M<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F
M9B<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F
M=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^56YR96%L:7IE9"!L;W-S(&]N
M(&-A<V@@#0H@("!E<75I=F%L96YT<R!A;F0@<VAO<G0M=&5R;2`-"B`@(&EN
M=F5S=&UE;G1S#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT/C0V/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H
M=#XT-CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,7!X)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@(#PO
M9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS
M1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G
M8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P
M,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^/"$M+2!";&%N:R!3<&%C
M92`M+3X-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL
M969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@(#PO9&EV
M/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@
M/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^#0H@("`\9&EV('-T
M>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY#
M;VUP<F5H96YS:79E(&QO<W,@*&EN8V]M92D-"B`@(#PO9&EV/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^-BPU-C(\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1L969T/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^*#$U-#PO=&0^#0H@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XI/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M86QI9VX],T1R:6=H=#XY+#8P-SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,BPX.3`\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD
M(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A8FQE/@T*("`@/"]D:78^#0H@("`\
M+V1I=CX-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?8F(X-C)D-C5?8F8T,%\T9#5F7V)C,61?.&(Q.3-A,V5D-3DT#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)B.#8R9#8U7V)F-#!?-&0U9E]B
M8S%D7SAB,3DS83-E9#4Y-"]7;W)K<VAE971S+U-H965T,30N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$4R2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6)S97%U96YT($5V
M96YT<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P
M+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-U8G-E<75E;G0@179E;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4U5"4T51545.5"!%
M5D5.5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-4
M65!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I
M=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O
M>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!"
M;&]C:R!486=G960@3F]T92`Y("T@=7,M9V%A<#I3=6)S97%U96YT179E;G1S
M5&5X=$)L;V-K+2T^#0H@("`\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M5&EM97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@;6%R9VEN+6QE9G0Z(#!I
M;CL@)SX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^.2X@4U5"4T51545.5"!%
M5D5.5%,\+V(^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^5&AE
M($-O;7!A;GD@:&%S('!E<F9O<FUE9"!A;B!E=F%L=6%T:6]N(&]F(&5V96YT
M<R!O8V-U<G)I;F<@<W5B<V5Q=65N="!T;R!*=6YE)B,Q-C`[,S`L(#(P,3$N
M($)A<V5D(&]N#0H@("!O=7(@979A;'5A=&EO;BP@;F\@;6%T97)I86P@979E
M;G1S(&AA=F4@;V-C=7)R960@<F5Q=6ER:6YG(&9I;F%N8VEA;"!S=&%T96UE
M;G0@9&ES8VQO<W5R92X-"B`@(#PO9&EV/@T*("`@/"]D:78^#0H\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V)B.#8R9#8U7V)F
M-#!?-&0U9E]B8S%D7SAB,3DS83-E9#4Y-`T*0V]N=&5N="U,;V-A=&EO;CH@
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M1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,RYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,BYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$T+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R
J=%]B8C@V,F0V-5]B9C0P7S1D-69?8F,Q9%\X8C$Y,V$S960U.30M+0T*
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
